Investigation into how mitotic spindle checkpoint function is compromised by Sv40 large T antigen. by Lock, R.L.
REFERENCE ONLY
UNIVERSITY OF LONDON THESIS
Degree  Y ear^^oS "  Name of Author  CocV w   rL-
COPYRIGHT
This is a thesis accepted for a  Higher Degree of the  University of London.  It is an 
unpublished typescript and the copyright is held by the author.  All persons consulting 
toe thesis must read and abide by the Copyright Declaration below.
i
COPYRIGHT DECLARATION
I recognise that the copyright of the above-described thesis rests with the author and 
that no quotation from it or information derived from it may be published without the 
prior written consent of the author.
LOAN
Theses may not be lent to individuals,  but the University Library may lend a copy to 
approved libraries within the United Kingdom, for consultation solely on the premises 
of tooseiibraries.  Application should be made to: The Theses Section,  University of 
London Library, Senate House, Malet Street, London WC1E 7HU.
REPRODUCTION
University  of  London  theses  may  not  be  reproduced  without  explicit  written 
permission from the University of London Library.  Enquiries should be addressed to 
the  Theses  Section  of  the  Library.  Regulations  concerning  reproduction  vary 
according to the date of acceptance of the thesis and are listed below as guidelines.
A.  Before 1962.  Permission granted only upon the prior written consent of the 
author*  (The University Library will provide addresses where possible).
B.  1962 -1974.  In many cases the author has agreed to permit copying  upon
,  completion of a Copyright Declaration.
^S.  1976 -1988.  Most theses may be copied  upon completion  of a  Copyright
Declaration.
D.  1989 onwards.  Most theses may be copied.
This thesis comes within category D.
R K  This copy has been deposited in the Library of  ----------------------- -
□
  This  copy  has  been  deposited  in  the  University of  London  Library,  Senate 
House, Malet Street, London WC1E 7HU.
G:\Documents and Settings\lproctor.ULL\Local Settings\Temporary Internet Files\OLK36\Copyright-thesis.docInvestigation into how mitotic spindle checkpoint 
function is compromised by SV40 large T antigen.
By
Rowena Lesley Lock
A thesis submitted to the University of London 
for the degree of Doctor of Philosophy
Ludwig Institute for Cancer Research 
University College Branch 
91 Riding House Street 
London W1W 7BS
Department of Biochemistry and Molecular Biology 
University College London 
Gower Street 
London WC1E 6BT
2005
1UMI Number: U592290
All rights reserved
INFORMATION TO ALL USERS 
The quality of this reproduction is dependent upon the quality of the copy submitted.
In the unlikely event that the author did not send a complete manuscript 
and there are missing pages, these will be noted.  Also, if material had to be removed,
a note will indicate the deletion.
Dissertation Publishing
UMI U592290
Published by ProQuest LLC 2013.  Copyright in the Dissertation held by the Author.
Microform Edition © ProQuest LLC.
All rights reserved.  This work is protected against 
unauthorized copying under Title 17, United States Code.
ProQuest LLC 
789 East Eisenhower Parkway 
P.O. Box 1346 
Ann Arbor, Ml  48106-1346Abstract
The  viral  oncoprotein  Simian  virus  40  large  T  antigen  (LT)  efficiently 
immortalises  primary  rodent  cells  and  occasionally  transforms  them  to 
tumourigenicity. It has long been known that LT can cause genomic instability and 
induce aneuploidy,  and that it disrupts the mitotic  spindle checkpoint, involved in 
monitoring the segregation of sister chromatids.
LT has recently been shown to interact with the spindle checkpoint protein 
Bubl.  This thesis  describes research into the effects of LT  on spindle checkpoint 
function  and  examines  the  possibility  that  interaction  of  LT  with  Bubl  is 
responsible.
Novel  monoclonal  antibodies  against  Bubl  were  developed  to  aid  this 
research.
The interaction site of Bubl was mapped to amino acids 89-97 of LT using 
co-immunoprecipitation experiments in several cell lines, each expressing LT with a 
different mutation in the  amino-terminal  region.  The non-Bubl-binding  (dl89-97) 
mutant was capable of immortalising rat embryo fibroblasts as efficiently as wild- 
type LT, but was defective for focus formation, perhaps suggesting a role for Bubl 
in the mechanism for transformation by LT.
In  the  presence  of the  microtubule-depolymerising  drug  nocodazole,  the 
spindle  checkpoint  is  activated  and  cells  arrest  in  mitosis.  LT  was  shown  to 
compromise spindle checkpoint function, allowing some cells to pass through to the 
next  cell  cycle  even  in  the  presence  of  nocodazole.  However,  without  Bubl 
interaction, LT loses this ability and the spindle checkpoint is robust.
An investigation of the  checkpoint proteins  and  complexes present during 
spindle  checkpoint  activation  in  cells  expressing  wild-type  or  dl89-97  LT  was 
initiated to analyse possible mechanisms for perturbation of the spindle checkpoint 
byLT.
This  study  raises  the  possibility  that  LT  induces  genetic  instability  in 
mammalian cells by perturbation of spindle checkpoint function, and that this may 
be  a  critical  component  of  the  mechanism  by  which  LT  transforms  cells.
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Research  in  the  Jat  laboratory  is  focussed  on  elucidating  the 
mechanisms by which the viral oncoprotein SV40 large T antigen (LT) carries 
out its immortalisation and transformation functions, and in studying the other 
known  functions  of  LT.  It  has  long  been  known  that  SV40  LT  induces 
chromosome  aberrations,  and  can  disrupt  mitotic  checkpoints  that  are 
involved in maintaining genomic stability. However, the mechanism by which 
LT induces  genetic  instability in  cells  was  not known.  A previous  graduate 
student  in  the  laboratory,  Marina  Cotsiki,  carried  out  a  yeast  two-hybrid 
screen to  search  for novel  interacting proteins  of LT,  to  identify previously 
unknown mechanisms by which LT could be carrying out its varied functions. 
Using the amino terminal 136 residues of LT as bait and a HeLa cDNA library 
as prey,  the  spindle  checkpoint protein Bubl  was  identified  as  a novel  LT- 
interacting protein.  Bubl  plays  a critical  role  in the  spindle  checkpoint  and 
mutations  in the Bubl  gene have been associated with genetic  instability in 
human cancers. It was hypothesised that interaction of LT with Bubl  could be 
responsible for induction of chromosome aberrations by LT. In addition, these 
aberrations  may  be  important  for  the  immortalisation  and  transformation 
functions of the LT protein.
A  general  background  to  the  cell  cycle,  spindle  checkpoint,  genetic 
instability,  and  SV40  large  T  antigen  will  be  provided  in  this  introductory 
chapter.
1.1  THE CELL CYCLE
Cell division is fundamental for the growth of an organism and for the 
replacement  of cells  lost  during  normal  wear  and  tear.  This  occurs  via  an 
orderly process known as the cell cycle (for recent reviews, see (Pardee, 2004; 
Tessema et al., 2004)). Duplication of all molecules that comprise the cell is
22required during the course of the cell cycle, and occurs at different stages of 
the cycle.  For example,  deoxyribonucleic  acid (DNA),  the heredity-carrying 
material in chromosomes, is duplicated specifically during a period that occurs 
for only a few hours mid-cycle, known as S phase, for (DNA) synthesis. The 
eukaryotic  cell  cycle  is  divided  into  four phases:  gap  1  (G1  phase)  during 
which the cell prepares for DNA synthesis, DNA synthesis (S phase), gap 2 
(G2 phase) when the cell prepares for mitosis, and mitosis (M phase) during 
which the cell divides.  Following M phase the two new daughter cells  enter 
the next cycle. If a cell does not receive the necessary signals for proliferation 
or is terminally differentiated,  it withdraws  from the  cell  cycle  at G1  into  a 
non-dividing,  quiescent state known as  GO.  Most cells in the body of adults 
are maintained in this GO phase.
Cyclin dependent kinases (CDKs), along with their regulatory subunits, 
called cyclins, are the main engines that drive the cell cycle forward.
1.1,1  Cyclins and CDKs
The  family  of  closely  related  cyclin  proteins  appear  and  disappear 
during  the  cell  cycle  in  a  strictly  controlled,  “cyclic”  pattern.  It  was  the 
discovery  of  cyclin  (Evans  et  al.,  1983)  that  led  to  the  model  of  an 
autonomous oscillator driving the cell cycle of early embryonic cells. Cyclins 
are  accessory  subunits  that  activate  protein  kinases  known  as  “cyclin- 
dependent kinases” (CDKs). There are multiple cyclins and cyclin-dependent 
kinases,  and  they  are  involved  in  the  cell  cycle,  transcription  and 
differentiation (reviewed in (Murray, 2004)). Each cyclin associates with one 
or two  CDKs,  and most CDKs  associate with one  or two  cyclins.  However 
some,  such  as  CDK1  in  budding  yeast,  associate  with  as  many  as  nine 
different cyclins. In the cell cycle there are cyclins associated with G1  (cyclin 
D),  S  phase  (cyclins  E  and  A),  and  mitosis  (cyclins  B  and  A).  The  cyclic 
appearance  and  disappearance  of  the  cyclin  proteins  is  mediated  by
23transcriptional  activation  of  the  cyclin  genes,  and  ubiquitin-mediated 
degradation of the cyclin proteins, respectively.
CDKs are a family of serine-threonine protein kinases that are activated 
in  a  cell  cycle  stage-specific  manner  (reviewed  in  (Tessema  et  al.,  2004)). 
Association of CDKs with their regulatory subunit, the cyclin, is required for 
the kinase activity of the CDKs. Activities of the different CDKs are regulated 
both  by  availability  of  a  particular  cyclin,  and  also  by  binding  of  CDK- 
inhibitors (CKI), in addition to phosphorylation and dephosphorylation events, 
for example by CDK-activating kinase (CAK), or by CDK-associated protein 
phosphatase, respectively.
Approximately two thirds of the way through G1  the cell reaches the 
“restriction  (R)  point”  (Pardee,  1989),  when  it  assesses  the  environmental 
conditions (such as the presence of mitogens) and decides whether to continue 
through G1 and divide again, or to enter GO and become quiescent. Activity of 
almost all CDKs are suppressed in GO and early G1 by a combination of high 
CKI activity and low cyclin levels, and this absence of active CDK allows the 
retinoblastoma  protein  (pRB)  to  stay bound  to  the  transcription  factor  E2F 
(see  Figure  1.1).  pRB  inhibits  E2F  from  activating  transcription  of genes 
important for DNA replication.  D-type  cyclins  start to  accumulate  once  the 
cell  has  received  an  extracellular  signal  that  stimulates  proliferation,  and 
CDK4/6-Cyclin D becomes  fully activated via phosphorylation by CAK.  At 
the transition through R, CDK4/6-Cyclin D phosphorylates pRB (Bartek et al., 
1996; Weinberg, 1995), leading to the release of E2F transcription factors, and 
allowing transcription of genes that encode proteins required for entry into S 
phase. Active CDK2-Cyclin E and CDK4/6-Cyclin D together inactivate pRB 
completely,  inducing  more  E2F-responsive  genes  required  to  drive  cells 
through the Gl/S transition and initiate DNA replication (see Figure 1.1).
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Figure 1.1:  Cell cycle regulation.
A simplified summary of eukaryotic cell cycle regulation is shown with 
some of the major players represented. Progression through the cell cycle 
is regulated by sequential assembly and activation of cyclin-dependent 
kinase (CDK)-cyclin complexes.Cyclin A starts to accumulate during  S phase, and phosphorylation of 
components  of  the  DNA  replication  machinery  by  CDK2-Cyclin  A  is 
important for initiation of DNA replication.  E2F is responsible for activating 
the synthesis of Cyclin A, but E2F activity is also inhibited by CDK2-Cyclin 
A,  forming  a negative  feedback loop  (see  Figure  1.1).  Cyclin  A  is  abruptly 
destroyed before metaphase (M phase) via ubiquitin-mediated proteolysis.
Cyclin  A  is  also  required  for  the  G2/M  transition.  The  entry  into 
mitosis  (G2/M  transition)  is  triggered  by  CDK1-Cyclin  B,  also  known  as 
Maturation Promoting Factor (MPF).  CDK1  (also known as cdc2)  is kept in 
an inactive state during S and G2 phases by phosphorylation on two residues: 
Tyrl5 and Thrl4 (Hoffmann et al.,  1993). At the end of G2 MPF is activated 
via dephosphorylation by at least two phosphatases,  CDC25B  and CDC25C 
(Lee  and  Yang,  2001)  (see  Figure  1.1).  Activated  MPF  is  known  to 
phosphorylate  many  substrates,  including  motor  and  microtubule-binding 
proteins  important  for  chromosome  condensation,  nuclear  envelope 
breakdown, spindle assembly and centrosome separation (Nigg, 2001).
Ultimately the  degradation  of Cyclin  B  is  necessary to  exit  M  phase 
and start a new cell cycle.
2.7.2  Mitosis
The  cell  cycle  can be  divided up  into  two  phases:  interphase  (which 
contains  Gl,  S  and  G2  phases),  and  mitotic  phase  (M  phase).  Mitosis  has 
historically  been  separated  into  five  phases:  prophase,  prometaphase, 
metaphase,  anaphase  and  telophase,  the  definitions  of which  are  based  on 
morphology as seen via light microscopy. Mitotic phase consists of these five 
phases,  also  incorporating  a  process  called  cytokinesis  (for  a  review,  see 
(Sluder et al., 2004)).
The  start  of  mitosis  is  defined  as  prophase,  which  begins  when 
condensing chromosomes are first clearly seen,  and ends with breakdown of 
the  nuclear  envelope.  As  prophase  progresses,  the  chromosomes  become
26progressively  more  condensed  (Swedlow  and  Hirano,  2003),  the  nucleoli 
disappear,  and  the  cytoplasmic  microtubule  array  present  at  interphase 
becomes  reorganised  into  two  focal  arrays,  called  asters,  centred  on  the 
centrosomes.  Centrosomes are the microtubule organising centres which will 
divide to organise the two poles of the mitotic spindle. The extent to which the 
asters  are  formed and  separated by the time  of nuclear envelope breakdown 
varies  greatly  from  one  cell  to  the  next.  In  some  cells  the  duplicated 
centrosomes show little evidence of astral microtubule assembly at the end of 
prophase,  remaining  close  together.  In  others,  by  the  end  of prophase  both 
asters may be well developed and have already separated to opposite sides of 
the nucleus (reviewed in (Rieder, 1990)).
Nuclear  envelope  breakdown  signals  the  start  of prometaphase,  the 
stage when the mitotic spindle forms. During this phase, the cell establishes a 
bipolar  spindle  axis,  the  sister  chromatids  of each  replicated  chromosome 
become  attached  to  opposing  spindle  poles  (i.e.  bioriented),  and  the 
chromosomes become aligned at or near to the spindle equator (Rieder, 1990).
The cell is considered to be in the metaphase stage of mitosis once all 
the chromosomes  are bioriented and positioned near the  spindle  equator, i.e. 
once all chromosomes have aligned on the metaphase plate. During metaphase 
the spindle becomes progressively more compacted, resulting in a decrease in 
the distance between the spindle poles.
Anaphase  begins  when  the  sister  chromatids  of  each  replicated 
chromosome  are  separated to  form  two  independent  chromosomes,  each  of 
which  moves  towards  its  attached  spindle  pole.  Anaphase  ends  when  the 
poleward  motion  of  the  chromosomes  is  completed.  Anaphase  actually 
consists of two types of movement that act additively to increase the distance 
between the two separating groups of chromosomes: each chromosome moves 
to  its  respective  pole  (called  Anaphase  A),  and  the  poles  themselves  move 
further apart (called Anaphase B). Anaphase A and B movements usually start 
simultaneously upon chromatid disjunction in vertebrates, but they can begin 
at  different  times  in  some  organisms,  suggesting  that  they  can  be
27independently regulated (reviewed in (Mazia,  1961)). At some point in mid to 
late  anaphase  the  process  of  cytokinesis  (pinching  the  cytoplasm  of  the 
dividing cell in two between the separating sets of chromosomes) is initiated, 
although this is not always obvious (Oegema and Mitchison,  1997; Rappaport, 
1969; Salmon, 1989; White and Borisy,  1983).
Telophase  is  the  last  stage  of  mitosis,  consisting  of  events  that 
complete cell division and allow the cell to exit mitosis.  A nuclear envelope 
reforms around both masses of separated chromosomes. During telophase, the 
cell also  continues the process  of cytokinesis,  cleaving between the  separate 
nuclei.  The cleavage apparatus (consisting of a circumferential band of actin 
and myosin)  co-ordinately  contracts  and  disassembles  to  prevent  a  mass  of 
actomyosin  from  hindering  the  constricting  furrow  from  completing  cell 
division  (Fishkind  and Wang,  1993;  Oegema  and  Mitchison,  1997).  Before 
cleavage is  complete,  the two  daughter cells  remain  attached via a midbody 
composed  of tightly  bundled  microtubules  embedded  in  a  densely  staining 
matrix material. Cleavage is completed when the midbody has been ruptured, 
thought to be caused by the daughter cells crawling apart.
1.1.3  Cell cycle checkpoints
Cell  cycle  checkpoints  were  first  identified  in  yeast  (Hartwell  and 
Weinert,  1989)  and  are  also  present  in  mammalian  cells.  There  are  several 
checkpoints, each acting at a different stage of the cell cycle to ensure proper 
completion of cell cycle events.  Some checkpoints act by blocking cell cycle 
progression  until  errors  have  been  corrected  (for  example  by  requiring 
accurate  DNA  decatenation prior to  mitotic  entry (Deming  et al.,  2001),  or 
proper spindle formation and chromosome alignment prior to the initiation of 
anaphase  (Bharadwaj  and  Yu,  2004)).  Other  checkpoints  function  to  detect 
and correct errors that have occurred in previous steps (such as DNA damage 
checkpoints at G1  and G2 that prevent progression into S phase and mitosis, 
respectively  (Mercer,  1998)).  Many  cell  cycle  checkpoints  relate  to  DNA
28metabolism,  including  DNA  damage  responses  and  the  requirement  for 
completion  of DNA  replication prior to  mitotic  entry  (Sancar  et  a l,  2004). 
Other checkpoints monitor cytoskeletal function, including a pRB-dependent 
G1 checkpoint that monitors actin function (Reshetnikova et a l, 2000), a p53- 
dependent G1  checkpoint that monitors microtubule  function (Andreassen et 
al., 2001b), and the spindle assembly checkpoint which monitors microtubule 
polymerisation  and  ensures  accurate  segregation  of  sister  chromatids  at 
anaphase  (Bharadwaj  and  Yu,  2004).  Although  the  p53  tumour  suppressor 
protein plays  a role  in both the  Gl/S phase  and G2/M phase  checkpoints  in 
mammalian  cells,  no  proteins  homologous  to  p53  have  been  identified  in 
yeast.  However,  several  studies  have  suggested  that  certain  aspects  of p53 
function may exist in yeast (Bischoff et a l, 1992; Koerte et al., 1995; Nigro et 
al, 1992).
1.2  THE SPINDLE CHECKPOINT
Every time a cell divides, it is crucial that each daughter cell receives 
one and only one copy of each chromosome.  Failure to ensure the fidelity of 
sister  chromatid  segregation  in  each  mitosis  would  result  in  aneuploidy 
(having  a  chromosome  number that  is  not  an  exact  multiple  of the  haploid 
number).  Aneuploidy  can  lead  to  either  cell  death  or  the  accumulation  of 
cancer-causing  mutations  through  gains  or  losses  of  DNA.  The  spindle 
checkpoint  (also  called  “the  spindle  assembly  checkpoint”  and  “the  mitotic 
checkpoint”)  is  a  surveillance  mechanism  that  blocks  chromosome 
segregation until all sister chromatid pairs in the cell have successfully formed 
a  bipolar  attachment  to  spindle  microtubules  (for  a  recent  review,  see 
(Bharadwaj  and Yu,  2004)).  An  interaction between  the  viral  protein  SV40 
large T  antigen  (LT)  and an important component of the  spindle  checkpoint 
pathway, Bubl, has recently been identified (Cotsiki et al., 2004), suggesting 
that  aneuploidy  induced  by  SV40  LT  may  be  caused  by  inhibition  of the 
spindle checkpoint function of Bubl.
29The sister chromatids of a dividing cell are held together by a protein 
bridge  formed  by  a  multiprotein  complex  called  cohesin  (reviewed  in 
(Bharadwaj  and  Yu,  2004)).  Proteolysis  of the  cohesin  subunit  Sccl  by  a 
protease  called  separase  triggers  anaphase.  However,  separase  is  normally 
kept  inactive  by  an  associated  inhibitor  called  securin,  thus  preventing 
progression  to  anaphase  (see  Figure  1.2).  During  prometaphase  of mitosis, 
sister chromatids attach to microtubules emanating from opposite poles of the 
mitotic spindle via a specialised DNA-protein complex called the kinetochore, 
located  at  the  centromere  of each  sister  chromatid.  If any  kinetochores  are 
unattached,  or  have  not  formed  a  bipolar  attachment,  an  inhibitory  signal 
generated  by  the  spindle  checkpoint  blocks  the  transition  to  anaphase  by 
inhibiting  the  activity  of the  anaphase  promoting  complex  or  “cyclosome” 
(APC/C), an E3 ubiquitin ligase.
30Figure  1.2:  Regulation  of  chromosome  segregation  by  the  spindle
checkpoint.
A  simplified  diagram  showing  how  the  spindle  checkpoint  proteins 
function  to  regulate  the  metaphase-anaphase  transition.  For  simplicity, 
spindle  checkpoint  proteins  are  represented  by  generic  shapes  (A  more 
detailed description of the functions of the spindle checkpoint proteins in 
this pathway is shown in Figures 1.3 and 1.5).
When the spindle checkpoint is activated, separase is inhibited by securin 
from  cleaving  cohesin,  and  APC/Ccdc20  is  prevented  from  lifting  this 
inhibition by action of the spindle checkpoint (A).
Once  all  sister  chromatids  have  formed  a  bipolar  attachment  with  the 
mitotic  spindle  apparatus,  the  spindle  checkpoint  is  deactivated  and 
APC/CC dc2°  targets  securin  for  proteolytic  destruction,  resulting  in 
activation of separase which cleaves the cohesin subunit Sccl (B), allowing 
onset of anaphase and chromosome segregation to occur (C).
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Figure  1.2:  Regulation  of  chromosome  segregation  by  the  spindle 
checkpoint.
32This  prevents  degradation  of  the  securin  proteins  that  are  involved  in 
chromatid cohesion,  and thus  causes  mitotic  arrest.  However,  once  all  sister 
chromatids  in  the  cell  have  formed  bipolar  attachments  with  the  mitotic 
spindle,  the  spindle  checkpoint  is  satisfied,  and  APC/C  is  de-repressed. 
Securin  is  then  ubiquitinated  by  APC/C,  and  destroyed  by  the  proteasome. 
This  leads  to  separase  activation,  Sccl  cleavage,  loss  of  chromosome 
cohesion,  and  anaphase  onset  (see  Figure  1.2).  Later  in  anaphase  and 
telophase, APC/C also targets Cyclin B  for destruction, allowing mitotic exit 
to  occur  (Peters,  1999).  It  has  also  been  shown  that  Cyclin  B1-CDK1  is 
capable of blocking anaphase when present at high levels, indicating that both 
securin  and  Cyclin  B1  must  be  degraded  to  allow  separation  of  sister 
chromatids (Hagting et al., 2002).
Binding of the substrate recognition factor Cdc20 to APC/C is required 
for the ubiquitination of securin, and it is the interaction of APC/C with Cdc20 
that is modulated by the spindle  checkpoint.  A diffusible  signal that inhibits 
the cytoplasmic pool  of APC/CC dc20 is generated by unattached kinetochores, 
preventing the separation of all (including already aligned) chromosomes (see 
Figure  1.2).  Bubl  is  thought  to  act  as  a  scaffold  for  recruitment  of other 
checkpoint  proteins  (Madl,  Mad2,  Bub3  and  CENP-E  in  Xenopus,  and 
BubRl,  CENP-F,  CENP-E  and  Mad2  in  mammalian  cells)  to  unattached 
kinetochores  (Chen,  2004;  Johnson  et  al.,  2004;  Sharp-Baker  and  Chen,
2001),  and the activation of Bubl  kinase activity at unattached kinetochores 
correlates  with  generation  of  the  spindle  checkpoint  signal  that  inhibits 
APC/Ccde20 (Chen, 2004). Inhibition of Cdc20 (and thus of APC/C) is widely 
thought  to  be  accomplished  by  the  mitotic  checkpoint  complex  (MCC, 
composed of  Cdc20  and the  spindle  checkpoint proteins  Mad2,  BubRl  and 
Bub3), which is generated by unattached kinetochores and is conserved from 
yeast to humans  (Fang,  2002;  Fraschini  et al.,  2001;  Hardwick et al.,  2000; 
Millband  and  Hardwick,  2002;  Sudakin  et  al.,  2001;  Yu,  2002)  (see  Figure 
1.3).
33Figure 1.3: A simplified model for spindle checkpoint signalling
When the spindle checkpoint is activated (i.e.  in the presence of one or 
more kinetochores which have not formed a bipolar attachment with the 
mitotic  spindle),  checkpoint  proteins  that  act  upstream  in  the  spindle 
checkpoint pathway (e.g. the Bubl  and Mpsl kinases) may recruit and/or 
modify other spindle checkpoint proteins  at the unattached kinetochore, 
resulting  in  production  of  the  mitotic  checkpoint  complex  (MCC), 
consisting of Mad2,  BubRl,  Bub3  and  Cdc20  proteins.  The MCC  then 
inhibits  APC/C,  preventing  destruction  of  securin,  and  resulting  in  a 
continued metaphase arrest, with no cleavage of cohesin.
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35The MCC has been shown to have an APC/C-inhibitory activity that is 3000- 
fold  greater  than  that  of recombinant  Mad2  in  HeLa  cells,  also  known  to 
inhibit  APC/C  (Sudakin  et  al.,  2001).  However,  the  precise  details  of the 
spindle  checkpoint  pathway  remain  to  be  determined,  and  there  are  many 
more  components  that  play  important  roles  in  this  pathway,  as  shall  be 
discussed in more detail.
In  addition  to  the  spindle  assembly  checkpoint  (SAC),  a  spindle 
orientation checkpoint (SOC) has been identified in fission yeast, activated in 
the  absence  of  either  an  actomyosin  division  ring,  or  astral  microtubules 
(Gachet  et  al.,  2001;  Oliferenko  and  Balasubramanian,  2002).  These  two 
independent studies have shown that the SOC involves members of the  SAC 
pathway,  with  both  agreeing  on  the  involvement  of  Bubl  in  the  two 
checkpoints.  Mammalian  cells  also have  a mechanism that monitors  spindle 
orientation  and positioning,  and this is  likely driven by interactions between 
astral microtubules,  the motor protein  dynein  and the  cell  cortex  (O'Connell 
and  Wang,  2000).  Perhaps  this  could  represent  a  mitotic  checkpoint 
mechanism equivalent to the SOC seen in fission yeast.
1.2.1  Discovery of the spindle checkpoint
Genetic studies in the budding yeast Saccharomyces cerevisiae initially 
identified six components of the spindle checkpoint - Bubl, Bub2,  and Bub3 
(Hoyt et a l,  1991) and Madl, Mad2, and Mad3 (Li and Murray,  1991), each 
of which  was  essential  for establishment  or maintenance  of the  checkpoint. 
These genes are non-essential in yeast, but the mad (mitotic arrest defective) 
and  bub  (budding  wninhibited  by  Z?enomyl)  mutants  ignore  spindle 
abnormalities  and  attempt  mitosis  regardless.  The  S.  cerevisiae  Mpsl  gene 
product,  an  essential  protein  kinase  required  for  spindle  pole  body  (SPB) 
duplication,  is  also  required  for  spindle  checkpoint  function  (Weiss  and 
Winey, 1996).
36Vertebrate homologues of several of these proteins are associated with 
the kinetochore, including Bubl  (Jablonski et a l,  1998; Taylor and McKeon,
1997), Bub3  (Taylor et al.,  1998), Madl  (Chen et al.,  1998), Mad2  (Chen et 
al.,  1996; Li and Benezra,  1996), BubRl, a protein kinase with homology to 
both  Bubl  and  Mad3  (Cahill  et  al.,  1998;  Chan  et  al.,  1999;  Taylor et al.,
1998), and Mpsl (Stucke et al., 2002).
Bub2  forms  a  separate  branch  of the  spindle  checkpoint  that plays  a 
role in the exit from mitosis (reviewed in (Gardner and Burke, 2000)).
1.2.2  Genetic instability and the spindle checkpoint
Genetic instability has been proposed to underlie neoplasia (Hartwell, 
1992;  Loeb,  1991),  and  can  occur  in  two  different  forms.  Microsatellite 
instability  (MIN)  is  the  result  of  defective  mismatch  repair  and  a 
consequentially increased mutation rate at the nucleotide level. Chromosomal 
instability  (CIN)  leads  to  an  abnormal  chromosome  number,  known  as 
aneuploidy, and has been shown to be associated with loss of function of the 
spindle checkpoint protein Bubl  (Cahill et al.,  1998). In humans, aneuploidy 
is  a  hallmark  of  spontaneous  abortions,  birth  defects  and  most  cancers 
(Hassold and Hunt, 2001; Jallepalli and Lengauer, 2001; Thomas et al., 2001). 
However,  it  has  more  recently  been  suggested  that  CIN  cells  do  in  fact 
undergo mitotic arrest in response to spindle damage, and that they possess a 
robust  spindle  checkpoint,  although  the  checkpoint  may  nevertheless  be 
compromised to some extent (Tighe et al., 2001). While mutations in spindle 
checkpoint genes are rare in human tumours, the Adenomatous Polyposis Coli 
(APC) gene is frequently mutated in CIN cells, and Tighe et al  show that an 
APC  mutant  can  compromise  the  spindle  checkpoint  response,  perhaps 
contributing to CIN. The product of the APC gene, involved in familial colon 
cancer, has been shown to form a complex with the checkpoint proteins Bubl 
and  Bub3  during  mitosis  (Kaplan  et  al.,  2001).  APC  is  a  plus-end 
microtubule-binding  protein  that  localises  to  kinetochores.  Kaplan  et  al.
31suggested that APC may be stabilising the microtubules and therefore aiding 
their  attachment  to  the  chromosomes.  This  appears  to  be  supported  by  the 
recent finding that CIN tumour cells exhibit inefficient microtubule plus-end 
attachments during mitosis, and that this is correlated with the status of APC 
(Green and Kaplan, 2003). Despite the observed interaction between APC and 
the  Bub  proteins,  APC  has  not  been  found  to  be  necessary  for the  spindle 
checkpoint,  although  phosphorylation  of  APC  by  both  Bubl  and  BubRl 
kinases may be involved in regulation of kinetochore-microtubule attachment 
(Kaplan et al., 2001).
Deletion of one allele of Mad2, Bub3  or BubRl  in mice compromises 
the  spindle  checkpoint  and  results  in  higher  rates  of  chromosome 
missegregation  and  tumour  formation,  suggesting  a  causal  relationship 
between a weakened checkpoint and carcinogenesis  arising  from CIN (Babu 
et al., 2003; Dai et al., 2004; Michel et a l, 2001). Although initial weakening 
of  the  spindle  checkpoint  might  enhance  aspects  of  CIN-mediated 
tumourigenesis,  further  weakening  or  silencing  of  the  spindle  checkpoint 
pathway  has  been  shown  to  rapidly  lead  to  cell  death,  even  in  aggressive 
cancer cell lines (Kops et al., 2004; Michel et al., 2004). Kops et al.  showed 
that depletion  of BubRl  and Mad2  (or inhibition  of BubRl  kinase  activity) 
causes  apoptotic  cell  death  within  six  divisions  in  the  cells,  except  when 
cytokinesis  had  been  inhibited  by  addition  of  a  microtubule  poison 
(cytokinesis requires overlapping microtubules from the two spindle poles for 
recruitment  of  the  component(s)  necessary  for  cleavage,  (Maddox  and 
Oegema,  2003)).  In  the  presence  of microtubule  poisons  such  as  colcemid, 
nocodazole or taxol, reduced levels of BubRl  or Mad2 were shown to permit 
progression through the cell cycle without spindle checkpoint arrest, resulting 
in  giant  cells  and nuclei  as  a  consequence  of continued  cycling.  Since  the 
survival  of  CIN  (and  MIN)  tumours  depends  on  basal  levels  of  spindle 
checkpoint  signalling,  Kops  et  al.  suggest  that  drugs  targeting  essential 
spindle checkpoint functions such as BubRl  kinase activity could selectively 
kill these tumour cells.
381,2.3  The components of the spindle checkpoint pathway
The  fine  mechanistic  details  of the  spindle  checkpoint  remain  to  be 
elucidated,  but  by  dissecting  the  functions  of the  various  members  of the 
pathway a greater understanding of this complex process can be gained. This 
section gives  a  summary of some  of the latest  findings relating to  the main 
players in the spindle checkpoint pathway.
1.2.3.1  Bubl
The  human  Bubl  (hBubl)  is  a  protein  of  1085  amino  acids,  with  a 
predicted  molecular  weight  of  122kDa  (Ouyang  et  a l,  1998).  hBubl  is 
localised  to  kinetochores  during  mitosis,  and  its  expression  is  cell  cycle 
regulated, peaking  at G2/M phase  (Taylor et al.,  2001).  The  amino-terminal 
region of hBubl  shows  significant homology to yeast Mad3,  and contains  a 
nuclear targeting signal and also a domain homologous to the tail domain of 
murine kinesin-like protein (muKIF4, a microtubule-associated motor protein, 
(Sekine  et  a l,  1994)).  hBubl  also  has  a  GLEBS-like  (GLE2p-Binding 
Sequence) motif at residues 249-264 that was shown to be sufficient for Bub3 
binding  (Wang  et  a l,  2001b).  Wang  et  al  showed  that  the  mRNA  export 
factor Rael  (also called GLE2) can also bind to this region of hBubl, and a 
separate  study  in  mouse  cells  has  suggested  that  Rael  can  cooperate  with 
Bub3  in  the  spindle  checkpoint pathway  (Babu  et  a l,  2003).  The  carboxy- 
terminus  of hBubl  contains  a kinase  domain  and  an  ATP-binding  site  (see 
Figure 1.4).
The Bubl protein is essential for spindle checkpoint function, acting as 
a  scaffold  for  recruitment  of  other  checkpoint  proteins  to  unattached 
kinetochores.  A  recent  study has  shown  that  Bubl,  Mpsl  and  CENP-E  are 
dependent  upon  each  other  for  their  kinetochore  localisation,  and  for  the 
localisation  of the  other  spindle  checkpoint  components  (Vigneron  et  al, 
2004).
39Mutations  in  the  Bubl  gene  have  been  shown  to  result  in  loss  of 
spindle  checkpoint  function,  and  are  related  to  the  chromosome  instability 
(CIN)  phenotype  in  human  neoplasias  (Cahill  et  al.,  1998;  Hempen  et  al.,
2003).  hBubl  defects  have  also been  observed in leukaemia and lymphoma 
cells (Ru et al., 2002). Inhibition of Bubl  results in a CIN phenotype as well 
as  induction  of anchorage-independent growth  in normal  human  fibroblasts, 
suggesting  that  failure  of the  spindle  checkpoint  and  resulting  aneuploidy 
could lead to transformation and tumourigenesis (Musio et al., 2003).
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Figure 1.4: The Bubl spindle checkpoint protein.
A representation of the domain structure of human Bubl protein (hBubl). 
hBubl is a protein of 1085 amino acids with a calculated molecular mass of 
122kDa. It has a carboxy-terminal kinase domain, and the amino-terminal 
section  (161  residues)  shows  a  26%  amino  acid  identity  to  the  Mad3 
protein in budding yeast. Residues 249-264 are sufficient for binding to the 
spindle checkpoint protein Bub3. There also appears to be a domain (152 
residues)  that  is  homologous  to  the  tail  domain  of murine  kinesin-like 
protein, muKIF4. In addition, the kinase domain contains an ATP-binding 
site, and there is a putative nuclear localisation signal in the amino-terminal 
region of the protein (not shown).
41The  Bubl  protein  is  a  serine/threonine  kinase,  and  mutation  of the 
carboxy-terminal kinase domain in budding yeast Bubl  results in a defective 
spindle checkpoint,  suggesting that the kinase activity of Bubl  is  critical  for 
its  function  (Roberts  et al.,  1994).  Bubl  can phosphorylate  itself as  well  as 
Bub3 (Roberts et al., 1994) and Madl  (Seeley et al.,  1999) in vitro. However, 
the  kinase  activity  of fission  yeast  Bubl  is  required  but  not  sufficient  for 
complete spindle checkpoint function (Yamaguchi et al, 2003),  and separate 
studies have shown that the protein kinase activity of Bubl  is not responsible 
for  spindle  checkpoint  arrest  induced  by  nocodazole,  a  microtubule- 
depolymerising  agent  (Sharp-Baker  and  Chen,  2001;  Warren  et  al.,  2002). 
However,  it  has  recently  been  suggested  that  the  kinase  activity  of Bubl 
modulates  the  strength  of  the  checkpoint  signal  generated  from  each 
kinetochore (Chen, 2004). In experiments using Xenopus egg extracts, kinase- 
deficient Bubl  was found to be partially compromised in checkpoint function, 
with a reduced ability to recruit other checkpoint proteins to the kinetochore 
under  conditions  of  low  spindle  damage  (when  only  a  few  or  even  one 
kinetochore  is  unattached),  whereas  under  optimal  conditions  for  spindle 
checkpoint activation,  kinase-deficient Bubl  is  sufficient for full  checkpoint 
function.  It  was  therefore  suggested  that  the  kinase  activity  of Bubl  may 
become  crucial  in  late  prometaphase  for  efficient  assembly  of the  complex 
that binds and inhibits Cdc20 at the few unattached kinetochores that remain.
Bubl  is  associated  with  Bub3  throughout  the  cell  cycle  in  budding 
yeast (Brady and Hardwick,  2000).  Studies  in human cells  have  shown that 
interaction with Bub3 is required for Bubl  to localise to kinetochores (Taylor 
et al.,  1998)  and Drosophila Bub3  fails to localise to kinetochores when the 
Bubl  gene is deleted (Basu et al.,  1998), demonstrating a mutual dependency 
between Bubl and Bub3 in kinetochore binding.
In budding yeast, there are two distinct forms of Bubl  during G1 phase 
of the cell  cycle,  and up to  five  forms  during mitosis  (Brady and Hardwick,
2000).  Lambda  protein  phosphatase  treatment  revealed  that  these  different 
forms of Bubl  are all due to phosphorylation. This modification of Bubl  was
42not enhanced by spindle  checkpoint activation.  In  contrast,  the  fission  yeast 
Bubl  protein  (“Bublp”)  is  directly phosphorylated  by  the  cyclin-dependent 
kinase (CDK) Cdc2p in response to spindle damage in mitotic cells, and this 
phosphorylation  is  necessary  for  spindle  checkpoint  activation  following 
spindle damage (Yamaguchi et al., 2003). It has also been shown that human 
Bubl  is phosphorylated when the spindle is disrupted, but not during normal 
mitosis (Taylor et al., 2001), and putative CDK sites are present in Bubl  from 
human,  mouse,  fly,  budding  yeast  and  Xenopus  laevis  (albeit  without 
conservation of CDK site position). This suggests that CDK phosphorylation 
of Bubl  might play a role in the spindle checkpoint of eukaryotes generally. 
MAPK  (mitogen-activated  protein  kinase)  also  contributes  to 
hyperphosphorylation of Xenopus Bubl  on unattached kinetochores, resulting 
in  activation  of Bubl  kinase  activity  (Chen,  2004).  Although  Cdc2  is  not 
involved in the phosphorylation of Xenopus Bubl, sequence alignment of the 
fission  yeast  and  Xenopus  Bubl  proteins  indicates  a  homologous 
phosphorylation  site  for Cdc2  in  fission  yeast Bubl  and MAPK in Xenopus 
Bubl,  suggesting  that  regulation  of  Bubl  by  phosphorylation  (albeit  not 
necessarily by the same kinases) is evolutionarily conserved (Chen, 2004).
Bubl  is required for efficient kinetochore localisation of Madl, Mad2, 
Bub3  and CENP-E  in Xenopus  (Chen,  2004;  Sharp-Baker and Chen,  2001), 
and  BubRl,  CENP-F,  CENP-E  and  Mad2  proteins  in  mammalian  cells 
(Johnson  et  al.,  2004)  (CENP-F  is  a  kinetochore  protein,  CENP-E  is  a 
kinetochore-associated  microtubule  motor  protein).  In  turn,  the  Aurora  B 
protein (as  described later)  is required for kinetochore  localisation  of Bubl. 
BubRl  was  not  required  for  kinetochore  localisation  of  Bubl,  Mad2  or 
CENP-F  in  mammalian  cells,  in  contrast  to  work  carried  out  in  Xenopus 
(Chen,  2002),  suggesting  that  some  transient  kinetochore  proteins  may  be 
recruited simultaneously in the Xenopus system. A recent study suggested that 
repression of Bubl  does not compromise spindle checkpoint function during 
either normal mitosis or in response to spindle damage (Johnson et al., 2004), 
contradictory  to  previous  observations  in  yeast,  Xenopus,  and  HeLa  cells
43(Hoyt et al.,  1991; Roberts et al.,  1994;  Sharp-Baker and Chen, 2001; Taylor 
and  McKeon,  1997).  However,  the  authors  suggested  that  this  observation 
could be caused by more than one pathway contributing to  spindle  damage- 
mediated  arrest,  with  Bubl  or Aurora  B  only  required  for  one  pathway,  or 
alternatively that inhibition of either Bubl  or Aurora B only partially inhibits 
the spindle checkpoint pathway.
Bubl  appears  to  have  functions  beyond  its  role  in  the  spindle 
checkpoint  pathway.  Bubl  may  be  involved  in  regulating  mitotic  exit  in 
response to incomplete DNA replication. This is suggested by the observation 
that  Drosophila dup  (double park)  mutants,  defective  for initiation  of DNA 
replication,  arrest at the metaphase-anaphase transition, but dup bubl  double 
mutants  do not (Gamer et al., 2001).  Bubl  is  also thought to play a crucial 
role in meiosis, preventing loss  of sister chromatid cohesion  during the  first 
meiotic  division  (meiosis  I)  of fission  yeast  (Bernard et al.,  2001).  Bubl  is 
required for centromere localisation of Sgol  (shugoshin) which is responsible 
for  protection  of  Rec8,  the  Sccl  cohesin  subunit  counterpart  in  meiosis 
(Kitajima et al., 2004). In addition, localisation of Sgo2, a paralogue of Sgol 
in fission yeast that is required for faithful mitotic chromosome segregation, 
was also shown to require Bubl.
1.2.3.2  Bub3
Bub3 is a small WD-repeat protein. The S.  cerevisiae Bub3 consists of 
seven WD-repeat domains that fold together to  form a  p-propellor structure, 
devoted to protein-protein interactions, and perhaps acting as a stable platform 
to  coordinate  sequential  and/or simultaneous  interactions  of several proteins 
(Fraschini et al., 2001;  Smith et al.,  1999). Bub3 function is required for both 
spindle  checkpoint  activation  and  for maintenance  of a  checkpoint  arrest  in 
Xenopus egg extracts (Campbell and Hardwick, 2003).
Bub3  is  associated  with  Bubl  throughout  the  cell  cycle  in  budding 
yeast  (Brady  and  Hardwick,  2000).  Xenopus  Bub3  (XBub3)  is  found  in 
complex with both XBubl  and XBubRl  kinases,  although  a  complex  of all
44three  proteins  is  not  seen  (Campbell  and  Hardwick,  2003).  The  authors 
observed that XBub3 has a diffuse nuclear localisation during interphase, and 
is  recruited to  kinetochores  during  early prophase,  prior to  the  kinetochore 
localisation  of XMad2  and XMadl.  XBub3  staining  of kinetochores  is  lost 
once all chromosomes have aligned at the metaphase plate. Bub3 protein has 
been  localised  to  kinetochores  in  a  number  of  species  when  the  spindle 
checkpoint is active (Basu et a l,  1998; Martinez-Exposito et a l,  1999; Taylor 
et al.,  1998). Bub3  forms part of the mitotic checkpoint complex (MCC) that 
inhibits APC/C when the spindle checkpoint is activated.
While  mice  heterozygous  for  the  mammalian  Bub3  gene  show  no 
apparent  abnormalities  in  development  or  fertility,  Bub3  null  mice  fail  to 
survive  beyond  day  6.5-7.5  postcoitus,  with  accumulation  of mitotic  errors 
early in development resulting in formation of micronuclei, chromatin bridges, 
lagging chromosomes and irregular nuclear morphology, similar to the defects 
seen in Mad2 null embryos (Dobles et a l, 2000; Kalitsis et a l, 2000).
1.2.3.3  Madl
Budding  yeast  Madl  is  a  90kDa  protein  that  becomes 
hyperphosphorylated  during  normal  mitosis  and  when  spindle  assembly  is 
disrupted  (Hardwick  and  Murray,  1995).  The  upstream  kinase  for  Madl  is 
likely  to  be  Mpsl,  the  overexpression  of  which  results  in 
hyperphosphorylation  of  Madl  and  a  mitotic  arrest.  However, 
phosphorylation of Madl  also requires Mad2,  Bubl  and Bub3  (Hardwick et 
a l,  1996;  Weiss  and Winey,  1996).  Madl  forms  a complex with Mad2  and 
this interaction is essential for Madl  phosphorylation in budding yeast (Chen 
et a l,  1999), and studies in Xenopus showed that Madl  is required to recruit 
Mad2 to kinetochores (Chen et a l,  1996). In addition, human Madl  binds to 
and is phosphorylated by Bubl in vitro (Seeley et a l, 1999).
The human Madl  protein was originally identified during a search for 
cellular  targets  of  the  Human  T  cell  leukaemia  virus  type  1  (HTLV-1) 
oncoprotein Tax (Jin et a l,  1998), making it the  first member of the  spindle
45checkpoint  pathway  to  be  found  in  complex  with  a  viral  oncoprotein. 
Unexpectedly, expression of human Madl  is G1 rather than M phase specific, 
and intracellular levels of Madl  correlate with the proliferative status of cells, 
both in primary and transformed cells (Iwanaga and Jeang, 2002).  The same 
study found that human Madl promoter responds to mitogenic stimuli, but not 
to  microtubule  inhibitors.  In  addition,  expression  of  human  Madl  was 
enhanced by a gain-of-function p53 mutant, suggesting that Madl  could be a 
p53  downstream  cellular  factor that  could link p53  to  aneuploidy  in  human 
cells. This was in agreement with studies showing that human Madl mRNA is 
induced more than  10-fold by p53  (Polyak et al.,  1997),  suggesting that p53 
may have  a true  spindle  checkpoint  function,  rather than  simply  serving  to 
prevent  cells  from  reinitiating  DNA  replication  following  errors  in  mitosis 
(Minn et al., 1996).
1.2.3.4  Mad2
Human  Mad2  is  a  24kDa  protein,  and  its  expression  is  cell  cycle 
regulated in  human  fibroblasts,  peaking  in  mitosis  (Hernando  et  a l,  2004). 
However, the budding yeast Mad2 protein remains at a constant level during 
the  cell  cycle  (Chen et al.,  1999).  Mad2  null  yeast  cells  are  viable but lose 
chromosomes  at  a  higher  rate  than  wild-type  cells  due  to  chromosome 
missegregation  (Li  and  Murray,  1991).  Mad2  null  mice  also  missegregate 
their  chromosomes,  but  they  lose  viability  after  day  6.5  postcoitus, 
highlighting the importance of chromosome stability for normal development 
(Dobles et al., 2000).  However,  Mad2+/-  mouse  embryonic  fibroblasts have 
enhanced chromosome instability without loss of viability, and consistent with 
this  increased  aneuploidy,  Mad2+/-  mice  are  tumour  prone  (Michel  et  al.,
2001).  Partial  reduction  in  Mad2  protein  levels  resulting  in  aneuploidy  and 
tumourigenesis is consistent with the finding that several human tumour types 
have reduced levels of Mad2 protein expression (Li and Benezra,  1996; Wang 
et al.,  2002;  Wang  et  al.,  2000).  Mad2+/-  cells  cycle  normally,  form  intact 
spindles and do not degrade  Cyclin B prematurely.  However,  in response to
46the microtubule poison nocodazole they degrade securin prematurely (but not 
Cyclin B) and exhibit premature sister chromatid separation with completely 
condensed  chromosomes,  suggesting  that  securin  and  Cyclin  B  degradation 
are uncoupled in the presence of one copy of Mad2 in these mammalian cells 
(Michel  et  al.,  2004;  Michel  et  al.,  2001).  This  had  not  been  shown  in 
mammalian cells before, but uncoupling of Pdsl  (securin) and clb2 (Cyclin B) 
destruction has been demonstrated in budding yeast, although the basis of this 
differential sensitivity of the two proteins to APC/CC dc20 in yeast is unknown 
(Wasch and Cross, 2002; Yeong et al., 2000).
Xenopus Mad2 is recruited to unattached kinetochores by Madl  (Chen 
et al., 1998). Mad2 is only a transient component of kinetochores, with a  of 
24-28  seconds  (Howell  et  al.,  2000).  Mad2  has  been  shown  to  bind 
phosphorylated  but  not  unphosphorylated  kinetochores,  suggesting  a  link 
between  attachment-sensitive  kinetochore  phosphorylation  and  the  spindle 
checkpoint (Waters et al., 1999) (see also Section 1.2.6).
Mad2 is a two-state protein that undergoes  a dramatic conformational 
change in response to Madl-binding, and adopts a very similar structure when 
bound to its molecular target, Cdc20 (Luo et al., 2002).  Luo et al  suggest a 
model in which Mad2  is recruited to unattached kinetochores via interaction 
with Madl  when the  checkpoint  is  activated.  It  is  proposed that the  Madl- 
bound Mad2 protein is then transferred to Cdc20 to allow efficient formation 
of  a  Mad2-Cdc20-containing  checkpoint  complex,  and  that  this  could  be 
facilitated by Mad2 transiently retaining its altered conformation.  The empty 
preformed ligand binding site (induced by interaction with Madl) would then 
also  be  recognised  by  Cdc20.  Immunodepletion  studies  in  Xenopus  egg 
extracts  have  shown  that  Madl-free  Mad2  protein  is  required  for 
establishment  and  maintenance  of the  spindle  checkpoint  response,  but  is 
unable to bind Cdc20,  consistent with the model that Mad2-Cdc20  complex 
formation is facilitated by kinetochore localisation of Mad2 (Chung and Chen, 
2002).  Both  Madl-bound  and  Madl-free  Mad2  are  required  for  spindle 
checkpoint  function,  and  the  ratio  between  Madl  and  Mad2  in  the  cell  is
47critical for maintaining a pool of Mad 1-free Mad2. It was suggested that Mad2 
may become activated and dissociated from Madl  at kinetochores,  and then 
replenished  by  the  pool  of Madl-free  Mad2.  The  human  Mad2  protein  is 
modified  via  phosphorylation  on  several  serine  residues  in  a  cell  cycle- 
dependent manner, and it is  only unphosphorylated Mad2  that interacts with 
Madl  or APC/CC dc20 in vivo (Wassmann et a l, 2003). It was suggested that a 
phosphorylation-dephosphorylation cycle might be required to  allow transfer 
of Mad2  from Madl  to the APC/CC dc20 complex.  Mad2  is  also a member of 
the MCC complex (along with Cdc20, BubRl and Bub3) that inhibits APC/C.
It has recently been shown that Mad2 is a direct E2F target, and is as a 
consequence expressed aberrantly in cells with pRB (Retinoblastoma protein) 
pathway  defects  (Hernando  et  al.,  2004).  The  authors  showed  that  Mad2 
expression was increased, and was expressed at high levels throughout the cell 
cycle  in  cells  with inactive pRB  (due  to  expression  of Adenovirus  El A,  or 
knockdown of pRB levels via RNAi,  as well  as in carcinoma cell lines with 
inactive  pRB).  This  can  lead  to  aneuploidy,  perhaps  as  the  result  of  a 
hyperactive spindle checkpoint.
Mad2B,  a  novel  human  gene  homologous  to  Mad2  has  also  been 
identified,  and both genes  are thought to be  derived  from a  single  ancestral 
Mad2 gene (Cahill et al.,  1999). Unlike Mad2, Mad2B does not interact with 
Madl, and has been shown to inhibit APC/CC dhl in vitro and in vivo (Chen and 
Fang, 2001; Pfleger et a l, 2001b). (See Section  1.2.3.8  for more information 
about APC/Ccdhl).
1.2.3.5  BubRl (Mad3)
The budding yeast Mad3 gene encodes a 58kDa nuclear protein that is 
not  essential  for  viability,  but  is  an  integral  component  of  the  spindle 
checkpoint (Hardwick et a l, 2000). Two regions of homology were identified 
between  the  budding  yeast  Mad3  and Bubl  proteins,  and these  regions  are 
crucial for Mad3  interaction with Bub3, Mad2  and Cdc20 proteins  (forming 
the  MCC  complex).  The  fission  yeast  Mad3  homolog  is  also  nonessential
48under  normal  growth  conditions,  but  required  for  the  spindle  checkpoint 
response  to  microtubule-depolymerising  agents  (Millband  and  Hardwick, 
2002).  Like  the  budding  yeast  Mad3,  fission  yeast  Mad3  forms  a  complex 
with  Bub3,  Mad2,  and  Slpl  (the  fission  yeast  Cdc20  homolog).  Genetic 
evidence  also  suggests  that  Mad3,  along  with  Mad2  plays  a  crucial  role  in 
inhibition  of APC/C,  and  showed  that  Mad3  is  functioning  either  with  or 
downstream of Mad2 to carry out this inhibition.
BubRl  is  a mammalian  Bubl  and Mad3  homolog.  hBubRl  (human 
BubRl)  is a  120kDa protein, identified by Cahill et al  (Cahill et a l,  1998), 
and is an essential component of the spindle checkpoint required for mitotic 
arrest  in  response  to  microtubule  inhibitors  (Chan  et a l,  1999).  Unlike  the 
yeast Mad3 proteins, BubRl  is also necessary for normal mitotic progression 
as it prevents cells from prematurely entering anaphase.
Complete  loss  of BubRl  causes  early  embryonic  lethality,  but  mice 
with low  levels  of BubRl  protein have  been  shown  to  develop progressive 
aneuploidy  along  with  early  onset  of  several  aging-associated  phenotypes 
including  a  severely  shortened lifespan,  and  infertility  (Baker  et  a l,  2004). 
The rate  of tumours  in mice  with lowered BubRl  expression  was  very  low 
despite  substantial  chromosome  number  instability,  an  unexpected  finding 
because aneuploidy is a hallmark of most human cancers, and because BubRl 
is also known to be mutated or expressed at low levels in a subset of colorectal 
carcinomas  with  CIN  (Cahill  et  a l,  1998;  Shichiri  et  a l,  2002).  BubRl 
expression was also shown to decline with age in several tissues of wild-type 
mice, indicating that BubRl may be a key regulator of normal aging (Baker et 
a l, 2004). BubRl haploinsufficiency in mouse embryonic fibroblasts has also 
been  shown  to  result  in  a  compromised  spindle  checkpoint,  along  with 
significantly  reduced  expression  levels  of  securin  and  Cdc20  (Dai  et  a l,
2004).
Mammalian BubRl  has a C-terminal kinase domain, whereas Mad3  of 
both  budding  and  fission  yeast  lack  this  domain  (Millband  and  Hardwick,
2002).  Human  BubRl  (hBubRl)  is  cell  cycle  regulated,  increasing
49significantly in  late  S  phase  and  G2  (Li  et a l,  1999).  Although hBubRl  is 
present throughout the cell cycle its kinase activity is detected only after cells 
have entered mitosis. The phosphorylation status of hBubRl  is also regulated 
during spindle disruption.
hBubRl  is  associated  with  p55Cdc  (the  human  homolog  of Cdc20), 
and  in  response  to  spindle  damage  this  interaction  is  enhanced  and  BubRl 
phosphorylates  p55Cdc  (Wu  et  a l,  2000).  BubRl  also  associates  with  the 
kinetochore-associated kinesin motor protein CENP-E (Chan et a l, 1998), and 
spindle checkpoint activation or silencing was shown to be mediated through 
CENP-E-dependent  activation  or  inactivation  of the  BubRl  kinase  (Mao  et 
al,  2003).  In  addition,  it  has  recently  been  shown  that  BubRl  (or  Mad2) 
inactivation  results  in  an  accelerated  mitosis,  and  that  this  regulation  of 
mitotic  timing  is  kinetochore-independent  (Meraldi  et  al,  2004a).  It  was 
proposed that BubRl  and Mad2 might be essential for restraining the onset of 
anaphase at a point early in mitosis when the kinetochores are still assembling. 
Finally, BubRl  mutation has recently been linked to the rare human disorder 
mosaic variegated aneuploidy, which has a high risk of malignancy (Hanks et 
al, 2004).  This  supports the suggestion of a causal link between aneuploidy 
and cancer development.
1.2.3.6  Mpsl
The  founding  member  of the  Mpsl  kinase  family  in  Saccharomyces 
cerevisiae, Mpslp, regulates many cell cycle-related processes, including the 
duplication  of the  spindle  pole  body  (SPB)  (Winey  et  al,  1991),  and  the 
spindle checkpoint (Weiss and Winey, 1996). Spindle checkpoint activation in 
yeast leads to Mpsl-dependent hyperphosphorylation of Madl  and formation 
of  a  Madl-Bub 1-Bub3  complex,  a  crucial  step  in  the  spindle  checkpoint 
mechanism  (Brady  and  Hardwick,  2000;  Hardwick  et  al,  1996).  Mpsl  is 
highly  homologous  to  a  previously  identified  human  gene  TTK,  now  re­
named hMpsl  (Fisk and Winey, 2001; Mills et al,  1992). However, while the 
human Mpsl  kinase is required for the spindle checkpoint, it is not necessary
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hMpsl  is  a  cell  cycle  regulated  protein,  with  maximal  protein  levels  and 
kinase activity occurring during mitosis. hMpsl  is  found in both the nucleus 
and  cytoplasm  of  interphase  cells,  and  localises  to  kinetochores  during 
mitosis.
Mpsl  is  required  for kinetochore  recruitment  and retention  of active 
CENP-E  protein  in  Xenopus  egg  extracts,  which  in  turn  is  necessary  for 
kinetochore  association  of the  Madl/Mad2  complex  (Abrieu  et  al.,  2001). 
Heel,  a  mammalian  homolog  of the  budding  yeast  kinetochore-associated 
protein Ndc80p, is required for the kinetochore association of Mpsl, and both 
Heel  and  Mpsl  are  necessary  for recruitment  of the  Madl/Mad2  complex 
(Martin-Lluesma et al., 2002).
1.2.3.7  CENP-E
Centromere-associated  protein-E  (CENP-E)  is  a  large  (~300kDa) 
kinetochore-associated,  kinesin-like  microtubule  motor  protein  that 
accumulates in G2 and is degraded in telophase (Brown et al.,  1994). CENP-E 
also  binds  to  both  spindle  microtubules  and  to  the  kinetochore-associated 
checkpoint kinase BubRl  (Chan et al.,  1998; Putkey et a l, 2002; Yao et al, 
2000). Human CENP-E is detectable only in the cytoplasm of interphase cells 
(Yen et al,  1992), whereas Xenopus CENP-E is  a nuclear protein (Wood et 
al,  1997). However, in both cases CENP-E is localised to kinetochores very 
early in mitosis.
CENP-E  is  required  for  the  establishment  and  maintenance  of  the 
spindle checkpoint in Xenopus egg extracts  (Abrieu et al, 2000).  Disruption 
of  CENP-E  function  by  immunodepletion  results  in  failure  to  arrest  in 
response to spindle damage, although the mitotic arrest is restored by addition 
of high levels of the Mad2 protein.  This demonstrated that although CENP-E 
is necessary in Xenopus extracts for kinetochore-dependent signalling, it is not 
required  for  signal  transduction  further  downstream  in  the  checkpoint 
pathway.  Paradoxically,  inhibition  of  CENP-E  function  in  mammalian
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CENP-E  function  resulting  in  a  G2/M  arrest  due  to  a  chronically  activated 
spindle  checkpoint  (Chan  et  al.,  1999;  Yao  et  al.,  2000).  In  the  Xenopus 
system  depletion  of  CENP-E  prevents  the  association  of  Mad2  with 
kinetochores, and thus blocks the activation of Mad2  at kinetochores not yet 
attached to  the  mitotic  spindle  apparatus.  Conversely,  in  human  HeLa  cells 
removal  of  CENP-E  leaves  active  BubRl  and  Mad2  in  association  with 
unattached kinetochores, perhaps offering an explanation for the discrepancy 
seen  between  the  two  model  systems.  However,  a  more  recent  study  has 
demonstrated  that  CENP-E  is  essential  for  spindle  checkpoint  function  in 
mammalian  cells,  with  single  unattached  kinetochores  depleted  of CENP-E 
being unable to block entry into anaphase, resulting in aneuploidy (Weaver et 
al.,  2003).  CENP-E  enhanced the recruitment  of BubRl  to  each unattached 
kinetochore, and stimulated BubRl kinase activity.
These  discrepancies  in  CENP-E  function  are  probably  a reflection  of 
species-specific  distinctions  between  the  spindle  checkpoint  of  frogs  and 
mammals or perhaps the difference between the meiotic state of egg extracts 
and  the  mitotic  state  of  cultured  cells.  Although  the  spindle  checkpoint 
pathway is  itself widely conserved,  its  individual  components  are not and a 
prime  example  of this  is  the  absence  of a  CENP-E-like  protein  in  budding 
yeast. Also, the BubRl  protein with which CENP-E directly interacts is itself 
an apparent fusion of yeast Mad3 with the kinase domain of Bub 1   (Taylor et 
al.,  1998).  Nevertheless,  CENP-E  is  a  key  vertebrate  spindle  checkpoint 
component that links checkpoint signalling to the binding of microtubules to 
sister chromatids.
1.2.3.8  APC/C
The  anaphase  promoting  complex/cyclosome  (APC/C)  is  a  multi­
subunit  complex  that  acts  as  an  E3  ubiquitin  ligase,  targeting  proteins  for 
destruction by the 26S proteasome. It functions at the metaphase to anaphase 
transition,  as  well  as  in  late  mitosis,  G1  and  in  differentiated  cells.  APC/C
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(Vodermaier,  2001)).  APC/CC dc20  and  APC/CC dhl  appear  to  have  different 
substrate specificities  (Visintin et al.,  1997).  APC/Ccdc20 may target proteins 
such  as  securin  whose  destruction  is  required  at  the  metaphase-anaphase 
transition, while APC/CC dhl may be targeting proteins such as Cyclin B whose 
degradation  is  important  for  mitotic  exit.  In  vitro,  APC/CC dc20  recognises 
proteins  that  contain  a  destruction box  (D-box),  a  loosely  conserved  motif 
with  the  consensus  RxxLxxxxN,  whereas  APC/CC dhl  is  able  to  recognise 
proteins  with  either  a  D-box  or  a  KEN  box  (a  general  targeting  signal  for 
APC/CC dhl  composed  of  the  amino  acid  sequence  K-E-N)  (Pfleger  and 
Kirschner, 2000).
1.2.3.9  p55Cdc (Cdc20f
Cdc20  serves  as  a  substrate  receptor  for  APC/C,  targeting 
securin for degradation by APC/C (Hilioti et al., 2001; Pfleger et al., 2001a). 
The  level  of Cdc20  is  cell  cycle  regulated,  rising  in  S  phase,  peaking  in 
mitosis,  and declining upon exit  from mitosis  in both yeast and mammalian 
cells  (Kramer  et  al.,  2000;  Prinz  et  al.,  1998;  Shirayama  et  al.,  1998; 
Weinstein,  1997).  The  spindle  checkpoint prevents  activation  of APC/C  by 
Cdc20,  thus  blocking  anaphase  onset.  Mad2  is  an  interacting  protein  for 
Cdc20 in both budding and fission yeast (the fission yeast Cdc20 homolog is 
called  Slpl)  (Hwang  et  al.,  1998;  Kim  et  al.,  1998).  Mutations  in  Slpl  or 
Cdc20  that  disrupt  their  interaction  with  Mad2  result  in  a  compromised 
spindle  checkpoint.  Cdc20  is  also  found  in  complex  with  Mad2,  Bub3  and 
Mad3/BubRl  from  various  organisms,  forming  the  mitotic  checkpoint 
complex  (MCC)  that  inhibits  APC/C  in  vitro  (Fang,  2002;  Fraschini  et  al., 
2001;  Hardwick et al,  2000;  Millband and Hardwick,  2002;  Sudakin et al., 
2001; Yu, 2002).
In vitro CDKl-phosphorylated Cdc20 has been shown to interact with 
Mad2 rather than APC/C, suggesting that CDK activity is required to restrain
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a l, 2003).
p55Cdc is the mammalian homolog of Cdc20 (Weinstein et al.,  1994), 
but is also related to the Cdhl protein  (another substrate receptor for APC/C). 
The  p55Cdc  protein  is  degraded  by  APC/CC dhl  during  late  mitosis,  and 
recognition of p55Cdc by APC/C depends  on the presence  of a KEN box in 
the p55Cdc protein (Pfleger and Kirschner, 2000).
1.2.3.10  Securin
The budding yeast securin is called Pdsl, and is an anaphase inhibitor 
that plays an essential role in both the spindle checkpoint and DNA damage 
pathways  (Yamamoto  et al.,  1996a;  Yamamoto  et  al.,  1996b).  In  the  DNA 
damage  checkpoint,  Pdsl  is required  for inhibition  of cytokinesis  and DNA 
replication  as  well  as  anaphase.  In  the  spindle  checkpoint  pathway,  Pdsl 
inhibits  sister  chromatid  separation  by  binding  and  inhibiting  the  separase 
protein Espl  (Ciosk et al.,  1998), a cysteine protease that causes cleavage of 
the cohesin Sccl  that binds sister chromatids together (Uhlmann et al.,  1999; 
Uhlmann et al., 2000). In fission yeast, the securin protein is called Cut2, and 
the  separase  is  called  Cutl.  The  vertebrate  separase  is  called  separin.  No 
sequence  similarity has been  found between  Pdsl  and Cut2,  or between the 
yeast  and vertebrate  securin proteins,  although the vertebrate  securins  share 
sequency similarity with each other (Zou et al., 1999).
The human securin was identified via its association with the putative 
human separin, and is the product of the pituitary tumour transforming gene, 
PTTG-1  (also  known  as  hPTTG)  (Zou  et  al.,  1999).  Human  securin  is 
regulated  in  a  cell  cycle-dependent  manner,  peaking  in  mitosis,  and  is 
phosphorylated  by  Cdc2  (also  known  as  CDK1)  during  mitosis  (Ramos- 
Morales et al., 2000). Human securin, like Pdsl  and Cut2, is required not only 
to inhibit the separase but also to generate the active form of the separase, and 
is essential for maintenance of euploidy  (i.e. a chromosome number that is an
54exact multiple of the haploid number for the species) (Jallepalli et al., 2001). 
It has been shown that human  securin can be ubiquitinated in  vitro  by both 
APC/CC dc20  and  APC/CCdhl,  and  that  both  a  destruction  box  (D-box)  and  a 
KEN box within the  securin protein have  to  be  mutated to  generate  a non- 
degradable protein (Zur and Brandeis, 2001). Destruction of both securin and 
Cyclin  B1  is  initiated  at  the  beginning  of  metaphase,  well  before  sister 
chromatid separation, but degradation of a mutant form of securin lacking its 
D-box has been shown to occur later in mitosis,  at anaphase (Hagting et al.,
2002). This destruction required a KEN box in the amino terminus of securin, 
perhaps  indicating  the  time  in  mitosis  when  ubiquitination  switches  from 
APC/Ccdc20 to APC/Ccdhl.
In budding yeast, mitotic arrest in response to DNA damage that occurs 
in metaphase is achieved by maintaining abundance of Pdsl  (Sanchez et al.,
1999).  It has been shown that Pdsl  is phosphorylated by Chkl  (a conserved 
kinase that plays a critical role in the DNA checkpoint pathways) in response 
to  DNA  damage  but  not  spindle  disruption  (Wang  et  al.,  2001a).  This 
phosphorylation stabilises Pdsl  without alteration of APC/Ccdc20 activity. The 
human  securin protein  (hPTTG)  has  also been  implicated in  DNA  damage- 
response pathways by virtue of interaction with Ku, the regulatory subunit of 
the  DNA-dependent  protein  kinase  (DNA-PK),  involved  in  repair  of DNA 
double-strand breaks  (DSBs)  (Romero et al.,  2001).  In addition,  Zhou et al. 
have recently shown that human securin is a p53  target gene and may play a 
role in the p53-mediated DNA damage response pathway (Zhou et al., 2003).
1.2.3.11  Aurora kinases
Aurora kinases have been shown to play critical roles in chromosome 
segregation  and  cell  division,  including  roles  in  the  spindle  checkpoint 
(reviewed  in  (Meraldi  et  al.,  2004b)).  This  subfamily  of  serine-threonine 
kinases comprises three members in mammals, Aurora A, B and C, each with 
a different expression pattern,  subcellular localisation and timing of activity.
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frequently altered in human tumours.
The Aurora A gene is commonly amplified in epithelial malignancies, 
and Aurora A overexpression,  found in breast, colorectal and gastric cancers 
(up  to  62%  of breast  cancers  overexpress  Aurora A),  has  been proposed to 
constitute  an  alternative  mechanism  for  spindle  checkpoint  dysregulation 
during  carcinogenesis  (Anand  et  al.,  2003;  Miyoshi  et  al.,  2001).  Cells 
overexpressing  Aurora  A  entered  anaphase  despite  defective  spindle 
formation  and  persistence  of  Mad2  at  kinetochores  indicating  continued 
spindle checkpoint activation (Anand et al., 2003). These abnormalities were 
suppressed by expression of a truncated (trans-dominant inhibitor) form of the 
Bubl  protein.  This  suggested  that  Aurora  A  overexpression  is  perturbing 
processes  that  are  normally  carried  out  or  monitored  by  Bubl,  resulting  in 
instability of chromosome number during cell division.  A separate study has 
shown that Aurora A overexpression is compromising the spindle checkpoint 
triggered by nocodazole by disrupting formation of the MCC (BubRl-Mad2- 
Bub3-Cdc20)  complex,  but  that  this  is  independent  of  Aurora  A  kinase 
activity (Jiang et al., 2003). The results support a hypothesis in which Aurora 
A antagonises BubRl function in spindle checkpoint regulation.
Aurora B  is  also proposed to regulate the  spindle  checkpoint,  among 
other functions, and forms a tight complex with two proteins, INCENP (inner 
centromere protein) and survivin, although the precise role of this complex in 
spindle  checkpoint  signalling  is  unknown.  Aurora  B  controls  kinetochore 
localisation  of both  motors  and  checkpoint  components,  including  dynein, 
CENP-E, BubRl  and Mad2 (Ditchfield et al., 2003; Hauf et al., 2003; Kallio 
et al., 2002b;  Lens et al., 2003;  Murata-Hori  and Wang, 2002).  Aurora B  is 
also required for kinetochore localisation of Bubl, and it has been suggested 
that Aurora B increases the affinity of BubRl  and CENP-E for Bubl-positive 
kinetochores (Johnson et al., 2004).
561,2,4  Spindle checkpoint  function in a normal cell division
Many  studies  have  provided  evidence  in  favour  of activation  of the 
spindle checkpoint in each and every' mitosis.
In  budding  yeast,  Bub3,  Bubl  and  Madl  form  a  complex  upon 
checkpoint activation, but this complex is also found during a brief period of a 
normal  cell  cycle  (unperturbed by microtubule poisons  such  as  nocodazole) 
(Brady and Hardwick,  2000).  It was  suggested that this  could be the period 
when  the  newly  replicated  centromeres  have  not  yet  formed  stable 
kinetochore-microtubule  interactions.  The  authors  demonstrated  that  this 
complex formation was due to activation of the spindle checkpoint rather than 
cell cycle position by comparing levels of the complex in nocodazole-arrested 
cells with the level seen in cdc26A metaphase arrest.  Cdc26 is a subunit of the 
anaphase promoting complex (APC/C) and cdc26A cells have inactive APC/C 
at their restrictive temperature, resulting in metaphase  arrest.  High levels  of 
Madl-Bub 1-Bub3  were  detected  in  the  nocodazole-arrested  cells,  whereas 
very little was seen in the metaphase arrest in the cdc26A cells, in which the 
spindle  microtubules  would have been  attached to kinetochores.  It has been 
suggested that formation of a Bub3-Bubl-Madl  complex causes the release of 
Mad2 from Madl  (Brady and Hardwick, 2000;  Sironi et al., 2001). A similar 
Madl-Bub 1-Bub3  complex was  also  observed in  in  vitro  experiments  using 
recombinant mammalian proteins (Seeley et al., 1999).
The spindle checkpoint protein hBubRl has been shown to be essential 
during a normal mitosis, as it prevents cells from exiting mitosis prematurely 
(Chan et al., 1999).
In  addition,  disruption  of Bubl  or Mad2  function  accelerates  mitotic 
exit  in  human  cells,  suggesting  that  spindle  checkpoint  function  may  be 
required  to  complete  normal  somatic  cell  divisions  (Gorbsky  et  al.,  1998; 
Michel  et al.,  2001;  Taylor and McKeon,  1997).  Inactivation  of the  spindle 
checkpoint by targeting Mad2  with RNAi  (RNA interference) has  also been 
shown  to  result  in  a  consistently  shortened  mitosis  in  mammalian  cells,
57providing direct evidence that the internal mitotic timing mechanism is much 
faster in cells that lack the spindle checkpoint and indicating a more general 
requirement for the spindle checkpoint, beyond its role in correcting errors in 
mitosis (Jones et al., 2004).
However,  a  recent  study  has  shown  that  while  all  known  spindle 
checkpoint proteins  are recruited to kinetochores  during a normal mitosis in 
animal cells, in contrast, only Bubl  and Bub3 bind kinetochores in a normal 
cell cycle in budding yeast, with Madl and Mad2 only binding kinetochores in 
the presence of spindle damage or kinetochore lesions (Gillett et al., 2004).
1.2.5  Activation of the checkpoint in response to spindle damage
The microtubule poisons taxol, nocodazole, and the colchicine relative 
colcemid  all  block  normal  chromosome  segregation,  activating  the  spindle 
checkpoint and causing cell cycle arrest in mitosis (reviewed in (Peterson and 
Mitchison,  2002)).  Taxol  stimulates  microtubule  polymerisation,  while 
nocodazole and colcemid are microtubule-depolymerising agents. However, at 
low  (nanomolar)  concentrations,  nocodazole  has  been  shown  to  stabilise 
microtubules,  causing  spindle  checkpoint  activation  by  suppressing 
microtubule  dynamic  instability  (the  alternating  periods  of  microtubule 
elongation  and  shortening),  a  process  required  for  efficient  mitotic  spindle 
assembly  (Vasquez  et  al.,  1997).  Perhaps  at  low  drug  concentrations 
kinetochore-microtubule  attachment remains  largely unaffected,  but the  loss 
of microtubule dynamic instability results in lack of tension across the paired 
kinetochores, leading to spindle checkpoint activation (see also Section 1.2.6). 
Nocodazole is structurally related to benomyl, the microtubule-polymerisation 
inhibitor  that  was  used  in  the  initial  genetic  screens  in  S.  cerevisiae  that 
identified the Bub and Mad spindle checkpoint components (Hoyt et al., 1991; 
Li and Murray,  1991), and is frequently used to study the spindle checkpoint 
pathway.  In  addition,  nocodazole  is  used  to  conveniently  synchronise  cells 
because the arrest that it induces is reversible. Once cells have accumulated in
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induced microtubule-depolymerisation, they can be synchronously released by 
removing the compound from the media.
The spindle checkpoint can also be activated without directly affecting 
microtubule dynamics by use of the Eg5 kinesin inhibitor monastrol (Kapoor 
et  al.,  2000).  Instead  of bipolar  spindles,  monastrol-treated  cells  produce 
monoastral  spindles,  resulting  in  syntelic  (mono-oriented)  kinetochore- 
microtubule attachments that lack tension (Mayer et al.,  1999), thus activating 
the spindle checkpoint, as will be discussed further in Section 1.2.6.
In  addition,  it  has  been  shown  that  the  spindle  checkpoint  can  be 
activated  in  response  to  substantial  DNA  damage  (Mikhailov  et al.,  2002). 
The delay in mitosis observed is not due to the ATM-mediated DNA damage 
checkpoint pathway (reviewed in (Motoyama and Naka, 2004)), but is caused 
by  defects  in  kinetochore  attachment  and  function  due  to  the  presence  of 
damaged DNA.
1.2.6  The spindle checkpoint signal: tension vs. attachment
The  spindle  checkpoint  can  detect  a  broad  range  of spindle  defects, 
from the presence of a single unattached kinetochore, to the massive defects 
induced by microtubule-depolymerising drugs such as nocodazole.  There are 
two  models  for  generation  of  a  “wait  anaphase”  signal  by  unattached 
kinetochores,  leading to activation of the spindle  checkpoint:  the  absence  of 
tension  at kinetochores  vs.  the  simple presence  of even  a  single  unattached 
kinetochore. Alternatively, both attachment and tension could be monitored by 
the spindle checkpoint (Skoufias et al., 2001).
The  argument  for  tension  being  the  signal  was  provided  by  studies 
using mantid spermatocytes (Li and Nicklas,  1995; Li and Nicklas,  1997). In 
these  cells  the  presence  of  a  single  mono-oriented  sister  chromatid  pair 
prevents progression into  anaphase,  due to  arrest by the  spindle  checkpoint. 
However, cells were found to proceed into anaphase when tension was applied
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antibody that recognised an unidentified phosphoepitope  (3F3/2) was  shown 
to bind to the unattached chromosome, but antibody binding was  eliminated 
when tension was introduced via a microneedle, suggesting that it is the lack 
of physical  tension  that  is  translated  into  a  chemical  signal  that  leads  to 
phosphorylation  changes  on  kinetochore-associated  proteins.  The  3F3/2 
phosphoepitope  may  be  regulated  by  the  mitogen-activated  protein  (MAP) 
kinase ERK (extracellular signal-regulated protein kinases  1  and 2: ERK1  and 
ERK2) at unattached kinetochores (Shapiro et al., 1998). It was suggested that 
CENP-E could be the tension-sensitive 3F3/2 phosphoepitope at kinetochores, 
because  MAP  kinase  can phosphorylate  CENP-E  in  vitro  at  sites  known  to 
regulate its interactions with microtubules (Chen, 2004; Zecevic et al.,  1998). 
3F3/2  has  also  been  shown  to  bind  directly  to  M-phase-specific 
phosphorylations on one or more components of the APC/C,  suggesting that 
the  checkpoint-sensitive  staining  of 3F3/2  at  kinetochores  could  be  due  to 
kinetochore  localisation  of APC/C  (Acquaviva  et  al.,  2004;  Daum  et  al., 
2000).
Alternatively,  in  favour  of the  other model  of checkpoint  activation, 
loss  of  tension  at  kinetochores  is  not  sufficient  to  localise  the  spindle 
checkpoint  components  Mad2  and  Bub3  to  kinetochores  in  vertebrate  cells 
(Martinez-Exposito et al.,  1999; Waters et al.,  1998). Treatment of cells with 
the microtubule poison taxol leads to loss of tension at kinetochores but does 
not  disturb  kinetochore-microtubule  attachment.  In  cells  treated  with  taxol, 
3F3/2 localises to all kinetochores, whereas Mad2 and Bub3 were only found 
to  localise  to  kinetochores  not  yet  attached  to  spindle  microtubules.  In 
addition,  Skoufias  et  al.  have  shown  that  mammalian  Bubl  and  BubRl 
respond  to  lack  of  tension,  while  Mad2  responds  specifically  to  lack  of 
microtubule attachment at kinetochores (Skoufias et al., 2001).
However, a slightly different observation has been made in Drosophila 
cells,  where  Mad2  and  Bubl  have  been  shown  to  monitor  microtubule 
occupancy at the kinetochore, while BubRl  and Bub3 monitor tension across
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be  recruited to  some  kinetochores  in  which both  sisters  are  attached to  the 
same spindle pole, suggesting that the checkpoint is activated, possibly via a 
lack of tension, despite the presence of attached microtubules (Kapoor et al., 
2000).  The  authors  therefore  suggest  that  Mad2  may  be  sensing  a  subtler 
aspect of microtubule attachment such as the exact number of microtubules at 
the kinetochore  or  even  the  dynamic  behaviour  of kinetochores.  It  has  also 
been  proposed  that  binding  of  Mad2  is  governed  by  tension-sensitive 
kinetochore phosphorylation (in addition to lack of microtubule  attachment), 
whereas loss of Mad2 from kinetochores is largely governed by accumulation 
of kinetochore microtubules (Waters et al., 1999).
Absence  of tension  is  sufficient to  activate  the  spindle  checkpoint  in 
budding yeast (Stem and Murray, 2001). However, a recent paper has shown 
that  both  tension-sensitive  and  attachment-sensitive  spindle  checkpoint 
pathways operate in budding yeast (Kitagawa et al., 2003). It was shown that 
Bubl  associates with centromeric DNA via Skpl, a protein located within the 
core  of the  kinetochore,  and while  this  interaction was  required  for mitotic 
delay in response to outer kinetochore or cohesion defects (lack of tension), it 
was  not  required  for  the  response  to  spindle  depolymerisation  (lack  of 
attachment).  The  authors  therefore  suggested  that  at  least  two  different 
checkpoint signals are generated at the kinetochore of budding yeast, one for 
microtubule attachment (independent of Bubl-Skpl  interaction),  and one  for 
later events (dependent on Bubl-Skpl  interaction, assessing tension). Also, a 
recent  study has  shown  that  Madl  and  Mad2  are  required  for  detection  of 
bipolar  orientation  and/or  tension  at  budding  yeast  kinetochores,  whereas 
Mad3 is not (Lee and Spencer, 2004).
Finally,  Aurora B  kinase  also  appears to be  involved in  sensing both 
tension  and  attachment.  Aurora  B  is  thought  to  destabilise  syntelic  (mono­
oriented) microtubule kinetochore interactions in a tension-sensitive manner, 
thereby  favouring  bipolar  attachments  (Buvelot  et  al.,  2003;  Dewar  et  al., 
2004; Tanaka et al., 2002). Aurora B is also required for checkpoint activation
61in  response  to  impaired  microtubule  attachment  in  metazoan  cells,  perhaps 
reflecting  the  role  of  Aurora  B  in  kinetochore  assembly  (Meraldi  et  al., 
2004b).
1.2.7  Models for generation  of the  “wait anaphase”,  spindle  checkpoint
signal
Two models currently exist for how unattached kinetochores produce a 
diffusible signal in the cytoplasm that prevents activation of APC/CC dc20.
The  “catalytic  model”  suggests that transient  association  of Cdc20  or 
its inhibitors with unattached kinetochores catalyses formation of the BubRl- 
Bub3-Mad2-Cdc20 (MCC) complex, resulting in inactivation of Cdc20 in the 
cytoplasm  (Gorbsky  et al.,  1998;  Howell  et al.,  2000;  Kallio  et  al.,  1998; 
Kallio et al., 2002a) (see Figure 1.5, Panel A).
Alternatively,  the  “APC/C  sensitisation  model”  suggests  that 
checkpoint-active  kinetochores  sensitise  the  APC/C  to  inhibition  by 
cytoplasmic  MCC,  perhaps  by  phosphorylation  (Sudakin  et al.,  2001)  (see 
Figure  1.6,  Panel  B).  The  MCC  was  shown  to  be  present  and  active  in 
interphase cells, indicating that it is not generated from kinetochores, but only 
APC/C  from  mitotic  cells  was  sensitive  to  inhibition  by  MCC.  This  could 
occur via rapid exchange of APC/C with kinetochores, as there has been some 
evidence  for APC/C  kinetochore  localisation  in  the  literature  (Acquaviva  et 
al., 2004; Huang and Raff, 2002; Jorgensen et al.,  1998; Topper et al., 2002; 
Tugendreich  et al.,  1995).  Mpsl  also  binds  APC/C  (Liu  et al.,  2003),  and 
could  therefore  perhaps  be  the  diffusible  “wait  anaphase”  signal  from  an 
unattached  kinetochore  responsible  for  sensitising  APC/C  to  inhibition  by 
MCC.
A  recent  study  has  provided  data  with  elements  in  support  of both 
models  for  the  spindle  checkpoint  pathway  (Howell  et  al.,  2004).  FRAP 
(fluorescence  recovery  after  photobleaching)  experiments  in  PtK.2  (Potoroo 
kidney  epithelial)  cells  showed  that  Madl  and  Bubl  are  relatively  stable
62components  of  the  kinetochore,  and  unlikely  to  form  part  of  the  “wait 
anaphase”  signal,  whereas  both  BubRl  and  Mad2  (Cdc20  inhibitors)  cycle 
rapidly on and off unattached kinetochores but are depleted from kinetochores 
that  have  formed  a  bipolar  attachment  with  the  mitotic  spindle  apparatus. 
Cdc20 was also found to cycle rapidly through kinetochores, with 50% of the 
Cdc20 bound to unattached kinetochores also bound to Mad2.
63Figure  1.5:  Models  for  generation  of the  “wait  anaphase”  spindle
checkpoint signal.
Two models exist for how unattached kinetochores produce a diffusible 
signal in the cytoplasm that prevents activation of APC/Ccdc20. In Model 
A, the unattached kinetochore acts as a template to catalyse formation of 
the  BubRl -Bub3-Mad2-Cdc20  complex  (mitotic  checkpoint  complex, 
MCC), which then diffuses away from the kinetochore to inhibit APC/C. 
In  Model  B,  APC/C  is  modified  by  the  unattached  kinetochore, 
promoting its association with MCC complex that is already present in 
the cytoplasm, leading to inhibition of APC/C. (Adapted from Bharadwaj 
and Yu, 2004).
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Figure  1.5:  Models  for  generation  of the  “wait  anaphase”  spindle 
checkpoint signal.
65This fraction of (Mad2-bound) Cdc20 dissociated from kinetochores with the 
same kinetics as the other MCC components, BubRl  and Bub3, in support of 
the catalytic model, in which Cdc20-Mad2 and MCC complexes are produced 
at  the  kinetochore,  resulting  in  inhibition  of APC/CC dc20.  Howell  et al  also 
reported  much  faster  kinetics  of Cdc20,  BubRl  and  Mpsl,  data  that  may 
support the APC/C  sensitisation model,  in  which kinetochores  modify these 
components  to  promote  formation  of  Cdc20  inhibitory  complexes  in  the 
cytoplasm.  In  a  similar  study,  Shah et al.  used the  same  technique  (FRAP), 
also  in  PtK2  cells,  and  showed  that  not  only  Madl  and  Bubl,  but  also  a 
portion  of the  Mad2  in  the  cell  is  stably  bound  to  unattached  kinetochores 
(Shah  et  al.,  2004).  While  Madl  and  Mad2  were  released  following 
microtubule  attachment  of kinetochores,  Bubl  remained  kinetochore-bound. 
Their  data  supports  the  model  in  which  an  unattached  kinetochore  and  its 
associated  proteins  acts  as  a  catalytic  platform  for  producing  a  Mad2- 
containing “wait anaphase” signal.
However,  in disagreement with others (Sudakin et al., 2001),  Tang et 
al.  have  shown  that  Mad2  is  not  present  in  a  mitotic  checkpoint  complex 
identified  in  HeLa  cells,  and  that  a  BubRl-Bub3-Cdc20  complex  inhibits 
APC/C independently of Mad2 (Tang et al., 2001). Mad2 and BubRl  may be 
acting in parallel pathways and sequester different pools of Cdc20 to block the 
activation of APC/C, in agreement with the suggestion that Mad2 might sense 
attachment  of  microtubules  to  kinetochores,  while  BubRl  might  be 
responding to lack of tension at kinetochores (Skoufias et al., 2001).
1.2.8  Silencing the spindle checkpoint
Once  all  of the  chromosomes  in  a  cell  are  properly  aligned  on  the 
metaphase plate the spindle checkpoint must be silenced to allow progression 
to anaphase. There are some clues to the mechanisms that lead to this spindle 
checkpoint silencing.
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implicated  in  this  process  by  studies  in  Drosophila  neuroblasts  and 
mammalian  PtKi  cells  (Howell  et  al,  2001;  Wojcik  et  al.,  2001).  It  was 
suggested  that  dynein  might  function  to  switch  off  the  checkpoint  by 
transporting  checkpoint  proteins  (including  Mad2  and  BubRl)  from  the 
kinetochores to the spindle poles, thus abolishing the wait anaphase signal.
However,  the  existing  cytoplasmic  APC/C  inhibitory complexes  such 
as MCC must also be dismantled for the spindle checkpoint to be silenced. A 
yeast two-hybrid screen has  identified a novel human Mad2-binding protein 
called  p31com et  (formerly  known  as  Cmt2,  but  now  named  p31com et  for  its 
comet tail-like cellular localisation pattern in mitosis) that may play a role in 
checkpoint  silencing  (Habu  et  al.,  2002).  The  association  of p31com et  with 
Mad2 coincides with the dissociation of the Mad2-Cdc20 interaction in HeLa 
cells. Also, depletion of p31com et by RNA interference (RNAi) results in cells 
escaping  a  spindle  checkpoint-mediated  arrest  with  significantly  slower 
kinetics (Xia et al, 2004).  It was suggested that p31com et functions in spindle 
checkpoint silencing by counteracting the function of Mad2. Phosphorylation 
of  Mad2  may  also  be  involved  in  the  mechanism  of  spindle  checkpoint 
silencing.  Mad2  phosphorylation  increases  as  cells  exit  from  a  nocodazole- 
mediated  mitotic  arrest  (Wassmann  et  al,  2003).  Since  it  is  only  the 
unphosphorylated Mad2 that can bind Madl  or APC/C, it was suggested that 
phosphorylation  of  Mad2  inhibits  its  function  and  may  be  an  important 
mechanism for checkpoint inactivation.
1.2.9  Adaptation of the spindle checkpoint: The G1 tetraploidy checkpoint
The spindle checkpoint (like the G2 checkpoint) is only maintained for 
a limited duration and following a period of time in arrest, cells can progress 
to the next stage of the cell cycle without the checkpoint being satisfied.  This 
has  been  referred  to  as  adaptation  (reviewed  in  (Andreassen  et al,  2003)). 
Most  mammalian  cells  undergo  adaptation  of the  spindle  checkpoint  in  the
67presence of microtubule inhibitors.  Adaptation with a half-time of 3 hours has 
been observed in mouse embryonic fibroblasts (Lanni  and Jacks,  1998).  The 
cells return to interphase in a tetraploid state,  and thus exit from mitosis has 
occurred without satisfaction of the spindle checkpoint and the cells become 
micronucleated  due  to  the  failure  of  normal  chromosome  segregation 
(Andreassen  et al,  1996;  Sablina et al.,  1998).  This  indicates  that the  cells 
have  adapted  to  the  checkpoint,  and  have  not  simply  metabolised  the 
microtubule poison or exported it from the cell.  To counter this, mammalian 
cells  have  a  G1  tetraploidy  checkpoint  that  induces  a  stable  G1  arrest  of 
tetraploid cells that arise either following G2 or spindle checkpoint adaptation, 
or errors in mitosis (Andreassen et al., 2001b; Borel et al., 2002).  It remains 
to be determined whether the G1 tetraploidy checkpoint would similarly arrest 
cells  following aneuploidisation with gain or loss  of only a small number of 
chromosomes (Margolis et al., 2003).
Fibroblasts  respond  to  spindle  checkpoint  adaptation  and 
tetraploidisation by inducing  G1  arrest in  a p53-dependent manner, whereas 
lymphoblasts respond with a p5 3-dependent induction  of apoptosis  (Minn et 
al.,  1996).  A recent study has suggested that propagation of cells arrested at 
the  G1  tetraploidy  checkpoint  following  spindle  checkpoint  adaptation  is 
prevented by hBubRl-mediated apoptosis (Shin et al., 2003).
Although experimental evidence has excluded a direct role for p53  in 
the spindle checkpoint, the response to long-term nocodazole-induced spindle 
damage  in  normal  cells  (triggering  the  tetraploidy  checkpoint)  has  recently 
been  shown  to  require  an  intact  spindle  checkpoint  (Vogel  et  al.,  2004), 
suggesting a functional link between these two checkpoints. p53  is  stabilised 
and  activated  during  a  damage-induced  spindle  checkpoint  arrest,  and  this 
activation is due to the prolonged arrest rather than the nature of the damage. 
No accumulation of p53 is observed when the spindle checkpoint is activated 
during a normal mitosis.  In addition, this  spindle  damage-induced activation 
of p53 is independent of ATM, ATR, Chkl  and Chk2 proteins, indicating that 
it  does  not  require  components  of  the  DNA  damage  pathway.  A  p53-
68dependent  checkpoint  mechanism  that  arrests  cells  in  G2  upon  prolonged 
spindle damage, preventing polyploid cells from re-entering mitosis, was also 
identified.
Interestingly,  a  recent  study  has  demonstrated  that  triggering  of the 
p53-dependent  tetraploidy  checkpoint  involves  Bubl-mediated 
phosphorylation  of p53  at serine-37,  suggesting that Bubl  could be  the link 
between the spindle and tetraploidy checkpoints (Personal communication: Dr 
O.  Gjoerup,  Dana-Farber  Cancer  Institute,  Boston,  MA).  It  is  therefore 
proposed that by interacting with Bubl, SV40 large T antigen (LT) is usurping 
a cellular mechanism normally active at the tetraploidy checkpoint, in order to 
stabilise p53. LT is thought to do this by acting as a scaffold to bring p53 into 
proximity  with  Bubl  (Cotsiki  et  al.,  2004),  which  phosphorylates  p53  on 
serine-37. Bubl  is also shown to be required for LT binding to p300/CBP and 
the resulting acetylation of p53. LT could therefore induce p53 stabilisation in 
the absence of spindle damage by recruitment of Bubl  to phosphorylate p53 
on serine-37, and also by inducing acetylation at lysines 373  and 382 of p53 
via  recruitment  of  p300/CBP.  However,  it  is  important  to  note  that 
stabilisation of p53 by LT does not alter p53 activity, which is sequestered by 
LT (see Section 1.3.2.2).
1.3  SV40
Simian  Virus  40  (SV40)  is  a  member  of the  papovavirus  family  of 
DNA tumour viruses.  It is  a double  stranded DNA virus  of rhesus  monkey 
origin, with a circular genome of 5243 base pairs (Tooze,  1981).  SV40 was 
first isolated in the late  1950s as a contaminating virus from rhesus macaque 
monkey kidney  cells  that  were  being  used to  grow  poliovirus  for the  early 
polio  vaccine.  It  was  later  shown  to  be  capable  of  inducing  tumours  in 
hamsters (reviewed in (Hilleman, 1998)).
The SV40 genome codes for seven gene products (see Figure 1.6).
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Figure 1.6: The genomic organisation of the SV40 virus.
SV40 vims has a circular double-stranded DNA genome, with promoters 
for early and late genes (PE and PL, respectively) located on either side 
of the  origin  of replication  (Ori).  The  early  genes  encode  the  large  T 
antigen  (LT),  small  t  antigen  (st),  and  tiny t  antigen  (17kT)  proteins, 
involved in regulation of early and late gene transcription, up-regulation 
of transcription  in  the  host  cell,  replication  of viral  DNA  and  virion 
assembly, among other functions. The late genes encode VP1, VP2, and 
VP3, the structural proteins that form the viral capsid. The open reading 
frames that give rise to these proteins are indicated. (Adapted from Lock 
et al., 2004).
70The early genes are encoded by three alternatively spliced mRNAs that give 
rise to proteins that are identical for the amino-terminal  82 residues (referred 
to as “T/t common region”).  These gene products are called large T antigen, 
small t antigen, and  17kT antigen (sometimes known as tiny t antigen). They 
are involved in many functions which include regulation of early and late gene 
transcription, up-regulation of transcription in the host cell, replication of viral 
DNA and virion assembly (reviewed in (Ali and DeCaprio, 2001; Conzen and 
Cole,  1995;  Grand,  2001;  Sullivan  and Pipas,  2002)).  These  proteins  were 
called  T(umour)  antigens  because  they  were  first  identified  when  antisera 
from hamsters with  SV40-induced tumours were used to  search for antigens 
expressed in SV40 infected cells.  SV40 also encodes the late gene products 
VP1,  VP2  and VP3  which are  generated  from  alternatively  spliced  mRNAs 
and  alternative  initiation  codons,  and  which  are  the  structural  proteins  that 
form the viral capsid (see Figure  1.6).  SV40 also encodes the agno protein, a 
small  highly  basic  polypeptide  that  is  translated  from  the  leader  region  of 
SV40 late mRNAs and may have a role in the assembly of the capsid and/or 
its release from the host cell (Cole, 1996; Jay et al., 1981).
Replication of SV40 DNA begins when the virally encoded SV40 large 
T  antigen  binds  to  the  SV40  origin,  forming  a  double-hexameric  structure 
(reviewed  in  (Simmons,  2000)).  Three  cellular  proteins,  DNA  polymerase 
a/primase  (pol/prim),  followed  by  topoisomerase  I  (topo  I)  and  replication 
protein  A  (RPA)  then  associate  with  SV40  large  T  antigen  to  form  an 
initiation complex (Simmons et al.,  2004).  Following initiation, the majority 
of DNA synthesis on both the leading and lagging strands occurs in response 
to  additional  cellular proteins  such  as polymerase  5,  PCNA  and RF-C,  with 
approximately  11  cellular proteins  needed to  fully  replicate  the  viral  DNA. 
SV40  large  T  antigen  has  recently  been  shown  to  interact  with  Nbsl,  the 
Nijmegen breakage syndrome (NBS) protein, involved in double-strand break 
repair  (Wu  et  al.,  2004).  Nbsl  plays  a  role  in  preventing  DNA 
hyperreplication during the cell cycle, contributing to maintenance of genome 
stability,  but  LT  targets  Nbsl,  thereby  enhancing  the  yield  of new  SV40
71genomes during viral DNA replication. This provides a further mechanism by 
which SV40 large T antigen is able to induce aneuploidy in its cellular host.
SV40  large T  antigen  (LT)  is  largely responsible  for the  functions  of 
the virus that induce the host cell to produce the enzymes that are necessary 
for replication  of the  viral  genome.  Introduction  of LT  into  primary  rodent 
cells enables these cells to acquire an infinite proliferative potential  (Jat and 
Sharp,  1989)  but  does  not  necessarily  result  in  their  transformation. 
Inactivation  of LT  in these immortal  cells results  in  a rapid and irreversible 
loss of their proliferative potential in either G1  or G2 phases of the cell cycle, 
showing  that LT  is  continuously required to  maintain  the  proliferative  state 
(Gonos et al.,  1996; Jat and Sharp,  1989).  However, introduction of LT into 
immortalised cell lines can result in full transformation (reviewed in (Ali and 
DeCaprio, 2001)).  The potency of LT for inducing both immortalisation and 
transformation  of many  cell  types  has  led  to  its  extensive  use  as  a  model 
system to study the critical steps for this process (recently reviewed in (Lock 
et al., 2004)).  These studies have provided a great insight into many cellular 
mechanisms,  including  the  regulation  of cell  proliferation,  senescence  and 
apoptosis, in addition to the processes of immortalisation and tumourigenesis 
(see Section 1.3.1).
SV40  LT has been  shown to  rapidly disrupt mitotic  checkpoints  that 
help maintain genomic stability, suggesting mechanisms by which LT induces 
chromosome aberrations and promotes immortalisation and transformation of 
mammalian cells (Chang et al.,  1997). An interaction between SV40 LT and 
Ran,  a  small  GTPase  that  regulates  nucleocytoplasmic  transport,  cell  cycle 
progression, and mitotic spindle organisation, has been demonstrated in vitro 
(De  Luca  et  al.,  2003).  This  suggests  that  deregulation  of the  centrosome 
duplication cycle could be one mechanism by which SV40 LT causes genomic 
instability. In addition, elevated levels of Ran’s exchange factor, RCC1, have 
been  shown  to  abrogate  the  spindle  checkpoint  in  Xenopus  egg  extracts, 
restoring APC/C activity and disrupting the kinetochore localisation of Mad2, 
CENP-E, Bubl  and Bub3 (Amaoutov and Dasso, 2003).  Similar effects were
72seen  when  Ran’s  GTPase  activating  protein  (RanGAPl)  and  its  accessory 
factor  (RanBPl)  were  depleted,  suggesting  that  the  spindle  checkpoint  is 
directly responsive to levels of Ran-GTP in the cell,  and therefore leading to 
the  possibility  that  SV40  LT  interaction  with  Ran  could  be  affecting  the 
spindle checkpoint directly.
SV40  LT was recently  shown to  interact with the  spindle  checkpoint 
protein Bubl, leading to compromise of spindle checkpoint function (Cotsiki 
et al., 2004), the subject of this project.
1.3.1  Immortalisation and Transformation
Immortalisation  has  been  defined  as  the  ability  to  produce  cell  lines 
that can be serially cultivated indefinitely without any overt signs of cessation 
of growth. It can be tested in a variety of cell types but the critical property the 
cells must possess is that they must only be able to undergo a finite number of 
divisions, because established cell lines have  already undergone the changes 
necessary  for  immortalisation  (i.e.  are  already  genetically  abnormal). 
Immortalisation is measured by the ability to obtain colonies upon transfection 
or infection of primary cultures and expansion of these colonies into cell lines 
that can be serially cultivated.  The production of cell lines that can be serially 
cultivated is a critical component of this assay because it is possible to obtain 
an extension of life span without indefinite proliferation.  The most common 
cell type used is embryonic fibroblasts, since they can be easily prepared and 
propagated in vitro.
In contrast, transformation has been  defined as  the process that gives 
rise to oncogenically transformed cells.  The assays that are commonly used to 
measure  transformation  potential  are  production  of  dense  foci,  foci  that 
overgrow  a  monolayer,  growth  in  semi-solid  medium  i.e.  anchorage- 
independent  growth  or  growth  in  low  serum  concentrations  or  at  high 
saturation densities.  However, the ultimate test has to be whether tumours can 
be  induced  in  either  syngeneic  or  immunosuppressed  animals.  The  closest 
correlate  to  tumours  in  experimental  animals  is  anchorage-independent
73growth.  Transformation ability does not have to be measured in primary cells. 
It is usually carried out in established cell lines.  In fact, if primary cells are to 
be  used,  then  there  may  be  a  requirement  for  the  presence  of  an  active 
immortalising gene, because transforming genes such as activated ras induce 
premature senescence in the absence of an immortalising gene.  Senescence is 
the process of cellular aging, with cessation of cell division.
Mouse  embryo  fibroblasts  have  the  potential  to  undergo  about  20 
divisions  before  they  cease  dividing.  However  they  will  readily  undergo 
spontaneous immortalisation, and thus great care needs to be taken when these 
cells  are  used  for  immortalisation  assays.  Rat  embryo  fibroblasts  undergo 
slightly  fewer  divisions  but  immortalise  spontaneously  at  a  much  lower 
frequency.
In marked contrast, human  fibroblasts undergo  many more  divisions, 
approximately 50-70, defined as the Hayflick Limit (Hayflick,  1961) prior to 
undergoing  senescence,  and  have  never  been  demonstrated  to  undergo 
spontaneous immortalisation.  The addition of an immortalising gene such as 
SV40 large T antigen into human cells does not cause immortalisation, but can 
extend  the  in  vitro  lifespan  of the  cells,  adding  an  extra  20-30  population 
doublings for fibroblasts (reviewed in (Shay et al.,  1991)). At the end of the 
extended lifespan another proliferative decline known as “crisis” is observed. 
It has been proposed that senescence be defined as mortality stage I (Ml), and 
that crisis be  defined as mortality stage  II  (M2),  to make  a clear distinction 
between these two different states in the proliferative decline of human cells 
(Wright et al.,  1989).  The  inability  of human  cells  to  undergo  spontaneous 
immortalisation has led to the proposal that human cells have acquired extra 
control  mechanisms  to  prevent  tumour  formation  i.e.  a  tumour  suppressor 
mechanism.  This  most likely corresponds to  the  shortening  of telomeres  in 
human somatic cells (reviewed in (Sedivy,  1998)). In these cells the telomeres 
shorten each time the cells divide due to the end replication problem and the 
absence  of  functional  telomerase  activity  in  most  human  somatic  cells. 
Telomerase  activity  can  be  reconstituted by  ectopically  expressing  hTERT,
74the catalytic subunit of telomerase (Bodnar et al.,  1998; Counter et al.,  1998; 
Vaziri  and  Benchimol,  1998).  In  fact,  it  has  been  proposed  by  some  that 
reconstitution of telomerase activity is all that is required for immortalisation 
of  human  cells  (Bodnar  et  al.,  1998;  Ouellette  et  al.,  2000;  Vaziri  and 
Benchimol,  1998;  Yang  et  al.,  1999).  However,  others  have  found  that 
additional activities are required.  These can be provided by Human papilloma 
virus  16/18 E7 protein or SV40 large T antigen (Hahn et al.,  1999; Kiyono et 
al.,  1998;  O'Hare  et  al.,  2001).  In  contrast  rodent  cells  have  much  longer 
telomeres and it is not possible to demonstrate telomere shortening upon serial 
passaging.  Thus  cellular  senescence  in  rodent  cells  is  not  regulated  by 
telomere dependent mechanisms (reviewed in (Itahana et al., 2004)).
The loss of in vitro proliferative potential observed in rodent fibroblasts 
can  be  readily  overcome  by  the  action  of  any  member  of  the  family  of 
immortalising genes, including SV40 large T antigen (reviewed in (Katakura 
et al.,  1998)).  Furthermore,  it has been  shown that these  cells  only become 
dependent  upon  the  immortalising  gene  to  continue  dividing  when  their 
endogenous  life  span  has  elapsed  (Ikram  et al.,  1994).  If the  immortalising 
gene  is  removed  after  this  time,  the  resulting  growth  arrest  becomes 
irreversible  after about  72  hours,  and  can  occur  in  both  G1  and  G2  phases 
(Gonos  et al.,  1996;  Jat and  Sharp,  1989).  The  same result was  obtained in 
other rodent cell types (myoblasts, neural cells) and human cells immortalised 
with a combination of hTERT and SV40 LT were similarly unable to maintain 
growth when LT was removed (O'Hare et al., 2001). This property has led to 
large T antigen being  one  of the most frequently used agents  for generating 
immortal cell lines.
751.3,2  SV40 large Tantigen
SV40 large T antigen (LT) is a multifunctional phosphoprotein of 708 
amino  acids  that  localises  mostly  within  the  host  nucleus  via  a  nuclear 
localisation signal (NLS) in the N-terminal region of the protein (Kalderon et 
al.,  1984; Soule and Butel,  1979). However a very small fraction is bound to 
the plasma membrane  (Santos  and  Butel,  1982).  It has  various  biochemical 
activities  (Fanning,  1992)  including  ATPase  activity  (Tjian  and  Robbins, 
1979),  and  DNA  and  RNA  helicase  activity  (Scheffner  et  al,  1989)  (see 
Figure 1.7).  It can also bind to RNA covalently (Carroll et al.,  1988), as well 
as to DNA both specifically and non-specifically (Carroll et al.,  1974).  While 
these activities are necessary for replication of the viral DNA, none of them 
are required for the immortalisation or transformation of rodent cells (Manos 
and Gluzman,  1984; Peden et al.,  1990; Stringer,  1982).  LT can also activate 
and repress transcription from various viral and cellular promoters (Alwine et 
al.,  1977; Gilinger and Alwine,  1993; Gruda et al.,  1993; Hansen et al.,  1981; 
Mitchell et al.,  1987; Rice and Cole,  1993; Rushton et al.,  1997; Saffer et al., 
1990; Zhu et al., 1991).
LT associates with a number of host  cellular proteins,  which include 
p53 (Lane and Crawford,  1979; Linzer and Levine,  1979), pRB (DeCaprio et 
al.,  1988), pl07 (Dyson et al.,  1989; Ewen et al.,  1989), pl30 (Hannon et al.,
1993),  heat  shock  protein  Hsc70  (Sawai  and  Butel,  1989),  CREB-binding 
protein  (CBP),  p300  (Avantaggiati  et al.,  1996;  Eckner  et al.,  1996),  p400 
(Lill  et  al.,  1997b),  DNA  polymerase  a  (Smale  and  Tjian,  1986),  p i85 
(Kohrman  and  Imperiale,  1992),  SUG1,  a  regulatory  component  of  the 
proteasome (Grand et al.,  1999), TBP, the TATA-binding protein (Martin et 
al.,  1993), and the spindle checkpoint protein Bubl  (Cotsiki et al., 2004) (see 
Figure  1.7).  The abrogation of cellular pathways by SV40 large T antigen is 
summarised in Figure 1.8.
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Figure 1.7: SV40 large T antigen.
The  locations of the  functional  domains  of SV40  large T  antigen (LT) 
that are responsible for interaction with host proteins are indicated, along 
with  the  regions  responsible  for  other  activities  of the  protein.  The 
interaction site of the spindle checkpoint protein Bubl at amino acids 89- 
97 of LT is highlighted in red. (Adapted from Lock et al., 2004).
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Figure 1.8: Cellular pathways affected by SV40 large T antigen.
This  figure  summarises  some  of the pathways that  are  involved  in  cell 
cycle progression, and shows the proteins that are affected by SV40 large 
T  antigen  (LT).  Compromise  of  the  spindle  checkpoint  by  LT  via 
interaction with the checkpoint kinase Bubl  is the focus of this project, 
and is highlighted in red. (Adapted from Lock et al., 2004).
78Mutational  analyses  of LT  have  indicated  that  three  regions  of the 
protein  are  critical  for  its  immortalising  activity  (Conzen  and  Cole,  1995). 
These regions are the amino terminal 82 amino acids (the T/t common region), 
amino acids  102-114 and amino acids 350-560.  It should be noted however 
that while all three regions are required for immortalisation, C3H10T1/2 cells 
(an  established  cell  line)  are  still  at  least  partially  transformed  by  LT  with 
mutations in the second or third regions, but mutations in the amino terminal 
82 residues abrogate transformation of these cells.  This illustrates the reduced 
requirement  of  LT  functions  for  the  transformation  of  established  lines 
compared with immortalisation of primary cells.  These regions of LT are all 
involved  in  interactions  with  host  proteins,  and  these  interactions  and  their 
possible functions will now be discussed in detail.
1.3.2.1  The Retinoblastoma family of proteins
The retinoblastoma protein (pRB) is the product of the retinoblastoma 
susceptibility  gene,  Rbl,  which  was  the  first  tumour  suppressor  gene  to  be 
identified  in  humans.  The  RB  gene  as  well  as  genes  involved  in  the  RB 
regulatory  pathway  are  known  to  be  mutated  in  a  diverse  range  of human 
cancers (reviewed in (Malumbres and Barbacid, 2001)).
pRB  is  a  ubiquitously  expressed  protein  of  928  amino  acids  and 
contains  at  least  three  domains:  an  N-terminal  domain,  a  central  A/B 
(bipartite) pocket domain, and a C-terminal (C pocket) domain.  There are two 
other pRB-family members, pl07  and p i30,  and these proteins  also possess 
the  A/B  pocket  region,  which  is  found  to  be  the  region  with  which  most 
cellular and viral interacting proteins bind, and also the region in which most 
tumour-associated RB mutations occur (Classon and Dyson, 2001;  Hu et al., 
1990; Huang et al., 1990).
The  pRB  family  of  proteins  functions  to  control  proliferation, 
differentiation  and  apoptosis,  by  maintaining  a  tight  control  on  cell  cycle 
progression.  pRB  is  phosphorylated  and  dephosphorylated  during  the  cell 
cycle,  and the  site-specific phosphorylation of pRB  appears to coincide with
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al., 1996; Weinberg,  1995).  pRB acts to prevent the cell-cycle transition from 
G1 to S phase partly via its interaction with E2F, a transcriptional activator for 
S  phase-specific  genes.  It  is  only  the  active,  underphosphorylated  form  of 
pRB  that  binds  to  E2F,  thus  inhibiting  its  transactivation  activity.  The 
interaction  of pRB  with  E2F  is  regulated  by  phosphorylation  of pRB  by 
several  cyclin-dependent kinases  (CDKs),  in  a  cell  cycle-dependent manner 
(Adams, 2001) (see Figure 1.1).
SV40 large T antigen (LT) forms a stable complex with pRB, and this 
interaction  is  critical  for immortalisation because  mutants  that are  defective 
for binding pRB  have  a reduced  immortalisation potential  (DeCaprio  et al., 
1988; Powell et al.,  1999).  Some transformation defective mutants of LT are 
defective  for  binding  to  pRB,  indicating  the  additional  importance  of this 
interaction  for  the  transforming  function  of  LT  (reviewed  in  (Ali  and 
DeCaprio,  2001)).  All  viral  oncoproteins  including  SV40  LT  and  many 
cellular proteins that bind to pRB have in common the LxCxE motif, which is 
responsible for the interaction with the conserved pocket region of pRB (Lee 
et al.,  1998).  The LxCxE motif of LT is located at residues  103-107, within 
the  region  of the  protein  that  has  homology  to  conserved  region  2  (CR2) 
domain of adenovirus El A and the human papilloma virus type 16 E7 protein 
(see Figure 1.7).  The CR2 domain of each of these proteins is responsible for 
their  interactions  with  the  pRB  family  of proteins  (DeCaprio  et  al.,  1988; 
Moran,  1988;  Munger  et  al.,  1989).  LT  only  binds  to  the 
underphosphorylated  growth  suppressing  form  of pRB  that  normally  binds 
E2F, resulting in its sequestration (Ludlow et al.,  1989; Ludlow et al.,  1990). 
This has a similar effect to the phosphorylation-mediated inactivation of pRB. 
In the presence of LT,  E2F  is thus free to activate transcription, resulting in 
entry into S phase.  LT also targets the other pRB family members, p i07 and 
pi30,  similarly  disrupting  their  interactions  with  E2F  proteins,  and 
additionally is able to perturb the phosphorylation state of p i07 and p i30 and 
stimulate pl30 (but not pl07) degradation (Stubdal et al.,  1996).  It has been
80suggested  that  p i07  and  pi30  are  the  critical  targets  of  LT  for  its 
immortalisation  function,  and  that  pRB  may  not  be  so  important  for  this 
activity  (Srinivasan  et  al.,  1997).  The  N-terminal  “J  domain”  of  large  T 
antigen  (residues  1-82)  is  also  involved  in  the  interaction  with  pRB  family 
members, and it has been suggested that a functional J domain as well as the 
LxCxE motif are required for a productive  interaction with pRB  (Zalvide et 
al., 1998).
1.3.2.2  p53
p53  was  originally  identified  as  a  cellular  protein  that  co- 
immunoprecipitated  with  SV40  LT  using  antisera  from  tumour-bearing 
animals (Lane and Crawford,  1979; Linzer and Levine,  1979).  Interaction of 
LT with p53 leads to its stabilisation. Although it was originally believed that 
p53  was  an  oncogene,  it  was  later  found  that  wild-type  p53  is  a  tumour 
suppressor, whereas mutant p53 is an immortalising gene.  p53 has proven to 
be one of the most commonly mutated genes in human cancer (Hollstein et al.,
1994).  It has sequence-specific DNA binding activity, and acts to increase the 
transcription of genes that cause growth arrest in G1  and G2,  and to  induce 
apoptosis in response to genotoxic stress.  Its function as a tumour suppressor 
and “guardian of the genome” (Lane,  1992) has been attributed to its negative 
regulation of cell proliferation in the presence of DNA damage.  p53  activity 
is also critical for maintenance of the senescent state, since microinjection of 
anti-p53  antibodies  can  induce  DNA  synthesis  in  senescent  cells  (Gire  and 
Wynford-Thomas, 1998).
p53  is ubiquitously  expressed in  all  cells, but is not  stable  due  to  its 
interaction with MDM2, a ubiquitin E3 ligase which targets it for degradation 
by the proteasome  (Momand et al,  2000).  However,  upon genotoxic  stress 
such  as  irradiation,  chemotoxin  exposure,  or  unscheduled  DNA  synthesis 
induced by a virus, the normally short-lived p53  protein becomes  stabilised, 
resulting in a corresponding increase in p53-mediated transcription (Kastan et 
al.,  1991;  Kuerbitz  et  al,  1992;  Maltzman  and  Czyzyk,  1984).
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damage  causes  p53  to  dissociate  from  MDM2  resulting  in  its  stabilisation 
(Kussie et al.,  1996).  These modifications are also crucial for acetylation of 
C-terminal residues and these together result in the full p53-mediated response 
to genotoxic stress.  Activation of p53 by ionising radiation requires the ATM 
protein, which mediates the direct phosphorylation of serine-15 and indirectly 
mediates  the phosphorylation  of serine-20 by  controlling  activation  of chk2 
(Turenne  et al.,  2001).  The  ATM-Rad3-related protein  ATR  also  regulates 
phosphorylation  of serine-15  in  response  to  UV  DNA  damage.  Additional 
sites for DNA damage-induced phosphorylation at serine-33  and -37 may be 
regulated by  ATR  and  other kinases  (Tibbetts  et a l,  1999).  When  the  C- 
terminus  of p53  is modified, the ability of this region to negatively regulate 
sequence-specific  DNA  binding  is  inhibited,  resulting  in  activation  of 
transcription of downstream targets in response to DNA damage (Appella and 
Anderson,  2001;  Lill  et al,  1997a).  This  leads  to  a  cascade  of events  that 
include  the  transcriptional  activation  of the  CDK  inhibitor  p21Cipl/W afl/sdl1, 
MDM2,  as  well  as  the  apoptotic  protein  bax,  cyclin  G1  and  several  other 
factors.  In  addition,  p53  can  also  repress  the  transcription  of other  genes 
including  those  encoding  the  anti-apoptotic  protein  bcl-2,  pRB,  the 
transcription factors c-fos, c-jun, and c-myc and the proliferating cell nuclear 
antigen  (PCNA,  a  component  of  the  DNA  replication  machinery  that  is 
required  for  both  replication  and  repair  of  DNA)  (Ginsberg  et  a l,  1991; 
Mercer et al,  1991; Miyashita et al,  1994; Moberg et al,  1992;  Shiio et al,
1992).
If the DNA damage is  too  extensive  to be repaired, p53  induces  exit 
from  the  cell  cycle  and  cell  death  via  apoptosis.  p53  can  also  halt  DNA 
replication  during  S  phase  of the  cell  cycle  if damage  has  occurred,  again 
either promoting arrest until the DNA is repaired, or inducing apoptosis if the 
DNA  is  irreparable,  indicating  the  pivotal  role  played  by  p53  as  a  signal 
integrator in the determination of cell fate.  MDM2 acts to down-regulate p53, 
inducing  its  ubiquitin-mediated  degradation  and  providing  a  negative
82feedback loop mechanism that restores the normal  functions  of the cell  once 
the genotoxic stress has diminished (Momand et al., 2000).
It is not yet fully understood how the interaction of SV40 LT with p53 
affects  the  functions  of  p53.  However,  it  is  generally  accepted  that  LT 
inactivates p53 tumour suppressor function by directly binding to the region of 
p53  involved  in  specific  DNA  binding,  preventing  p53  from  acting  as  a 
transcriptional  activator of genes that induce  cell  cycle  arrest in response to 
genotoxic  stress.  The  failure  of  p53  to  monitor  the  genome  in  SV40- 
immortalised cells is thought to be the reason behind the increased occurrence 
of mutations  in  these  cells  (Ray  et al.,  1990;  Stewart  and  Bacchetti,  1991; 
Woods et al.,  1994).  Paradoxically, interaction of LT with p53 has also been 
shown to increase the half-life and steady-state levels of p53  (Deppert et al., 
1987;  Oren  et al.,  1981).  The  observation  that MDM2  binds  LT  directly  in 
vitro  and  co-precipitates  in  a  complex  with  p53  in  vivo  has  led  to  the 
suggestion that LT enhances the stability of p53  partly by entrapment of the 
p300/MDM2/p53 complex responsible for targeting its degradation (Brown et 
al., 1993; Grossman et al., 1998; Henning et al., 1997).
The region of LT required for interaction with p53 is actually bipartite, 
consisting  of  amino  acids  351-450  and  533-626  (see  Figure  1.7).  The  C- 
terminal region of LT beyond amino acid 627 can be removed without loss of 
immortalisation,  transformation  or  tumourigenic  activity  (Tevethia  et  al., 
1988).  Interestingly,  immortalisation of mouse cells is very much dependent 
upon the direct inactivation of p53 (Conzen and Cole, 1995), whereas rat cells 
can  be  immortalised  by  amino  terminal  fragments  of large  T  antigen  that 
cannot interact with p53  (Powell et al.,  1999;  Sompayrac and Danna,  1991). 
However,  it  has  been  suggested  that  these  mutants  may  be  able  to  act 
downstream  of p53  to  inactivate  the  pathway,  e.g.  via  pRB  family  binding 
(Michael-Michalovitz et al.,  1991; Quartin et al.,  1994; Rushton et al.,  1997). 
The  sequestration  of p53  by  LT  may  also  abrogate p53-mediated  apoptosis 
(McCarthy  et  al.,  1994).  In  cell  lines  conditionally  immortalised  by  a 
temperature-sensitive  mutant  of  LT,  its  inactivation  has  in  some  studies
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while  in  others  its  inactivation  resulted  in  cell  death  by  apoptosis,  perhaps 
caused  by  a  sudden  release  of  a  large  amount  of  stable  p53  (Yanai  and 
Obinata, 1994).
1.3.2.3  p300 and the CBP family of proteins
p300 was first identified as an adenovirus El A interacting protein and 
has also been shown to bind to SV40 large T antigen (LT) (Avantaggiati et al., 
1996;  Eckner  et  al.,  1996).  p300  and  the  related  proteins  p400  and  CBP 
(CREB-binding  protein)  are  members  of  a  family  of  transcriptional  co­
activators  involved  in  coordinating  the  formation  of  specific  transcription 
factor complexes (Struhl,  1998).  They enhance the transcriptional activity of 
many  proteins,  including  p53  and  NFaB  p65  subunit,  either  by  directly 
interacting with transactivators, or by modulating the chromatin structure via 
recruitment  of  histone  acetyltransferases  (Goodman  and  Smolik,  2000; 
Hottiger  and  Nabel,  2000).  p300/CBP  acetyltransferases  promote  the 
acetylation of p53, thus activating p53-mediated transcription (Avantaggiati et 
al., 1997). This activation of p53 by p300 is potentiated by ionising radiation.
In addition to their role in transcriptional regulation, these proteins may 
also be involved in cell cycle control and development.  p300 and CBP may 
also have a tumour suppressor function, as mice with a null mutation in one 
allele of CBP are known to develop haematological malignancies (reviewed in 
(Janknecht, 2002)), and various human carcinomas have been linked to p300 
mutations (Gayther et al., 2000; Muraoka et al.,  1996).  The binding site for 
p300  and  CBP  on  LT  has  been  mapped to  both  the N-terminal  and  the  C- 
terminal domains of the protein (Eckner et al.,  1996; Lill et al.,  1997b).  It is 
not clear if interaction of these proteins with LT is direct or via p53, but it has 
been  shown  that  LT  expression  inactivates  the  transcriptional  activation 
function  of  p300,  and  also  changes  the  phosphorylation  state  of  p300 
(Avantaggiati  et  al.,  1996;  Eckner  et  al.,  1996).  This  inactivation  of p300 
leads to the inhibition of p53 transcriptional activation activity, further helping
84the  virus  to  maintain  an  environment  in  which  it  can  replicate  in  an 
uncontrolled manner.
1.4  AIM OF THE RESEARCH
The main aim of this project was to examine the function of SV40 large 
T  antigen  interaction  with the  checkpoint protein  Bubl.  The  importance  of 
this interaction was investigated in terms of the known functions of SV40 LT, 
and also as a model for mechanisms of the spindle checkpoint.
The  first  aim  was  to  identify  a  LT  mutant  that  is  defective  for  Bubl 
interaction. Such a mutant could then act as a tool for examining if interaction 
with Bubl  is critical for the cell cycle de-regulating functions of LT, such as 
the immortalising and transforming activities of the protein, in addition to its 
abilities to induce chromosomal instability.
The  next  aim  was  to  examine  the  possibility  that  LT  is  inhibiting  the 
spindle  checkpoint  function  of  Bubl,  making  use  of  a  non-Bubl-binding 
mutant of LT as a negative control. The generation of good Bubl  monoclonal 
antibodies to aid in these experiments was also a priority.
If  LT  was  shown  to  compromise  spindle  checkpoint  function  via 
interaction with Bubl, the final aim of the research was to investigate how this 
was  achieved,  perhaps  also  gaining  insights  into  the  spindle  checkpoint 
function of Bubl in the absence of LT.
852. Materials and methods
2.1 MAMMALIAN CELL CULTURE
2.1.1 Cell media
Tissue  culture  media  and  cell  culture  reagents  were  purchased  from 
Invitrogen.  All  cell  lines,  except  for hybridoma  cells,  were  maintained  in 
Dulbecco’s modified Eagle medium (DMEM) (Invitrogen) supplemented with 
2mM  glutamine,  100  units/ml  penicillin,  100  pg/ml  streptomycin  and  10% 
(v/v)  heat  inactivated  foetal  calf  serum  (FCS)  for  BOSC  23,  U20S,  Rat 
embryo fibroblast (REF) cell lines and other Rat cell lines, or  10% (v/v) heat 
inactivated donor calf serum (DCS)  for NIH  3T3  cell lines.  Hybridoma cells 
were  maintained  in  RPMI  1640  Medium  with  GlutaMAX™  I  and  25mM 
HEPES  (Invitrogen)  supplemented  with  2mM  glutamine,  100  units/ml 
penicillin,  lOOug/ml streptomycin, 10% (v/v) FCS and ImM sodium pyruvate.
2.1.2 Cell culture conditions
All  cell  lines  were  maintained  in  a  5%  C02  and  20%  oxygen 
atmosphere at 37°C in medium supplemented with additives as above.
2.1.3 Primary cells
Rat embryo fibroblasts (REFs) were maintained in a 5% C02 and 20% 
oxygen  atmosphere  at  37°C  in  DMEM  supplemented  with  10%  FCS, 
glutamine and antibiotics as above.
862.1.3.1  Preparation of REFs
REFs were prepared from 13-day-old Sprague-Dawley rat embryos.  A 
13-day-old  day  pregnant  rat  was  sacrificed  by  cervical  dislocation  and  the 
uterus was removed.  The embryos were then isolated from the uterus under 
sterile  conditions  and  immediately  placed  into  Leibovitz’s  L-15  medium 
(Invitrogen).  These  first  steps  were  carried  out  by  the  UCL  Biological 
Services  department.  Heads  and tails were then removed from the  embryos 
and the  remaining  tissues  were  disaggregated  by  fine  mincing  followed by 
treatment with trypsin-EDTA (ethylenediaminetetraacetic acid) (Invitrogen) to 
produce a cell suspension.  The cells were subsequently plated in 15 cm dishes 
(one dish was used for each embryo prepared).  This was defined as passage 1 
(PI).  REFs  were  maintained in  a  5%  CO2  and 20%  oxygen  atmosphere  at 
37°C  in  DMEM  supplemented with  10%  FCS,  glutamine  and antibiotics  as 
above.
2.1.4 Sub-culturing of adherent cells
Cells  were  grown  until  a  sub-confluent  (80%  confluence)  state  was 
reached.  The  media  was  then  removed  and  the  monolayer  of  cells  was 
washed once with  IX trypsin-EDTA (0.25% v/v trypsin, 0.03% w/v EDTA). 
The monolayer was then detached using  IX trypsin-EDTA (1ml was used per 
10 cm dish, for 5 min at 37°C) and the trypsin-EDTA was then inactivated by 
adding 10ml of complete media.  The cells were then either plated at a defined 
ratio (e.g.  1  in  10  of the total cells were re-plated),  or were  counted using  a 
haemocytometer and plated at the required density, and were then maintained 
at 37°C in a 5% C02 and 20% oxygen atmosphere.
2.1.5 Preservation of cells
Adherent  cells  from  a  sub-confluent  (-80%  confluence)  dish  were 
trypsinised,  washed once in  complete media  and spun  down  at  lOOOrpm for
875min to remove any traces of trypsin, and resuspended in FCS (or DCS in the 
case of NIH  3T3  cell  lines)  with  10%  DMSO  (dimethyl  sulphoxide)  (BDH) 
(3ml  for  each  10cm  dish  of cells).  1ml  aliquots  were  then  transferred  to 
cryotubes  and  frozen  at  -70°C  wrapped  in  several  layers  of  tissue  for 
insulation.  The tubes were transferred into liquid nitrogen after 24 hours.
Similarly,  hybridoma  cells  were  spun  down  at  lOOOrpm  for  5min, 
resuspended  in  RPMI  1640  medium  (Invitrogen)  with  20%  FCS  and  10% 
DMSO, and frozen in aliquots as for other cell types.
2.1.6 Recovery of  frozen cells
Cells were removed from liquid nitrogen storage and thawed rapidly at 
37°C.  The cells were added to 9ml of complete media in a  15ml falcon tube 
and  then  pelleted  at  lOOOrpm  for  5min  to  remove  the  DMSO-containing 
media.  The pellet was then resuspended in  10ml of complete media and the 
cells split between two  10 cm dishes and incubated at 37°C in a 5% C02 and 
20% oxygen atmosphere until sub-confluence was reached, at which point the 
cells were then sub-cultured.
2.1.7 DNA transfection of mammalian cells
Cells  were  transfected  using  FuGENE  6  Transfection  reagent 
(ROCHE)  according  to  manufacturer’s  instructions.  The  DNA:transfection 
reagent ratio was  1:2.  Cells were plated at a density of 1 x 106 cells per 10cm 
plate the  day prior to transfection.  The  following  day the  cells  were  -50% 
confluent, and were transfected with 6pg of the vector DNA per plate. Where 
lysates were to be prepared from a transient transfection, media was changed 
the following day, and lysates prepared two days after the transfection.
882.1.8 Retroviral infection of rodent cells
2.1.8.1  Packaging the retroviral vectors
BOSC 23  cells (an ecotropic retroviral packaging cell line (Pear et al.,
1993))  were  plated  at  1.7  x  106  cells  per  6cm  plate  the  day  prior  to 
transfection.  Cells  were transfected the  following  day (at -50%  confluence) 
with 3pg of the retroviral vector DNA per plate using FuGENE 6 Transfection 
reagent  (ROCHE)  according  to  manufacturer’s  instructions.  The 
DNA:transfection  reagent  ratio  was  1:2.  Media  was  changed  the  following 
day,  adding  only  3ml  of  media  per  plate  rather  than  the  usual  5ml,  to 
concentrate  the  retroviral  supernatant.  Two  days  after  the  transfection,  the 
retroviral  supernatant  was  harvested,  filtered  through  a  0.45pm  filter,  and 
quickly frozen in aliquots at -80°C.
2.1.8.2  Retroviral infection
Cells for retroviral infection were plated at 7 x  105  cells per 10cm plate 
for NIH  3T3  cells,  or  1   x  106  cells  per  10cm plate  for REFs  (2  days  after 
preparation of the REFs, i.e. approximately passage 2). The following day at 
-50%  confluence),  media was  aspirated  from the plates,  and the  cells  were 
infected with retroviral  supernatant (thawed on ice,  volumes  in the range  of 
0.1-0.5ml  supernatant  were  used)  mixed  with  2ml  of media  per  plate,  and 
8 jig/ml polybrene, added dropwise of the surface of the plate. Cells were then 
incubated at 37°C for 2 hours, at which point the infection mixture was diluted 
out by adding a further 8ml of fresh medium per plate. Cells were maintained 
at 37°C, and 24-48 hours after infection, plates were split (1  in 10 and 1  in 50 
to  10cm plates  for NIH  3T3  cells,  or  1  in  8  and  1   in  16  to  15cm plates  for 
REFs).  48  hours  following  the  infection,  antibiotic  selection  was  added 
(2pg/ml puromycin), and media (including antibiotic) was changed every 3-4 
days.
892.1.8.3  Colony counting
Once cells transduced with the retrovirus had formed visible  colonies 
(approximately 10 days for NIH 3T3 cells, and 15 days for REFs), media was 
removed  from  the  plates  and  cells  were  stained  with  methylene  blue  (2% 
(w/v) methylene blue with 50% EtOH in ddH20) at room temperature for 10- 
15 minutes. Plates were then gently rinsed with water, and cell colonies were 
counted  to  allow  calculation  of retroviral  titre  (from  the  NIH  3T3  colony 
counts),  and  efficiency  of immortalisation  of the  retroviral  constructs  (from 
the REF colony counts, taking into account the retroviral titre calculated from 
the NIH 3T3 counts).
2.1.8.4  Isolation of clonal cell lines
After  retroviral  transduction  and  selection  with  2pg/ml  puromycin, 
single clones were expanded from the resulting colonies into cell lines.  Single 
clones  were  picked  using  sterile  cloning  cylinders  (Sigma).  The  growth 
medium  was  removed  from  each  dish  and  a  cloning  cylinder  (diameter  0.5 
cm) was applied around each selected clone by pressing it lightly against the 
plate after the bottom edge of the cloning cylinder had been dipped into sterile 
silicone grease.  Two drops of trypsin were then added and the cells incubated 
at  37°C  for  5  min.  The  detached  cells  were  then  collected  with  a  Pasteur 
pipette  and  the  trypsin  inactivated  with  complete  medium.  The  cells  were 
then plated into a 24 well plate and allowed to adhere and grow.  When 80% 
confluence was reached (from a couple of days to a week, depending on the 
growth rate for each clone) the cells were transferred into 3 cm dishes.  When 
80% confluence was reached again the cells were transferred to 6 cm dishes 
and  eventually  to  10  cm  dishes  and  subsequently  passaged  to  new  10  cm 
plates after lin 5 dilutions.
902.1.9 Focus formation assay
Cells  were  transduced  with  appropriate  (equivalent)  volumes  of 
retroviral  vectors  as  previously  described,  and  24  hours  later  cultures  were 
split,  but  into  medium  with  only 2%  serum  in  the  medium  (rather  than  the 
usual  10%, to reduce the number of spontaneous foci), and with no antibiotic 
selection. Cells were maintained at 37°C with media changes every 3-4 days. 
23 days post-transduction, all plates were washed twice with ice-cold IX PBS 
(without CaCl2 or MgCl2),  fixed with ice-cold methanol  for  lOmin, and then 
stained  at  room  temperature  for  lOmin  with  0.5%  crystal  violet  (Sigma) 
solution  (made  in  25%  methanol).  Plates  were  then  carefully  rinsed  in  tap 
water, and allowed to dry at room temperature.
2.2 BACTERIAL MANIPULATIONS
2.2.1 Bacterial strains
The JS4 Escherichia Coli strain (kindly provided by J.  Sedivy, Brown 
University)  was  used  for  plasmid  manipulation  and  preparation.  JS4  is  a 
recA\  derivative  of MCI061,  and  has  the  following  genotype:  F'araD139, 
A(ara, leu)7691, A(lac)%14, galU, galK, hsdRl (rk‘ mk ), mcrA, mcrBC, rpsL 
(Strr) thi, recAl.
E.  coli  strain  BLR  AJDE3  pLysS  (Novagen)  was  used  for  bacterial 
protein  expression  with the  Novagen  pET  System.  BLR  A,DE3  pLysS,  is  a 
recA- high-stringency derivative of E.  coli strain BL21, and has the following 
genotype:  F-  ompT  hsdSB   (rB   mB)  gal  dcm  A(srl-recA)306::Tnl0  (DE3) 
pLysS. It is also resistant to chloramphenicol (34pg/ml).
2.2.2 Media and maintenance
E.  coli cells were grown in Luria Broth, (LB medium, made up using 
25 g/L Luria Broth Base, Invitrogen).  15g/L of Agar (Oxoid) was added when
91plates  were  prepared.  To  make  up  the  media  all  the  components  were 
dissolved  in  ddH20   and  autoclaved  for  20  min  at  37°C.  When  required, 
ampicillin (Sigma) was added to 100 pg/ml final concentration.
2.2.3 Preparation of competent bacteria
500ml  of  LB  was  inoculated  with  a  single  bacterial  colony  and 
incubated with shaking at 37°C overnight.  5ml of the overnight culture were 
then diluted into  500ml of LB  and grown at 37°C with aeration for 2 to 2.5 
hours until the OD60o reached  1.0-1.2  (mid-exponential phase).  The bacteria 
were harvested by centrifugation at 2500rpm for 20 min, resuspended in 5ml 
ice cold 0.1M CaCl2 and incubated on ice for 20 min.  The bacteria were then 
centrifuged  again  and  resuspended  in  5ml  of ice-cold  85:15  solution  0.1M 
CaCl2  and  glycerol.  50pl  aliquots  were  frozen  in  pre-chilled  1.5ml  tubes 
using liquid N2, and then stored at -70°C.
2.2.4 Bacterial transformations
A single 50pl aliquot of frozen competent bacteria was thawed on ice. 
950pl ice cold 0.1M CaCl2 was added;  lOOpl of this mixture was then added 
to each DNA to be transformed.  The DNA was incubated with the bacteria on 
ice for 30 min followed by heat shock at 42°C for 90 sec.  The transformations 
were  returned  to  ice  for  2  min,  after  which  1ml  of LB  medium  (without 
ampicillin) was added and the transformations incubated at 37°C with shaking 
for 30 min.  The cells were then concentrated by centrifugation (2500rpm for 
10  min)  and resuspended  in  100pi  LB  medium.  The  transformations  were 
finally  plated  onto  10cm  pre-warmed  LB-agar  plates  containing  lOOpg/ml 
final concentration ampicillin and incubated overnight at 37°C.
922.3  DNA MANIPULATION
2.3.1 Polymerase Chain Reaction (PCR)
For  PCR  amplification  of  mBubl(l-561)  and  mBub 1(562-1058), 
incorporating a 6x His-tag, and restriction sites (see Chapter 4, Figure 4.2 for 
primer  sequences),  50pl  PCR  reactions  were  carried  out  (consisting  of  IX 
Thermophil  Buffer  (New  England  Biolabs,  contains  2mM  MgS04),  200pM 
mixed dXTPs (nucleotides), 0.5pM mixed forward and reverse primers, 250ng 
of  plasmid  DNA  (pcDNA3.1(+)-mBubl,  “B3”),  0.5jul  of  Vent  DNA 
polymerase (New England Biolabs), and ddH20).
The  following  PCR program was  used to  amplify the  mBubl( 1-561) 
and mBub 1(562-1058) DNA fragments, using a MJ Research Peltier Thermal 
Cycler:  94°C  for  3min,  then  5  cycles  of  denaturing  at  94°C  for  30sec, 
annealing  at  51°C  for  lmin  and extending  at  72°C  for 2min,  followed by  a 
further 25  cycles  the  same but with  an  annealing  temperature  of 64°C,  and 
then finally a further extension at 72°C for  lOmin,  followed by a  15°C hold. 
The two different annealing temperature were used to allow initial annealing 
of the vector sequence specific regions of the primers to the vector at a lower 
temperature,  followed  by  more  specific  annealing  at  a  higher  temperature 
suitable for the entire length of the primers.
2.3.2 DNA sequencing
The following primers, in addition to the forward and reverse primers 
used  for the  initial  PCR,  were used to  check the  mBubl  DNA  sequence  in 
clones of the mBubl(l-561)-pET and mBub 1(562-105 8)-pET vectors:
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BUB1SEQ1  5'FW ACT  GG  AAT  CCATTT  GCCAGCT  C 502
BUB1SEQ1  3'RV ATGCAATTT  CTT  GT  GAAGTT  CA 960
BUB1SEQ2 5'FW GAAATTGCATCAAGTGGTGGA 951
BUB1SEQ2 3’RV GT  CC  AT  GAT  G  AAACCT  AATGC 1443
BUB1SEQ3 5’FW G C  ATTAG GTTT  CAT  CAT  G  G  AC 1423
BUB1SEQ3 3'RV T  CTTTAT  CTT  CTGG  AAT  CT  GT  ACT 1895
BUB1SEQ4 5'FW GATT  CCAGAAGATAAAGAAAAT  GTGG 1878
BUB1SEQ4 3'RV GGCTCCTTCTCCAAGAAGGTG 2373
BUB1SEQ5 5'FW GCCTTTGCT  CAAGT  CTTT  G  AAG 2371
BUB1SEQ5 3’RV GTTT  CAT  AT  CT  AT  ACT  CT  G  ACCC  AGGT 2842
BUB1SEQ6 5'FW GATATGAAACTTTTCCCTAAAGGAAC 2833
BUB1SEQ6 3'RV T  CC  AT  ATT  C  ATTTT  AI  ITTCTTGAAC 3249
For  each  sequencing  reaction,  a  mixture  of 3.2pmol  primer,  500ng 
plasmid DNA, 8 pi ABI dRhodamine TRR Mix, made up to a final volume of 
20pl with ddH20, was submitted to 25  cycles of 95°C  for 30sec,  followed by 
50°C  for  30sec,  and  finally  60°C  in  a  PCR  machine  (MJ  Research  Peltier 
Thermal  Cycler).  After the  final  cycle,  sequencing reactions  were  cooled to 
4°C,  and  cleaned  using  a  DyeEx  spin  kit  (QIAGEN),  according  to 
manufacturer’s  instructions.  Samples  were then vacuum  dried,  and run  on  a 
sequencing  gel  and  analysed  by  the  Ludwig  Institute  for  Cancer  Research 
DNA sequencing facility.
2.3.3  Plasmid DNA preparation
All  the  plasmid  preparations  (both  small  scale  and  large  scale 
preparations)  were  carried  out  using  QIAGEN  kits,  and  following  the 
manufacturer’s instructions.
2.3.3.1  Small scale preparation
Bacterial  stocks  were  kept  at  -70°C  in  LB  containing  15%  glycerol. 
Liquid  cultures  of bacteria  picked  from  single  colonies  were  grown  in  a 
bacterial shaker (vigorous shaking)  overnight at 37°C  in  5ml of LB medium 
with  lOOpg/ml  ampicillin.  1.5ml  of  culture  was  then  transferred  to  an 
eppendorf  tube  and  microfuged  at  13000rpm  for  30sec.  The  pellet  was
94resuspended in 250pl of solution PI  (50mM Tris/HCl, pH 8.0,  lOmM EDTA, 
100  mg/ml  RNAse  A).  Then  250pl  of  solution  P2  (200mM  NaOH,  1% 
sodium dodecyl sulphate (SDS)) was added and gently mixed by inverting the 
tube 4-6 times.  To the same tube, 350pl of solution N3 (3.0M sodium acetate, 
pH 5.5) was added and immediately mixed by inverting the tubes 4-6 times. 
The mixture was then centrifuged in a microfuge for lOmin at  13000rpm and 
the  supernatant  transferred  to  a  QIAprep  column.  The  column  was  then 
centrifuged  for  30sec  at  13000rpm  and  the  flow-through  discarded.  The 
columns were first washed with 0.5ml of PB buffer (QIAprep Spin Miniprep 
kit,  QIAGEN)  and  then  0.75ml  of PE  buffer  (QIAprep  Spin  Miniprep  kit, 
QIAGEN).  The DNA was then eluted with 50pi of ddH20. (All solutions used 
were from the QIAprep Spin Miniprep kit, QIAGEN)
2.3.3.2  Large scale preparation
200ml  of LB  containing  1  OOpg/ml  ampicillin was  inoculated with  an 
overnight  culture  of bacteria  and  grown  overnight  at  37°C  with  vigorous 
shaking.  Bacteria were harvested at 7000rpm for lOmin at 4°C and the pellet 
resuspended  in  10ml  of resuspension  buffer  PI  (50mM  Tris-HCl  pH  8.0, 
lOmM EDTA,  100 pg/ml RNAse A, stored at 4°C).  10ml of lysis buffer P2 
(200mM  NaOH,  1%  SDS)  were  added.  After  5min  incubation  at  room 
temperature,  10ml  of  ice-cold  neutralisation  buffer  P3  (3mM  potassium 
acetate pH  5.5) were added and the mixture was  further incubated on ice for 
20min  with  occasional  inversion.  The  cell  debris  was  pelleted  by 
centrifugation  at  15000rpm  in  a  Beckman  JA-17  rotor  for  30  min.  The 
recovered supernatant was  applied to  a previously equilibrated QIAGEN-tip 
500 column (equilibration buffer QBT: 750mM NaCl, 50mM MOPS  [3 - (N- 
morpholino) propanesulphonic acid]  pH 7.0,  15% Ethanol v/v, 0.15% Triton 
X-100)  and allowed to  enter the resin by gravity.  The  column was  washed 
twice with 30ml  of wash buffer QC  (1M NaCl,  50mM  MOPS pH  7.0,  15% 
Ethanol).  The DNA was then eluted with  15ml of elution buffer QF (1.25M
95NaCl,  50mM  Tris-HCl  pH  8.5,  15%  Ethanol)  and precipitated in  10.5ml  of 
isopropanol at room temperature.  Centrifugation was performed for 30 min at 
15000rpm at 4°C in the same rotor previously used and the DNA pellet was 
then  washed  with  70%  ethanol.  The  pellet  was  air  dried  for  5  min  and 
resuspended in ddH20.  The DNA obtained was then checked by appropriate 
restriction digests and run on an agarose gel. (All solutions used were from the 
QIAfilter Plasmid Maxi kit, QIAGEN)
2.3.3.3  DNA quantification
To  determine  DNA  concentration,  the  optical  density  of the  solution 
was measured at 260nm (OD26o) using a BioRad spectrophotometer (Bio-Rad 
Smart Spec™ 3000  Spectrophotometer).  DNA concentration was  calculated 
using the relationship:
1  OD unit at 260nm = 50pg/ml DNA.
The DNA was also checked by running 1  pi on an agarose gel.
2.3.4 Restriction digests
Restriction  digestions  of DNA plasmids  were performed using 
restriction  enzymes  from  New  England  Biolabs  and  Boehringer  Mannheim 
according  to  the  specified  conditions.  The  10X  buffer  provided  for  each 
enzyme  was  diluted  to  IX  in  the  final  reaction  mixture.  Bovine  serum 
albumin  (BSA,  New  England  Bio  Lab)  was  used  at  IX  dilution  when 
required.  Other  conditions  such  as  incubation  time  and  temperature  were 
performed according to the manufacturer’s guidelines for the specific enzyme.
2.3.5 DNA agarose gel electrophoresis
DNA  fragments  were  loaded  with  IX  DNA  loading  buffer  (2.5% 
Ficoll, 0.04% (w/v) bromophenol blue and 0.04% Xylene) and fractionated by
96electrophoresis  on  1%  (w/v)  agarose  (Invitrogen)  gels,  prepared in  IX  TAE 
(40mM Tris-acetate and 2mM EDTA) with 1   pg/ml ethidium bromide (BDH). 
Electrophoresis in  IX TAE was carried out in electrophoresis tanks and DNA 
fragments were  separated at a constant voltage  of 80V  for  1  or more hours. 
Samples  were  loaded  alongside  double  stranded  DNA  molecular  weight 
markers,  lkb-ladder (GibcoBRL).  Ethidium bromide stained DNA fragments 
were  then visualised on  a UVP  (Dual  intensity ultraviolet trans-illuminator) 
and an image was produced and printed with a Sony video graphic printer.
2.3.6 Extraction of  DNA from agarose gels
DNA  restriction  fragments  separated  on  agarose  gels  were 
purified using the QIAquick Gel Extraction Kit (QIAGEN),  according to the 
manufacturer’s instructions.  After agarose separation DNA was viewed with 
a long wavelength ultraviolet emission (UV) transilluminator and the desired 
band was cut out using a scalpel and transferred to an eppendorf tube.  The gel 
slice  was  dissolved  by  adding  3  volumes  (per  weight  of gel  slice)  of QG 
buffer (QIAquick spin kit, QIAGEN) and incubating at 50°C for 10 min.  The 
sample was then transferred to a QIAquick spin column and centrifuged for 1  
min after which the DNA in the column was washed with 0.75ml of PE buffer 
(QIAquick  spin  kit,  QIAGEN).  Traces  of wash  buffer  were  removed  by 
centrifugation  for  lmin.  Finally,  the  DNA  was  eluted  by  adding  30p,l  of 
ddH20  and  centrifugation  for  lmin  at  full  speed in  a  microcentrifuge.  The 
DNA was collected in a 1.5ml microfuge tube.
2.3.7 Ligation
All ligations performed during this project were cohesive-end (“sticky- 
end”)  ligations.  Ligation  reactions  were  performed  using  lpl  of T4-Ligase 
(New England Biolabs) in IX ligation buffer (50mM Tris-HCl pH 7.5,  lOmM 
MgCl2,  lOmM  dithiothreitol,  ImM  ATP,  25  pg/ml  BSA).  The  amount  of
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The ligation mixture was incubated at 16°C overnight or at room temperature 
for at least 2 hours before transforming competent E. coli cells.
2.3.8  Plasmids used
pBabe-puro-L 13V,  D44N  E90A,  W91A,  E92A,  Q93A,  W94A  & 
W95A  and  dl89-97  (each  containing  mutated  full-length  SV40  LT  cDNA), 
pBabe-puro-wild-type  LT,  pBabe-puro-(empty  vector),  pSUPERretro-Bubl 
(Oligoengine  vector  allowing  knockdown  of  Bubl  expression  via  RNAi 
interference  (RNAi)),  pSUPERretro(empty vector),  pcDNA3.1(-)HA-mBubl 
were kindly provided by Dr Ole Gjoerup of the Dana-Farber Cancer Institute, 
Boston, MA, USA.
mBubl  cDNA  originally  cloned  into  the  Notl  and  Sail  sites  of the 
pcDNA3.1(+)  (Invitrogen)  expression  vector  by  T.  Puri,  a  final  year 
undergraduate  project  student  in  the  laboratory,  was  PCR  amplified  in  two 
sections, incorporating restriction sites and a 6 x His-tag, and cloned into the 
pET-23a+  bacterial  expression  vector  (Novagen)  between  the  Xbal  and 
BamHI sites.
2.4  PROTEIN ANALYSIS
2.4.1  Preparation of  total protein extracts
Cells were either seeded (3  x  106 cells per  15cm plate for U20S, REF 
or NIH 3T3 cells, to give -80% confluence on day of lysis), or were fed with 
fresh media the day prior to lysis. For the lysis, cells were washed twice with 
cold IX PBS (Phosphate Buffered Saline (without CaCl2 or MgC^)), and 1ml 
of  IX  RIPA  Lysis  Buffer  [150mM  NaCl,  1%  Triton-X-100,  0.5%  sodium 
deoxycholate (NaDOC), 0.1% SDS and 50mM Tris pH 8.0] or IX NP40 Lysis 
Buffer  (150mM  NaCl,  1%  Nonidet  P-40,  50mM  Tris  pH8.0,  5mM  EDTA)
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P2714,  1  bottle  dissolved  in  10ml  of ddH20)  was  included  per  ml  of lysis 
buffer.  The  cells  were  incubated  for  30min  on  ice  and  then  scraped  and 
transferred to  a  1.5ml microfuge tube.  For the RIPA lysates  only,  the  lysate 
was then passed three times through a 21  gauge needle to shear the DNA. The 
cell  extracts  were  then  centrifuged  for  30min  at  lOOOOrpm  at  4°C  and  the 
supernatant  transferred  to  a  fresh  microfuge  tube.  The  cell  lysates  were 
aliquoted and stored at -20°C.
2.4.2 Determination of  protein concentration
Protein  concentrations  were  determined  using  the  Bio-Rad  protein 
assay  (Bio-Rad  Laboratories),  a  protein  assay based  on  the  Bradford  assay 
(Bradford,  1976).  The dye reagent was diluted  1:5 in PBS.  A BSA standard 
curve was established with protein dilutions ranging from  1  to  15pg/ml.  2pi 
of each sample were mixed with  1ml of freshly diluted dye and incubated at 
room temperature  for 5  min.  OD595  was  measured  (Bio-Rad  Smart  Spec™ 
3000  Spectrophotometer)  and  plotted  against  protein  concentration  of 
standards.  Regression  coefficient  was  calculated  and  the  unknown  sample 
concentrations determined.
2.4.3  Sodium  dodecyl  sulphate-polyacrylamide  gel  electrophoresis  (SDS-
PAGE)
8%  Sodium  dodecyl  sulphate-polyacrylamide  gel 
electrophoresis  (SDS-PAGE)  gels  were  prepared  from  a  30%  (w/v) 
acrylamide  stock  solution  (containing  a  ratio  of 29.2  aerylamide:0.8  NN’- 
methylenebisacrylamide; Genomic Solutions) in 375mM Tris-HCl pH 8.8 and 
0.1%  (w/v)  SDS.  Gels  were  polymerised  by  addition  of  ammonium 
persulphate  (APS)  (0.1%  (w/v)  final;  Bio-Rad)  and  TEMED  (N,N,N’,N’ 
tetraethylenemethyldiamine, 0.0006% (w/v) final; BDH Laboratory). For 12%
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polymerising agents were adjusted slightly.
For  direct  immunoblot  50pg  of  each  cell  lysate  (unless  otherwise 
stated) was heated at 90°C for 5min with 2X Laemmli sample buffer (IX final 
concentration,  Sigma;  4%  SDS,  20%  glycerol,  10%  2-mercaptoethanol, 
0.004% bromophenol blue and 0.125 M Tris-HCl, pH 6.8) and fractionated by 
SDS-PAGE  on  8%,  12%  or  5-15%  gradient  polyacrylamide  gels,  as  more 
convenient.  Electrophoresis  was  carried  out  at  a  constant  voltage  of  100- 
150V  during  the  day  (or  40V  overnight)  in  running  buffer  (25mM  Tris, 
190mM  Glycine,  0.1%  (w/v)  SDS).  Proteins  were  stacked through 2cm  of 
stacking gel  (5%  polyacrylamide,  125mM  Tris-HCl pH  6.8  and 0.1%  (w/v) 
SDS, polymerised by addition of APS and TEMED as before).  Proteins were 
fractionated alongside broad-range prestained SDS-PAGE standards (Bio-Rad 
Laboratories).
2.4.4 Coomassie staining of  SDS-PAGE
Following  SDS-PAGE,  for visualisation  of total  protein,  the  gel  was 
incubated at room temperature for 4-5 hours in a stain containing 0.05% (v/v) 
Coomassie Blue,  10% (v/v) methanol and  10%  (v/v)  glacial acetic  acid.  The 
gel was then de-stained for several hours in the same solution but without the 
Coomassie  Blue,  and dried using  a  gel  drier  (Hoefer  Scientific  Instruments, 
San Francisco) attached to a vacuum pump.
2.4.5 Western blotting of  SDS-PAGE
Following  separation  via  SDS-PAGE,  proteins  were  transferred  to  a 
nitrocellulose  membrane  Hybond-c  extra  (Amersham  Life  Science)  by 
electrophoretic  transfer in a wet tank blotting  system  (Bio-Rad Laboratories 
Trans-Blot cell).  The transfer was carried out in transfer buffer (25mM Tris,
100190mM glycine and 20% (v/v) methanol) for 4 hours at a constant voltage of 
60V at 4°C or alternatively overnight at a constant voltage of 20V (4°C).
The  nitrocellulose  membrane  was  then blocked by  incubation  in  5% 
(w/v)  skimmed  milk  powder  (Marvel,  Premier  Brands)  and  0.005%  (v/v) 
Tween-20 (BDH Laboratory) in 0.5X PBS (PBS/Marvel) at room temperature 
for 1   hour (or overnight at 4°C).  The filter was then incubated for  1   hour at 
room temperature,  or overnight at 4°C  with the primary antibody diluted in 
PBS/Marvel  at the  indicated dilutions  (see Paragraph 2.4.8).  The  filter was 
then  washed  three  times  (15min  each  at  room  temperature)  in  0.05%  (v/v) 
Tween 20  and 0.5X  PBS  (PBS/Tween)  prior to  incubation with horseradish 
peroxidase  (HRP)  conjugated  secondary  antibody  (Amersham  Life  Sciences 
ECL™ western blotting analysis system) diluted  1:2000 in PBS/Tween for  1  
hour.  Following three  further washes  (15min  each  at room  temperature)  in 
PBS/Tween, the filters were developed in HRP detection reagents  for 90sec, 
according  to  manufacturer’s  instructions  (ECL™,  Amersham  Pharmacia 
Biotech).  The membrane was then wrapped with Saran-wrap and exposed to 
an  auto-radiographic  film  for  times  varying  from  lOsec  to  lhour  (Fujifilm 
Super RX X-ray film).  The films were developed with an AGFA X-ray film 
processor.
2,4.6  Immunoprecipitation
All  immunoprecipitations  (IPs)  were  carried  out  using  pre-prepared 
NP40 lysates. 0.4-1 mg of each lysate for IP was made up to a final volume of 
500pl  or  1ml,  as  appropriate,  with NP40  lysis  buffer  in  a  1.5ml  eppendorf 
tube. Antibody for IP (50-100pl per IP for monoclonal antibody supernatants, 
or 2-5 jil  per IP  for polyclonal  antisera)  was  added,  and  lysates  were  mixed 
with the  antibody  on  a wheel  at 4°C  for  1-2  hours.  50pl  of 50%  Protein A- 
sepharose beads in  IX PBS  (Amersham Pharmacia Biotech) were added per 
IP,  and  the  tubes  were  incubated  at  4°C  on  the  wheel  for  a  further  hour 
(Protein G-sepharose beads in  IX PBS (Amersham Pharmacia Biotech) were
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pelleted at 6000rpm for lmin at 4°C, and washed three times with 800pi NP40 
lysis  buffer  and  further  centrifugation.  Following  a  final  spin,  the  last 
remnants of the wash were removed, and 50pl of 2X Laemmli Sample buffer 
(Sigma) was added per tube. Each tube was then vortexed briefly, and heated 
at  90°C  for  10-15min,  after which  the  beads  were  pelleted  at  6000rpm  for 
lmin,  and  the  supernatant  was  removed  to  a  fresh  eppendorf,  ready  for 
separation via SDS-PAGE, and western blotting.
2.4.7  Immunofluorescence
Cells were seeded at 3 x 10  cells per well onto glass coverslips in a 24- 
well  plate.  3  days  later cells  were  50-70%  confluent  on  the  coverslips,  and 
were  fixed  with  ice-cold  methanol  for  lOmin  at  -20°C.  All  antibody 
incubations and washes were in “IF Buffer” (IX PBS with  1% BSA (bovine 
serum albumin) and 0.5% CHAPS (3-[(3-cholamidopropyl)dimethylamino]-l- 
propanesulphonate)), and were carried out at room temperature. Cells on each 
coverslip  were  blocked  with  40pl  1:1  medium:IF  Buffer  for  lOmin,  and 
washed 5 times (IF Buffer). Cells were then incubated with primary antibody 
for 30min, and washed 5 times.  Finally, cells were incubated with secondary 
antibody for 30min (in the dark).  Where used, propidium iodide (PI,  1:1000 
dilution of ImM stock) was included with the secondary antibody, to visualise 
the DNA.  After 5  final washes, the coverslips were mounted on microscope 
slides using DAKO  Fluorescent Mounting Medium,  and images  of the  cells 
were  obtained  using  a  Zeiss  LSM  510  confocal  laser-scanning  microscope 
(Welwyn  Garden  City,  UK),  using  the  accompanying  LSM  510  software. 
Some  of  the  immunofluorescence  images  presented  in  this  thesis  were 
captured from cells stained by Miss S. Klischies.
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Anti-Cyclin B1  mouse monoclonal (clone GNS-11),  1:1000 anti-Mad2 
mouse monoclonal (clone 48), and  1:1000 anti-p55Cdc (clone 41) were from 
BD  Pharmingen;  anti-Mad2Ll  mouse  monoclonal  (ab 10691)  was  from 
Abeam;  anti-hPTTG-1  rabbit polyclonal was  from Zymed Laboratories  Inc.; 
anti-actin mouse monoclonal (AC-40) was from Sigma.
Rabbit polyclonal antiserum raised against amino acids 1-303 of hBubl 
fused in-frame to GST (“NT hBubl  serum Ab”), NT hBubl  affinity purified 
rabbit polyclonal,  and rabbit polyclonal raised against amino acids  691-1085 
of  hBubl  fused  in-frame  to  GST  (“CT  hBubl  serum  Ab”)  were  kindly 
provided  by  Dr  Raimundo  Freire  (Hospital  Universitario  de  Canarias, 
Tenerife,  Spain).  anti-Bub3  rabbit  polyclonal  “953”,  was  a  gift  from  Prof 
Peter Sorger (Massachusetts Institute of Technology, Cambridge, MA, USA). 
Anti-HA mouse monoclonal was kindly provided by Dr Claire Wells (LICR- 
UCL).  Anti-SV40  LT  mouse  monoclonal  antibodies  PAb416,  PAb419  and 
PAb423,  and  p53  mouse  monoclonal  antibody  PAb421  (hybridoma 
supernatants) were harvested at LICR-UCL by Prof Parmjit Jat.
HRP  (Horseradish peroxidase)-conjugated secondary antibody against 
whole  mouse  serum  or  against  whole  rabbit  serum  were  from  Amersham 
Pharmacia Biotech.
The antibodies used for western blots were  diluted as  follows:  Cyclin 
B1  (GNS-11)  1:500;  Mad2  (48)  1:1000;  p55Cdc  (41)  1:1000;  Mad2Ll 
(abl0691)  1:1000 (used 2pl per 500pg lysate IP); hPTTG-1  1:125; actin (AC- 
40  1:10000;  NT  hBubl  serum Ab  1:2000;  NT  hBubl  Affinity Pure  1:2000 
(used  3pl per  500pg  lysate  IP);  CT hBubl  serum Ab  1:2000  (used  3pl  per 
500pg  lysate  IP);  Bub3  (953)  1:2000  (used  3pl  per  500pg  lysate  IP);  HA 
1:1000; PAb416  1:50; PAb419  1:50; PAb423  1:50; hybridoma tissue culture 
supernatants of anti-mBubl mouse monoclonals generated during this project, 
2B8,  13G9  and  17E9,  were  used  at  1:25;  HRP-conjugated  secondary 
antibodies 1:2000.
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anti-mBubl  mouse monoclonals 2B8,  13G9, and  17E9 were used at  1:8; anti- 
p-Tubulin (Sigma)  1:100. FITC- and TRITC-conjugated secondary antibodies 
used  for  immunofluorescence  were  from  Jackson  Immunoresearch 
Laboratories Inc., and were used at 1:100.
2.5  GENERATION OF MONOCLONAL ANTIBODIES
2.5.1 Protein expression
2.5.1.1  IPTG induction of protein expression
500pl  of an overnight culture of E.  coli expression  strain BLR >JDE3 
pLysS, transformed vector for expression of the protein of interest (mBubl(l- 
561)-pET  or  mBubl(562-1058)-pET)  was  inoculated  in  5ml  LB  (with 
100pg/ml  ampicillin)  and  grown  at  37°C  with  shaking  until  an  OD6oo 
spectrophotometer reading of 0.4-1  was reached.  1ml of the culture was saved 
as  an  “uninduced”  sample,  while  a  final  concentration  of  0.4mM  IPTG 
(isopropyl-P-D-thiogalactopyranoside)  was  added  to  the  remainder  of  the 
culture to induce protein expression. Protein expression was induced at 37°C 
for 2 hours.
To  extract  total  protein  from  these  induced  samples,  cells  were 
harvested  from  both  uninduced  and  induced  samples  by  centrifugation  at 
lOOOOrpm  for 5min at 4°C.  The pellets were washed with  1ml ice-cold PBS 
and  resuspended  in  a  1:1  mix  of  PBS  and  2X  Laemmli  Sample  Buffer 
(Sigma), heated at 90°C for 5min, and run on an 8% SDS-PAGE gel. The gel 
was  then  Coomassie  stained  to  check  for  induction  of  expression  of  the 
protein of interest.
2.5.1.2  Native protein mini-prep: protein solubility test
Protein  expression  was  IPTG  induced  as  described  above,  but 
following a 30°C induction for 3 hours (induces better than 37°C, but takes a
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4°C, then air-dried on ice,  and frozen at -20°C.  The protein mini-prep under 
native  conditions  was  carried  out  as  suggested  by  QIAGEN 
(QIAexpressionist™  manual).  The  cell  pellet  was  thawed  on  ice  and 
resuspended in  IOOjl iI  IX Ni- Bind Buffer (50mM Tris-HCl pH 7.9,  300mM 
NaCl,  ImM  imidazole),  followed  by  incubation  with  1  mg/ml  lysozyme  for 
30min on ice.  Cells were then lysed by vortexing (avoiding frothing),  spund 
down  at  lOOOOrpm  for  lOmin  (4°C)  to  remove  cellular  debris,  and  the 
supernatant was transferred to a fresh tube. 20pl of a 50% slurry of Ni-NTA 
His-Bind resin (QIAGEN) was added, and mixed on a wheel at 4°C for 30min. 
The resin was then pelleted at 6000rpm for  lmin,  and the resin was washed 
twice  with  lOOpl  of  IX Ni-  Wash  Buffer  (50mM  Tris-HCl  pH7.9,  300mM 
NaCl,  lOmM  imidazole),  with  spinning  at  6000rpm  for  lmin.  The  His-tag 
protein was then eluted three times with 20pl of IX Ni- Elute Buffer (50mM 
Tris-HCl pH7.9,  300mM NaCl,  250mM imidazole),  and half of each elution 
was mixed with  10pl 2X Laemmli Sample Buffer (Sigma) and separated on a 
8% SDS-PAGE gel via Coomassie staining.  Successful elution of the protein 
of interest indicated that the protein was expressed in a soluble form.
2.5.1.3  Bulk soluble protein purification
5ml  of an overnight culture was used to inoculate each of 8  flasks  of 
500ml  LB  +  antibiotics  (50pg/ml  ampicillin  and  34pg/ml  chloramphenicol) 
and grown at 37°C with shaking until an OD60o spectrophotometer reading of 
0.4-1  was reached.  Protein  expression was  IPTG  induced  (0.4mM  IPTG)  at 
30°C for 4 hours, after which cells were harvested at 3000rpm for 20min and 
the cell pellets frozen on dry-ice/ethanol,  and stored at -20°C  overnight.  Cell 
pellets were thawed on ice and resuspended in a total volume of 80ml Native 
Lysis  Buffer  (50mM  NaH2PC>4  pH  8.0,  300mM  NaCl,  ImM  imidazole), 
followed by incubation on ice  for 30min with  1 mg/ml lysozyme.  The lysate 
was then sonicated on ice 6 times for  lOsec, with  lOsec breaks, followed by 
drawing the mixture 5 times through a 21-gauge needle.  The lysate was then
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was  incubated  with  1ml  of  a  50%  slurry  of  Ni-NTA  His-Bind  resin 
(QIAGEN) for 60min on a wheel at 4°C. The supematant/resin mix was then 
loaded  onto  a  column  (the  flow-through  was  retained  for  a  further 
preparation), and the resin was washed 5 times with 4ml Native Wash Buffer 
(50mM  NaH2PC>4  pH  8.0,  300mM  NaCl,  lOmM  imidazole).  His-tagged 
protein  was  then  eluted  5  times  with  0.5ml  Native  Elution  Buffer  (50mM 
NaH2PC >4 pH 8.0, 300mM NaCl, 250mM imidazole), and stored at -20°C. The 
protein  was  later  thawed  on  ice,  dialysed  into  IX  PBS  at  4°C,  and 
concentrated  10-fold  using  Centricon-30  columns  (No.  4208),  ready  for 
immunisation of mice.
2.5.1.4  Bulk insoluble protein purification
IPTG  induction  of  protein  expression  and  harvesting  of  cells  was 
carried out as described for Bulk soluble protein purification (Section 2.5.1.3). 
Cell pellets were thawed on ice and resuspended in a total volume of 80ml of 
Denaturing  Lysis  Buffer  (6M  GuHCl  (guanidine  hydrochloride),  lOOmM 
NaH2P04 5   lOmM  Tris,  adjusted to pH  8.0 using NaOH)  and incubated on  a 
wheel  at  room  temperature  for  30min,  followed by  vortexing  until  a  clear, 
“translucent”  solution  was  achieved.  The  lysate  was  then  cleared  by 
centrifugation at 9000rpm for 20min at room temperature, and the supernatant 
was  incubated  with  1ml  of  a  50%  slurry  of  Ni-NTA  His-Bind  resin 
(QIAGEN) for 60min on a wheel at room temperature. The supematant/resin 
mix was then spun down at  lOOOrpm for  lmin (the supernatant was retained 
for  a  further preparation),  and  the  resin  was  washed  2  times  with  10ml  of 
Denaturing Lysis Buffer for 30min on a wheel at room temperature, followed 
by  4  washes  with  5ml  of  Denaturing  Wash  Buffer  (6M  GuHCl,  lOOmM 
NaH2P0 4 5 lOmM Tris, adjusted to pH 6.0 using HC1) . His-tagged protein was 
then eluted 10 times with 1ml Denaturing Elution Buffer (6M GuHCl, lOOmM 
NaH2P04,  lOmM Tris, adjusted to pH 3.0 using HC1) for 5min on a wheel at 
room  temperature  (for  each  elution,  resin  was  spun  down  at  lOOOrpm  for
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at -20°C. The protein was later thawed on ice, dialysed into 2M Urea at 4°C, 
and concentrated 10-fold using “Centriplus” Centricon YM-10 columns, ready 
for immunisation of mice.
2.5.2 Immunisations, generation of hybridomas, and ELISA screening
Immunisations of mice with the His-tag fusion proteins, generation of 
hybridomas via somatic cell fusions, single cell cloning, ELISA screening and 
isotyping of the resulting hybridomas was carried out by Dr T. Jowett (UCL 
monoclonal antibody facility).
2.5.3 Harvesting monoclonal antibody tissue culture supernatant
Hybridoma  cells  were  cultured  until  large  volumes  (300-600ml)  of 
media with dense cells was achieved. Dense cultures of cells were maintained 
at  37°C  for  1-2  weeks,  allowing the  cells  to  die.  Tissue  culture  supernatant 
was then harvested by centrifugation at 2000rpm for  15min at 4°C,  followed 
by filtration using a 0.22pm Stericup™ filter (Millipore). Stocks of hybridoma 
tissue culture supernatant were stored at -20°C, supplemented with 0.1% NaN3  
(sodium azide).
2.5.4 Affinity purification of monoclonal antibodies
Affinity  purification  of  monoclonal  antibodies  was  carried  out  in 
collaboration  with  Dr  G.  Mallinson  at  the  MRC  Prion  Unit,  Institute  of 
Neurology,  UCL.  Approximately  350ml  of  hybridoma  tissue  culture 
supernatant (without sodium azide) was concentrated down to approximately 
40ml  using  an  Amicon  8200  stirred  cell  with  a  Millipore  Ultrafiltration 
membrane.  The  AKTAprime  machine  (automated  liquid  chromatography 
system  from  Amersham  pharmacia  biotech)  was  used  to  purify  the
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in the concentrated hybridoma tissue culture supernatant were bound to a 1ml 
HiTrap  Protein  G  column  (Amersham  pharmacia  biotech)  with  Buffer  A1 
(50mM  sodium  phosphate,  pH  7.2),  and  the  column  was  washed  with  the 
same buffer.  Affinity purified IgG was  eluted in Buffer B  (lOOmM  glycine- 
HC1, pH 2.5), and stored in aliquots at -80°C with 0.1% NaN3.
2.6 TIME LAPSE MICROSCOPY
Time  lapse  movies  were  created  using  Tempus  software  (Kinetic 
Imaging  Ltd,  Liverpool,  UK)  with  images  captured using  a  KPM1E/K-S10 
CCD  camera (Hitachi  Denshi,  Japan),  in  collaboration with Dr A.  Entwistle 
(Ludwig  Institute  for  Cancer  Research  Microscopy  Facility,  UCL  branch, 
London).
2.7 KARYOTYPE ANALYSIS
2.7.1  Metaphase spreads
Cells were grown to 60-80% confluence, and 2 hours after feeding the 
cells with  fresh  medium,  0.1 pg/ml  colcemid  (KaryoMAX  colcemid  solution 
Invitrogen) was added to the medium. Cells were incubated with colcemid for 
4  hours  at  37°C,  after which time  many  “rounded”  cells  arrested  in  mitosis 
could be seen under the microscope. Cells were then trypsinised as usual, and 
pelleted at 700g for 5min. The pellet was then washed twice (700g for 5min) 
with  10ml  IX PBS, and carefully resuspended in  1ml of Hypotonic  Solution 
(0.56%  KC1)  until  a  single  cell  suspension  was  obtained.  A  further  4ml  of 
Hypotonic  Solution was then  added,  and the  cells  were  incubated  in  a 37°C 
waterbath  for  5min.  The  cells  were then pelleted at  300g  for  5min,  and the 
supernatant was removed, leaving 200-400pl behind,  in which the pellet was 
resuspended. Cells were then fixed by very carefully adding ice-cold Fixative
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tube  to  mix  it),  and  then  gradually  adding  up  to  5ml  of the  fixative,  and 
leaving at room temperature for 5min. Cells were then spun down at 300g for 
5min, the supernatant removed, and the fixing step repeated to a total of 2-3 
times, after which cells were resuspended in  l-2ml of the fixative.  1-2 drops 
of cells were then dropped from a height of 30-50cm onto clean glass  slides 
(the slides had been pre-soaked in 5% acetic acid in EtOH for a few hours and 
air dried). The slides were allowed to air dry overnight, after which they were 
stained with 5pM propidium iodide (PI) for  lOmin. The stain was blotted off 
with a tissue,  and the slides were mounted under a coverslip with 5pM PI in 
glycerol and sealed with nail varnish.
2,7,2  Image capture of metaphase spreads
Images  of metaphase  spreads  were  captured  using  a  Zeiss  LSM  510 
confocal laser-scanning microscope (Welwyn Garden City, UK).
2.8  FACS ANALYSIS
2,8,1  Fixing cells for FACS (fluorescence-activated cell sorting)
Cells  plated  at  a  density  of 3  x  105   per  10cm  plate  were  treated  as 
required  (e.g.  drug  treatment),  and  trypsinised  as  usual.  Cells  were  then 
pelleted at  lOOOrpm for 5min,  washed once  with  IX PBS  (lOOOrpm,  5min), 
and resuspended in  a  few remaining  drops  of IX  PBS.  The  cell  suspension 
was then vortexed very gently while adding ice-cold 70% EtOH dropwise, up 
to a final volume of 4ml, transferred to a 5ml round-bottomed polypropylene 
tube (Falcon), and stored at 4°C for at least 30min, and until ready for FACS 
analysis.
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analysis
EtOH  from the fixed cells was spun off at 2000rpm for 5min, and the 
cells were washed twice with 5ml  IX PBS (2000rpm, 5min), being careful to 
avoid cell loss when discarding the supernatant. To ensure that only DNA is 
stained,  cells  were  next  treated  with  50pl  of  lOOpg/ml  RNase  (Sigma)  for 
15min at room temperature. Cells were then incubated for a further 30min at 
room temperature  with  200pl  of 50pg/ml  propidium  iodide,  at  which  point 
they were ready for analysis by flow cytometry.
2.8.3 PI FACS analysis
All  FACS  analysis  was  carried  out  by  Dr  Derek  Davies  (Cancer 
Research  UK  FACS  laboratory),  using  a  FACSCalibur  machine  (Becton 
Dickinson).
1103. Mapping of the Bubl interaction site on SV40
large T antigen
3.1  OBJECTIVES
The first objective of this study was to determine the exact residue(s) of 
SV40 large  T  antigen  (LT)  that are required for interaction with the  spindle 
checkpoint protein Bubl. This was an important step for the project, as cells 
expressing a non-Bubl-binding mutant of LT would be an invaluable negative 
control in experiments examining the importance of the LT-Bubl  interaction 
for cell cycle control. In addition, it would also allow examination of whether 
Bubl  interaction  is  necessary  for  any  of the  well-characterised  functions  of 
LT,  including  its  immortalisation  and  transformation  functions.  Part  of the 
work presented in this chapter is already published (Cotsiki et al., 2004).
3.2  EXPERIMENTAL STRATEGY
As  previously  described,  the  interaction  of Bubl  with  LT  was  first 
identified using the amino terminal 136 residues of LT as a bait in a yeast two- 
hybrid  screen,  and  a  HeLa  cDNA  library  as  prey.  It  was  therefore  already 
known that the binding site of Bubl  on LT was present within this region of 
the  viral  protein.  For  this  reason,  full  length  cDNAs  of several  previously 
characterised LT mutants within this region were transduced into primary Rat 
Embryo Fibroblasts (REFs), and the resulting cell lines generated were used to 
determine the Bubl-LT binding site via co-immunoprecipitation experiments. 
Primary  REFs  were  used  so  that  the  immortalising  efficiency  could  be 
determined concomitantly with the Bubl  binding efficiency of each of the LT 
mutants.
Initially,  the  LT  mutations  chosen  for  the  mapping  were  the  point 
mutants L13V and D44N, and the deletion mutant dl89-97.  L13V and D44N
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within  the  amino  terminus  of LT.  dl89-97  was  included  because  Professor 
Tom Roberts’  laboratory had found that an unknown protein kinase binds to 
LT  and this binding is  disrupted in the dl89-97 mutant.  It was hypothesised 
that this unknown kinase could be Bubl  and thus residues 89-97 would be the 
Bubl interaction site on LT.
LT  constructs  containing  single  amino  acid  point  mutations  in 
conserved  residues  within  the  89-97  region  were  also  investigated  for 
immortalisation efficiency and ability to interact with Bubl.
Finally, the ability of wild-type and dl89-97 LT to transform NIH 3T3 
cells  was  investigated  via  focus  formation  assay,  in  both  NIH  3 T3 (empty 
vector control), and NIH 3T3(Bubl RNAi knockdown) cells.
3.3  RESULTS
3.3.1  Initial immortalisation efficiency and mapping experiments
3.3.1.1  All LT mutants tested were able to efficiently immortalise REFs 
pBabe-puro-  constructs  for  each  of the  LT  mutants,  wild-type  LT  or
empty vector (see Figure 3.1, (Morgenstem and Land,  1990)) were packaged 
using  the  ecotropic  retroviral  packaging  cell  line  BOSC  23  and  used  to 
transduce  NIH  3T3  cells,  to  calculate  the  viral  titre  (NIH  3T3  is  a  line  of 
Swiss  mouse  embryo  fibroblasts  that were  immortalised  spontaneously,  and 
are highly contact inhibited). The viral titre is a measure of the total number of 
infected cells that grow into drug resistant colonies, and is calculated to allow 
normalisation between the different constructs.  These constructs were kindly 
provided by Dr Ole Gjoerup of the Dana-Farber Cancer Institute, Boston, MA, 
USA. Retroviral transduction results in a greater efficiency of stable insertion 
of the gene  of interest into the host cell  genome,  and each  cell  successfully 
transduced is  likely  to  have  a  single  copy  of the  gene  inserted,  rather  than 
multiple copies as seen with DNA transfection.
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Figure 3.1: pBabe-puro vector used for transduction of SV40 LT cDNAs into rodent cells.
LT cDNAs with various mutations were cloned  into  the BamHI  site  in the pBabe-puro  vector.  The  striped boxes represent  72bp 
enhancer repeats, and the blackened boxes the R (Repeat) region between the transcriptional start and the polyadenylation sites within 
the Mo MuLV LTRs (Moloney murine leukaemia virus Long Terminal Repeats). The ^-packaging site in the pBabe vectors is flanked 
by both an attenuated splice donor and ATG-gag sequences, to yield high viral titres. (Adapted from Morgenstem & Land, 1990)Primary  cells  are  also  notorious  for  being  difficult  to  transfect.  For  these 
reasons retroviral transduction was chosen to generate the cell lines needed to 
map the  Bubl-LT  interaction,  and to  determine  immortalisation  efficiencies 
for the LT mutants.
NIH 3T3  cells were seeded, and for each of the constructs, two plates 
were  transduced  with  lOOpl,  and  two  plates  with  500jil  of the  retroviral 
supernatant  in the presence  of 8pg/ml  polybrene.  This  is  a  small,  positively 
charged molecule  that binds  to  cell  surfaces  and neutralises  surface  charge. 
This allows the viral glycoproteins to bind more efficiently to their receptors, 
because it reduces the repulsion between sialic acid-containing molecules. 24 
hours post-transduction  (to  allow  for expression  of the  resistance  gene),  the 
duplicate plates  for  each  volume  of retroviral  supernatant  were  pooled  and 
split  1   in  10  and  1   in  50  (in  duplicate)  into  antibiotic  selection  media 
containing  2pg/ml  puromycin,  resulting  in  a  total  of  8  plates  for  each 
construct. The selective media was changed every 3-4 days, and 10 days post­
transduction the NIH  3T3  cells had grown into  colonies  large  enough to be 
stained with methylene blue and counted (see Table 3.1).
Colonies were counted on all plates for each construct, and the average 
counts from the  lOOjil retroviral supernatant,  1   in  10 split plates were used to 
calculate the viral titre using the following formula:
Formula 3.1:
Viral Titre (per ml of retroviral supernatant) = Average number colonies xl0xl0x2
The x 10 factors in the equation account for the 1 in 10 split and the use 
of lOOpl supernatant for the transduction, to give the number of colonies you 
would expect from  1ml of retroviral supernatant.  The factor of 2 is included 
because  the  lOOpl  of  retroviral  supernatant  was  in  fact  divided  equally 
between the two plates in the initial transduction step.
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Retroviral vector 
pBabe-puro(ori-) •
Number of colonies
VIRAL
TITRE
Volume (pi) retroviral 
supn equivalent to 
500jil of 5.00E+03 titre virus:
500jj.l retrovral supn., 1   in 50 split 100pl retrovral supn.,  1   in 50 split iOOpI retroviral supn., 1 in 10 split
Plate 1 Plate 2 Average Plate 1 Plate 2 Average Plate 1 Plate 2 Average
empty vector 275 255 265 78 64 71 233 214 224 4.48E+04 56
wild-type LT 32 39 36 9 15 12 33 37 35 7.00E+03 357
L13V LT 36 41 39 7 8 8 28 29 29 5.80E+03 431
D44N LT 32 34 33 6 8 7 21 29 25 5.00E+03 500
dl89-97 LT 46 58 52 7 10 9 25 33 29 5.80E+03 431
Table 3.1: Retroviral transduction of NIH 3T3 cells with LT mutants to determine viral titres for initial mapping 
of Bubl-LT interaction.
All colony count data is shown, excluding counts from the 500pl retroviral supernatant, 1  in 10 split plates which had too 
many colonies to accurately count. The average counts from the  lOOpl retroviral supernatant,  1   in  10 split plates were 
used to calculate the viral titre because they had many colonies,  while representing a large proportion of the original 
transduced population of cells. Volume of retroviral supernatant required for doses equivalent to 500pl of 5.00E+03 titre 
were calculated by dividing 5.00E+03 (titre wanted) by the viral titre and multiplying by 500(pl), for each construct.The  calculation was performed using the counts  from these particular 
plates because they had enough colonies to  ensure an  accurate  estimation of 
the  transduction  efficiency  of the  viral  supernatants,  but  not  too  many  to 
accurately count.  The  500pi viral supernatant,  1   in 50  split plates also had a 
suitable number of colonies  for the calculation,  but it was  thought that they 
would not give  as accurate  a result for the viral titre,  as the  sample is taken 
from a smaller proportion of the original population of cells, due to the 1 in 50 
split.
The viral titres (calculated using Formula 3.1; see Table 3.1) were very 
similar in magnitude, except for the empty vector construct, which had a titre 
almost 10-fold higher than the other constructs. This is to be expected because 
the  empty  vector  does  not  contain  the  LT  cDNA,  and  is  therefore  much 
smaller, allowing more efficient packaging of the viral RNA.
The  viral  titres  were  then  used  to  calculate  the  volume  of retroviral 
supernatant that should be used for each construct to ensure an equal dose of 
viral particles  when transducing  REFs  with the  same  retroviral  supernatants 
(see Table 3.1). If all of the constructs were equally efficient at immortalising 
REFs, the use of equivalent doses of retroviral supernatant would result in all 
transduced REF plates having an equal number of colonies, making the colony 
counts more accurate  for the immortalisation efficiency experiment.  Primary 
REFs  were  seeded,  and transduced  in  duplicate  with  an  equivalent  dose  of 
retroviral supernatant for each of the constructs, and NIH 3T3 cells were also 
transduced  with  the  same  doses,  to  confirm  the  viral  titres  calculated 
previously.  48 hours later, the duplicate plates were pooled and split  1  in  10 
and  1   in 50 in duplicate, into antibiotic selection (as before).  The viral titres 
(per ml  of retroviral  supernatant)  were  calculated from the NIH  3T3  colony 
counts, 10 days post-transduction, this time using the following formula:
116Formula 3.2:
Viral Titre = Average number colonies x 50 x 2 x  ^
Volume (pi) retroviral supernatant 
used to infect duplicate plates
All cells (NIH 3T3  and REF) were split 48 hours post-transduction on 
this occasion instead of 24 hours, in order to allow the REFs to recover prior 
to being  split  into  antibiotic  selection.  This  resulted  in  many more  colonies 
than seen in the previous experiment, and so the  1  in 50 split NIH 3T3 plates 
were used to calculate the viral titre this time, accounting for the factor of 50 
in the equation. Different volumes of retroviral supernatant were used for each 
construct, and each amount was divided between duplicate plates, accounting 
for the final factors in the equation.
When NIH 3T3  cells were transduced with the equivalent doses of the 
LT  constructs,  the  viral  titres  were  comparable  to  those  seen  previously, 
although 10 times higher (due to leaving the cells for 48 hours before splitting 
into selection, rather than 24 hours, thus allowing them to divide before being 
selected) See Table 3.2.
The REFs were split into selective media (with 2pg/ml puromycin) at 
the same time as the NIH 3T3 cells, but were split 1   in 8 and 1   in 16, and into 
15cm plates  rather than the  10cm plates used  for NIH  3T3  cells.  The REFs 
were plated at higher density than the NIH 3T3 cells because they were likely 
to  result  in  fewer  colonies  due  to  some  cells  dying,  others  becoming 
senescent,  and  also  because  they  generally  grow  slower  than  the  NIH  3T3 
cells.  Selective  media  was  changed  every  3-4  days,  and  17  days  post­
transduction  the  colonies  on  the  REF  plates  were  large  enough  to  allow 
isolation  via  ring  cloning,  followed  by  staining  and  colony  counting.  6 
colonies were ring-cloned for each construct, and these were serially cultured 
for  5  passages  to  determine  if they  could  be  expanded  into  cell  lines,  and 
hence were truly immortal.
117Table 3.2: Raw data for immortalisation efficiency of initial mapping 
constructs for Bubl-LT interaction site.
Duplicate experiments are shown (A & B). For each experiment the first 
table  shows  the  viral  titres  re-calculated using NIH  3T3  colony counts 
from  plates  infected  with  the  new,  equivalent  doses  of  retroviral 
supernatant  (Formula  3.2).  The  second  and  third  tables  for  each 
experiment show colony counts from the retroviral transduction of REFs, 
1   in 8 and 1  in 16 (or 1  in 32) split plates, respectively. Immortalisation 
efficiencies  relative  to  wild-type  LT  are  calculated  for  each  table 
(Formula  3.3),  and  number  of  colonies  expanded  are  also  shown. 
(Colonies were single cell cloned from a mixture of split plates for each 
construct, and so the number expanded shown in the second table for each 
experiment represents results from both split plates).
118A: Immortalisation Efficiency Experiment 1
NIH 3T3: 
Retroviral vector 
pBabe-puro(ori-) -
Volume (pi) retroviral 
supn used to infect 
two plates of cells:
Number of colonies 
1 in 50 split VIRAL
TITRE Plate 1 Plate 2 Average
empty vector 56 270 281 276 4.93E+05
wild-type LT 357 203 254 229 6.41 E+04
L13V LT 431 285 262 274 6.36E+04
D44N LT 500 295 247 271 5.42E+04
dl89-97 LT 431 346 314 330 7.66E+04
REF:
Retroviral vector 
pBabe-puro(ori-) -
Volume (pi) retroviral 
supn used to infect 
two plates of cells:
VIRAL
TITRE
Number of colonies 
1  in 8 split
Immortalisation 
efficiency relative 
to wild-type LT (%)
Number
colonies
expanded Plate 1 Plate 2 Average
empty vector 56 4.93E+05 2 0 1 1.22 (0/0)
wild-type LT 357 6.41 E+04 68 67 68 100.00 6/6
L13V LT 431 6.36  E+04 35 40 38 46.65 5/6
D44NLT 500 5.42 E+04 34 55 45 55.88 5/5
dl89-97 LT 431 7.66E+04 134 151 143 145.76 6/6
REF: Volume (pi) retroviral Number of colonies Immortalisation Number
Retroviral vector supn used to infect VIRAL 1 in 16 split efficiency relative colonies
pBabe-puro(ori-) - two plates of cells: TITRE Plate 1 Plate 2 Average to wild-type LT (%) expanded
empty vector 56 4.93E+05 2 0 1 2.24
wild-type LT 357 6.41 E+04 32 41 37 100.00 (as
L13V LT 431 6.36E+04 16 24 20 45.13 above)
D44NLT 500 5.42E+04 19 20 20 45.64
d!89-97 LT 431 7.66  E+04 75 81 78 146.12
B: Immortalisation Efficiency Experiment 2
NIH 3T3: 
Retroviral vector 
pBabe-puro(ori-) -
Volume (pi) retroviral 
supn used to infect 
two plates of cells:
Number of colonies 
1 in 50 split VIRAL
TITRE Plate 1 Plate 2 Average
empty vector 28 122 141 132 4.71 E+05
wild-type LT 179 113 119 116 6.48 E+04
L13V LT 216 117 124 121 5.60 E+04
D44N LT 250 109 126 118 4.72E+04
d!89-97 LT 216 135 114 125 6.79E+04
REF:
Retroviral vector 
pBabe-puro(ori') •
Volume (pi) retroviral 
supn used to infect 
two plates of cells:
VIRAL
TITRE
Number of colonies 
1  in 8 split
Immortalisation 
efficiency relative 
to wild-type LT (% )
Number
colonies
expanded Plate 1 Plate 2 Average
empty vector 168 4.71 E+05 13 16 15 5.55 (0/0)
wild-type LT 1071 6.48E+04 211 262 237 100.00 6/6
L13V LT 1293 5.60E+04 162 143 153 61.88 5/6
D44NLT 1500 4.72E+04 153 (-) 153 63.28 5/5
dl89-97 LT 1293 5.79E+04 472 508 490 191.66 6/6
REF: Volume (pi) retroviral Number of colonies Immortalisation Number
Retroviral vector supn used to infect VIRAL 1 in 32 split efficiency relative colonies
pBabe-puro(ori-) - two plates of cells: TITRE Plate 1 Plate 2 Average to wild-type LT (% ) expanded
empty vector 168 4.71 B-05 10 7 9 8.87
wild-type LT 1071 6.48 E+04 92 85 89 100.00 (as
L13V LT 1293 5.60  E+04 40 35 38 40.92 above)
D44NLT 1500 4.72E+04 63 66 65 71.59
dl89-97 LT 1293 5.79E+04 165 182 174 181.24
Table 3.2: Raw data for immortalisation efficiency of initial mapping 
constructs for Bubl-LT interaction site.The average  colony counts  from both the  1   in  8  and the  1   in  16  split plates 
were  used  to  determine  the  immortalisation  efficiency  of  each  construct, 
relative to wild-type LT, using the following formula:
Formula 3.3:
Av
Im .  = lO O x  9 -^ --------
*  f  V,T,  A   Av  — 
wt  V  T V  wt  Wt  J
where:
Im^ = % Immortalisation efficiency of LT mutant A relative to wild-type LT. 
A v a  = Average  number  colonies  on  LT  mutant  A  (1  in  8  or  1   in  16  split) 
plates.
Avw , =  Average  number colonies  on  wild-type  LT  (1  in  8  or  1   in  16  split) 
plates.
VA  = Volume (pi) of retroviral supernatant used for LT mutant A.
Vw t = Volume (pi) of retroviral supernatant used for wild-type LT.
Ta = Viral titre (per ml of retroviral supernatant) for LT mutant A 
Tw t = Viral titre (per ml of retroviral supernatant) for wild-type LT.
This formula normalises the volume of retroviral supernatant used and 
the viral titre  for each construct against these variables  for the wild-type LT 
construct, allowing the REF colony counts  (number of immortal  cells) to be 
directly compared.
Colony  count  data  collected  from  two  independent  immortalisation 
experiments  in  REFs  (using  the  equivalent  doses  of  the  retroviral 
supernatants) revealed the relative immortalisation efficiencies of each of the 
LT mutants tested (Table 3.2).
These  results  are  summarised  in  Figure  3.2.  All  LT  constructs  were 
able  to  efficiently  immortalise  REFs,  and  almost  all  colonies  could  be 
expanded into cell lines and cultured to passage 5.
120REF: Immortalisation Efficiency Relative to Wild-fr/pe LT (%)
Number Retroviral vector 
pBabe-puro(ori-) -
Expt 1
calculated using 
1  in 8 split plates
Expt. 1
calculated using 
1  in 16 split plates
Expt. 2
calculated using 
1  in 8 split plates
Expt. 2
calculated using 
1  in 32 split plates
colonies
expanded
empty vector 1.22 2.24 5  55 8.87 (0/0)
wild-type  LT 100 100 100 100 12/12
L13V LT 46 65 45.13 61.88 40.92 10/12
D44N LT 55 88 45.64 63.28 71.59 10/10
dl89-97 LT 145 76 146.12 191.66 181.24 12/12
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Figure  3.2:  Immortalisation  efficiency  relative  to  wild-type  LT  of the 
initial Bubl-LT interaction site mapping constructs.
Summary  of  immortalisation  efficiencies  calculated  from  REF  colony 
counts at two different plating densities, in two independent experiments, 
and the number of colonies that expanded (A).  A graphical view of these 
results (B).
121This was chosen as a measure of immortality because it has been observed in 
the laboratory that once  cell  lines  have been  cultured to passage  5  they  are 
immortal  and do not stop  dividing thereafter.  As  expected, the empty vector 
construct was not able to efficiently immortalise REFs, and the small numbers 
of colonies  seen  on  these  plates  were  probably  due  to  cells  dividing  a  few 
times after infection (prior to senescence).  The L13V and D44N LT mutants 
only immortalised approximately half as efficiently as the wild-type LT. The 
dl89-97  LT  mutant  seemed  able  to  consistently  immortalise  REFs  more 
efficiently than wild-type LT, an unexpected finding.
3.3.1.2  Bubl interacts in the region of residues 89-97 of LT
Whole cell lysates were prepared from the immortalised REF lines, and 
compared in immunoprecipitation experiments.  Lysates  from one REF clone 
expressing either wild-type, L13V and D44N LT were compared with lysates 
from three REF clones expressing dl89-97 LT, and with lysate from a cell line 
called  GSE-8,  which  is  a  REF  line  immortalised  by  a  genetic  suppressor 
element derived from p53 (Tarunina et al., 2004) to act as a negative control. 
NIH  3T3  cells  were  not  used  to  map  the  Bubl-LT  interaction  site  due  to 
difficulties  with  immunoprecipitating  the  mouse  Bubl  protein  using  the 
antibodies available at this point in the project.
First of all, protein expression levels of Bubl, LT, Bub3 and p53 in the 
lysates  were  compared  via western  blotting.  30pg  of the  whole  cell  lysates 
were  separated  on  SDS-PAGE  and western  blotted  for Bubl  using  a rabbit 
polyclonal  antiserum  raised  against  amino  acids  1-303  of hBubl  fused  in­
frame to GST. This antiserum shows specificity to both the human and the rat 
Bubl  proteins  when used  for immunoblotting.  See Figure  3.3A.  A band of 
approximately  150kDa was  observed in all  lanes,  at approximately the same 
intensity  for  each  cell  line  expressing  LT,  demonstrating  that  the  level  of 
expression of Bubl  was not altered from wild-type by any of the mutations in 
LT.
122Figure 3.3: The Bubl interaction site on LT maps to residues 89-97.
REF cell lines,  established by transduction with different mutants of LT, 
with wild-type LT, or with a p53-derived genetic suppressor element, were 
used to map the Bubl-LT interaction site.  Co-immunoprecipitation of LT 
with  Bubl  is  observed  for  wild-type,  L13V  and  D44N  LT,  but  is  not 
observed for dl89-97 LT in any of the 3 clonal REF cell lines tested. GSE- 
p53 cell line is included as a negative control, and the relative expression 
levels of Bubl, LT, Bub3 and p53 are shown for all cell lines (A). dl89-97 
LT  is  further  shown  to  be  defective  for  Bubl  binding  by 
immunoprecipitating with either affinity purified NT Bubl  antibody or a 
Bub3 antibody, and blotting for LT, using the same lysates as before (B).
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Figure 3.3: The Bubl interaction site on LT maps to residues 89-97.
124Bubl  has  a predicted molecular weight  of approximately  120kDa,  but from 
examination of the specificity of the Bubl monoclonal antibodies generated in 
this project (see Chapter 4), Bubl appears to migrate to a higher than expected 
molecular weight of 150kDa.
5pg  of each  of the  lysates  were  also  separated  on  SDS-PAGE  and 
western blotted for LT, Bub3 and p53.
A mixture of LT mouse monoclonal  antibodies PAb416, PAb419  and 
PAb423 were used to show the relative levels of LT in the different cell lines. 
Approximately  lOOkDa  bands  were  observed  in  all  lanes  for  the  cell  lines 
expressing  LT  (wild-type  or  mutant).  As  expected,  the  GSE-p53  negative 
control lysate did not show evidence of LT expression. The intensity of the LT 
bands was very similar between the wild-type, L13V, D44N and clone 2  for 
dl89-97  LT  lanes, but was not as  intense  for clones  1  and 3  of dl89-97 LT, 
indicating that these cell lines express LT at a lower level.  Several clones  of 
wild-type,  L13V  and D44N LT have been tested for level  of LT  expression 
(data  not  shown)  and  had  consistently  similar  high  levels  of LT,  whereas 
different  clones  of dl89-97  LT  were  observed  to  have  different  and  always 
lower expression levels  of LT than the  other mutants.  It was  for this reason 
that  three  different  clones  of  dl89-97  LT  were  used  to  determine  the 
interaction of Bubl with LT in Figure 3.3.
The western blot of the whole cell lysates using Bub3 rabbit polyclonal 
antibody  resulted  in  40kDa  Bub3  bands  in  all  lanes,  and  indicated 
approximately  equal  expression  of the  Bub3  protein  in  all  of the  cell  lines 
tested. However,  dl89-97  LT clone 2 demonstrated a slightly higher level  of 
expression of Bub3 than the other cell lines. This appears to correlate with this 
clone  also having the  highest  level  of LT  expression  of all the  dl89-97  cell 
lines, whereas Bubl expression levels were the same for all LT lines.
The p53  mouse  monoclonal  antibody PAb421  was  used to  determine 
the relative expression level of p53 in each of the RET cell lines. LT is known 
to stabilise p53 protein (Lane and Crawford,  1979), and so the purpose of this 
blot was to determine if any of the mutations tested had an effect on the ability
125of LT  to  carry  out  this  function.  Strong,  approximately  50kDa  bands  were 
observed in  all  lanes  except  D44N  LT  and  dl89-97  LT  clone  1.  There  is  a 
positive correlation between level of expression of p53 with that of LT in the 
dl89-97  LT  lanes,  presumably  due  to  the  p53-stabilising  functions  of LT 
previously described. This shows that the dl89-97 mutation does not affect the 
p53 stabilisation function of LT. However, there are two unexpected results in 
this blot. Cells expressing GSE-p53 display a high p53  expression level, with 
the p53 band being the same intensity as is seen for wild-type LT and L13V 
LT  cells.  This  is  seen  in  the  absence  of LT  in  the  GSE-p53  cells,  and  in 
addition  can  not  be  a  manifestation  of the  p53-derived  genetic  suppressor 
element used to immortalise these cells, as this was only a very small cDNA 
fragment of p53, much smaller than the 50kDa band seen here. This high level 
of p53  seen in the GSE-p53  line could be due to stabilisation resulting from 
interaction between the GSE polypeptide and the endogenous full length p53 
protein,  although  this  remains  to  be  determined.  The  second  unexpected 
observation  from  this  blot  is  that  only a  very  faint p53  band  is  seen  in  the 
D44N LT lane, despite the relatively high level of LT expression seen in these 
cells. This is a J domain mutant of LT, and it is not clear why a mutation at 
residue 44 of this region should prevent LT from stabilising the p53 protein, 
while a mutation at residue 13 of the J domain (L13V LT) does not.
To determine the ability of each LT mutant to interact with Bubl,  an 
antibody raised against the carboxy terminal amino acids 691-1085 of hBubl 
fused in-frame  to  GST was used to  immunoprecipitate  Bubl  from the  REF 
lysates. It had been shown that an antibody raised against the amino terminal 
of human Bubl  (hBubl) was able to detect the rat Bubl, and so it was hoped 
that  an  antibody  raised  against  the  carboxy  terminal  of hBubl  would  also 
recognise  the  rat  protein,  and  perhaps  immunoprecipitate  the  protein  more 
efficiently than other antibodies tested. The carboxy terminal hBubl  antibody 
clearly  detected  rat  Bubl  in  co-immunoprecipitation  experiments 
immunoblotted using  the  amino  terminal  hBubl  antibody,  and was  used to 
immunoprecipitate Bubl  from  lmg of whole cell lysate for each of the REF
126cell lines. The resulting precipitates were then immunoblotted for LT using a 
mixture of LT mouse monoclonals PAb416 and PAb423 (see Figure 3.3 A). As 
expected,  no  lOOkDa  LT  band  is  co-immunoprecipitated  with  Bubl  in  the 
GSE-p53  cell  line,  because  this  line  does  not  express  LT.  A  very  strong 
approximately  lOOkDa  LT band  in  the  wild-type  LT  lane  demonstrates  the 
recently published  interaction between  LT  and Bubl  (Cotsiki  et  al.,  2004). 
Equally strong  lOOkDa LT bands are seen to be brought down with Bubl  in 
REFs expressing LI3V and D44N LT, indicating that these mutations do not 
compromise  interaction  of LT  with  Bubl.  However,  only  extremely  faint 
lOOkDa LT bands could be seen in the dl89-97 LT lanes for the Bubl-LT co- 
immunoprecipitation  experiment.  When  a  comparison  is  made  between  the 
level of expression of Bubl  and LT in each cell line in Figure 3.3A, and the 
relative amounts of LT protein being co-immunoprecipitated with Bubl, it is 
clear that all three dl89-97 clones are deficient for Bubl  interaction. The faint 
bands seen in the  dl89-97  LT  co-immunoprecipitation lanes  are likely to be 
due to LT being a relatively “sticky” protein, resulting in non-specific binding 
to Protein A-sepharose beads, as has been observed by others. Alternatively, it 
could be the case that these bands represent a low level  of direct or indirect 
interaction between Bubl and dl89-97 LT.
The same whole cell lysates were also used to immunoprecipitate either 
Bubl  (this  time  using  an  affinity purified rabbit polyclonal  antibody raised 
against amino acids  1-303 of hBubl  fused in-frame to GST) or Bub3 (using a 
rabbit polyclonal antibody), and the resulting precipitates were immunoblotted 
for LT using mouse monoclonals PAb416 and PAb423 (see Figure 3.3B). The 
binding  of  Bub3  to  Bubl  is  thought  to  be  critical  for  the  kinetochore 
localisation of Bubl (Taylor et a l, 1998) and it has been shown that LT, Bubl 
and Bub3 are present in the same protein complex (Cotsiki et al., 2004). When 
the Bubl  or Bub3  immunoprecipitates were western blotted for LT,  lOOkDa 
bands indicating co-immunoprecipitation were only observed in the wild-type, 
L13V and D44N LT  lanes, where  Bubl,  Bub3  and LT  are part of the  same 
complex.  As  expected,  no  lOOkDa  LT  bands  are  seen  in  the
127immunoprecipitations  from  GSE-p53  in  Figure  3.3B,  because  this  cell  line 
does not express LT. No lOOkDa LT bands are observed in the dl89-97 lanes, 
indicating that neither Bubl nor Bub3 were able to interact with dl89-97 LT in 
any of the three clones tested. Figure 3.3B therefore further demonstrates that 
LT mutant dl89-97  is  defective  for Bubl  interaction,  and  concomitantly  for 
Bub3 interaction also.
3.3.2  Immortalisation  efficiency  and  mapping  experiments  using  single
amino acid mutations to alanine in residues 89-97 ofLT
A  further examination  of residues  89-97  of LT was undertaken,  with 
the intention of mapping of the Bubl-LT interaction site in finer detail. Within 
the  89-97  region  of  LT  a  EWEXWW  motif  was  found  to  be  conserved 
between  all  large  T  antigens,  with the  exception  of murine polyomavirus  T 
antigen (see Figure 3.4, (Cotsiki et al., 2004)). For this reason, the amino acids 
in this motif were mutated to alanine by Dr Ole  Gjoerup using  site-directed 
mutagenesis, and these mutated full length LT cDNAs were then cloned into 
the pBabe-puro vector as described previously (see Figure 3.1).
These retroviral constructs (pBabe-puro-  E90A, W91A, E92A, Q93A, 
W94A & W95A)  were packaged in BOSC  23  cells  as before.  The resulting 
retroviral  supernatants  were  used  to  determine  the  immortalising  efficiency 
and ability to  interact  with  Bubl  for  each  of these  single  amino  acid point 
mutations  of  LT,  using  the  same  methods  as  described  for  the  initial 
immortalisation and mapping experiments in this chapter.
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Figure 3.4: Conservation within the 89-97 amino acid region of SV40 LT, and other large T antigens.
Sequence  alignment  of the  polyomavirus  large  T  antigens:  SV40,  human  BK  polyomavirus  (BKV),  human  JC 
polyomavirus (JCV), bovine polyomavirus (BPV), Kilham strain of polyomavirus (Kilham) and murine polyomavirus 
(PyV) were aligned using the DNASTAR program. The sequence (E/Q)W(E/D)XWW (amino acids 90-95 of SV40 
LT) is conserved between SV40, BKV, JCV, BPV, and Kilham T  antigens, but there is no  obvious homologous 
sequence in the same region of PyV. (Adapted from Cotsiki et al, 2004)3.3.2.1  Individual substitution mutations in the 89-97 region of LT were not 
able to disrupt the immortalising functions of LT.
As  previously  described,  NIH  3T3  cells  were  transduced  with  the 
retroviral  supernatants,  and  the  viral  titres  for  each  construct  (pBabe-puro- 
empty vector, wild-type LT, dl89-97, E90A, W91A, E92A, Q93A, W94A & 
W95A)  were  calculated  (see  Table  3.3).  The  colony  counts  from  the  100pi 
supernatant,  1  in  50  split plates  were used  on this  occasion  to  calculate the 
titre,  due  to  the  other  plates  having  a  very  large  number  of colonies,  and 
therefore a greater possibility of counting errors. The viral titres were used to 
calculate  how  much  retroviral  supernatant  should  be  used  to  give  an 
equivalent dose  of each retrovirus  when  infecting  the  REF s.  As before,  the 
empty vector construct gave the highest viral titre, with comparable titres for 
the other constructs.
Duplicate plates of REFs were transduced with these equivalent doses 
of the retroviral  supernatants,  and NIH  3T3  cells  were  also transduced with 
half these  doses  (to  counter the  fact that they produce  many more  colonies 
than REFs).  See Table  3.4.  This retroviral transduction  of REFs was in fact 
performed  in  duplicate,  with  the  two  experiments  kept  completely  separate 
(i.e.  for each experiment,  two plates  of REFs  were  initially transduced with 
each  retroviral  construct,  and  plates  from  each  individual  experiment  were 
pooled and split, independently). As before, the NIH 3T3 cells were split 1   in 
10  and  1  in  50  (in  duplicate)  into  antibiotic  selection  48  hours  post­
transduction,  and  10  days  later  colonies  were  counted  to  determine  a more 
accurate viral titre. The REFs were split 1 in 8 and 1 in 16 (in duplicate) at the 
same time as the NIH 3T3 cells, and 15 days post-transduction 3 to 5 colonies 
from the REF plates were ring cloned from each separate experiment, and the 
rest were stained for colony counting. Immortalisation efficiencies of each LT 
construct  were  determined  for  each  experiment,  using  both  the  1  in  8  split 
colony counts, and the  1 in 16 counts (See Table 3.4). The number of colonies 
that  could  be  expanded  to  passage  5  are  also  shown  for  each  separate 
experiment.
130NIH 3T3:
Retroviral vector 
pBabe-puro(ori-) -
Number of colonies
VIRAL
TITRE
Volume (pi) retroviral 
supn equivalent to 
500jxl of 2.00E+04 titre virus:
500|j.l retroviral supn., 1   in 50 split 100p,l retroviral supn.,  1   in 10 split iOOpI retroviral supn., 1  in 50 split
Plate 1 Plate 2 Average Plate 1 Plate 2 Average Plate 1 Plate 2 Average
empty vector 760 680 720 640 604 622 194 190 192 1.92E+05 52
wild-type LT 123 143 133 100 123 112 36 28 32 3.20E+04 313
dl89-97 LT 119 97 108 75 63 69 24 37 31 3.10E+04 323
E90A LT 56 54 55 57 55 56 20 18 19 1.90E+04 526
W91A LT 56 71 64 62 38 50 8 17 13 1.30E+04 769
E92A LT 77 113 95 64 58 61 17 23 20 2.00E+04 500
Q93A LT 138 124 131 115 99 107 27 37 32 3.20E+04 313
W94A LT 114 116 115 131 135 133 72 49 61 6.10E+04 164
W95A LT 120 147 134 135 150 143 28 20 24 2.40E+04 417
Table 3.3:  Fine  mapping of the Bubl-LT  binding site:  retroviral  transduction  of NIH 3T3  cells  with  LT  substitution 
mutants to determine viral titres.
All colony count data is shown, excluding counts from the 500pl retroviral supernatant,  1  in 10 split plates which had too many 
colonies to accurately count. The average counts from the lOOpl retroviral supernatant, 1  in 50 split plates were used to calculate 
the viral titres because the other plates had larger and possibly less reliable colony counts. Volume of retroviral supernatant 
required for doses equivalent to 500pl of 2.00E+04 titre were calculated by dividing 2.00E+04 (titre wanted) by the viral titre 
and multiplying by 500(pl) for each construct.Table  3.4:  Raw  data  for  immortalisation  efficiency  of  the  LT 
substitution mutant constructs.
Duplicate experiments are shown (A & B).  The first table in section A 
shows viral titres re-calculated using NIH 3T3 colony counts from plates 
infected  with  the  new  equivalent  doses  of  retroviral  supernatants 
(Formula 3.2). The tables of REF colony counts in A and B use these new 
titres  to  calculate  the  immortalisation  efficiencies  of  the  constructs 
relative to wild-type LT from the 1  in 8 and the  1  in 16 plates (Formula 
3.3).  The number of colonies that expanded for each construct are also 
shown for each experiment.
132A: Alanine Linker Scan Immortalisation Efficiency Expt. 1:
NIH 3T3: 
Retroviral vector 
pBabe-puro(orl-) ■
Volume (pi) retroviral 
supn used to Infect 
two plates of cells:
Number of colonies 
1  in 50 split VIRAL
TITRE Plate 1 Plate 2 Average
empty vector 26 131 123 127 4.88E+06
wild-type LT 167 83 96 91 6.80E+04
dl89-97 LT 162 132 116 124 7.66E+04
E90ALT 263 12 42 27 1.03E+04
W91A LT 386 124 124 124 3.22E+04
E92ALT 260 37 63 60 2.00E+04
Q93A LT 167 80 48 64 4.08E+04
W94ALT 82 47 39 43 6.24E+04
W96ALT 209 89 97 93 4.46E+04
REF:
Retroviral vector 
pBabe-puro(ori-) -
Volume (pi) retroviral 
supn used to infect 
two plates of cells:
VIRAL
TITRE
Number of colonies 
1  in 8 split
Immortalisation 
efficiency relative 
to wild-type LT (% )
Number I  
colonies 
expanded Plate 1 Plate 2 Average
empty vector 52 4.88E+05 (contam.) (contam.) - . (0/0)
wild-type LT 313 5.80E+04 34 35 35 100.00 1/3
dl89-97 LT 323 7.65E+04 71 57 64 134-34 2/3
E90ALT 626 1.03E+04 58 51 55 526.56 3/3
W91A LT 769 3.22  E+04 136 142 139 291.16 5/5
E92ALT 500 2.00E+04 56 45 51 264.53 3/3
Q93ALT 313 4.08E+04 53 72 63 255.88 1/2
W94ALT 164 5.24E+04 41 60 51 307.82 4/5
W96ALT 417 4.45  E+04 80 74 77 215.23 5/5
REF: Volume (pi) retroviral Number of colonies Immortalisation Number
Retroviral vector supn used to infect VIRAL 1 in 16 Split efficiency relative colonies
pBabe-puro(ori-) • two plates of cells: TITRE Plate 1 Plate 2 Average to wild-type LT (% ) expanded
empty vector 62 4.88E+06 (contam.) (contam. - .
wild-type LT 313 6.80  E+04 16 22 19 100.00
dl89-97 LT 323 7.66E+04 23 34 29 112.14
E90ALT 626 1.03E+04 29 (contam.) 29 611.44 (as
W91A LT 769 3.22E+04 98 (contam.) 98 378.16 above)
E92ALT 600 2.00E+04 27 29 28 267.63
Q93ALT 313 4.08  E+04 24 38 31 231.94
W94ALT 164 6.24E+04 18 30 24 266.84
W96ALT 417 4.46E+04 36 38 37 190.61
B: Alanine Linker Scan Immortalisation Efficiency Expt. 2:
(Viral titres are identical for the two experiments, which were conducted simultaneously)
REF:
Retroviral vector 
pBabe-puro(ori-) -
Volume (pi) retroviral 
supn used to infect 
two plates of cells:
VIRAL
TITRE
Number of colonies 
1 in 8 split
Immortalisation 
efficiency relative 
to wild-type LT (% )
Number
colonies
expanded Plate 1 Plate 2 A\«rage
empty vector 52 4.88E+05 0 1 1 2.98 (0/0)
wild-type LT 313 5.80  E+04 30 18 24 100.00 1/3
dl89-97 LT 323 7.65E+04 69 62 66 202.04 3/3
E90ALT 526 1.03E+04 70 67 63 879.59 3/3
W91A LT 769 3.22E+04 120 145 133 406.28 5/5
E92ALT 500 2.00E+04 58 50 54 408.47 3/3
Q93ALT 313 4.08E+04 78 66 72 426.47 3/3
W94ALT 164 5.24E+04 31 32 32 281.67 5/5
W95A LT 417 4.45  E+04 85 109 97 395.40 5/5
REF:
Retroviral vector 
pBabe-puro(ori-) -
Volume (pi) retroviral 
supn used to infect 
two plates of cells:
VIRAL
TITRE
Number of colonies 
1 in 16 split
Immortalisation 
efficiency relative 
to wild-type LT (% )
Number
colonies
expanded Plate 1 Plate 2 Average
empty vector 52 4.88E+05 2 0 1 4.77
wild-type LT 313 5.80E+04 16 13 15 100.00
dl89-97 LT 323 7.65E+04 31 24 28 137.14
E90ALT 526 1.03E+04 33 37 35 781.85 (as
W91A LT 769 3.22E+04 78 66 72 351.91 above)
E92ALT 500 2.00E+04 31 24 28 338.87
Q93ALT 313 4.08E+04 45 25 35 331.70
W94A LT 164 5.24E+04 14 18 16 225.33
W95ALT 417 4.45E+04 46 58 52 339.15
Table  3.4:  Raw  data  for  immortalisation  efficiency  of  the  LT 
substitution mutant constructs.
133The  immortalising  efficiencies  of the  constructs  relative  to  wild-type 
LT are summarised and displayed in a graphical format in Figure 3.5. Within 
each separate  experiment,  and between the repeated experiments,  the  1  in  8 
and  1  in  16  split plate  counts  reveal  consistent results  for the immortalising 
efficiencies of the constructs tested. All LT constructs were able to efficiently 
immortalise REFs, and almost all clones tested could be expanded to passage 
5, indicating that the cells really were immortal. Only 2 colonies out of 6 that 
were single cell cloned and passaged for the wild-type LT construct reached 
passage 5 on this occasion (See Figure 3.5A). This is in contrast to the results 
from the initial immortalisation efficiency tests (see Figure 3.2A) where all 12 
wild-type LT-immortalised REF clones could be expanded, but should not be 
given too much importance because the clones that failed to grow did so at the 
first  passage,  most  likely  due  to  too  few  cells  surviving  the  ring-cloning 
process.
As expected, empty vector is not able to immortalise REFs efficiently 
(See Figure 3.5B).  D189-97 LT appears (as  seen previously)  to be  a slightly 
better immortalising gene than wild-type LT.  Surprisingly, each of the single 
amino acid mutations to alanine tested within the 89-97 region of LT cause LT 
to be an even more efficient immortaliser than the deletion mutant dl89-97.
3.3.2.2  D189-97 mutant of LT is the most defective for Bubl binding.
Whole  cell  lysates  were  prepared  from  selected  single  cell  clones  of 
REFs expressing each of the LT substitution mutants,  and wild-type LT and 
dl89-97 LT.  Passage 2  (P2)  REFs were lysed as  a negative control,  as these 
cells do not express LT, but are still proliferative as they have yet to senesce.
30jig  of  whole  cell  lysates  were  western  blotted  using  a  rabbit 
polyclonal antiserum raised against the amino terminal 303 residues of hBubl 
(see Figure 3.6). A 150kDa Bubl band was seen in all lanes, at approximately 
the same intensity for each lysate, indicating that the expression level of Bubl 
protein was equivalent between the different cell lines.
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REF: Immortalisation Efficiency Relative to Wild-tyrpe LT (%)
Expt. 1 Expt. 1 Expt. 2 Expt. 2 Number
Retroviral vector calculated using calculated using calculated using calculated using colonies
pBabe-puro(ori-) - 1  in 8 split plates 1  in 16 split plates 1  in 8 split plates 1  in 16 split plates expanded
empty vector - - 2.98 4.77 (0/0)
wild-type LT 100 100 100 100 2/6
dl89-97 LT 134.34 112.14 202.04 137.14 5/6
E90A LT 526.56 511.44 879.59 781.85 6/6
W91A LT 291.16 378.44 406.28 351.91 10/10
E92A LT 264.53 267.53 408.47 338.87 6/6
Q93A LT 255.88 231.94 426.47 331.7 4/5
W94A LT 307.82 266.84 281.67 225.33 9/10
W96A LT 215.23 190.51 395.4 339.15 10/10
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Figure 3.5:  Immortalisation  efficiency relative to wild-type of the LT 
substitution mutants.
Summary  of immortalisation  efficiencies  calculated  from  REF  colony 
counts at two different plating densities in two independent experiments, 
and the number of colonies that could be expanded (A). A graphical view 
of these results (B).
□ Expt.  1   (1  in 8 split)
■ Expt.  1   (1  in 16 split)
□ Expt. 2 (1  in 8 split)
■ Expt. 2 (1  in 16 split)
135CT Bubl  serum Ab IP, 
Blotted for T antigen
Figure 3.6:  No single  conserved  residue  in  the 89-97  region  of LT  is 
necessary for Bubl  interaction.
REF  cell  lines,  established  by  transduction  with  wild-type  LT  or  with 
different substitution mutants of LT were used to fine map the Bubl-LT 
interaction site.  In repeated co-immunoprecipitation experiments (one of 
which is shown here), the dl89-97 LT deletion mutant was very defective 
for Bubl  binding, and the tryptophan mutants W91A, W94A and W95A 
were  also  defective  for  Bubl  binding.  E90A,  E92A  and  Q93A  LT 
mutants interact with Bubl  as strongly as wild-type LT.  Passage 2 (P2) 
REF lysate is included as a negative control,  and the relative expression 
levels of Bubl and LT are shown.Relative expression levels of the LT proteins in the different cell lines 
were demonstrated by western blotting 5pg of the whole cell  lysates using a 
combination of LT mouse monoclonals PAb416, PAb419 & PAb423.  lOOkDa 
LT  bands  were  observed  for  all  cell  lines  except  for  the  P2  REF  negative 
control,  as  expected.  However,  it  was  noted  that  the  dl89-97  and  the 
tryptophan  mutants,  W91A,  W94A  and  W95A  of LT  were  expressed  at  a 
much lower level than wild-type LT, E90A, E92A or Q93A LTs. The dl89-97 
LT clone shown in Figure 3.6 is “dl89-97 LT clone 2” as shown in Figure 3.3, 
where  it  appeared  to  have  a  similar  level  of expression  to  wild-type  LT. 
However it is possible that the dl89-97 LT clone 2 lane shown in Figure 3.3 
may have been overloaded (as suggested by the apparently higher expression 
level of Bub3 in the dl89-97 LT clone 2 lane of Figure 3.3, when compared to 
the  other  samples),  resulting  in  an  incorrect  observation  of equivalent  LT 
expression level between wild-type LT and dl89-97 LT clone 2 in Figure 3.3. 
The LT mutants with lowered expression also demonstrated a slightly slower 
migration  on  SDS-PAGE,  possibly  due  to  a post-translational  modification, 
and this  was  particularly  noticeable  for the  tryptophan  mutants  (See  Figure 
3.6).
Bubl  was  immunoprecipitated  from  lmg  of each  of the  whole  cell 
lysates using a rabbit polyclonal antibody raised against the carboxy terminal 
amino  acids  691-1085  of  hBubl.  The  resulting  precipitates  were  then 
immunoblotted  for LT  using  a mixture  of LT  mouse  monoclonals  PAb416, 
PAb419 and PAb423, to determine which of the LT constructs was the most 
defective for interaction with Bubl (Figure 3.6).
As  expected,  the  P2  REF  lane  does  not  show  Bubl-LT  co- 
immunoprecipitation due to the  absence  of LT in these  cells.  LT is  strongly 
co-immunoprecipitated  with  Bubl  in  the  wild-type  LT,  E90A,  E92A  and 
Q93A lysates,  as  can be  seen by comparing the intensity of the  lOOkDa LT 
bands  brought  down  via  Bubl  with  the  level  of LT  expression  seen  in  the 
whole  cell  lysates  LT  blot.  In  repeated  experiments,  the  most  defective  for 
Bubl  binding was the original non-Bubl  binding mutant dl89-97 LT protein,
137as virtually no  LT band can be  seen  in the Bubl  immunoprecipitate  for the 
cell line expressing this version of LT. The tryptophan mutants W91A, W94A 
and W95A appeared slightly defective  for Bubl  binding,  as the  lOOkDa LT 
bands seen in the Bubl  immunoprecipitations  for cell lines expressing these 
LT  proteins  were  of a  lower  intensity  than  would  be  expected  given  the 
amount of LT expressed in these cell lines. In the experiment shown in Figure 
3.6 the tryptophan mutants appear to be just as defective for Bubl binding as 
the  dl89-97  deletion  of LT.  However  when  repeated  they  showed  slightly 
more intense bands. Therefore, the co-immunoprecipitation data in Figure 3.6 
should be treated qualitatively. One interpretation of the data could be that the 
LT mutants that co-immunoprecipitate decreased levels of Bubl  do so purely 
due  to  their  lowered  LT  expression  levels,  and not because  of a  decreased 
ability of the  LT to  interact with Bubl.  However the reduced interaction  of 
dl89-97 LT (and to some extent W91A, W94A and W95A LT) with Bubl  has 
also been demonstrated very convincingly in experiments using the same LT 
mutants,  but  expressed  in  Rat-1  cells  (Cotsiki  et  al.,  2004).  The  level  of 
expression  of LT  in the  Rat-1  cells  was  very  similar between the wild-type 
and the mutant LT cell lines,  due to prior screening of single cell  clones  for 
equivalent  LT  expression  levels.  Transient  transfected  cells  or  a  pool  of 
permanently transfected  cells  were  not used  because  it  was  not possible  to 
obtain pools  of cells  with  equivalent  LT  expression between  the  cell  lines. 
REFs  expressing wild-type  or mutant LT  were  also  screened  for single  cell 
clones  with  high  and  equivalent  expression  levels  of the  LT  protein,  but 
unfortunately it was not possible to find clones of dl89-97, W91A, W94A or 
W95A LT expression any higher than that shown in Figure 3.6.  Given more 
time a greater number of clones would have been screened for LT expression 
level to try to remedy this issue.
1383.3.3  Transformation efficiency of wild-type L T versus dl89-97 LT
Bubl  mutations  have  been  occasionally  identified  in  certain  types  of 
human cancer characterised by chromosomal instability and aneuploidy, such 
as colorectal cancer (Cahill et a l,  1998; Ru et al., 2002; Shichiri et al., 2002), 
raising the possibility that interaction of Bubl  with LT might be contributing 
to  its  transforming  activity.  It  has  long  been  known  that  SV40  LT  has  the 
ability to transform, but that it is not a bona fide transforming gene such as ras 
or Polyoma middle T antigen.  The Roberts laboratory have shown that when 
transfected with dl89-97 LT or one of the tryptophan substitution LT mutants, 
Rat-1  cells  fail  to  form  the  dense  foci  indicative  of transformation  that  are 
seen when the cells are transfected with wild-type LT or one of the other LT 
mutants (Cotsiki et al., 2004).
These  findings  are  reiterated  by  a  similar  focus  assay,  this  time 
conducted  in  NIH  3T3  cells.  NIH  3T3  cells  stably  transfected  with  either 
pSUPERretro (empty vector) or pSUPERretro-Bubl  (allowing knockdown of 
Bubl  expression via RNAi  interference  (RNAi);  vectors  kindly provided by 
Dr Ole Gjoerup,  and described in more detail in Chapter 4) were transduced 
with retroviral  supernatants  containing packaged pBabe-puro(empty vector), 
pBabe-puro(wild-type LT) or pBabe-puro(dl89-97 LT), as described earlier in 
this chapter.
Viral  titres  calculated  previously were  used  to  determine  the  relative 
volume  of each  supernatant  to  use  for  equivalent  infections.  Untransfected 
NIH  3T3  cells  were  transduced with these  volumes  of supernatant,  split 24 
hours later (1  in  10  and  1  in  50,  in duplicate)  into puromycin selection,  and 
stained with methylene blue  8  days later to count the number of colonies on 
each plate.  Estimations  for equivalent volumes  of the retroviral  supernatants 
were  very  accurate  for  pBabe-puro(wild-type  LT)  and  pBabe-puro(dl89-97 
LT),  as  can be  seen by the  average  colony counts  from the viral  titre plates 
(see  Figure  3.7A).  The  colony  counts  for  these  vectors  were  very  similar, 
allowing focus assay plates using these volumes of retroviral  supernatant for
139the infection to be directly compared for the relative transformation potential 
of wild-type  versus  dl89-97  LT.  The  colony  counts  for  the  NIH  3T3  cells 
transduced  with  pBabe-puro(empty  vector)  were  higher  than  those  for  the 
other vectors,  but this was not so  crucial  as  this vector was not expected to 
induce focus  formation in the cells, and so using too much of this retrovirus 
would only highlight the relative inability of the empty vector to transform.
NIH  3T3(pSUPERretro-empty  vector)  and  NIH  3T3(pSUPERretro- 
Bubl) cells were transduced (on duplicate plates) with four times the volume 
of pBabe-puro- retroviral supernatants used to confirm similar colony counts, 
as  shown  in  Figure  3.7A.  (four times  the  volume  of supernatant  was  used 
compared  to  the  viral  titre  infections,  to  account  for  the  relatively  low 
transformation  efficiency  of LT).  24  hours  later,  the  duplicate  plates  were 
pooled,  and split  1   in  8  to 4 plates,  with only 2%  serum (donor calf serum, 
DCS)  in  the  medium.  The  reason  for this  reduction  in  serum  concentration 
was to reduce the number of spontaneous foci that are seen when conducting 
this assay in NIH  3T3  cells.  Puromycin selection was not used for the focus 
assay plates  because  the  cells  were  already puromycin  resistant,  due  to  the 
pSUPERretro- vectors that they already carried.
Cells were maintained at 37°C with media changes every 3-4 days. 23 
days post-transduction, all plates were stained with Crystal Violet, to visualise 
the transformed foci  (see Figure 3.7B&C).  The results  of the transformation 
assay conducted by Dr Roberts laboratory in Rat-1  cells (Cotsiki et al., 2004) 
is  reiterated  by  this  focus  assay  using  NIH  3T3  cells,  as  seen  in  the 
representative  plates  shown  in  Figure  3.7B.  pBabe-puro(empty  vector- 
transduced NIH 3T3(pSUPERretro-empty vector) cells do not show any dense 
foci,  indicating  that  the  low  serum  conditions  have  reduced  spontaneous 
transformation of NIH 3T3 cells.
140Figure 3.7:  Transformation-competence of wild-type versus dl89-97 LT 
in NIH 3T3 cells with normal and lowered levels of Bubl expression.
Table  showing  the  relative  proportions  of retroviral  supernatants  used  for 
each pBabe-puro construct (empty vector, wild-type LT or dl89-97 LT)  for 
focus  formation  assays  in  NIH  3T3  cells,  indicating  that  they  result  in 
approximately equal colony counts (and hence transduction efficiencies) for 
the  LT  constructs  (A).  Representative  plates  showing  focus  formation  for 
each construct in NIH 3T3(pSUPERretro-empty vector) cells (B), and in NIH 
3T3(pSUPERretro-Bubl)  cells  (C),  which  have  reduced  expression  of the 
Bubl protein.
Wild-type  LT  has  the  ability to  induce  foci  (indicative  of transformation) 
whereas dl89-97 (non-Bubl -binding) LT does not. The same result is seen in 
cells with both normal and reduced levels of Bubl expression.
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Retroviral vector:
Vol. (pi) retroviral 
supn.  per infection
Colony counts:
1  in 10 split: Average: 1  in 50 split: Average:
pBabe-puro(empty vector) 
pBabe-puro(wild-type LT)
30
250
1568
992
1504
904
1536
948
592
412
640
420
616
416
pBabe-puro(d!89-97 LT) 102 784 840 812 414 450 432
B
NIH 3T3(pSUPERretro):
pBabe-puro- 
(empty vector)
pBabe-puro- 
(wild-type LT)
pBabe-puro- 
(dl89-97 LT)
c
NIH 3T3(pSUPERretro-Bub1):
pBabe-puro-  pBabe-puro-  pBabe-puro-
(empty vector)  (wild-type LT)  (dl89-97 LT)
Figure 3.7: Transformation-competence of wild-type versus dl89-97 LT 
in NIH 3T3 cells with normal and lowered levels of Bubl  expression.
142The cells transduced with pBabe-puro(wild-type LT) show a moderate number 
of dense foci, indicating the transforming abilities of this protein. As seen in 
Rat-1  cells  however,  the  dl89-97  LT-containing  retrovirus  induces  a  much 
lower number of dense foci than the wild-type LT, indicating that dl89-97 LT 
is transformation defective. The NIH 3T3 colony counts shown in Figure 3.7A 
are very similar between the wild-type and dl89-97 LT constructs, verifying 
that these focus assay plates can be directly compared.
Figure 3.7C shows representative plates for the focus assay carried out 
in the Bubl  knockdown cells, NIH 3T3(pSUPERretro-Bubl). The results are 
almost identical to those seen in the NIH 3T3 cells with normal levels of Bubl 
expression (Figure  3.7B).  The Bubl  knockdown cells  express  a much lower 
level  of Bubl  protein  compared  to  that  seen  in  normal  NIH  3T3  cells  (see 
Chapter 4, Figure 4.15). It was proposed that if wild-type LT induces efficient 
transformation via sequestering Bubl, dl89-97 LT might be able to efficiently 
transform cells in which Bubl  levels have been reduced. However, this is not 
observed (compare Figure  3.7  sections B  and C).  This does not rule out the 
possibility that Bubl  levels were not sufficiently reduced to see  an  effect in 
this experiment.
3.4  SUMMARY & DISCUSSION
The results presented in this chapter demonstrate that residues 89-97 of 
the SV40 LT protein are necessary for interaction with the spindle checkpoint 
protein Bubl. Finer mapping of the interaction site indicated that residues 90, 
92 and 93  of LT are not important, whereas the tryptophan residues  (91,  94 
and 95) are important for the interaction with Bubl. The binding of LT with 
Bubl  is not involved in the immortalisation functions of the LT protein, but 
LT-Bubl interaction is necessary for the transformation functions of LT.
Although the results presented in this chapter highlight the importance 
of the  tryptophan  residues  in  the  89-97  region  of LT  for  Bubl  binding,  it 
remains to be seen if a particular set of these tryptophan residues delimit the
143Bubl  binding  site.  The  mapping  experiments  shown  here  have  also  been 
replicated  in  human  U20S  cells  and  in  Rat-1  cells  by  members  of  Tom 
Roberts’  laboratory at the Dana Farber Cancer Institute, Boston, MA (Cotsiki 
et  al.,  2004),  providing  further validation  for  the  results  presented  here.  In 
Rat-1  cells the dl89-97 mutant and the tryptophan substitution mutants in this 
region  showed  a  retarded  mobility  on  SDS-PAGE  and  a  lower  level  of 
expression  than  wild-type  LT,  reiterating  the  results  seen  in  the  REFs.  The 
retarded mobility could be due to some form of post-translational modification 
of the LT protein caused by the mutations, or could merely be a consequence 
of the substitution or deletion mutations. Further experiments are required to 
find  the  cause  of these  mobility  differences.  The  significance  of the  low 
expression  level  of the  LT  mutants  defective  for Bubl  binding is  not clear, 
although  it  may be  related to  inability of the  cells  to  survive  high  levels  of 
expression  of these  particular LT  mutants.  It remains  to  be  proven  that  the 
Bubl-LT interaction is  direct.  In the  future,  it would be  interesting to try in 
vitro binding assays using recombinant Bubl  and LT proteins to try to answer 
this question.
Most importantly of all, the knowledge of the binding site of Bubl  on 
the LT protein  opens  up  many  avenues  of research  into  the  function  of the 
interaction.  The  dl89-97  LT-expressing  cell  lines  generated  can  now  act  as 
tools to study the effects that LT is having on the spindle checkpoint, as they 
provide a control for the difference between effects caused specifically by the 
Bubl-LT interaction, and effects caused by other functions of LT.
It has also been shown that an additional mutant of LT lacking residues 
98-102  (dl98-102)  fails to co-precipitate with Bubl,  suggesting that residues 
89-97  of LT  may  not  represent  the  entire  Bubl  interaction  site  (personal 
communication,  Dr  Ole  Gjoerup).  However  the  Bubl-LT  interaction  is 
sufficiently  disrupted  in  cells  expressing  dl89-97  LT  to  prevent  co- 
immunoprecipitation,  and  also  to  prevent  the  compromise  of Bubl  spindle 
checkpoint functions seen in cells with wild-type LT (See Chapter 5). It would 
be interesting to investigate the immortalisation efficiency of the dl98-102 LT
144mutant in the future, as well as to determine the checkpoint function of Bubl 
in the context of this LT deletion mutant.
The Roberts laboratory has proposed that LT is acting as a scaffold to 
bring  p53  into  proximity  with  Bubl,  causing  p53  to  be  phosphorylated  on 
serines  15  and  37  (Gjoerup  et  al.,  submitted  2004:  SV40  large  T  antigen 
reveals  a  functional  connection  between  Bubl  and  p53).  They  have 
demonstrated  that  this  Bubl-mediated  phosphorylation  is  essential  for  the 
stabilisation  of  p53  elicited  by  LT,  and  is  also  required  for  LT-induced 
acetylation of p53. In addition, it may also contribute to CBP/p300 binding by 
LT. It was also  shown that the microtubule-depolymerising drug nocodazole 
induced phosphorylation  of  p53  on serines  15  and  37 in a Bubl-dependent
manner.  They  suggest  that  LT  is thus  taking  over a  cellular  signalling
mechanism by recruiting Bubl  to phosphorylate p53 on serines  15 and 37 and 
inducing acetylation at lysines 373 and 382, leading to p53 stabilisation in the 
absence  of spindle  damage.  In  this  way,  LT  is  inactivating  but  at  the  same
time  stabilising  one  tumour  suppressor,  p53,  in  order  to make  a  trap  for  a
second tumour suppressor, p300. However, the data presented in Figure 3.3 of 
this chapter (showing the relative expression levels of p53 in REFs expressing 
different  LT  mutants)  is  contradictory  to  the  findings  of  the  Roberts 
laboratory. Two of the cell lines expressing dl89-97 LT displayed equally high 
levels of p53 as that seen in cells expressing wild-type LT, indicating that the 
protein  is just  as  stable,  even  in  the  absence  of Bubl  interaction.  If these 
results were consistent with the Roberts laboratory, all dl89-97 clones would 
show  low  p53  expression,  as  seen  in  the  p53  blot  of dl89-97  LT  clone  1. 
Further  verification  of  these  results  would  be  needed  to  determine  their 
significance, as currently no explanation can be given for these observations.
The inability of the  dl89-97  LT to interact with Bubl  does not affect 
the ability of the protein to stably immortalise primary REFs. Furthermore, the 
results presented here suggest that inability to bind to Bub 1  actually increases 
the  immortalising  efficiency  of  LT.  The  E90A  LT  mutant  was  the  most 
efficient immortalising protein  of all the mutants tested.  However,  this  does
145not appear to be directly related to Bubl binding of LT because E90A was not 
defective for Bubl  binding. Perhaps the inability of dl89-97 LT to disturb the 
spindle checkpoint is in some way increasing the survival rate of its primary 
cell  targets,  possibly  via  protection  from  the  problems  associated  with 
aneuploidy.  Alternatively,  this  apparent gain  of function could be  due to  an 
increase  in proliferation  (see  Figure  5.2  for an indication  of a faster growth 
rate of dl89-97 LT-expressing cells), or perhaps a decrease in apoptosis in the 
dl89-97  LT-expressing  cells,  resulting  in  observation  of  a  higher  than 
expected immortalisation efficiency. The LT mutants with single substitutions 
to  alanine that  were  tested in the  dl89-97  region  appeared to be  even  more 
powerful immortalising proteins than dl89-97 or wild-type LT, although there 
is currently no obvious explanation for this. This result has been repeated and 
is therefore unlikely to be trivial, although further work is needed to determine 
the cause of the apparent increased immortalisation efficiency of LT mutated 
within  residues  89-97.  However  this  observation  is  very  interesting  and 
unexpected,  and suggests that dl89-97  LT could in  some way act as  a more 
efficient immortalising agent than the wild-type LT protein.
Published data (Cotsiki et al., 2004), along with data presented in this 
chapter  demonstrate  that  dl89-97  LT  is  defective  for  transformation,  while 
retaining the  ability to  immortalise primary  cells.  This  demonstrates  for the 
first time that the immortalisation functions of LT can be separated from the 
transformation functions of the protein. If the interaction with Bubl  turns out 
to be crucial  for the  ability of LT to  induce  aneuploidy,  then this  finding is 
given  greater  credence  by  the  link  between  aneuploidy  and  tumourigenesis 
that has been  suggested many times  in the  literature  (Draviam et al.,  2004; 
Saraga et a l,  1997; Tutt et al.,  1999). It has also been shown that reduction of 
Bubl  levels  in  human  fibroblasts  results  in  a  low  frequency  of aneuploid 
clones  capable  of  anchorage-independent  growth  (another  measure  of 
transformation), providing more evidence in support of a role for Bubl  in LT- 
mediated  oncogenic  transformation  (Musio  et  al.,  2003).  Further  work  is 
necessary  to  demonstrate  the  link  between  LT,  Bubl  and  aneuploidy  in
146primary  cells,  especially  in  human  cells,  which  are  known  to  have  a  more 
stable  genome.  In  fact,  initial  studies  of the  karyotype  of human  mammary 
fibroblasts and epithelial cells immortalised with hTERT and either wild-type 
or dl89-97 LT recently carried out in the laboratory indicate that while dl89- 
97-immortalised  cells  are  near  diploid,  wild-type  LT  appears  to  induce  an 
aneuploid phenotype.
Tom  Roberts’  colleagues  have  also  shown  that  these  Bubl-binding 
deficient LT mutants, along with D44N LT, are defective for replication of the 
SV40 viral DNA (personal communication). In vivo DNA replication assays 
were performed  essentially using  a previously  described method  (Gjorup  et 
al.,  1994).  Initiation  of SV40  viral  DNA replication requires  formation of a 
complex at the SV40 origin, consisting of the virus-encoded LT protein, and 
three  cellular  proteins,  replication  protein  A  (RPA),  DNA  polymerase 
ct/primase  (pol/prim)  and  topoisomerase  I  (topo  I)  (reviewed  in  (Simmons, 
2000)).  Replication  of SV40  DNA  is  initiated when  LT  binds  to  the  SV40 
origin  and  forms  a  double-hexameric  structure.  Pol/prim  is  the  first  cellular 
protein to  interact with the  origin-bound double-hexameric  LT,  followed by 
topo I and RPA (Simmons et al., 2004).  It has been shown that topo I binds 
LT at two sites,  the  first mapping to amino terminal residues  83-160  of LT, 
and the  second  mapping  to  carboxy terminal  residues  602-708  (Roy  et al, 
2003). The possibility therefore presents itself that the inability of dl89-97 LT 
to allow viral DNA replication could be due to deletion of residues crucial for 
the binding  of topo  I,  although  this  remains  to  be  determined.  However,  it 
could  be  the  ability  of  LT  to  bind  Bubl  that  is  critical  for  viral  DNA 
replication and hence  survival  of the  SV40 virus itself,  and the inhibition of 
Bubl  function resulting in failure of accurate chromosome segregation could 
be secondary to this. The tryptophan residues in the 89-97 region of LT were 
the most critical  for viral DNA replication (personal communication, Dr Ole 
Gjoerup), consistent with their importance for the transformation function of 
LT, and further suggesting a link between Bubl and SV40 viral replication.
147Future experiments that may aid in our understanding of the Bubl-LT 
interaction would include mutation of all 3  tryptophan residues in the  89-97 
region of LT simultaneously, to determine if they constitute the core binding 
region  of  Bubl  on  LT.  Primary  cells  could  also  be  transduced  with  the 
different  LT  mutants  and  their  karyotype  determined  over  successive 
passages, to further examine the possibility that LT is inducing aneuploidy via 
its interaction with the Bubl  spindle checkpoint protein.  This  seems a likely 
possibility, as temporary inhibition of Bubl by RNAi and ribozyme-mediated 
methods  in  primary  human  fibroblasts  has  been  shown  to  result  in  a 
statistically significant number of aneuploid cells (15%) (Musio et al., 2003). 
Although most of these aneuploid cells underwent apoptosis, some were able 
to  escape  programmed  cell  death  and  gave  rise,  at  low  frequency,  to 
anchorage independent clones. The aneuploidy phenotype persisted in culture, 
even though the inhibition of Bubl was only temporary. It was noted however 
that  these  anchorage  independent  clones  had  not  yet  acquired  a  neoplastic 
phenotype, because they were unable to grow when injected subcutaneously in 
nude mice. This suggests that a second mutational event is required for the full 
transformation phenotype. It may therefore be interesting to inject nude mice 
with  pools  of  clones  expressing  either  wild-type  LT,  dl89-97  LT  or  the 
tryptophan  point  mutants  of LT  in  this  region  to  determine  if the  cells  can 
induce  tumours.  Perhaps  the  inhibition  by  LT  of p53,  pRB  and  other  host 
proteins  could  provide  the  primary  event,  and  aneuploidy  caused  by  LT 
inhibition  of Bubl  could provide  the  secondary  event required for  effective 
neoplastic transformation.  If the predictions  made  in this  chapter are correct 
and  dl89-97  LT-expressing  cells  have  a  stable  chromosome  content,  these 
cells should not have the capacity to induce tumour formation in nude mice. 
Alternatively, the capacity of the LT mutants to induce tumours in mice could 
also  be  tested  by  generating  transgenic  mice  expressing  recombinant  LT 
linked to the rat insulin promoter, as described in (Hanahan,  1985). Wild-type 
LT was shown to cause tumours exclusively in the beta-cells of the endocrine 
pancreas in these transgenic mice, and it would be interesting to determine if
148the LT mutants  deficient for Bubl  binding are capable of generating similar 
tumours.
A  sequence  alignment  of  the  polyomavirus  large  T  antigens 
demonstrated conservation within the 89-97 region of SV40 LT for several of 
these large T antigen proteins, in particular human BK polyomavirus, human 
JC  polyomavirus,  bovine  polyomavirus,  and Kilham  strain  of polyomavirus 
(see Figure 3.4). A prediction could therefore be made that each of these large 
T antigens is likely to interact with Bubl  in the same way as SV40 LT, due to 
the homology observed in these residues. However, this remains to be tested. 
Murine polyomavirus large T antigen did not show any obvious homology in 
this region of the protein,  and so it would be interesting to determine if this 
protein is able to interact with Bubl. If all polyomavirus large T antigens are 
found to  interact with Bubl,  regardless  of sequence homology to  the  89-97 
region of SV40 LT, perhaps the protein structure of these regions need to be 
studied rather than their sequence in order to further elucidate the features of 
the  Bubl-LT  interaction  site.  These  kinds  of  studies  may  provide  more 
information  about the  mechanism by which  LT is  inhibiting the  function of 
the Bubl checkpoint kinase.
1494. Generation of monoclonal antibodies against Bubl
4.1  OBJECTIVES
High quality antibodies against the mammalian Bubl  protein were not 
readily  available  when  this  project  was  begun.  There  were  no  good 
commercial antibodies  against this protein,  and only very small  quantities  of 
Bubl  antibody were obtainable via request from other laboratories. Attempts 
to  use  the  available  Bubl  antibodies  for  immunoprecipitation  and 
immunofluorescence studies of the Bubl-LT interaction in the mouse had not 
been  very  successful,  and  the  antibodies  tested  did  not  appear  to  be 
particularly specific for Bubl in either mouse, rat or human, recognising many 
bands on a western blot. For this reason it was decided to develop monoclonal 
antibodies against the mouse Bubl  protein to aid future studies of the Bubl- 
LT interaction in NIH 3T3 cells.
4.2  EXPERIMENTAL STRATEGY
The mouse Bubl  protein  (mBubl)  was  cloned in two halves  into the 
expression vector pET-23a(+),  incorporating  a histidine tag into the  carboxy 
terminus of each protein sequence.  The mBubl  protein is on the upper limit 
for expression  of proteins  in E.  coli (1058  amino  acids),  and it was  for this 
reason  that  it  was  decided  to  express  it  as  two  separate  his-tag  proteins, 
representing the amino-terminal (NT) and carboxy-terminal (CT) halves of the 
protein.  A  rabbit  polyclonal  antibody  raised  against  the  carboxy-terminal 
region  of Bubl  immunoprecipitated  Bubl  better  than  an  antiserum  raised 
against the amino-terminus of Bubl  (Personal communication, Dr Raimundo 
Freire).  Conversely,  Bubl  antibodies  directed against the  amino-terminus  of 
Bubl  appeared to be particularly good for western blotting, while also being 
useful for immunoprecipitation. Also, the kinase domain of Bubl  is located in 
the  carboxy-terminus  of the  protein,  whereas  the  amino-terminus  has  other
150activities. For these reasons, it was thought that raising antibodies against the 
Bubl  protein in two halves would increase the chances of obtaining reagents 
for  future  studies  of the  Bubl-LT  interaction,  and  would  possibly  result  in 
antibodies  targeted  against  the  different  activities  of the  Bubl  checkpoint 
kinase.
His-tagged mBubl  proteins were expressed in the E.  coli strain BLR 
XDE3 pLysS, and purified via affinity chromatography in sufficient quantities 
for immunisation.  Several mice were immunised and boosted with either NT 
or  CT  mBubl  protein,  and  test  bleeds  were  screened  by  western  blotting. 
Splenocytes were prepared from the mice with the most promising test bleeds 
for the NT and CT mBubl  antibodies, and fused with a myeloma cell line to 
produce hybridomas.  Pools of hybridoma cells then went through successive 
rounds  of screening  by  ELISA,  western  blotting  and  immunoprecipitation, 
isotyping, and sub-cloning of the best pools until single cell clones  secreting 
the best possible antibodies were obtained.
The  specificities  of  the  monoclonal  antibodies  generated  were 
determined  via  several  means,  including  western  blotting  of  exogenously 
expressed  HA-tagged  Bubl  protein,  western  blotting  of lysates  with  Bubl 
levels  knocked-down  by  RNAi,  and  immunolocalisation  experiments.  The 
monoclonal  antibodies  were  also  affinity purified using  Protein  G  columns, 
and tested for their abilities to detect the Bubl-LT interaction.
4.3 RESULTS
4.3.1  Generation of mBubl antigens
4.3.1.1  PCR and cloning strategy for generation of pET-23a(+)-mBubl-His-
Tag expression vectors
The mBubl  cDNA (a gift from the McKeon laboratory that originally 
cloned  it  (Taylor  and  McKeon,  1997))  had previously been  cloned  into  the 
pcDNA3.1(+)  (Invitrogen)  expression  vector  by  Teena  Puri,  a  final  year
151undergraduate project student in the laboratory, to allow ectopic expression of 
mBubl  in mammalian cells (see Appendix I for pcDNA3.1(+/-) vector map). 
This  vector  was  used  as  a  template  for  PCR  amplification  of the  mBubl 
cDNA in two  sections, which were then cloned into the bacterial expression 
vector pET-23a(+)  (Novagen).  The  cDNA  sequence  of mBubl  was  divided 
into two sections of approximately equal size, representing codons  1-561  and 
562-1058,  and  thus  between  them  coding  for  the  entire  mBubl  protein. 
Residue  562  of mBubl  (a methionine residue)  was  chosen to begin  the  CT 
mBubl protein sequence to prevent the need to add a start site to the sequence, 
possibly changing the structure of the protein.
The  vector  map  for  pET-23a(+)  is  shown  in  Figure  4.1.  The  pET 
system was developed for cloning and expression of recombinant proteins in 
E.  coli.  Plasmids  are  established  in  a  non-expression  host,  and  are  later 
transformed  into  a  host  bearing  the  T7  RNA  polymerase  gene  (X  DE3 
lysogen)  for  expression  of target proteins.  Figure  4.2  shows  the  context  in 
which the mBubl  PCR products were cloned into the pET-23a(+) vector, and 
the  primer  sequences  used.  The  restriction  sites  of many  of the  favoured 
restriction  enzymes  present  in  the  multiple  cloning  site  of the  pET-23a(+) 
vector were  also  found in  the  mBubl  cDNA  sequence.  For this  reason,  the 
restriction enzymes Xbal and BamHI were chosen for the cloning because the 
mBubl  cDNA  sequence  does not contain  any restriction  sites  recognised by 
these enzymes (See Figure 4.2A). The Xbal site is upstream of the ribosome 
binding site in the pET-23 a(+) vector, and for this reason it was necessary to 
include the ribosome binding site sequence in the forward primers for the PCR 
amplification of the two Bubl proteins (See Figure 4.2B). The reverse primers 
were  designed  to  incorporate  a  6  residue  histidine  tag  into  the  carboxy- 
terminus  of the  mBubl  proteins,  and thus  did not make  use  of the  His-Tag 
sequence already incorporated into the pET-23a(+) expression vector.
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Eag 1(166)
Hind 111(173)
Sal 1(179)
Hinc 11(181)
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- Bbs 1(506)
- Bsg 1(548)
- Eco47 111(642)
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(3666bp)
Pvu 1(2651)
Pst 1(2526)
Bgl 1(2401)
Ahd 1(2281)
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Bst1107 1(1159)
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Figure 4.1: Vector map of expression vector pET-23a(+).
Vector designed by Novagen for expression of recombinant proteins in 
E. coli (plasmid map taken from novagen website, www.novagen.com). 
pET-23a(+)  is  an  expression vector,  and target  genes  are  transcribed 
under control of the strong bacteriophage T7 promoter.
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T7 terminator primer *69337-3
pET-23a-d(+) cloning/expression region
B
Forward and  Reverse primers to amplify codons 1-561  of mBubl:
mBubl sequence
Xbal  rbs
F1: 5' -  CGCCCtT  CT  AGA ^AT  AATTTT  GTTT  AACTTT  AAG  AAGG  AGAT  AT  AC  AT  AT  GGACAACCT  AG  AAAATG -  3'
R1: 5’ -  C
BamHI
3GAT  cdT  CAGT  GGTGGTGGTGGT  GGT '^AGTC
STOP 6 x His Tag
G/^,CT  CAT  CAGT GT  GAG -  3’
mBubl  sequence
Forward and  Reverse primers to amplify codons 562-1058 of mBubl:
rbs Xbal
F2: 5’  -  CGCCC T  CT  AGA °iATAATTTT  GTTT  AACTTT  AAGAAGGAG  AT  AT  ACAT  AT  GGAT  GATT  CAA'
mBubl  sequence
cfe-:
BamHI
R2: 5’  -  CGGAT  CUT  CAGT  GGT  GGTGGTGGTGGT  GTTJT  CTT GAACGCTT  AT  ATT  C -  3'
6 x His Tag
3TTJTC
mBubl  sequence
Figure 4.2: Cloning mBubl into the pET-23a(+) expression vector.
Location of the Xbal and BamHI restriction sites in the pET-23 a(+) vector 
used for cloning of mBubl  PCR products (A).  Sequence of the forward 
(F)  and reverse (R) primers used to PCR amplify mBubl  codons  1-561 
and  codons  562-1058  (B).  A  Xbal  restriction  site  and  the  prokaryotic 
ribosomal  binding  site  (rbs)  are  incorporated  into  each  of the  forward 
primers, and a BamHI restriction site, stop codon and 6 x Histidine Tag 
are incorporated into each of the reverse primers.
154The NT-  (“mBubl(l-561)”)  and  CT-  (“mBub 1(562-1058)”)  halves  of 
mBubl  were PCR amplified using each of the two sets of primers.  The Vent 
{Thermococcus  litoralis)  polymerase  was  used  because  it  has  3’-5’ 
exonuclease  function,  resulting  in  a higher fidelity than that  seen  with  other 
polymerases  such  as  Taq.  The  resulting  PCR  products  and  the  pET-23a(+) 
vector  were  then  digested  with  Xbal  and  BamHI  restriction  enzymes  (see 
Figure 4.3).  Bands  of 1746bp  and  1554bp were  expected  for mBubl(1-561) 
and mBubl(562-1058)  PCR products, respectively, when digested with Xbal 
and  BamHI.  The  pET-23 a(+)  vector  was  expected  to  produce  a  band  of 
3588bp when digested with these enzymes. The digested DNAs showed bands 
of the expected sizes when separated on a 1% agarose gel containing Ethidium 
Bromide (See Figure 4.3). These digested DNAs were excised and gel purified 
using  a Qiagen  kit.  Purified digested PCR products  were  then  ligated to the 
cut  pET-23 a(+)  vector  using  T4  DNA  ligase,  and  transformed  into  CaCl2- 
competent JS4  strain E.  coli cells  (Sedivy et al.,  1987).  JS4  strain,  a recA\ 
derivative  of MC1061  that  does  not  contain  the  T7  RNA  polymerase  gene, 
was  used  for  the  cloning  stage  to  eliminate  plasmid  instability  caused  by 
expression of proteins potentially toxic to the host cell.  Colonies were grown 
overnight  at  37°C  on  ampicillin  selection  agar plates,  and  these  were  PCR 
screened  for positive  transformants.  The  screen  produced  6  mBub 1(1-561)- 
pET-23a(+) and 4 mBub 1(5 62-105 8)-pET-23a(+) positives, all of which were 
then transformed into CaCl2-competent cells of the protein expression E.  coli 
strain  BLR  7.DE3  pLysS.  The  DNA  sequence  of  the  mBubl  insert  was 
checked for each resulting positive  clone,  concomitantly with testing protein 
expression, as described below.
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Lane:
1   -  1  kb Ladder (gibco brl)
2 -  mBubl (1-561) PCR product, Xbal & BamHI  restriction digest
(expect 1746bp band)
3 -  mBubl (562-1058) PCR product, Xbal & BamHI restriction
digest (expect 1554bp band)
4 -  pET-23a(+) vector, Xbal & BamHI  restriction digest
(expect 3588bp band)
Figure 4.3: Restriction digests of mBubl  PCR products and pET-23a(+)
PCR products encoding the amino- and carboxy-terminal halves of mBubl, 
along with the expression vector pET-23 a(+) were digested with Xbal and 
BamHI restriction enzymes, yielding fragments of the expected sizes, ready 
for gel extraction and ligation.
1564.3.1.2  Protein  expression,  solubility  testing,  and  optimisation  of protein
purification
BLR A.DE3  pLysS  strain is a MDE3  lysogen derived from BL21  strain 
of E. coli and bears a copy of the T7 RNA polymerase gene under the control 
of the lacUV5 promoter,  which is  inducible upon addition of isopropyl-p-D- 
thiogalactopyranoside  (IPTG)  to  a  growing  culture  (see  Novagen  website: 
www.novagen.com).  T7 RNA polymerase transcribes the  target DNA  in the 
plasmid. Even in the absence of IPTG there is some residual expression of the 
T7  RNA  polymerase  from  the  lacUV5  promoter,  and  therefore  basal 
expression of the target protein.  To minimise the effects  of potential toxicity 
of the target protein to the host cells, this host strain is also pLysS. This means 
that  it  also  contains  a plasmid  that provides  a  low  level  of T7  lysozyme,  a 
natural  inhibitor  of  T7  RNA  polymerase.  This  plasmid  also  carries  the 
chloramphenicol resistance gene.  In addition, the BLR >J}E3  pLysS  strain is 
also recA-, allowing improved plasmid monomer yields, and stability of target 
genes containing repetitive sequences.
BLR  >.DE3  pLysS  cells  transformed  with  mBubl (1-56 l)-pET-23(a)+ 
and mBubl(562-1048)-pET-23(a)+  positive  clones,  were  IPTG  induced,  and 
total  protein  was  extracted  from  both  “uninduced”  and  “induced”  cultures. 
Samples were then run on  8%  SDS-PAGE gels,  and stained with Coomassie 
blue.  All  mBubl(l-561)-pET  or  mBubl(562- 1058)-pET  clones  tested 
demonstrated expression  of a  90kDa or a  70kDa protein,  respectively,  upon 
induction  with  IPTG  (data  not  shown).  It  was  therefore  possible  to  check 
protein  solubility  and  optimise  purification  conditions  for the  proteins,  now 
that it was  known  that protein  expression  was  being  effectively  induced by 
IPTG for both constructs.
Soluble proteins are fully folded in a (supposedly) native conformation, 
and  often  yield  good  monoclonal  antibodies  with  relatively  low  injection 
doses. Monoclonal antibodies generated against a soluble protein are likely to 
be useful for immunoprecipitation, immunofluorescence, and other techniques 
where  the  target  protein  is  in  its  native  conformation  (Carey  Hanly  et  al.,
1571995).  Many proteins  do  not  fold  properly  when  expressed  as  recombinant 
proteins  in bacteria,  and  form  insoluble  inclusion  bodies  in  the  cells.  These 
insoluble  proteins  can  be  solubilised  and  if  necessary  refolded  in  vitro, 
although  unfolded  antigens  are  more  immunogenic  than  antigens  in  their 
native  form  (Mayer,  2000),  and  often  result  in  antibodies  that  are  good  at 
recognising  the  denatured  form  of the  protein  of  interest,  e.g.  for  use  in 
western blotting.
To  test  the  purification  protocol  for  each  of  the  mBubl  proteins, 
following  IPTG-induction,  the  proteins  were  bound  to  nickel-nitrilotriacetic 
acid His-bind resin (Ni-NTA; Novagen) under native purification conditions, 
and  tested  for  the  ability  to  bind  to  and  elute  from  the  resin  under  these 
conditions.  Ni-NTA resin has  a very high affinity for proteins  containing an 
affinity tag of six consecutive histidine residues - the 6xHis tag. Total protein 
extracts  were  prepared  for  “uninduced”  and  “induced”  samples  from  two 
different clones of the mBubl(1-56l)-pET construct (named 1-2-1  and 2-2-1), 
and for two  different clones  of the mBub 1(562-1058)-pET  construct (named 
4-1-1 and 4-4-1). For each clone, 2ml of the induced culture that had not been 
subjected to total protein extraction was tested for solubility of the expressed 
protein,  via protein  mini-prep  under native  conditions.  Cells  were  lysed and 
the His-tagged mBubl-derived protein was bound to Ni-NTA His-Bind resin, 
washed  and  eluted.  The  binding  (and  lysis)  buffer  contained  a  very  low 
concentration  (ImM)  of  imidazole,  a  small  molecule  which  at  high 
concentrations  has  a  better  affinity  for  the  Ni-NTA  resin  than  the  His-tag 
proteins.  This  was  included  to  reduce  non-specific  binding  to  the  resin  by 
proteins  containing  a  few  consecutive  histidine  residues.  The  wash  buffer 
contained  lOmM  imidazole  to  wash  away  any proteins  without  a  6xHis-tag 
that  had  bound  to  the  resin,  and  the  elution  buffer  contained  250mM 
imidazole, to dissociate (elute) the protein of interest from the resin. Finally, 
samples  were  heated with  Laemmli buffer,  loaded  on  SDS-PAGE  gels,  and 
stained with Coomassie blue (See Figures 4.4 and 4.5).
158Figure 4.4: Native mini-prep of mBubl(l-561)-His protein.
For  each  of  two  bacterial  clones  expressing  (NT)  mBubl(l-561)-His 
(clones  1-2-1  and 2-2-1), expression of a 90kDa protein (indicated by an 
arrow) is induced by IPTG (20pl (out of lOOpl) of uniniduced (lanes  1   & 
7) and IPTG-induced (lanes 2 & 8) total bacterial lysate are shown). This 
protein is successfully bound to Ni-NTA resin, as indicated by lack of this 
90kDa protein in the  “unbound protein”  (20pi  out of lOOpl  of the  first 
resin wash) lanes (3 & 9). 20pl, successive elutions of the His-tag protein 
from each clone (lanes 4-6 & 10-12) demonstrate that this 90kDa protein 
can be purified in its soluble form.
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Figure 4.4: Native mini-prep of mBubl(l-561)-His protein.
160Figure 4.5: Native mini-prep of mBubl(562-1058)-His protein.
For each of two bacterial  clones  expressing (CT) mBubl(562- 1058)-His 
(clones 4-1-1  and 4-4-1), expression of a 70kDa protein (indicated by an 
arrow) is induced by IPTG (20pl (out of lOOpl) of uniniduced (lanes 1 & 7) 
and  IPTG-induced  (lanes  2  &  8)  total bacterial  lysate  are  shown).  This 
protein is successfully bound to Ni-NTA resin, as indicated by lack of this 
70kDa protein in the “unbound protein” (20pi out of lOOpl of the first resin 
wash) lanes (3 & 9). 20pl, successive elutions of the His-tag protein from 
each clone (lanes 4-6 & 10-12) demonstrate that this 70kDa protein could 
not be eluted from the affinity resin, and thus cannot be easily purified in 
its soluble form.
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90kDa  is  induced  by  addition  of  IPTG  to  the  bacterial  culture,  in  both 
mBub 1(1-56l)-pET clones 1-2-1  and 2-2-1, as a strong 90kDa band is seen in 
the “induced” lane that is not so strong in the “uninduced” lane for each clone 
(compare lane  1   with lane 2, and lane 7 with lane  8). This strong band is no 
longer detected in the  “unbound protein” lane  for each clone  (lanes  3  and 9, 
representing the first wash of the protein-bound Ni-NTA resin), indicating that 
this protein  is  His-tagged,  and has  successfully bound to  the  His-bind resin. 
Finally, it is clear that the His-tagged NT mBub 1  protein from both clones can 
be eluted very cleanly as a 90kDa band using native conditions for the mini- 
prep  (see  lanes  4-6  and  10-12).  Therefore,  mBubl(l-561)  protein  is 
approximately  90kDa  in  size,  and  can  be  successfully  purified  as  a  soluble 
protein.
Figure 4.5 shows the mini-prep under native conditions for purification 
of  mBubl(562-1058)-His  protein  from  clones  4-1-1  and  4-4-1.  A  strong 
70kDa  band  in  the  “induced”  lanes  for  each  clone,  not  present  in  the 
“uninduced”  lanes  indicates  that  expression  of  this  protein  is  being 
successfully induced by IPTG  (compare  lane  1   with lane  2,  and lane  7  with 
lane  8).  As  would be  expected  from the  number  of residues  in  each  of the 
mBubl(l-561)  and  mBub 1(562-1058)  His  Tag  proteins,  the  CT  mBubl 
protein has  a  lower  molecular weight  of 70kDa,  compared  with  the  90kDa 
observed for the NT mBubl protein. This 70kDa band is no longer seen in the 
“unbound  protein”  lanes  (3  and  9)  of Figure  4.5,  indicating  that  it  is  the 
mBub 1(562-1058)-His  protein,  and  has  successfully  bound  to  the  Ni-NTA 
resin. However, no strong 70kDa band is observed in the elution lanes of this 
figure (lanes 4-6 and  10-12)  indicating that mBub 1(562-1058)-His  cannot be 
eluted and thus  cannot be purified  in  its  native  form,  and would need to be 
purified  as  insoluble  protein.  In  fact,  when  attempting to  purify this protein 
under native  conditions,  two  faint bands  were  observed  in  the  elution  lanes 
when more sample was loaded, at 70kDa and also at 90kDa (data not shown).
163Two clones of mBubl(l-561)-pET in BLR XDE3 pLysS cells, “1-2-1” 
and  “2-2-1”  were  sequenced  to  confirm  the  fidelity  of PCR,  and  that  the 
correct sequence  had been  cloned.  The  DNA  sequence  of 1-2-1  contained a 
single base change, whereas the sequence of clone 2-2-1  was a perfect match 
to  the  sequence  of mBubl  in  the  original  pcDNA3.1-mBubl  plasmid.  One 
clone  of  mBubl(562- 1058)-pET,  “4-1-1”,  was  sequenced  and  perfectly 
matched the mBubl  sequence from the pcDNA3.1-mBubl plasmid.
Therefore,  clone  2-2-1  was  chosen  to  express  and  purify  (NT) 
mBubl(l-561)-His  protein  in  bulk  using  a  soluble  protein  purification 
method.  Similarly,  clone  4-1-1  was  chosen  to  express  and  purify  (CT) 
mBubl(562- 1058)-His protein in bulk using an insoluble protein purification 
protocol.
Figure 4.6  shows  samples  from the native protein purification process 
for the NT mBubl  protein, mBubl(l-561)-His, run on an 8% SDS-PAGE gel 
and Coomassie stained. As expected, a strong approximately 90kDa protein is 
seen in the “induced” sample (lane 2), but not in the “uninduced” sample (lane 
1). This protein is not seen in the “unbound protein” (lane 4) suggesting that it 
successfully bound to the Ni-NTA resin on the column. Only very faint 90kDa 
bands are seen in the “wash” (lanes 5 and 6) samples, indicating that very little 
was removed by the wash steps. The “cleared lysate” sample (lane 3) does not 
show a strong 90kDa band as would be expected. This may suggest that most 
of the  90kDa  protein  precipitated  out  and  was  lost  to  the  pellet  during  the 
lysis. Nevertheless  some of the protein of interest must have been present in 
the cleared lysate and then successfully bound to the Ni-NTA resin, because 
strong 90kDa protein bands can be seen clearly in the elution lanes (7-11  and 
15-19).  The  90kDa  protein  NT  mBubl  protein  appears  to  cleanly  elute  in 
elution fractions 2-5 (lanes 7-11) of the first prep, “Prep  1” (lanes  1-11). Prep 
2 (lanes  12-19) represents “unbound protein” from Prep  1, loaded onto a fresh 
Ni-NTA resin column, and washed and eluted separately.
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Figure 4.6: Bulk purification of soluble mBubl(l-561)-His protein.
Samples of all stages of the protein purification process are shown. The 
(arrowed) 90kDa (NT) mBubl(1-561 )-His protein (expressed in clone 
2-2-1)  was  eluted  cleanly,  and  the  strongest  elution  fractions  were 
pooled and dialysed into  1   x PBS, ready for immunisation of mice for 
generation of monoclonal antibodies against NT mBubl.
(Equal volumes of the samples (5 pi) were loaded in lanes 1-19).
165The 90kDa protein is eluted cleanly in elution fractions 2 and 3  (lanes  16-17) 
of Prep  2,  even  though  the  unbound  protein  from  Prep  1   (lane  4)  did  not 
appear to  contain  any  of this protein.  This  indicates  that not  all NT  mBubl 
protein was binding to the Ni-NTA resin in the original prep. Elutions 2-5  of 
Prep  1   and elutions  2-3  of Prep  2  were pooled,  dialysed into  1  x phosphate 
buffered  saline  (PBS),  and  concentrated  (using  30 kDa  NMWL  (nominal 
molecular weight unit) columns from Millipore), ready for injection into mice. 
These elutions were chosen because they had the greatest quantity of the NT 
mBubl  90kDa  protein  (mBubl(1-561)-His).  Figure  4.6  lanes  20-22  show 
0.1 jig,  lpg and 5pg samples of this pooled and concentrated protein, ready for 
immunisation  of  mice  for  monoclonal  antibody  production.  The  most 
abundant band was the Bubl protein, and this was very clean in comparison to 
the crude “induced” sample (lane 2) from which it was purified.
Attempts  to  optimise  the  bulk  denaturing  purification  of  (CT) 
mBub 1(562-1058)-His  protein  from  clone  4-1-1  using  urea-based  buffers 
were unsuccessful. Buffers containing Guanidine-HCl were found to be much 
better for purification of the denatured 70kDa protein from 4-1-1.  Figure 4.7 
shows samples of total bacterial lysate from the uninduced and IPTG-induced 
4-1-1 cells used for the purification (lanes 1  and 2, respectively), run on an 8% 
SDS-PAGE gel and Coomassie stained. As before, a strong ~70kDa protein is 
seen in the “induced” (lane 2) sample upon addition of IPTG, and this cannot 
be seen in the “uninduced” sample (lane  1).  The 70kDa band was present in 
the cleared lysate lane as expected, but an equal amount was also seen in the 
“unbound  protein”  sample  that  didn’t  bind  to  the  Ni-NTA  resin  (data  not 
shown),  indicating  that  not  all  of  the  available  70kDa  HisTag  protein 
successfully bound to the Ni-NTA resin. This was perhaps due to overloading 
the capacity of the resin.  10  elutions  from the Ni-NTA resin were  collected, 
and in addition the unbound protein sample was used as the starting material 
for a second prep,  from which a further  10 elutions of the 70kDa CT mBubl 
protein were collected.
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Figure  4.7:  Bulk  purification  of  insoluble  mBubl(562-1058)-His 
protein.
Uninduced and IPTG-induced total bacterial lysate samples from clone 4- 
1-1  are  shown  (lanes  1-2).  The  70kDa  (CT)  mBubl(562-1058)-His 
protein  (arrowed)  was  eluted  cleanly,  and  20  separate  elutions  were 
pooled, dialysed into 2M urea and concentrated, ready for immunisation 
of mice for generation of monoclonal antibodies against CT mBubl.
167These elution samples are not shown in Figure 4.7 because only a very small 
quantity of each was run on a  SDS-PAGE gel  and stained,  so as to retain as 
much as possible for immunisation, and the bands seen were very faint. All 20 
elutions (i.e. the elutions from both preps) were pooled, dialysed into 2M urea, 
and  concentrated,  ready  for  injection  into  mice.  Figure  4.7  lanes  3-5  show 
O.lpg,  lpg  and  5pg  samples  of  this  purified  mBubl(562-1058)-HisTag 
protein,  and  demonstrates  that  the  70kDa  protein  samples  have  very  few 
impurities.
The bulk purifications  detailed above resulted in  sufficient protein for 
immunisation  of mice  for monoclonal  antibody production  and for antibody 
screening, for both NT and CT mBubl  proteins. The total yield was 200pl of 
(NT)  mBubl(1-56l)-HisTag  (in  1   X  PBS)  at  2.1 mg/ml,  and  2ml  of (CT) 
mBubl(562-1058)-HisTag (in 2M urea) at 2.2mg/ml.
4.3.2  Generation  of  hybridoma  cell  lines  that  secrete  monoclonal
antibodies specific to mBubl
4.3.2.1  Immunisation and test bleed validation
Immunisations  of  two  mice  for  each  purified  mBubl  protein  were 
carried out by Dr Terry Jowett at the UCL monoclonal antibody facility. Test 
bleeds were taken from the mice, and fusions were carried out for spleen cells 
derived from the most promising mouse for each of the mBubl  antigens.
Figure 4.8 shows western blot results using the test bleed samples from 
the immunised mice. NIH 3T3  whole cell lysate (lane  1), and uninduced and 
IPTG-induced whole bacterial  lysates  from antigen-expressing  cells  for both 
the NT (lanes 3  and 4) and CT (lanes  5  and 6) mBubl  were blotted with the 
test bleeds, and also with normal mouse  serum (negative control),  and rabbit 
polyclonal NT hBubl  antiserum (positive control).
168Figure 4.8:  Western blot analysis using test bleeds from mBubl- 
immunised mice.
Whole cell lysate from NIH 3T3 cells, and whole bacterial lysate from 
uninduced  and  induced  bacteria  expressing  either  NT  mBubl 
(mBubl(l-561)-His  from  clone  2-2-1)  or  CT  mBubl  (mBub 1(562- 
1058)-His  from  clone  4-1-1)  were  separated  on  SDS-PAGE  and 
western  blotted  using  either  normal  mouse  serum  (A),  NT  Bubl- 
immunised  mouse  1   (B)  or  mouse  2  (C)  test  bleeds,  CT  Bubl- 
immunised  mouse  1  (D)  or  mouse  2  (E)  test  bleeds,  or  rabbit 
polyclonal NT  hBubl  antiserum  (F).  Specificities  of the  test bleed 
antisera  for  both  endogenous  mBubl  protein  (predicted  molecular 
weight  120kDa,  as  seen in the NIH  3T3  lane),  and  for the  antigen 
expressed  in  bacteria  (90kDa  NT  mBubl  protein,  or  70kDa  CT 
mBubl  protein) were used to select which mouse to recommend for 
hybridoma generation for each antigen.
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Figure 4.8: Western blot analysis using test bleeds from mBubl- 
immunised mice.
170As  expected,  normal  mouse  serum  (Figure  4.8A)  did  not  show  any  strong 
bands of the expected size, i.e. ~120kDa is the predicted molecular weight of 
mBubl  in the whole cell lysate, while the NT mBubl  antigen is ~90kDa, and 
the  CT  mBubl  antigen ~70kDa.  NT  mBubl-immunised mouse  1   test bleed 
(Figure 4.8B) blotted several very strong bands at around 120kDa in the NIH 
3T3 whole cell lysate lane (lane  1), and also showed strong recognition of the 
90kDa antigen in both lanes 3  and 4.  This is  slightly surprising,  as  lane 3  is 
loaded with “uninduced” bacterial lysate from clone 2-2-1, and so would not 
contain as high a level of the NT mBubl  antigen as the “induced” sample in 
lane 4.  Perhaps  the pLysS  plasmid in  the  BLR  >.DE3  pLysS  cells  does  not 
reduce basal expression in the absence of IPTG as well as hoped, but it seems 
most likely that this  result is  simply indicative  of the  sensitivity  of western 
blotting.  NT  mBubl-immunised  mouse  2  test  bleed  (Figure  4.8C)  showed 
fewer bands in lane  1   (NIH 3T3 lysate) than mouse  1, with very strong bands 
only at 120kDa (the predicted molecular weight of mBubl), and at ~150kDa. 
Similar  to  mouse  1,  NT-mBubl-immunised  mouse  2  showed  very  strong 
90kDa bands in lanes 3 and particularly in lane 4, indicating recognition of the 
antigen. NT mBubl-immunised mouse 2 was chosen for monoclonal antibody 
production, due to its recognition of only two, rather than several very strong 
bands in lane  1. It was also chosen because it blotted equally strongly for the 
120kDa  and  150kDa  bands,  and  the  120kDa  band  matched  the  predicted 
molecular weight  for mBubl.  Mouse  1  however blotted most  strongly  for a 
150kDa  and  a  90kDa band in the NIH  3T3  lysate  (lane  1),  and  so  was  not 
thought to be recognising the correct protein.
CT (carboxy-terminal)  mBubl-immunised mouse  1  test bleed (Figure 
4.8D) was specific to a 120kDa band in the NIH 3T3 lysate (lane  1), and was 
also  able  to  recognise  the  70kDa  antigen  in  lanes  5  and  6  (although  more 
strongly  in  lane  6,  where  the  expression  of the  protein  has  actually  been 
induced).  CT  mBubl-immunised mouse  2  test bleed  (Figure  4.8E)  was  also 
specific  to  a  120kDa  band  in  the  NIH  3T3  lysate,  but  was  not  able  to 
recognise  the  antigen  in  lanes  5  and  6,  as  no  70kDa  band  is  seen  in  these
171lanes.  For  this  reason,  CT  mBubl-immunised  mouse  1   was  chosen  for 
monoclonal antibody generation.
Figure  4.8F  is  a  positive  control,  showing  the  same  lysates  blotted 
using rabbit polyclonal antiserum against the NT hBubl  (kindly provided by 
Dr Raimundo  Freire).  This  demonstrates  the  relative  non-specificity  of this 
antibody,  as  many bands  are  strongly recognised  in  the  NIH  3T3  lysate.  It 
should also be noted that the  120kDa (predicted molecular weight  of Bubl) 
band is not the strongest of these.  Interestingly, the pattern of bands  seen in 
lanes 3 and 4 of Figure 4.8F match the patterns seen in the equivalent lanes in 
panels  B  and  C,  providing  further  indication  that  these  antibodies  are 
recognising  the  same  protein,  and  suggesting  that  the  bands  of molecular 
weight lower than 90kDa seen in these lanes are degradation products. Finally, 
the native,  NT  mBubl  protein resulted in  a  stronger  immune  response  than 
that  seen  with  the  CT  mBubl  protein.  This  is  slightly  unexpected,  as  it  is 
usually  the  denatured,  unfolded  antigens  that  give  the  strongest  immune 
response, as mentioned previously.
4.3.2.2  Fusion and initial screening
Spleen  cells  were  isolated  from NT  mBubl-immunised mouse  2  and 
CT  mBubl-immunised  mouse  1,  and  were  fused  with  myeloma  cells  to 
produce  hybridomas  by  Dr  Terry  Jowett,  using  standard  protocols.  Initial 
screening  of the  hybridomas  via  ELISA  (Enzyme-Linked  ImmunoSorbent 
Assay),  antibody  isotyping  and  cloning  and  cultivation  of hybridoma  cells 
were also performed by Dr Jowett. The wells of the ELISA screen microtitre 
plates were coated with either the native NT mBubl  antigen,  or the dialysed 
CT mBubl  antigen. Although unfolded proteins do not stick to ELISA plates, 
some of the CT mBubl protein would have refolded in the dialysis buffer, and 
it was hoped that this would be sufficient to carry out the screen. It would of 
course have been better to use a soluble CT mBubl protein for the ELISA, but 
this  was  not  possible  to  purify.  After  blocking  with  BSA  (Bovine  Serum 
Albumin), hybridoma supernatants for each antibody were  added to wells of
172microtitre plates coated with the relevant antigen, and positives were detected 
by addition of HRP (Horseradish peroxidase)-conjugated secondary antibody 
against  whole  mouse  serum,  and  an  HRP-substrate.  The  use  of anti-whole 
mouse serum:HRP secondary antibody (a standard protocol used by Dr Terry 
Jowett)  resulted  in  detection  of both  IgM  and  IgG  class  antibodies  by  the 
ELISA screen.
Hybridoma  supernatants  that  tested  positive  in  these  initial  ELISA 
screens  were  tested  via  western  blot  and  immunoprecipitation,  and  the 
positives  from  these  screens  were  then  single  cell  cloned,  isotyped  and  re­
screened by  ELISA.  It  should  be  noted  that  the  ELISA  screen  of the  NT- 
mBubl  hybridoma  supernatants  produced  many  more  positives  than  the 
ELISA  screen  of  the  CT-mBubl  hybridoma  supernatants  (40  versus  22, 
respectively),  probably  due  to  the  dialysed  (mostly  unfolded)  CT  mBubl 
antigen being used for the latter ELISA screen.
4.3.2.3  Screening via western blot and immunoprecipitation
Figure  4.9  shows  the  results  of  the  western  blot  screen  for  40 
hybridoma  supernatants  from  the  NT  mBubl  fusion,  all  of  which  gave 
positive results in the ELISA screen. Each supernatant was used at a dilution 
of  1:100  to  western  blot  one  lane  of NIH  3T3  (expressing  wild-type  LT) 
whole cell lysate (50pg), and one lane of induced whole bacterial lysate from 
clone  2-2-1  (NT  mBubl-expressing  cells),  transferred  from  an  8%  SDS- 
PAGE gel.  Autorads  from each blot  for the NT hybridoma  supernatants  are 
shown,  along  with  blots  for  media  only  (negative  control),  and  a  rabbit 
polyclonal antiserum against NT hBubl (positive control).
173Figure 4.9: Initial western blot screen of the NT mBubl hybridoma 
tissue culture supernatants.
NIH  3T3(wild-type LT)  whole  cell  lysate  and whole bacterial  lysate 
expressing the NT mBubl  antigen were blotted with 1:100 dilution of 
each  of 40  hybridoma  supernatants  from  the NT  mBubl  fusion  that 
tested  positive  for  antigen  recognition  in  the  ELISA  screen.  Strips 
blotted with supernatants giving the most positive results are enlarged. 
The 90kDa bacterial antigen is indicated by an arrow. The supernatants 
were  single  cell  cloned,  and  new  single  cell  clone  names  and  the 
isotype  of  these  clones  are  indicated.  Negative  (media  only)  and 
positive (rabbit polyclonal NT hBubl antiserum) control strips are also 
shown.
174Each  strip shown  below is western  blotted for a different NT m Bubl 
hybridoma supernatant (1:100):
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Figure 4.9: Initial western blot screen of the NT mBubl  hybridoma 
tissue culture supernatants.
175The most interesting blots are enlarged in the bottom half of Figure 4.9, 
and these  (no’s 8, 2, 3, 26 & 34) were chosen for single cell cloning and for 
further analysis. NT Bubl  hybridoma supernatant no.’s  8  and 2 were chosen 
because they both strongly recognise the 90kDa NT mBubl  antigen in lane 2 
(indicated by an arrow). (The 90kDa band in lane 2 of the supernatant 8 blot, 
although strong, appears a little fuzzy, but this was probably due to a running 
problem with the gel, as the band was seen on several exposures). Supernatant 
2  also  recognised  a  ~120kDa  band  (the  predicted  molecular  weight  for 
mBubl) in the NTH 3T3 lysate in lane  1, but a band of this size was not seen 
in lane 1   of the supernatant 8 blot. Supernatants 3 and 26 did not recognise the 
bacterial antigen in lane 2, but were chosen because strong bands of ~120kDa 
were seen in lane  1   for these supernatants. Supernatant 34 was chosen because 
an extremely faint 90kDa antigen band could be seen in lane 2, although this 
is  not  visible  in  the  scanned  image  for this  figure.  As  expected,  no  strong 
bands are observed in the  120kDa region of lane  1   and no 90kDa antigen is 
detected  in  lane  2  for  the  negative  control,  media  only  blot.  The  positive 
control strip, NT hBubl rabbit polyclonal antiserum blot showed strong bands 
in  the  120kDa  region  in  lane  1,  and  a  very  strong  90kDa  band  (and  other 
smaller  bands  representing  either  degradation  products  or  prematurely 
terminated proteins)  in lane 2. NT Bubl  hybridoma supernatants  8,  2,  3,  26 
and 34 were single cell cloned and renamed (the new names for the single cell 
clones  from  these  supernatants  are  shown  in  Figure  4.9).  The  single  cell 
clones were also isotyped to determine their antibody sub-class, and they were 
all IgMs except for supernatant 8 (single cell clone name “2B8”), which was 
IgGl. The IgG (2B8) is likely to be a better antibody than the IgMs, as IgGs 
are produced by the stronger, secondary immune response, whereas IgMs are 
produced  as  the  primary  immune  response  and  therefore  may  not  be  as 
specific as the IgG sub-class of antibodies.  In hindsight,  it would have been 
better to have used a mixture of anti-IgG antibodies (specific to the different 
mouse IgG sub-classes)  conjugated to HRP to  detect positives in the  ELISA 
screen to prevent IgM  antibodies  from being  selected  for further validation,
176allowing  more  time  to  be  spent  verifying  the  potentially  more  useful  IgG 
candidate monoclonals.
All of the NT Bubl hybridoma supernatants shown were also tested via 
immunoprecipitation, as shown in Figure 4.10.  50pl of each supernatant was 
used for immunoprecipitation from  500pg of NIH 3 T3 (wild-type LT) whole 
cell lysate. Media only and CT hBubl  rabbit polyclonal antibody (previously 
shown  to  immunoprecipitate  well,  but  not  western  blot  for  Bubl,  kindly 
provided by Dr Raimundo Freire) were used as negative and positive controls, 
respectively,  for  the  immunoprecipitation.  When  blotted  using  the  rabbit 
polyclonal  antiserum  against  NT  hBubl,  the  positive  control 
(immunoprecipitation using polyclonal  CT hBubl  antiserum)  showed a very 
strong band in the  120kDa-200kDa region of the blot,  in addition to  several 
other  very  strong  bands  (data  not  shown,  due  to  strong  non-specific  bands 
making scanning of a clear image difficult). The only other lane that showed a 
strong band in this region (co-migrating with the band in the positive control 
lane) was NT mBubl  hybridoma supernatant 8 (as previously mentioned, this 
was  later  single  cell  cloned  and  renamed  2B8,  and  was  found  to  be  IgGl 
subclass).  This was a very clear result and provided further evidence for the 
Bubl  specificity of this particular hybridoma supernatant, which when single 
cell cloned was identified as the only IgG from all those picked out from the 
western  blotting  screen  in  Figure  4.9,  and  the  best  monoclonal  antibody 
generated  against  NT  mBubl.  It  should  also  be  noted  that  these 
immunoprecipitations  were  all carried out using Protein A-Sepharose beads. 
Protein A is a cell wall component of Staphyloccocus aureus that binds the Fc 
portion of IgGs from many species. However, 2B8 is IgGl, a sub-class that is 
not easily precipitated using Protein A (Protein G, a cell surface receptor from 
Streptococcus which  is  able to recognise both the  Fc  and Fab portions  of a 
wide  range  of  immunoglobulins,  would  have  been  better  for 
immunoprecipitation experiments with this antibody, as it has a much greater 
affinity for IgGl).
177IPs blotted for rabbit polyclonal NT hBubl  antiserum (1:2000):
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Lane:
1  = IP : NIH 3T3(wt T) lysate (500/yg) + 50/d NT mBubl  hybridoma supn. 1
2 = IP : NIH 3T3(wt T) lysate (500//g) + 50//I NT mBubl  hybridoma supn. 2 
  etc......
40 = IP :  NIH 3T3(wt T) lysate (500/vg) + 50//I NT mBubl  hybridoma supn. 40
41  = IP :  NIH 3T3(wt T) lysate (500//g) + 50//I media only
Figure  4.10:  NT  mBubl  hybridoma  supernatant  screening  via 
immunoprecipitation.
50/d of each of the 40 NT mBubl  hybridoma tissue culture supernatants 
picked out from the ELISA screen was used to  immunoprecipitate (IP) 
mBubl from NIH 3T3(wild-type LT) whole cell lysate. IPs were then run 
on  SDS-PAGE  and western  blotted  using  rabbit  polyclonal  NT  hBubl 
antiserum,  to  determine  which  if  any  supernatants  were  able  to 
immunoprecipitate  a  band  of approximately  120-200kDa  (Bubl).  The 
arrowed lane (NT mBubl supernatant 8) was the only monoclonal to give 
a strong band in the region expected for Bubl. A negative control (media 
only, lane 41) is also shown.
178This  suggests  that  2B8  must  be  a  very  effective  antibody  for 
immunoprecipitation, as Bubl was effectively brought down even by the weak 
affinity  this  antibody  has  to  Protein  A.  Immunoprecipitation  experiments 
using  antibody  2B8  and  Protein  G  later  in  this  chapter  (see  Figure  4.19), 
demonstrate that this antibody immunoprecipitates Bubl extremely well.
Figure  4.11  shows  the  results  of  the  western  blot  screen  for  22 
hybridoma  supernatants  from  the  CT  mBubl  fusion,  all  of  which  gave 
positive results in the ELISA screen.  Similar to the screen in Figure 4.9, each 
supernatant was used at a dilution of 1:100 to blot nitrocellulose strips,  each 
with one  lane  of NIH  3T3(wild-type  LT)  whole  cell  lysate  (50pg),  and  one 
lane  of  induced  whole  bacterial  lysate  from  clone  4-1-1  (CT  mBubl - 
expressing cells).  Control  strips were also blotted with media only (negative 
control),  or  a  rabbit  polyclonal  antibody  directed  against  NT  hBubl 
(positive/negative control).
Strips  giving  interesting  results  are  enlarged  at  the  bottom  half  of 
Figure 4.11.  These hybridoma pools were all  selected for single cell cloning 
(their new single cell clone names are shown) and the single cell clones were 
also  isotyped.  Supernatants  3,  12,  19  and  20  were  chosen  because  they  all 
strongly  recognise  the  bacterially  expressed  70kDa  CT  mBubl  antigen 
(indicated by an arrow in Figure 4.11) in lane 2. It is likely that the reason for 
these  70kDa  bands  being  so  strong  (compare  strength  of  90kDa  bands 
observed  in  Figure  4.9)  is  because  the  ELISA  screen  of these  supernatants 
used insoluble protein. This would have been less efficient than a screen using 
soluble  protein,  and  so  the  resulting  positives  must  have  had  very  strong 
affinities for the antigen. It should be noted that these hybridoma supernatants 
gave rise to  single cell clones that were all IgG  sub-class, whereas the other 
supernatants  singled out for further analysis  did not recognise the  antigen in 
lane 2, and gave rise to IgM single cell clones.
179Figure 4.11: Initial western blot screen of the CT mBubl  hybridoma 
tissue culture supernatants.
NIH  3T3(wild-type  LT)  whole  cell  lysate  and  whole  bacterial  lysate 
expressing  the  CT  mBubl  antigen were blotted with  1:100  dilution  of 
each of 22 hybridoma supernatants from the CT mBubl fusion that tested 
positive for antigen recognition in the ELISA screen. Strips blotted with 
supernatants  giving  the  most positive  results  are  enlarged.  The  70kDa 
bacterial antigen is indicated by an arrow. A  150kDa protein in the cell 
lysate that is recognised by many of the supernatants is indicated by an 
arrowhead. The supernatants were single cell cloned, and new single cell 
clone  names  and  the  isotype  of these  clones  are  indicated.  Negative 
(media  only)  and  positive  (rabbit  polyclonal  NT  hBubl  antiserum) 
control strips are also shown.
180Each strip shown below is western blotted for a different CT mBubl 
hybridoma supernatant (1:100):
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Figure 4.11:  Initial western blot screen  of the CT mBubl  hybridoma 
tissue culture supernatants.
181Of the  IgG  sub-class  hybridomas,  19  (and  to  some  extent  also  hybridoma 
supernatant number  12)  not  only recognised the  antigen  in  lane  2,  but  also 
recognised  a  band  at  around  150kDa  (indicated  in  Figure  4.11  by  an 
arrowhead).  This  band  co-migrated  with  a  very  strong  band  seen  in  the 
positive control blot using the polyclonal NT hBubl  antiserum.  Supernatants 
1, 2, 9 and 16 were chosen because they all showed a strong band in the  120- 
150kDa region in the NIH 3T3 lysate, lane 1. As expected, media only did not 
show a strong  120-150kDa band in lane  1,  and did not recognise the 70kDa 
antigen  in  lane  2.  The  NT  hBubl  rabbit  polyclonal  antibody  again  (as  in 
Figure 4.9) revealed a strong band at 120kDa (the predicted molecular weight 
of Bubl) and a particularly strong band at  150kDa, but did not recognise the 
70kDa CT mBubl  antigen in lane 2.  This is as expected, because the rabbit 
polyclonal  antibody is  prepared  against the  amino-terminus  of human  Bubl 
protein that is not present in this  CT  mBubl  protein.  The  CT hBubl  rabbit 
polyclonal antibody (used for immunoprecipitation experiments in Chapter 3) 
could not be  used  in  this  case  because  it  does  not  western  blot.  The  weak 
lOOkDa  band  seen  in  lane  2  for  the  rabbit  polyclonal  hBubl  antibody  is 
presumed to be a non-specific interaction.
All 22 hybridoma supernatant pools for CT mBubl  were also screened 
by  immunoprecipitating  from  500pg  of NIH  3T3 (wild-type  LT)  whole  cell 
lysate using  50pl  of each  supernatant,  and western  blotting  using  the rabbit 
polyclonal  antiserum  against  NT  hBubl  (see  Figure  4.12).  Media  only 
(negative  control)  and  rabbit  polyclonal  CT  hBubl  antiserum  (positive 
control) immunoprecipitations were also carried out. The CT hBubl antiserum 
brought down a protein of ~150kDa that was recognised strongly by the NT 
hBubl polyclonal antiserum, but as before this is not shown due to very strong 
non-specific bands making production of a clear scanned image very difficult. 
As for the immunoprecipitations shown in Figure 4.10, it was quite surprising 
that the immunoprecipitated band seen with these  antibodies was  150kDa in 
size, because the predicted molecular weight for Bubl is 120kDa.
182IPs blotted for rabbit polyclonal NT hBubl  antiserum (1:2000):
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2 = IP  : NIH 3T3(wt T) lysate  (500/yg)  +  50/yl  CT mBubl  hybridoma supn. 2
  etc.....
22 = IP : NIH 3T3(wt T) lysate (500/yg) + 50//I CT mBubl  hybridoma supn. 22
23 = IP : NIH 3T3(wt T) lysate (500/yg) + 50//I media only
Figure  4.12:  CT  mBubl  hybridoma  supernatant  screening  via 
immunoprecipitation.
50/xl  of  each  of  the  22  CT  mBubl  hybridoma  tissue  culture 
supernatants  picked  out  from  the  ELISA  screen  was  used  to 
immunoprecipitate  (IP)  mBubl  from  NIH  3T3(wild-type  LT)  whole 
cell lysate. IPs were then run on SDS-PAGE and western blotted using 
rabbit  polyclonal  NT  hBubl  antiserum,  to  determine  which  if any 
supernatants were able to immunoprecipitate a band of approximately 
120-200kDa  (Bubl).  The  arrowed  lanes  (CT  mBubl  supernatants  3, 
12,  19 and 20) were the only monoclonals to give a strong band in the 
region expected for Bubl. A negative control (media only, lane 23) is 
also shown.
183It is demonstrated that the 150kDa protein recognised by these antibodies is in 
fact  Bubl  in  section  4.3.3  below.  Media  only  (lane  23)  is  not  able  to 
immunoprecipitate  the  150kDa  protein.  Of the  22  hybridoma  supernatants, 
only 3,  12,  19 and 20 are able to immunoprecipitate this  150kDa protein. The 
other hybridoma supernatants did not immunoprecipitate any proteins at all. It 
is  interesting  to  note  that  these  hybridomas  were  all  chosen  for  single  cell 
cloning from their western blotting abilities, and they represent all of the IgGs 
out of those shown in Figure 4.11. Also,  12 and 19 show very strong 150kDa 
bands  in  the  immunoprecipitation  experiment  compared  to  the  weak  bands 
seen  for 3  and 20.  This  was  a  further indication  that  12  (IgG2a,  single  cell 
clone name “13G9”) and  19 (IgG2b, single cell clone name “17E9”) were the 
best of the CT mBubl hybridoma supernatants chosen.
Single cell clones isolated from the hybridomas shown at the bottom of 
Figures 4.9 and 4.11  were further analysed and it was decided to concentrate 
on NT Bubl  hybridoma number 8  (IgGl  sub-class, which gave rise to three 
identical  clones,  2B8/A4,  2B8/D2  and  2B8/H4,  from  now  on  known  as 
“2B8”),  CT  Bubl  hybridoma  number  12  (IgG2a,  three  identical  clones, 
13G9/A9,  13G9/B9 and  13G9/F11, from now on known as “13G9”), and CT 
Bubl  hybridoma  number  19  (IgG2b,  three  identical  clones,  17E9/E2, 
17E9/E10 and 17E9/F3, from now on known as “17E9”).
4.3.3  Confirmation  that  the  antibodies  truly  detect  Bubl,  and  species
specificity tests
Having identified three potentially good monoclonal antibodies against 
mBubl, it was necessary to determine their specificity. The band detected by 
the mBubl  monoclonal antibodies via western blotting (150kDa) was not the 
expected molecular weight of Bubl  (120kDa). This  150kDa band had already 
been shown to co-migrate with a strong band recognised by a polyclonal NT 
hBubl  antiserum  (see  arrowhead,  Figure  4.11),  but  further  testing  was 
required to determine if this band (rather than the  120kDa band also detected
184by  the  polyclonal  antibody)  was  actually  Bubl.  Species  specificity  of the 
antibodies  was  tested,  followed  by  confirmation  of  the  specificity  of  the 
antibodies  to  the  Bubl  protein  itself.  Finally,  immunolocalisation  studies 
were  carried out to  investigate  if the protein  identified by these monoclonal 
antibodies localises as expected for Bubl, both spatially and temporally.
4.3.3.1  Species specificity
Although  the  monoclonal  antibodies  were  developed  to  specifically 
recognise the mouse Bubl  protein, it was important to determine if they were 
also able to recognise the Bubl protein of other species. Studies on the Bubl- 
LT interaction in the laboratory have focussed on rat and human cell lines in 
addition to experiments in mouse, and for this reason, western blotting of NIH 
3T3  cells  expressing  wild-type  LT  (mouse),  REFs  expressing  wild-type  LT 
(rat) and U20S (human -  no cells expressing LT were available for testing at 
this stage of the project) was used to examine the species  specificities of the 
antibodies. As well as 50pg of each whole cell lysate, induced whole bacterial 
lysate of the relevant bacterial clone (2-2-1  for NT Bubl monoclonal 2B8, and 
4-1-1 for CT Bubl monoclonals 13G9 and 17E9) were also blotted.
Figure  4.13  shows  the  results  of these  western  blotting  experiments 
using  mBubl  monoclonals  2B8  (lanes  5-8),  13G9  (lanes  9-12)  and  17E9 
(lanes  13-16),  and  also  using  polyclonal  antiserum  against  NT  hBubl,  for 
comparison  (lanes  1-4).  The  polyclonal  NT  hBubl  antiserum  (lane  1)  and 
monoclonal 2B8 (lane 5) recognise the 90kDa NT mBubl  antigen band very 
strongly,  and  monoclonals  13G9  and  17E9  (lanes  9  and  13)  recognise  the 
70kDa CT mBubl  antigen very strongly,  as  expected.  The rabbit polyclonal 
hBubl  antibody  detects  a  strong  ~150kDa band  (among  others,  including  a 
faint  120kDa band)  in the mouse, rat and human lysates  (lanes  2-4).  2B8  is 
capable of recognising, albeit very weakly, a ~150kDa band in the mouse and 
human lysates (lanes 6 and 8, respectively), but not in the rat lysate (lane 7).
185Figure 4.13: Species specificity of the Bubl monoclonal antibodies.
Rabbit  polyclonal  NT  hBubl  antiserum  (1:2000)  (lanes  1-4)  or 
hybridoma  tissue  culture  supernatants  from  each  mBubl  monoclonal 
antibody  (1:50)  (lanes  5-16)  were  used  to  blot  whole  bacterial  lysate 
expressing  the  antigen  used  for  immunisation  (20pl  (of a  1   in  200 
dilution) of a small scale induction was loaded), or 50pg of whole cell 
lysate from either mouse (NIH 3T3 (wild-type LT)), rat (REF (wild-type 
LT)) or human (U20S) cells. The rabbit polyclonal NT hBubl antibody, 
and  NT  mBubl  monoclonal  2B8  recognise  the  90kDa  NT  mBubl 
antigen  (indicated  by  an  arrow,  lanes  1   and  5),  while  CT  mBubl 
monoclonals  13G9  and  17E9 recognise the  70kDa CT mBubl  antigen 
(indicated by an arrow, lanes 9 and 13). A ~150kDa protein (indicated 
by an arrow) is detected in mouse, rat and human lysates by the rabbit 
polyclonal antibody (lanes 2-4), by monoclonal 2B8 (albeit very weakly 
in western blot)  in mouse  and human lysates  (lanes  6  and  8),  and by 
monoclonals  13G9  and  17E9 in mouse lysates only (lanes  10 and  14). 
Later experiments (see Figures 4.14 and 4.15) indicate that this ~150kDa 
band is Bubl.
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Figure 4.13: Species specificity of the Bubl  monoclonal antibodies.
187Both 13G9 and 17E9 monoclonal antibodies are seen to detect a strong 
~150kDa  band  in  the  mouse  (NIH  3T3(wt  LT))  lysate  (lanes  10  and  14). 
However, neither antibody detects this protein in either the rat (lanes  11  and 
15)  or  human  (lanes  12  and  16)  lysates.  Therefore,  13G9  and  17E9 
monoclonals are specific for the  150kDa mouse protein, but not for the rat or 
human proteins.
It is interesting to note that in the 2B8 blot, the human  150kDa band in 
lane 8 appears to migrate slightly slower than the mouse band in lane 6. The 
mouse, rat and human Bubl  proteins seen at ~150kDa in the polyclonal NT 
hBubl  antiserum blot (lanes 2-4)  also  appear to migrate  at slightly different 
rates.  The  predicted  molecular  weights  for  the  human  and  mouse  Bubl 
proteins  are  122kDa  and  119kDa,  respectively,  which  could  explain  the 
differences in migration seen between them, but does not explain the observed 
mobility of these proteins at ~150kDa on  SDS-PAGE.  This  could be  due to 
post-translational  modification(s),  although  the  nature  of this  remains  to  be 
determined.  Therefore  it  was  important  to  prove  the  specificity  of  these 
antibodies to Bubl.
4.3.3.2  Specificity of the monoclonal  antibodies  to the  Bubl  protein:  HA-
mBubl and RNAi tests
Most important of all, it was necessary to determine the specificity of 
the  monoclonal  antibodies  generated  to  the  mBubl  protein  itself.  Several 
papers in the literature have suggested that antibodies raised against the Bubl 
protein  recognise  a  band  of  the  correct  predicted  molecular  weight  for 
mammalian Bubl  of ~120kDa on SDS-PAGE (Grabsch et al., 2004; Taylor et 
a l,  2001;  Taylor  and  McKeon,  1997).  The  mBubl  monoclonal  antibodies 
described in this chapter all appeared to be specific to a band that migrated to 
~150kDa on  SDS-PAGE,  causing concern that the protein detected by these 
antibodies  was  not  Bubl.  However,  in  the  papers  mentioned  above  which 
describe  Bubl  antibodies  detecting  a  ~120kDa  band  in  mammalian  cell 
lysates, western blots are presented that appear to show that these antibodies
188actually detect a slower migrating band of ~150kDa,  as  seen  for the mBubl 
monoclonal antibodies 2B8, 13G9 and 17E9. This suggested that the ~150kDa 
protein  detected  by  the  mBubl  monoclonal  antibodies  could  be  the  Bubl 
protein,  even  though  it  migrates  much  slower  than  the  predicted  molecular 
weight  for  mammalian  Bubl  proteins  of ~120kDa.  Similarly,  the  Xenopus 
Bubl  homolog has a predicted molecular weight of 131  kDa, but antibodies 
raised against this protein have been  shown to  detect  a protein migrating  at 
150kDa  on  SDS-PAGE  (Sharp-Baker  and  Chen,  2001).  When  Bubl 
immunoprecipitates  prepared  from mitotic  extract were  treated with lambda 
protein  phosphatase,  the  apparent  molecular  mass  of Bubl  was  reduced  to 
140kDa,  indicating  that phosphorylation  during  mitosis  was  partly to blame 
for the slower migration of the Xenopus Bubl protein.
To  confirm  the  specificity  of the  mBubl  monoclonal  antibodies,  the 
finding  that  the  monoclonals  only  detect  the  mouse  protein  was  exploited. 
Experiments  were  undertaken  to  show  that  the  protein  that  the  antibodies 
detect  co-migrates  with  a  HA-tagged  mouse  Bubl  protein  ectopically 
expressed in human cells (“HA” is influenza A virus haemagglutinin protein; 
it  is  a  commonly  used  epitope  tag).  In  addition,  the  ability  of the  mBubl 
monoclonal antibodies to detect a reduction in Bubl protein levels induced by 
RNAi (RNA interference) was also tested.
pcDNA3.1(-) vector (Invitrogen,  see Appendix I  for vector map) with 
HA-tagged,  full  length mouse  Bubl  cDNA  cloned into  the  BamHI  site  was 
kindly provided by Dr Ole  Gjoerup.  The  species  specificity tests  detailed in 
section 4.3.3.1  had shown that only antibody 2B8  was  able to detect human 
Bubl  protein,  whereas  all  three  monoclonals  were  able  to  detect the  mouse 
Bubl.  For  this  reason,  the  pcDNA3.1(-)HA-mBubl  vector  was  transfected 
into  U20S  (human)  cells,  to  distinguish between  endogenous  Bubl  and  the 
ectopically expressed HA-mBub 1  protein.
Figure 4.14 shows the results of the HA-mBub 1  specificity test for the 
mBubl monoclonal antibodies.
189Figure  4.14:  Specificity  of  the  mBubl  monoclonals  to  Bubl:  HA- 
mBub 1 experiment.
50pg  of  whole  cell  lysates  from  U20S  (human)  cells,  U20S(empty 
vector),  and  U20S(HA-mBubl)  (expressing  HA-tagged  mouse  Bubl 
protein) were western blotted using anti-HA antibody, to show expression 
of the  tagged mBubl  protein  (lanes  1-3).  They were  also  blotted with 
hybridoma tissue culture supernatants for each of the mBubl monoclonal 
antibodies, to demonstrate that they are specific to mBubl, and not some 
other  protein  of  a  similar  molecular  weight  (~150kDa)  (lanes  4-12). 
Finally,  these  lysates  are  blotted  with  rabbit  polyclonal  NT  hBubl 
antiserum  (lanes  13-15),  to  demonstrate  the  strong  specificity  of the 
mBubl monoclonals by comparison.
All three mBubl monoclonal antibodies recognise the HA-mBub 1  protein 
(indicated by an arrow).
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Figure  4.14:  Specificity  of  the  mBubl  monoclonals  to  Bubl:  HA- 
mBubl experiment.
19150pg  of  whole  cell  lysates  of  either  untransfected  U20S  cells,  U20S 
transiently  transfected  with  pcDNA3.1(-)  (empty  vector  control),  or  U20S 
transiently transfected with the pcDNA3.1(-)HA-mBubl  vector were run  on 
SDS-PAGE  and  western  blotted  using  either  anti-HA  monoclonal  antibody 
(positive  control),  each  of the  mBubl  monoclonal  antibody  tissue  culture 
supernatants,  or  rabbit  polyclonal  antiserum  against  NT  hBubl.  In  Figure 
4.14,  the  anti-HA  antibody  detects  a  very  strong  ~150kDa  protein  in  the 
U20S(HA-mBubl) lysate (lane 3), but not in the lysates where the HA-tagged 
mBubl  protein is not expressed (lanes  1   and 2).  This indicates that the HA- 
tagged  mBubl  protein  migrates  at  ~150kDa.  Strong  bands  migrating  at  the 
same molecular weight are seen in the U20S(HA-mBubl) lysates in lanes 6, 9 
and  12,  indicating  that  all  three  mBubl  monoclonal  antibodies  detect  the 
ectopically  expressed  HA-mBub 1   protein.  NT  Bubl  monoclonal  2B8  also 
detects,  albeit  more  weakly,  150kDa  bands  in  the  U20S  and  U20S(empty 
vector)  lysates  (lanes  4  and  5),  representing  the  endogenous  human  Bubl 
protein.  This  is  as  expected because  in  the previous  tests  this  antibody was 
able to detect mouse  and human Bubl  proteins.  In  contrast  13G9  and  17E9 
were unable to detect the human Bubl, as confirmed by the lack of bands in 
the 150kDa region of lanes 7-8 and 10-11  of Figure 4.14, indicating that these 
antibodies cannot detect endogenous hBubl  protein in the U20S lysates.  The 
rabbit polyclonal NT hBubl antibody (lanes 13-15) detected a 150kDa band in 
all  three  lysates,  co-migrating  with  bands  in  lanes  3,  4-6,  9  and  12.  This 
antibody was raised against the  amino terminus  of the human Bubl  protein, 
and so  as  expected detects both the  endogenous  human Bubl  (lanes  13  and 
14), but more strongly detects the over-expressed HA-mBub 1  protein, which 
is very abundant in the U20S(HA-mBubl) lysate (lane  15). It is also notable 
that there  are  also  several bands  at ~80  and  lOOkDa  detected by this  rabbit 
polyclonal  antibody  (possibly  due  to  cross-reactivity  of this  antibody),  not 
seen when blotting with any of the mBubl monoclonal antibodies, or with the 
anti-HA monoclonal (see lanes  13 and  14), an indication that the new mBubl 
monoclonal  antibodies  are  cleaner  reagents  in  comparison.  The  rabbit
192polyclonal  antibody  also  detects  many  extra  bands  of  molecular  weights 
ranging  from  ~70-150kDa  in  the  U20S(HA-mBubl)  lysate  in  lane  15,  but 
these could perhaps be degradation products of the overexpressed HA-mBub 1  
protein, seen by this antibody due to its high efficiency of binding to the Bubl 
protein (as well as to -80 and  lOOkDa proteins, as seen in lanes  13  and  14). 
The  strong bands  of molecular weight below  60kDa in  size  seen  in  all  five 
blots  are  most  likely  to  be  non-specific  due  to  general  stickiness  of  the 
primary or the secondary antibodies, as identical bands are seen in all blots.
This experiment confirms two important points. Firstly, it confirms that 
all three monoclonal antibodies tested are specific to the Bubl protein, and not 
to some other protein of a similar molecular weight. Secondly, it also confirms 
that  both  the  HA-tagged  mBubl  protein,  and  in  particular  the  endogenous 
hBubl  protein migrate  at ~150kDa on  SDS-PAGE,  and not at the predicted 
molecular weight of ~120kDa.  This  is  very  clear in  lanes  4-6  and  13-15  of 
Figure 4.14,  where  endogenous  and  ectopically  expressed Bubl  are  seen  to 
co-migrate, even in the presence of the HA-tag (which is not surprising, as the 
HA-tag  consists  of only 9  amino  acids  (YPYDVPDYA)).  Also,  Figure  4.14 
reiterates the species specificity results obtained in Figure 4.13.
The Bubl-specificity of the monoclonal antibodies was further verified 
via western blotting of lysates from cells where the expression level of Bubl 
had been  knocked down via  RNA  interference  (RNAi).  RNAi  relies  on the 
observation  that  double-stranded  RNA  (dsRNA)  acts  as  a  signal  for  gene- 
specific silencing of expression in many organisms, from the nematode worm, 
C.  elegans  to  mammals  (Sharp,  1999).  pSUPERretro  plasmid  (see 
www.oligoengine.com,  and Appendix II  for vector map) with an oligo insert 
corresponding  to  a  19-nucleotide  sequence  within  the  mRNA  of  Bubl 
(specific to both mouse and human Bubl)  cloned into the Hindlll  and Bglll 
sites  was  kindly  provided  by  Dr  Ole  Gjoerup  (this  vector  is  called 
“pSUPERretro-Bubl”).  The transcript of this recombinant vector is designed 
so that it will  fold back on itself to form a  19-base pair stem-loop  structure. 
This  transcript  is  then  cleaved  in  the  cell  to  produce  a  functional  short
193interfering RNA (siRNA), which can mediate strong and specific suppression 
of gene  expression  (Brummelkamp  et  al.,  2002).  The  pSUPERretro-Bubl 
vector,  and  an  empty  vector  control  (pSUPERretro)  were  packaged  into 
retroviruses  using the  ecotropic packaging  line  BOSC  23,  and the  retroviral 
supernatant  harvested  was  used  to  infect NIH  3T3  cells  in  the  presence  of 
polybrene.  Stable transductants were  selected  for by culturing in media with 
2pg/ml puromycin, and several colonies were isolated and expanded into cell 
lines. Whole cell lysates were then harvested from these clones, and tested for 
Bubl  knockdown  via  western  blotting  using  the  three  mBubl  monoclonal 
antibodies, and the rabbit polyclonal NT hBub 1  antiserum, to demonstrate that 
the protein recognised by these antibodies is being silenced by RNAi.
Figure 4.15  shows the results  of these  western blots.  Each blot has  4 
lanes,  loaded  as  follows:  lane  1   contains  NIH  3T3  lysate,  lane  2  contains 
lysate from a clone of NIH 3T3(empty pSUPERretro vector), lane 3  contains 
lysate  from  a  clone  of NIH  3T3(pSUPERretro-Bubl),  and  lane  4  contains 
lysate from an independent clone  of NIH 3T3(pSUPERretro-Bubl).  60 pg of 
whole  cell  lysate were  loaded  for the  13G9  and  17E9  blots,  whereas  lOOpg 
were  loaded  for  the  2B8  strip,  and  30pg  for  the  rabbit  polyclonal  Bubl 
antiserum strip.  Different quantities were  loaded to  account  for the  different 
antibody affinities observed when blotting with each antibody, to allow a clear 
result  for  each.  For  all  three  mBubl  monoclonal  antibodies  (blots  A-C), 
blotting of these lysates detected strong ~150kDa bands in lanes 1   and 2 in the 
absence of Bubl  RNAi, but weaker 150kDa bands in lanes 3 and 4 where the 
Bubl  RNAi transcript is being expressed, and is thus resulting in knockdown 
of Bubl protein levels. These results are reiterated by the rabbit polyclonal NT 
Bubl  antiserum  positive  control  (blot  D).  Actin  levels  are  also  shown  to 
indicate protein loading levels for each blot. This experiment provides further 
evidence of the specificity of the mBubl  monoclonal antibodies for the Bubl 
protein, and again confirms that the Bubl  protein migrates at the higher than 
expected molecular weight of 150kDa on SDS-PAGE.
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Figure  4.15:  Specificity  of the  mBubl  monoclonals  to  Bubl:  RNAi 
experiment.
Whole cell lysate from untransfected NIH 3T3 and NIH 3T3 transfected 
with empty vector control (lanes 1   and 2) show a strong ~150kDa Bubl 
band,  whereas  NIH  3T3  in  which  Bubl  has  been  knocked  down  via 
RNAi (lanes 3  and 4) show a weak ~150kDa Bubl  band, when blotted 
using  the  mBubl  monoclonal  antibodies  (blots  A-C)  or  with  rabbit 
polyclonal  NT  hBubl  antiserum  (blot  D).  This  shows  that  these 
antibodies are specific  for the mBubl  protein (migrating at ~150kDa), 
and not some other protein of similar molecular weight. Actin re-blots of 
each strip are shown below, indicating protein loading levels.
N.B.  100/zg of each lysate was loaded for blot A, 60/xg of each lysate for 
blots  B  and  C,  and  30/xg  of each  lysate  for  blot  D,  to  account  for 
different affinities of the antibodies.
195These tests led to the conclusion that monoclonal antibodies against the 
mouse Bubl protein had been successfully generated.
4.3.3.3  Immunolocalisation  of Bubl  as  seen  with  the  mBubl  monoclonal
antibodies
The three mBubl  monoclonal  antibodies were then used to determine 
the localisation of the Bubl protein. There were several reasons for doing this. 
Firstly,  Bubl  antibodies  available  prior  to  generation  of  the  monoclonal 
antibodies  described here detected non-specific proteins  in  addition to  Bubl 
via  western  blotting,  and  so  were  not  suitable  for  localisation  studies. 
Nevertheless  attempts  had been  made  to use  these polyclonal  antibodies  for 
immunofluorescence in the laboratory, but there had been no success.  It was 
therefore important to determine if the new Bubl  monoclonals were useful for 
this technique. Secondly, a further test of the specificity of the antibodies was 
possible  by  double  staining  cells  with  the  Bubl  monoclonals,  which  was 
possible because they are fortunately all different IgG sub-classes. Finally, the 
antibodies  were  used  to  determine  the  subcellular  localisation  of  Bubl 
throughout  the  different  stages  of  the  cell  cycle  in  cells  expressing  LT, 
something that had not been shown before.
Figure  4.16A  shows  a  field  of  several  cells  as  seen  via  confocal 
microscopy, all of which are in interphase except for one cell (indicated by the 
arrow)  which  has  entered  early  prophase.  Asynchronous  NIH  3T3  cells 
expressing LT (“SE” cells) were grown on glass coverslips and fixed with ice- 
cold  methanol.  NT  mBubl  monoclonal  2B8  (IgGl)  was  used  to  determine 
Bubl  localisation in Figure 4.16A (Bubl  shown in green), and was visualised 
using a FITC (Fluorescein)-conjugated secondary antibody. Propidium Iodide 
(PI) was added to the secondary antibody to stain the DNA in the cells, shown 
in red.  It has previously been  shown  that  Bubl  localises  to the  kinetochore 
during mitosis in normal mammalian cells (Taylor and McKeon, 1997).
196Figure  4.16:  Immunofluorescence  in  LT-expressing  cells  using  the 
mBubl monoclonal antibodies: detection of Bubl, and co-localisation 
of epitopes.
(A):  Staining of NIH 3T3(wild-type LT) cells (“SE”) with PI (for DNA 
localisation)  and  NT  mBubl  monoclonal  2B8.  The  arrowed  cell  has 
entered mitosis (prophase) and shows punctate spots of Bubl, a protein 
that is known to be localised to the kinetochores at this stage of the cell 
cycle  in  normal  cells.  (B):  Double  staining  using  pairs  of  mBubl 
monoclonal  antibodies  in  prometaphase  cells,  to  demonstrate  co­
localisation of epitopes.  The upper panels  show double staining of NT 
mBubl  monoclonal  2B8  and  CT mBubl  monoclonal  13G9,  the  lower 
panels  show co-localisation of the two  CT mBubl  monoclonals (13G9 
and 17E9). (Scale bars represent 10pm).
1972B8 Merge
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Figure  4.16:  Immunofluorescence  in  LT-expressing  cells  using  the 
mBubl  monoclonal antibodies: detection of Bubl, and co-localisation 
of epitopes.
198Kinetochores  are  present  on  each  replicated  chromosome,  and  can  be 
described as two macromolecular protein complexes located on opposite sides 
of the  primary  constriction,  at  the  centromeres  (Rieder  and  Salmon,  1998). 
Some  kinetochore  proteins,  including  Mad2  and  Bubl  are  only  found 
transiently at the kinetochore,  during mitosis  (Chen et al.,  1996;  Taylor and 
McKeon,  1997). The arrowed cell in Figure 4.16A is representative of a small 
proportion  of mitotic  cells  in the population,  and the  green  dots  seen  in the 
nucleus  of this  cell  are visualised using the Bubl  monoclonal  2B8, possibly 
suggesting labelling of the kinetochore via Bubl. This cell is in early prophase 
of mitosis, because the DNA is not very noticeably condensed as seen by the 
red PI  staining of the cells.  The interphase cells  in the field do not show the 
punctate  Bubl  staining  because  Bubl  is  not  localised  to  a  well  defined 
structure  such  as  the  kinetochore  at  this  stage  in  the  cell  cycle,  and  also 
because  Bubl  levels  are  low  in  interphase  due  to  its  expression  being  cell 
cycle  regulated,  peaking  at  G2/M  phase  (Davenport  et  al.,  1999).  This 
demonstrates that the Bubl  monoclonal antibody 2B8 recognises a protein via 
immunofluorescence  that  appears  to  have  the  same  spatial  and  temporal 
localisation proposed for Bubl,  a  further validation  of the  specificity  of this 
antibody.  However  it  remains  to  be  demonstrated  that  the  punctate  dots 
recognised by  the  Bubl  monoclonal  antibodies  in  mitotic  cells  are  actually 
located  at  the  kinetochore.  Figure  4.16A  also  perhaps  suggests  that  the 
localisation of Bubl described in the literature is unaffected by the presence of 
LT in these NIH 3T3 cells.
The three monoclonal antibodies raised against mBubl  were also used 
in  pairs  for  immunofluorescence,  to  demonstrate  co-localisation  of  the 
proteins recognised by the antibodies,  and hence  specificity.  The upper three 
panels  of Figure  4.16B  show  a prometaphase  SE  cell  stained with 2B8  (NT 
mBubl  monoclonal,  visualised  with  FITC-conjugated  secondary  antibody) 
and  13G9  (CT  mBubl  monoclonal,  visualised  with  TRITC 
(tetramethylrhodamine  isothiocyanate)-conjugated  secondary  antibody). 
Preparation  of these  double-stained  immunofluorescence  slides  was  carried
199out by  Sabine  Klischies,  a  short  term  student  in  the  laboratory.  The  yellow 
dots  in  the  merged  image  of the  upper  panels  in  Figure  4.16B  show  co­
localisation of the proteins  identified by 2B8  and  13G9,  indicating that they 
identify  the  same  protein.  2B8  and  13G9  were  raised  against  different 
recombinant  proteins  (NT  and  CT  mBubl,  respectively),  making  this  co­
localisation  an  even  better  indication  of the  specificity  of the  antibodies  to 
mBubl.  Similarly,  the  lower  three  panels  of  Figure  4.16B  show  a 
prometaphase SE cell, but this time stained with 17E9 (CT mBubl) and 13G9 
(CT mBubl), and again yellow dots indicate co-localisation of the epitopes for 
these two antibodies. Therefore, co-localisation of protein detected by all three 
mBubl  monoclonal  antibodies  further  verifies  their  specificity  to  the  same 
protein, Bubl.
Although  punctate  dots  had been  observed  when  staining  mitotic  SE 
cells with the mBubl  monoclonals,  it had not been determined whether they 
localised to the kinetochores, as would be expected if Bubl  was behaving in 
the  same  way  in  LT-expressing  cells  as  it  does  in  cells  with  no  LT. 
Unfortunately however, it was not possible during the course of the project to 
obtain good CREST  serum,  (an anti-centromere  antibody highly  specific  for 
CREST  syndrome  (Calcinosis  cutis,  Raynaud's  phenomenon,  Esophageal 
dysmotility,  Sclerodactyly  and  Telangiectasias)),  to  enable  verification  of 
kinetochore  localisation  of Bubl  in  LT-expressing  cells  using  the  mBubl 
monoclonal  antibodies.  Time  permitting,  it  would  have  been  appropriate  to 
have tried to verify this using antibodies raised against alternative centromere 
proteins  such  as  CENP-A.  However,  an  observation  made  when  capturing 
immunofluorescence images of SE (NIH 3T3/LT) prometaphase cells stained 
with the mBubl  monoclonal antibodies suggested that the punctate dots seen 
in these cells  could be  localised specifically at the kinetochores  of the sister 
chromatids:  the  chromosomes  of  several  of  the  prometaphase  cells  were 
forming  a  ring-like  structure,  with  the  punctate,  Bubl  dots  located  in  the 
centre of the ring (see Figure 4.17).
200Figure  4.17:  Immunolocalisation  of  Bubl  at  the  centre  of
prometaphase  chromosome  rosettes  was  observed  using  the  mBubl 
monoclonal antibodies.
(A):  During  prometaphase  of the  cell  cycle,  mammalian  chromosomes 
form a rosette structure, with their centromeres (and associated kinetochore 
proteins) oriented towards the middle of the ring (adapted from Nagele et 
al., 1995). (B): Staining of two prometaphase NIH 3T3(wild-type LT) “SE” 
cells  for DNA (using PI)  and Bubl  (using NT mBubl  monoclonal 2B8) 
shows that the Bubl  antibody recognises a protein that is localised to the 
centre  of  a  chromosome  rosette,  at  the  same  apparent  location  as  the 
kinetochores in this structure. (Scale bars represent 5pm).
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Figure  4.17:  Immunolocalisation  of  Bubl  at  the  centre  of 
prometaphase  chromosome  rosettes  was  observed  using  the  mBubl 
monoclonal antibodies.
202During  a  short  period  in  prometaphase  all  mammalian  chromosomes  are 
aggregated into a single, wheel-shaped ring known as a chromosome rosette, 
with most chromosomes oriented with their arms projecting outward, and their 
centromeres  (and  therefore  also  their  kinetochores)  in  a  ring  in  the  centre, 
(Nagele  et  al.,  1995)  as  shown  in  Figure  4.17A.  Figure  4.17B  shows  two 
different prometaphase SE cells observed to be forming chromosome rosettes, 
stained for mBubl  monoclonal antibody 2B8 (shown in green), and with their 
DNA also stained using PI  (shown in red).  It is  clear that the punctate green 
dots  seen  with  the  mBubl  monoclonal  in  these  LT-expressing  cells  are 
forming a ring in the centre of the chromosome rosettes, as would be expected 
if they were co-localised with the kinetochore. Furthermore, murine Bubl  has 
previously  been  noted  to  localise  at  the  kinetochores  in  the  centre  of  a 
prometaphase  chromosome rosette  (Taylor and McKeon,  1997).  Ftowever,  it 
should be noted that although this observation does not provide absolute proof 
of kinetochore  localisation  of Bubl  in  these  cells,  it  does  suggest  that  the 
localisation  of  Bubl  in  LT-expressing  cells,  as  seen  by  the  mBubl 
monoclonals, is very similar to that observed by others in cells with no LT.
Finally,  an  examination  of the  localisation  of Bubl  in  LT-expressing 
cells  (SE)  through  the  different  phases  of  mitosis  was  undertaken  in 
collaboration with S. Klischies. Figure 4.18  shows images of one cell in each 
stage  of mitosis,  stained for DNA  (red,  PI),  Tubulin  (green),  or Bubl  (blue, 
CT mBubl  monoclonal  13G9), with merged, colour images on the right-hand 
side.  Many  examples  of  each  mitotic  stage  were  observed,  but  only  one 
representative cell is shown for each stage, for clarity.
The subcellular localisation of mBubl  in LT-expressing cells shown in 
Figure  4.18  suggests  that  LT  is  not  altering  Bubl  localisation  from  that 
observed in normal cells (Taylor and McKeon,  1997). The stage of mitosis for 
each  cell  in  Figure  4.18  was  determined  by  observation  of both  the  DNA 
staining, the degree of chromosome condensation, and also by observation of 
the  tubulin  staining,  looking  for  spindle  pole  duplication  and  positioning 
within the cell.
203Figure 4.18:  Subcellular localisation  of mBubl  during  mitosis  does 
not appear to be affected by the presence of LT.
Asynchronous NIH 3T3 (wild-type LT) “SE” cells were fixed and stained 
for DNA (shown in red), tubulin (shown in green) and Bubl  (using CT 
mBubl  monoclonal  13G9,  shown in blue).  Representative cells for the 
different stages of mitosis are shown, and indicate that Bubl localisation 
through  these  stages  does  not  differ  in  cells  expressing  LT  from  the 
pattern previously described in the  literature  for normal cells. Bubl  is 
seen  in  punctate  spots  (presumably  at  the  kinetochores  of condensed 
chromosomes)  from  prophase  until  prometaphase,  but  once  all 
chromosomes have formed a bipolar attachment to the mitotic spindle at 
the  metaphase  plate,  the  spindle  checkpoint  is  inactivated,  Bubl 
dissociates from kinetochores,  and cells undergo  anaphase.  (Scale bars 
represent 10pm).
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Figure  4.18:  Subcellular  localisation  of mBubl  during  mitosis  does 
not appear to be not affected by the presence of LT.
205The  Bubl  staining  first  appears  as  punctate  spots  (presumably  at  the 
kinetochores,  although  again  this  has  not  been  confirmed)  when  the  DNA 
begins  to  condense,  in  early prophase.  By late prophase,  and prometaphase, 
the  punctate  spots  of  Bubl  are  very  clearly  seen.  In  the  cell  labelled  as 
metaphase  there  is  still  some  punctate  Bubl  staining,  but  this  may  be 
indicative  of  not  all  chromosomes  actually  being  properly  aligned  at  the 
metaphase  plate  with  a  bipolar  attachment,  rather  than  mislocalisation  of 
Bubl,  which  is  expected  to  have  dispersed  from  the  kinetochores  by  this 
stage. At anaphase the punctate Bubl  spots have disappeared, as is also seen 
in normal  cells  with  no  LT  (Taylor  and  McKeon,  1997).  In  addition  to  the 
punctate spots of Bubl  localised in the same region as the DNA in these cells, 
the Bubl  images in Figure 4.18 also appear to show dispersed staining in the 
regions of the cell not occupied by the DNA. It has not been determined if this 
is also Bubl protein or if it is simply due to some non-specificity of either the 
mBubl  monoclonal  antibodies  or  the  secondary  antibodies  used  for 
immunofluorescence. It should be noted that double staining for LT and Bubl 
localisation was also carried out in SE cells (data not shown), but no obvious 
co-localisation was observed. Dispersed nuclear staining was observed for LT 
throughout the cell cycle, with no punctate dots  seen that might indicate any 
possible  localisation  with  Bubl.  This  does  not  rule  out  the  possibility  that 
Bubl  and LT may co-localise in small quantities at some stage during the cell 
cycle, not necessarily during mitosis.
4.3.4  Affinity purification of mBubl monoclonal antibodies
The mBubl  monoclonal antibodies that were generated had previously 
been  tested  using  hybridoma  tissue  culture  supernatants.  Although  good 
results  were  obtained  for the  specificity  and utility  of the  antibodies,  it was 
thought  that  the  sensitivity  of the  antibodies  could  be  improved  by  affinity 
purification.
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antibody-binding properties have been well characterised. These proteins have 
been  purified  from  recombinant  producers  and  used  routinely  for  affinity 
purification of antibodies from a variety of species. Proteins A, G and L bind 
to  antibodies  at  sites  other  than  the  antigen-binding  domain,  and  for  this 
reason are useful for the purification of general immunoglobulin from a crude 
sample.  It  was  decided  to  use  Protein  G  immobilised  to  a  solid  support  in 
columns  to  affinity  purify  general  IgG  from  the  hybridoma  tissue  culture 
supernatants, for two reasons.  Firstly, it was not seen as necessary to use the 
antigen itself rather than Protein A or G (or any of the other commonly used 
IgG-binding  proteins)  for  the  purification  from  these  supernatants,  because 
they  contained  monoclonal  antibodies  with  a  proven  “clean”  and  high 
specificity  for  mBubl.  Monoclonal  antibodies  by  definition  have  a  single 
specificity  due  to  them  being  derived  from  a  single  hybridoma  clone.  In 
contrast, a polyclonal antibody would contain only a very small proportion of 
IgG  specific  to  the  antigen  of interest.  Secondly,  as  described  previously, 
Protein  G  is  able  to  bind  a  greater  range  of mouse  IgG  sub-classes  than 
Protein A, and in particular has a much greater affinity for IgGl, the sub-class 
of monoclonal 2B8. Protein G was therefore  suitable  for affinity purification 
of all three sub-classes of monoclonal antibody.
All  steps  of the  antibody purification process  were  carried out  at the 
MRC Prion Unit in the Institute of Neurology, UCL, under the supervision of 
Dr Gary Mallinson.
Each  antibody  supernatant  was  concentrated  by  ultrafiltration,  and 
bound  to  a  Protein  G  column,  washed,  and  eluted,  using  the  AKTAprime 
machine,  an  automated  liquid  chromatography  system  from  Amersham 
Biosciences.  The  elution  fractions  containing  the  most  protein  (typically 
fractions  2-4,  as  determined  from  the  UV  reading  recorded  during  the 
purification process, data not shown) were pooled, and 0.1% NaN3  was added 
to inhibit bacterial growth.
207The following yields  of affinity purified antibody were obtained from 
350ml  of initial  hybridoma  tissue  culture  supernatant:  3.6ml  of NT  mBubl 
monoclonal  2B8  at  0.8mg/ml,  1ml  of  CT  mBubl  monoclonal  13G9  at 
2.22mg/ml,  and 2ml  of CT mBubl  monoclonal  17E9  at  lmg/ml.  Storage  of 
the antibodies at these relatively high protein concentrations has the advantage 
that it tends to stabilise the native structure of the immunoglobulin molecule.
NIH 3T3  (mouse) and U20S (human) whole cell lysates were western 
blotted using  the  concentrated,  affinity purified mBubl  monoclonals,  and  it 
was found that these reagents can be used at a dilution of 1:250, i.e.  10-fold 
greater than the  1:25 dilution necessary when using tissue culture supernatant 
(data not  shown).  The  affinity purified  antibodies  showed  the  same  species 
specificities  seen  previously  (2B8  detects  both  mBubl  and hBubl,  whereas 
13G9 and  17E9 only detect the mBubl  protein). The non-specific bands seen 
when western blotting  with hybridoma tissue  culture  supernatant previously 
(see Figures 4.13 and 4.14) were not greatly reduced in intensity upon affinity 
purification  of  the  antibodies,  although  it  was  hoped  that  the  affinity 
purification  would  at  least  have  removed  the  majority  of  unwanted 
immunoglobulin proteins present in the BSA and other tissue culture medium 
components  in  the  hybridoma  supernatant,  leaving  almost  exclusively  the 
mouse IgG proteins specific to mBubl.
4.3.5  Validation of utility of mBubl monoclonals for Bubl-LT interaction 
studies
The focus of this project is the interaction between Bubl  and LT, and 
therefore it was very important to determine the ability of the newly generated 
monoclonal antibodies against Bubl  to detect the Bubl-LT interaction via co- 
immunoprecipitation.
Figure  4.19  shows  the  results  of  immunoprecipitation  experiments 
carried  out  using  both  mouse  (NIH  3T3)  and  human  (U20S)  whole  cell 
lysates,  either  untransfected,  or  expressing  wild-type  LT  or  dl89-97  (non-
208Bubl-binding) LT.  500jng of whole cell  lysate was  immunoprecipitated with 
either  no  antibody  at  all,  with  3pl  of  either  2B8,  13G9  or  17E9  affinity 
purified  mBubl  monoclonal  antibody  (the  concentrated  affinity  pure 
antibodies), with 3 pi of rabbit polyclonal CT hBubl  antiserum (as previously 
described),  or  with  30pl  of PAb423,  a  monoclonal  antibody  (tissue  culture 
supernatant)  directed  against  the  carboxy-terminal  region  of  LT.  The 
immunoprecipitates were then run on 8% SDS-PAGE and western blotted for 
Bubl  (using  polyclonal  NT  hBubl  serum),  followed  by  re-blotting  for  LT 
(using  PAb423).  These  immunoprecipitations  were  all  carried  out  using 
Protein  A-sepharose  beads,  except  for  the  immunoprecipitations  using 
antibody 2B8, for which Protein G-sepharose beads were used.
In NIH 3T3  (mouse) cells, Bubl  was immunoprecipitated equally well 
from all three cell  lines  (with  or without wild-type  LT  or dl89-97  LT)  with 
each of the mBubl  monoclonals, 2B8,  13G9  and  17E9, all of which brought 
down  strong  150kDa  Bubl  bands,  as  seen  by  blotting  with  the  rabbit 
polyclonal  antiserum  against  NT  hBubl  (See  Bubl  blot  of  lanes  4-12  in 
Figure  4.19).  The  CT  hBubl  rabbit  polyclonal  antiserum  also 
immunoprecipitated a strong  150kDa band in each NIH 3T3  cell line, as seen 
in the NT hBubl  antiserum blot of lanes  13-15, but these bands  appeared a 
little “smeary”, probably due to the fact that each of these antibodies recognise 
non-specific  bands  quite  strongly,  a  problem  not  seen  with  the  new,  clean 
Bubl  monoclonals.  No  150kDa  Bubl  bands  are  seen  in  the  control  lanes 
where NIH 3T3 lysates were immunoprecipitated without antibody (Bubl blot 
of lanes  1-3), as is to be expected. Also, no  150kDa Bubl  band was observed 
when the lysates were immunoprecipitated for LT with PAb423 (Bubl blot of 
lanes  16-18), whereas  a band would be  expected in the lane  containing NIH 
3T3 (wild-type LT) (Bubl blot of lane  17), the LT that is able to interact with 
Bubl, as shown previously.
209Figure  4.19:  Co-immunoprecipitation  of LT  with  Bubl  using  the
affinity purified mBubl monoclonal antibodies.
Whole cell lysates from NIH 3T3 (mouse) or U20S (human) cells, either 
untransfected,  or  expressing  wild-type  (wt)  LT  or  dl89-97  LT  were 
immunoprecipitated using either no antibody (negative control), affinity 
purified  mBubl  monoclonal  antibody  (2B8,  13G9  or  17E9),  rabbit 
polyclonal CT hBubl  antiserum (positive control), or PAb423 (anti-LT 
monoclonal),  and  blotted  for  Bubl  (using  NT  hBubl  polyclonal 
antiserum) or LT (using PAb423). CT mBubl monoclonal 2B8 is able to 
co-immunoprecipitate LT from NIH 3T3 cells expressing wild-type LT.
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Figure 4.19: Co-immunoprecipitation of LT with Bubl using the affinity purified mBubl  monoclonal antibodies.This has been a continuing problem during the course of this project, because 
even with many attempts at optimising conditions, it has not been possible to 
demonstrate  the  LT-Bubl  interaction by  co-immunoprecipitating  Bubl  with 
LT (although it is readily observed when lysates  are immunoprecipitated for 
Bubl  and blotted for LT, as shown in Chapter 3). Perhaps this observation is 
due  to  only  a  very  small  proportion  of the  LT  in  the  cells  interacting  with 
Bubl,  resulting  in  the  majority  of the  immunoprecipitated  LT  protein  not 
bringing Bubl  with it. The difficulty in detecting this small quantity of Bubl 
could  be  exacerbated  by  the  relative  insensitivity  of the  Bubl  antibody  in 
comparison to the LT antibody for western blotting. Conversely, even if only 
a small quantity of immunoprecipitated Bubl  is bringing down LT with it, the 
strong specificity of the LT antibody PAb423  allows its detection.  However, 
PAb423  has been  shown  to  be  capable  of co-immunoprecipitating  Bubl  by 
previous  members  of  the  laboratory  (Cotsiki  et  al.,  2004),  although  the 
reasons for the current difficulties remain elusive. Perhaps the exact cell lines 
used in the present study are in some way different to those used previously, 
but this would need further investigation. Given more time it would have been 
interesting  to  see  if  expression  of  an  epitope-tagged  LT  protein  and 
immunopreciptation using an antibody specific to the epitope tag would have 
allowed visualisation of the LT-Bubl interaction via co-immunoprecipitation.
When the Bubl immunoprecipitations in NIH 3T3 cells were re-blotted 
for LT (using monoclonal antibody PAb423),  a strong  lOOkDa LT band was 
seen to co-immunoprecipitate with Bubl  in the wild-type LT-containing cells 
only when immunoprecipitating with either Bubl monoclonal 2B8 (see Figure 
4.19,  LT blot of lane  5),  or with the rabbit polyclonal  antiserum against CT 
hBubl  (LT  blot  of  lane  14).  As  expected,  no  lOOkDa  LT  bands  were 
precipitated by any of the Bubl  antibodies  from the NIH  3T3  lysate that did 
not  contain  LT,  or  from  the  NIH  3T3(dl89-97  LT)  lysate  where  the  Bubl 
interaction  site  on  LT  is  deleted.  A  weak  lOOkDa  LT  band  is  co- 
immunoprecipitated by the Bubl  monoclonal  17E9  from the NIH  3T3(wild- 
type  LT)  lysate  (LT  blot,  lane  11),  but  this  does  not  indicate  a  strong  co-
212immunoprecipitation of LT with Bubl  by this antibody, as a  lOOkDa band of 
equal  strength  can  be  seen  in  the  equivalent  lane  for  the  co- 
immunoprecipitation using no antibody, (LT blot, lane 2, probably seen due to 
the  observation  noted  in  the  laboratory  that  LT  expressed  in  mouse  cells 
appears to stick to Protein A-sepharose beads).  However, this  does not offer 
an explanation  for why no  lOOkDa band is  seen at all in the NIH  3T3(wild- 
type LT)  lysate  immunoprecipitated using  antibody  13G9  (LT blot,  lane  8). 
Perhaps  the  epitope  on  Bubl  recognised  by  13G9  is  important  for  this 
observation.  As  expected,  in  the  LT  blot,  no  LT  is  seen  to  be 
immunoprecipitated by LT antibody PAb423  from NIH 3T3 cells that express 
no LT in the first place. The LT immunoprecipitation, blotted for LT shows a 
very strong  lOOkDa wild-type  LT band (lane  17),  and  a less  strong  lOOkDa 
dl89-97 LT band (lane  18),  indicating the relative  expression levels  of these 
proteins.
The  same  collection  of  immunoprecipitation  experiments  was 
conducted using  whole  cell  lysates  from untransfected U20S  cells,  or U20S 
cells expressing wild-type LT or dl89-97 LT,  as shown in the bottom half of 
Figure 4.19 (lanes  19-36). As seen in the NIH 3T3 cells, the CT hBubl  rabbit 
polyclonal  antiserum  was  able  to  immunoprecipitate  strong  150kDa  Bubl 
bands  in  all  three  U20S  cell  lines,  as  seen  in  the  NT  hBubl  polyclonal 
antiserum blot  (Bubl  blot  of lanes  31-33).  The  only  other  antibody  able  to 
immunoprecipitate  the  150kDa  human  Bubl  protein  was  NT  mBubl 
monoclonal  2B8,  as  seen  by  the  faint  150kDa  bands  in  each  lane  for  that 
antibody  (Bubl  blot,  lanes  22-24).  As  expected,  no  Bubl  bands  were  seen 
when immunoprecipitations were carried out in the absence of antibody (lanes 
19-21).  13G9 and  17E9 immunoprecipitations blotted for Bubl  (lanes 25-30) 
do  not  show  any  150kDa  bands  either,  indicating  that  these  CT  mBubl 
monoclonal  antibodies  are  not  able  to  immunoprecipitate  the  human  Bubl 
protein.  As  observed  in  the  NIH  3T3  co-immunoprecipitation  using  LT 
monoclonal  antibody  PAb423,  no  Bubl  could  be  seen  to  co- 
immunoprecipitate with LT from the U20S lysates (Bubl  blot, lanes  34-36).
213When  these  U20S  immunoprecipitations  were  re-blotted  for  LT  using 
PAb423,  the  only  Bubl  antibody  seen  to  be  capable  of  co- 
immunoprecipitating  LT  from  human  cells  was  the  rabbit  polyclonal 
antiserum raised against CT hBubl, as indicated by a strong  lOOkDa LT band 
in the U20S(wild-type LT) lane (LT blot, lane 32). This antibody also appears 
to reveal a weak interaction between the dl89-97 LT and Bubl  in U20S cells 
(weak  150kDa  band  in  LT  blot,  lane  33),  although  this  may  be  due  to  an 
indirect  interaction,  as  suggested  in  Chapter  3.  This  explanation  is  further 
validated  by  the  LT  immunoprecipitation  in  the  U20S  cell  lines  using 
PAb423, blotted using the  same  antibody (LT blot,  lanes  35  and 36),  which 
indicated  that  the  level  of LT  expression  was  approximately  equal  in  the 
U20S(wild-type LT) and the U20S(dl89-97) LT cells.
4.4  SUMMARY & DISCUSSION
In conclusion, three good monoclonal antibodies, 2B8,  13G9 and 17E9, 
have been  generated  against  the  mouse  Bubl  protein.  2B8  is  an  IgGl  sub­
class monoclonal and is specific to the amino-terminus of mBubl,  13G9 and 
17E9 are independent monoclonals specific to the carboxy-terminal region of 
mBubl,  and are IgG2a and IgG2b  sub-class,  respectively.  The  specificity of 
all  three  antibodies  for  the  Bubl  protein  itself has  been  verified  by  use  of 
several  techniques,  including  ectopic  expression  of  HA-tagged  mBubl 
protein,  and RNAi.  The  CT-specific mBubl  monoclonals  are  specific to the 
mouse Bubl  protein,  which they recognise  strongly and very  specifically in 
western blots,  whereas  the NT-specific  mBubl  monoclonal  detects  both the 
mouse and human Bubl  proteins, but does  not western blot so  strongly.  All 
three  monoclonals  immunoprecipitate  Bubl  well  from  mouse  whole  cell 
lysate,  but  only  2B8  can  effectively  co-immunoprecipitate  LT.  2B8  is  also 
able to immunoprecipitate Bubl  from human lysate (albeit very weakly), but 
unfortunately  the  Bubl-LT  complex  cannot be  demonstrated  in  U20S(wild- 
type  LT)  cells  using this  antibody.  Although it was  more  difficult to purify
214sufficient  native  Bubl  protein  for  monoclonal  antibody  production  in 
comparison to the large quantities of denatured protein that were more easily 
purified,  the  results  achieved here  suggest that  it  was  worth the  effort,  as  it 
was  the  native  antigen  (mBubl(1-561))  that  produced  the  most  effective 
monoclonal  for immunoprecipitation  studies,  a technique  used  frequently in 
this project for investigation of the LT-Bubl  interaction. In the future it would 
be interesting to see if the reciprocal co-immunoprecipitation, using PAb423 
to  bring  down  Bubl  would  work  if  one  of  the  new  mBubl  monoclonal 
antibodies  was  used  for  the  blotting,  rather  than  the  rabbit  polyclonal 
antiserum against NT hBubl  used in Figure 4.19.  This has been tried before 
without  success,  but  perhaps  the  immunoprecipitation  conditions  could  be 
further optimised.
Problems  were  initially  encountered  in  deciding  where  on  an  SDS- 
PAGE  gel  the  Bubl  protein  actually  migrates,  as  the  predicted  molecular 
weight  of 120kDa  for Bubl  was  much  lower than that observed  during  the 
screening  of  the  Bubl  monoclonals.  Also,  it  had  been  suggested  in  the 
literature  that  Bubl  migrates  at  120kDa  on  SDS-PAGE.  Subsequent 
experiments verified that Bubl actually migrates at around the 150kDa region, 
and  it  is  thought  that  this  could  be  due  to  some  as  yet  unidentified  post- 
translational modification. A good example of proteins that migrate on SDS- 
PAGE much slower than their molecular weight prediction would suggest, is 
the adenovirus El A proteins. The primary translation products of the  12S and 
13S  mRNAs  synthesised  from  the  El A  region  have  apparent  molecular 
weights  of  42  and  45  kDa,  respectively,  when  run  on  SDS-PAGE, 
significantly  different  from  their  predicted  molecular  weights  (26  and  32 
kDa). It was suggested that these aberrant migrations are probably due to the 
unusually high content of proline and acidic residues in these proteins, but in 
addition,  approximately 60 polypeptide  species  of the  12S  and  13S products 
have  been  resolved  via  high-resolution  two-dimension  gels,  induced  by 
differential phosphorylation of serine residues (Richter et a l,  1988). Had this 
information been known at the beginning of the project, the decision on which
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have been different, perhaps resulting in even better NT mBubl  monoclonal 
antibodies than 2B8. Nevertheless, the information obtained during the course 
of these experiments suggested that the  150kDa band seen in western blotting 
experiments really is Bubl, making future studies  of Bubl  and the LT-Bubl 
interaction much easier.
All three monoclonal antibodies against mBubl  were also shown to be 
very useful for immunofluorescence studies in mouse cells, and were used to 
demonstrate  Bubl  localisation  in  cells  expressing  LT,  throughout  the  cell 
cycle.  The  immunolocalisation  studies  in  SE  cells  using  the  mBubl 
monoclonal antibodies suggest that the subcellular localisation of Bubl  is not 
disrupted by the presence of LT at any point during the cell cycle.  However, 
parallel immunolocalisation studies in cells with no LT, or in cells expressing 
dl89-97  LT  would  be  necessary  to  establish  for  certain  that  the  subcellular 
localisation of Bubl is not affected by LT interaction.  In addition, it would be 
very interesting  to  determine  if localisation  of Bubl  in  LT-expressing  cells 
deviates  from  wild-type  behaviour  in  any  way  in  cells  treated  with  the 
microtubule-depolymerising drug nocodazole.
Although  the  purpose  of  generating  monoclonal  antibodies  against 
mouse Bubl  was for use in subsequent experiments to study the effect of the 
LT-Bubl  interaction  on  the  spindle  checkpoint,  later  on  in  the  project  it 
became clear that the most meaningful information about this mechanism was 
going to come from studies in human cells, and not from mouse cells. It seems 
that the spindle checkpoint is more robust in human cells than mouse cells, as 
seen in experiments conducted in this laboratory. NT mBubl  monoclonal 2B8 
was  shown  to  be  capable  of  detecting  by  western  blot  and 
immunoprecipitating  the  human  Bubl  protein,  but  unfortunately  was  not 
capable  of  co-immunoprecipitating  LT.  However  Dr  Raimundo  Freire 
(Hospital  Universitario  de  Canarias,  Tenerife,  Spain)  had  kindly  provided 
sufficient  CT  hBubl  rabbit  polyclonal  antiserum  to  enable  studies  of  the 
Bubl-LT interaction in human cells to go ahead.
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nevertheless provide a very useful tool for future studies of the localisation of 
Bubl  in mouse cells expressing LT or dl89-97 LT, under the influence of the 
microtubule-depolymerising drug nocodazole, for example. Dr Ole Gjoerup at 
the  Dana  Farber  Cancer  Institute  in  Boston,  MA,  USA  is  particularly 
interested  in  the  kinase  functions  of Bubl,  and  has  also  been  testing  these 
newly generated mBubl  monoclonal antibodies.  He reports that all three are 
able  to  immunoprecipitate  the  Bubl  kinase  in  an  active  form,  providing  a 
further future use for these antibodies.
In  summary,  several  highly  specific  monoclonal  antibodies  with 
multiple uses have been generated against the mouse Bubl  protein, providing 
cleaner reagents for future studies centred on this spindle checkpoint protein. 
In addition, monoclonal antibodies against the human Bubl  protein have now 
been generated in the laboratory using information learnt from this  study, to 
complement the reagents currently available for this project.
2175. Effects of SV40 LT-Bubl interaction on cell cycle
regulation
5.1  OBJECTIVES
The work described in the previous chapters provided the cell lines and 
reagents necessary to study the function of the LT-Bubl  interaction.  The aim 
of the experiments detailed in this chapter was to use these tools to examine 
the possibility that LT is able to inhibit spindle checkpoint function by virtue 
of its  interaction  with  the  checkpoint  kinase  Bubl.  Attempts  were  made  to 
elucidate the mechanism by which LT could be carrying out this function. In 
addition,  a  karyotyping  study  was  performed  to  determine  if  it  would  be 
possible to  detect aneuploidy caused specifically by this interaction.  Finally, 
the  effect  of LT-Bubl  interaction  on  the  Gl/S  (p53-dependent)  tetraploidy 
checkpoint  was  examined,  to  determine  if  this  post-mitotic  checkpoint  is 
abrogated by both  wild-type  and  non-Bubl-binding  LT,  and  to  look  at  the 
potential down-stream effects on genomic stability.
5.2  EXPERIMENTAL STRATEGY
Initial attempts to determine the ability of NIH 3T3 (mouse) and U20S 
(human)  cell  lines  either untransfected,  or  expressing  wild-type  LT  or non- 
Bubl-binding,  dl89-97  LT  to  arrest at the  spindle  checkpoint in response  to 
treatment  with  the  microtubule-depolymerising  drug  nocodazole  involved 
synchronisation  of  the  cells  prior  to  nocodazole  treatment.  Cells  were 
synchronised either using the mitotic shake-off technique (M phase block), or 
using  L-Mimosine  (S  phase  arrest).  The  response  of each  cell  line  to  drug 
treatment  was  monitored  via  fluorescence-activated  cell  sorting  (FACS),  or 
via  western  blotting.  However,  spindle  checkpoint  compromise  was  best
218demonstrated  by  treating  asynchronous  cultures  with  nocodazole,  and  this 
method was used for all subsequent experiments.
The soluble and insoluble fractions of protein lysates from cells treated 
with  nocodazole  were  compared  via  western  blot  to  determine  if observed 
differences in protein levels were due to changes in subcellular localisation of 
the proteins of interest. Also, the effect on securin levels of varying lengths of 
nocodazole treatment was examined to establish whether different growth or 
checkpoint  adaptation  rates  were  the  cause  of the  differences  seen  between 
cell lines, rather than a direct effect on the spindle checkpoint by LT via Bubl.
Having  demonstrated  differences  in  spindle  checkpoint  activation  via 
western  blot  for  cells  expressing  wild-type  LT,  in  comparison  to  cells 
expressing  either  dl89-97  LT  or  no  LT  at  all,  the  same  conditions  and 
nocodazole treatments were used to begin to examine the mechanism via co- 
immunoprecipitation experiments.
Time lapse microscopy was used to investigate the effect of nocodazole 
on REFs expressing either wild-type LT or dl89-97 LT.
A preliminary investigation of the  effect of wild-type LT  on genomic 
stability was carried out by investigating the karyotype of tumourigenic versus 
non-tumourigenic wild-type LT-expressing cell lines.
To  investigate  the  ability  of  wild-type  LT  versus  dl89-97  LT  to 
override  the  p53-dependent  Gl/S  tetraploidy  checkpoint,  NIH  3T3  cells 
expressing either of these LT proteins, or untransfected cells were treated with 
the  drug  dihydrocytochalasin  B  (DCB)  that  prevents  the  growth  of  actin 
filaments,  thereby  inhibiting  cytokinesis  and  triggering  the  tetraploidy 
checkpoint. The chromosome content of the cells was monitored via FACS at 
24  hours  following  release  from  the  drug,  and  also  at  48-hour  and  5-day 
release points.
2195.3  RESULTS
5.3.1  LT inhibits spindle checkpoint  function via interaction with Bubl
The  ultimate  aim  of  this  project  was  to  determine  whether  the 
interaction  of SV40  LT  antigen  with  Bubl  functionally  affects  the  spindle 
checkpoint.
5.3.1.1  Examination  of  spindle  checkpoint  function  using  FACS  and
western blot analysis, with synchronised cells
Spindle  checkpoint  function  experiments  were  first  carried  out  in 
untransfected NIH  3T3  cells  and NIH  3T3  cells  expressing  wild-type  LT  or 
dl89-97 LT, with the aim of identifying conditions under which a checkpoint 
defect can be demonstrated. It was then intended that the mBubl  monoclonal 
antibodies  generated  (see  Chapter 4)  would be  used  in  immunoprecipitation 
experiments to investigate spindle checkpoint function in these cell lines.
In initial experiments, NIH 3T3 cells (untransfected or expressing wild- 
type LT or dl89-97 LT) were treated with different doses of the microtubule- 
depolymerising  drug,  nocodazole  (De  Brabander  et  al.,  1976).  Nocodazole 
prevents  microtubule  polymerisation  and  hence  formation  of  the  mitotic 
spindle,  resulting  in  activation  of the  spindle  assembly  checkpoint  and  cell 
cycle arrest in mitosis.  The ability of this  drug to block normal chromosome 
segregation in a reversible manner has led to its widespread use for cell cycle 
synchronisation  of cultured  cells,  and  for  studies  of mitosis  and  the  spindle 
checkpoint  (reviewed  in  (Peterson  and  Mitchison,  2002)).  Asynchronous 
cultures of each of the NIH 3T3  cell lines were seeded and cultured at 37°C 
for 12 hours, at which point they were treated with nocodazole doses ranging 
from  10-100ng/ml  (encompassing  the range  of nocodazole  doses  commonly 
used  for  spindle  checkpoint  activation  in  the  literature),  for  12  hours.  Cells 
were then  fixed for PI (Propidium iodide)  FACS  (fluorescence-activated cell 
sorting) analysis to determine the proportion of cells in different phases of the
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measurement (meter) of certain physical and chemical characteristics of single 
cells (cyto)  as they flow in suspension one by one past a series of detectors. 
Cells  are  first  stained  with  Propidium  iodide  (PI),  a  DNA  intercalating 
fluorescent  dye  that  excites  at  495nm.  PI  does  not  penetrate  the  cell 
membrane,  and  thus  requires  cells  to  be  fixed  or  permeabilised  prior  to 
staining.  PI  interacalates  RNA  as  well  as  DNA,  and  so  to  ensure  that  the 
fluorescent  signal  observed  is  purely  from  the  DNA,  ribonuclease  (RNase) 
was included in the staining procedure to degrade the RNA. As the Pi-stained 
cells  flow through the  FACS  machine,  each  cell  scatters  some  light and the 
labelled cells generate fluorescent signals from the dye. These two parameters 
(light scatter and fluorescent signal) are gauged by photodetectors to generate 
a histogram indicating the relative DNA  contents  of the  cell population,  and 
hence the proportion of cells in G1  (2N DNA content), S and G2/M (4N DNA 
content) phase of the cell cycle, as well as any polyploid (>4N DNA content) 
cells. Control samples of the NIH 3T3  cell lines with no drug treatment were 
also examined by PI FACS at two time points corresponding to the addition of 
nocodazole  to  the  other  samples,  and  the  point  at  which  the  drug-treated 
samples were fixed.
Cell  cycle  analysis  was  carried out at the  FACS  laboratory at Cancer 
Research UK (Lincoln’s Inn Fields, London),  in collaboration with Dr Derek 
Davies,  using  the  BD  FACSCalibur™  system.  Samples  were  PI  stained, 
followed by analysis of 20,000 events (cells) via FACS. It was postulated that 
if interaction  of LT  with  Bubl  compromises  spindle  checkpoint  function,  a 
lower  proportion  of  cells  would  arrest  in  M  phase  at  the  checkpoint  in 
response to spindle damage in the NIH 3 T3(wild-type LT) cell line compared 
to untransfected NIH 3T3  or NIH 3T3(dl89-97 LT) cells.  Several nocodazole 
concentrations were tested because it was not known how sensitive to level of 
spindle  damage  this  experiment  would  be,  and  previous  experiments  had 
suggested a link to low levels of spindle damage and checkpoint leakiness. In 
repeated experiments, it did not seem possible to find a significant difference
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was the same for all drug concentrations tested, although there was a hint that 
slightly fewer NIH 3T3(wild-type LT) cells were being arrested at the spindle 
checkpoint by nocodazole than NIH  3T3(dl89-97  LT)  or untransfected cells 
(data not shown).
It is possible that the  difficulties  in detecting  differences between the 
responses  to  nocodazole  were  partly  due  to  starting  with  asynchronous 
cultures, with slightly different proportions of cells  for each cell line already 
in G2/M phase when the drug was added. These cells would contribute to the 
G2/M peak in  the  FACS  histograms,  and thus  their initial  variability would 
make any subtle differences between the cells lines due to spindle checkpoint 
defects difficult to detect. For this reason, it was decided to try synchronising 
the NIH  3T3  cells  so that virtually no  cells  were  in  G2/M phase  of the  cell 
cycle  prior to  carrying  out  the  nocodazole  treatment  and  subsequent  FACS 
analysis.
It was noted during the initial experiments with nocodazole and FACS 
that  the  M  phase  arrest  seen  with  30ng/ml  of  the  drug  and  higher  was 
extremely efficient, with around 90% of the cell population arresting with 4N 
DNA  content.  For  this  reason,  the  NIH  3T3  cell  lines  were  treated  with 
50ng/ml nocodazole for  12 hours,  at which point arrested cells were isolated 
via  mitotic  shake-off,  and  re-plated.  Samples  of these  cells  were  fixed  at 
regular time points up to 24 hours and analysed by PI FACS to determine the 
release  time  required  for  the  cells  to  enter  S  phase,  but  without  passing 
through to the  next round of mitosis.  Unfortunately,  no  time point could be 
found  at which  all  three  cell  lines  had reached the  correct phase  of the  cell 
cycle,  due  to  the  cell  lines  each  having  different  growth  rates.  To  try  to 
combat this  problem,  attempts  were  made  to pulse  label  S  phase  cells  with 
bromodeoxyuridine (BrdU) following an  11  hour release from mitotic shake- 
off (the point at which many cells in each cell line were in S phase, although 
not  in  equal  proportions),  and  then  to  specifically  examine  the  cell  cycle 
profiles  of these  BrdU-labelled  cells  following  treatment  with  nocodazole.
222BrdU is  an analogue  of thymidine  and is taken up  into the  DNA  of cycling 
cells.  This  is  then  detected  by  unwinding  the  DNA  (using  acid,  alkali  or 
enzyme)  and then using  an  antibody  against BrdU.  In  this  way,  Gl,  S  and 
G2/M cells can be separated. This method still failed to reveal any significant 
results,  as the  cells  quickly appear to become asynchronous  again  following 
mitotic shake-off and release (data not shown).
It  has  been  suggested  that  human  cells  might  be  more  easily 
synchronised  than  NIH  3T3  (mouse  cells),  and  so  attempts  to  demonstrate 
spindle  checkpoint  defect  in  LT-expressing  mouse  cells  was  abandoned  in 
favour of U20S cell lines, generated and kindly provided by our collaborators 
in  Tom  Roberts’  laboratory  (Dana  Farber  Cancer  Institute,  Boston,  MA, 
USA).  At  their  suggestion,  attempts  were  made  to  synchronise  U20S  cells, 
and U20S cells expressing wild-type LT or dl89-97 LT, with L-Mimosine ((3- 
A-[3-hydroxy-4-pyridone]-a-amino-propionic acid), a naturally-occurring rare 
amino acid derivative isolated from Mimosa and Leucaena plants. This drug is 
an  inhibitor  of  DNA  replication  in  mammalian  cells,  arresting  cells 
(reversibly) in S phase, at a point after DNA synthesis has begun (Hughes and 
Cook,  1996). Because the arrest caused by mimosine is at S phase, a point in 
the  cell  cycle  only  separated by  a  relatively  short  time  from  M  phase  (the 
phase  at which nocodazole  arrests),  it was  thought that problems  caused by 
different  growth  rates  of the  cell  lines  could  be  reduced  by  making  use  of 
mimosine  followed  by  a  short  release.  U20S  cell  lines  (untransfected,  or 
expressing wild-type LT or dl89-97 LT) were treated with 200pM mimosine 
for  18  hours to  arrest growth,  followed by washes in medium to remove the 
drug,  and  a  6  hour  release  in  fresh  medium  to  allow  the  cells  to  progress 
further  into  S  phase.  At  this  point,  cells  were  treated  for  12  hours  with 
nocodazole at concentrations between 0 and 1  OOng/ml, and the cells were then 
fixed  for  PI  FACS  analysis.  Samples  of  cells  taken  immediately  after 
mimosine treatment, and immediately before nocodazole treatment were also 
fixed for cell cycle analysis. The FACS results (data not shown) did not show 
a  strong  synchronisation  of the  U20S  cells,  as  a  small  proportion  of cells
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appear to send many cells into late  S phase,  as hoped,  although once treated 
with nocodazole no significant difference between the cell lines could be seen 
for the proportion of cells arrested at the spindle checkpoint in M phase.
Since FACS analysis did not provide a convincing demonstration of a 
spindle checkpoint defect caused by LT, subsequent experiments used western 
blotting  of  lysates  from  cells  treated  with  nocodazole,  to  examine  any 
differences  in  levels  of proteins  that  indicate  spindle  checkpoint  arrest,  e.g. 
securin  and  Cyclin  B.  These  proteins  are  destroyed  once  the  spindle 
checkpoint  has  been  satisfied,  immediately  prior  to  anaphase,  and  so  an 
accumulation  of  these  proteins  in  response  to  nocodazole  treatment  is 
indicative of spindle checkpoint arrest occurring in the treated cells.
The first attempt at using western blotting for securin and Cyclin B to 
demonstrate  a  spindle  checkpoint  defect  in  nocodazole-treated  cells  was 
carried out in the U20S cell lines, with mimosine synchronisation. As for the 
FACS  analysis  experiments,  untransfected  U20S  cells,  and  U20S  cells 
expressing wild-type  LT or dl89-97  LT were treated with 200pM mimosine 
for 18 hours,  followed by a 6 hour release in fresh medium.  Cells were then 
treated  with  different  doses  of  nocodazole  ranging  from  0-100ng/ml. 
Following  12  hours  of nocodazole  treatment,  plates  were  lysed  with  RIP  A 
buffer and  10pg samples of each were loaded on a  12%  SDS-PAGE gel and 
blotted for securin (using a rabbit polyclonal antibody against human PTTG-1 
(PTTG-1  (Pituitary Tumour-Transforming Gene  1) is the vertebrate homolog 
of securin  (Zou  et  al.,  1999)),  Cyclin  B  (Cyclin  B1  is  the  major  mitotic 
cyclin), and actin (for loading levels). This experiment was carried out twice, 
but neither experiment gave a very convincing result for a spindle checkpoint 
defect in wild-type LT-containing cells, although a very slightly lower level of 
securin was seen in these cells compared with cells with no LT, or dl89-97 LT 
(data not  shown).  It was presumed that  difficulties  in  seeing  a difference  in 
securin and Cyclin B levels between the cell lines in this experiment could be 
due  to  either  ineffective  mimosine  synchronisation,  some  cells  failing  to
224continue  cycling  following  mimosine  treatment,  or perhaps  due  to  different 
growth rates of the cell lines.
At this point members  of Tom Roberts’  group  had  demonstrated that 
LT does in fact cause a spindle checkpoint defect via interaction with Bubl, 
by determining  the  mitotic  index  of nocodazole  treated cells  (Cotsiki  et al., 
2004).  They  also  showed  that  bypass  of the  spindle  checkpoint  by  LT  is 
accompanied  by  increased  endoreduplication  (accumulation  of cells  with  a 
DNA  content  greater  than  4N)  in  the  presence  of nocodazole,  as  is  to  be 
expected  if the  LT-Bubl  interaction  is  causing  a  spindle  checkpoint  defect 
(Taylor  and  McKeon,  1997).  These  findings  only  served  to  reinforce  the 
importance  of  finding  reproducible  conditions  under  which  securin  (and 
Cyclin B) levels were significantly lower in response to nocodazole treatment 
in U20S(wild-type LT) cells than in untransfected U20S or U20S(dl89-97 LT) 
cells, so that these conditions could then be used to examine the biochemical 
mechanism by which LT inhibits the spindle checkpoint.
One final attempt was made at using synchronised cells to examine the 
effect of nocodazole treatment on levels of securin and Cyclin B in U20S cells 
(untransfected,  or expressing wild-type  LT  or dl89-97  LT).  Although FACS 
analysis using mitotic  shake-off synchronised lysates had not given  a  strong 
indication  of a spindle  checkpoint defect caused by LT  in the NIH  3T3  cell 
lines,  it was  thought that the  synchronisation  itself had been  very  effective. 
For this reason, three attempts at using western blotting to demonstrate protein 
level  differences  (securin  and  Cyclin  B)  between  the  U20S  cell  lines  in 
response to nocodazole treatment were made, one of which is shown in Figure 
5.1. U20S cell lines were treated with  lOOng/ml nocodazole overnight (for 15 
hours), and the rounded cells (arrested in mitosis) were shaken-off, harvested 
and re-plated on several plates per cell line at  1.75 x  105  per 10cm plate. This 
low plating density was used to ensure that cells could not reach confluency or 
near-confluency during the course of the experiment, which would cause cell 
cycle arrest in GO due to contact inhibition.
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Figure 5.1: Nocodazole treatment of synchronised cells reveals a spindle checkpoint defect of wild-type LT-expressing cells.
U20S cells (lanes  1-9), U20S expressing wild-type LT (lanes  10-18) or U20S  expressing non-Bubl-binding,  dl89-97 LT (lanes  19-27)
were treated with nocodazole overnight,  and mitotic cells were then collected by shake-off (lanes  1,  10 and 19).  These cells were re­
plated, and released in fresh medium for 14 hours (lanes 2, 11  and 20), at which point they were treated with nocodazole at doses ranging 
from 0 to lOOng/ml, to activate the spindle checkpoint. Following 15 hours of drug treatment, lysates were prepared from all plates. Half 
of the total  lysate  samples were run on  12%  SDS-PAGE  and western  blotted  for securin  and  actin.  “securin-P”  indicates  the  slower
migrating form of securin, phosphorylated by Cdc2 (also known as Cdkl) during mitosis.These re-plated cells were then allowed to progress through the cell cycle, i.e. 
they  were  “released”  from  mitotic  arrest,  for  14  hours,  at  which  point 
individual  plates  were  treated  with  nocodazole  doses  ranging  from  0- 
lOOng/ml,  for  15  hours  at  37°C.  The  experiment  shown  in  Figure  5.1  uses 
these  conditions,  which  were  optimised  through  several  previous  similar 
experiments using different release times and nocodazole treatment times. The 
14  hour  release  was  necessary  to  allow  a  large  enough  proportion  of the 
relatively slow growing untransfected U20S  cells to recover from the  shake- 
off, without allowing the fast growing U20S(dl89-97 LT)  cells to proceed as 
far as mitosis. Cells were treated for 15 hours with nocodazole, again to allow 
sufficient time  for accumulation of spindle checkpoint-arrested untransfected 
U20S cells, for comparison with the relatively fast growing U20S(dl89-97 LT) 
cells (see Figure  5.2 later for a comparison of growth rates of the U20S cell 
lines,  and  further  explanation  of  the  problems  encountered  in  trying  to 
synchronise  for  spindle  checkpoint  experiments).  Following  nocodazole 
treatment, all plates were lysed with equal volumes of RIPA buffer, and equal 
volumes (50pl, i.e. half of the total lysed protein for each sample) were loaded 
on  12%  SDS-PAGE,  western  blotted  for  securin  levels,  and  re-blotted  for 
actin  levels  (see Figure  5.1).  Equivalent quantities  of whole  cell lysate were 
also  loaded  for  cells  collected  at the  time  of mitotic  shake-off (Figure  5.1, 
lanes  1,  10  and  19),  and  for  cells  collected  immediately  after  the  14  hour 
release from shake-off, prior to nocodazole addition (lanes 2,11  and 20). The 
actin levels shown in Figure 5.1  are not entirely even because the nature of the 
experiment generated too little lysate to allow accurate protein concentration 
determination via the Bradford Assay. However, equal volumes of lysate were 
loaded, relying on the fact that all plates were seeded at the same cell density 
for the experiment, and comparison of the loading levels is sufficient to allow 
confident conclusions to be drawn from the results.
The  mitotic  shake-off  samples  for  U20S,  U20S(wild-type  LT)  and 
U20S(dl89-97  LT)  (lanes  1,  10  and  19,  respectively)  show  very  strong 
~28kDa  securin bands,  indicating that these  cells  are  arrested  at the  spindle
227checkpoint,  at  which  point  securin  has  not  been  degraded.  Human  securin 
(also known as hPTTG or hPTTG-1) has been shown to begin to accumulate 
at the onset of S phase, and peak at G2-M phases, in parallel with Cyclin B1 
(Zou et al.,  1999). After a 14 hour release from mitotic shake-off, all three cell 
lines  (lanes  2,  11  and 20)  show  much  reduced  securin  levels,  with  slightly 
faster  migrating  ~28kDa  securin  bands  (compare  strong,  slower  migrating 
securin band in lane 1  with weaker and faster migrating securin band in lane 2, 
and similarly compare lane  10 with  11, and  19 with 20). The reduced securin 
levels  in  lanes  2,  11  and  20  are  expected  because  securin  is  degraded  by 
anaphase promoting complex-mediated proteolysis at the metaphase-anaphase 
transition, i.e.  during the  14 hour release.  The difference in migration seen is 
due to phosphorylation. The mitotic kinase Cdc2  (also known as CDK1,  and 
p34cdc2,  see  (Doree  and  Hunt,  2002)  for  a  review)  phoshorylates  securin  at 
Serine-165  in  mitosis  (Ramos-Morales  et  al.,  2000),  resulting  in  the  highly 
phosphorylated,  slower migrating  form  seen  in lanes  1,  10  and  19.  The  low 
level of faster migrating (unphosphorylated) securin seen in lanes 2,  11  and 20 
of Figure 5.1  is probably representative of a low level of expression of securin 
in G1 and S phases of the cell cycle.
Cells lysed after  15 hours of no drug treatment (following the  14 hour 
release from mitotic shake-off)  show very low, almost undetectable levels of 
securin (see lanes 3,  12 and 21  of Figure 5.1), an indication that these cells are 
not  in  mitosis.  However,  15  hour  treatments  with  increasing  doses  of 
nocodazole  resulted  in  increasing  levels  of  the  slower  migrating, 
phosphorylated form of securin in both the U20S (lanes 4-9) and U20S(dl89- 
97  LT)  cell  lines  (lanes  22-27).  This  demonstrated  that  nocodazole  was 
arresting  the  cells  at the  spindle  checkpoint  in  these  cells,  resulting  in  high 
levels of the phosphorylated securin being maintained. It also showed that the 
spindle checkpoint is robust in both normal U20S cells, and also in U20S cells 
expressing  dl89-97  (non-Bubl-binding)  LT.  The  apparent  accumulation  of 
securin seen with increasing nocodazole dosage in these cell  lines  is thought 
to be due to higher nocodazole doses causing more severe spindle damage and
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spindle  checkpoint.  Low  (nanomolar)  concentrations  of  nocodazole  (N.B. 
lOng/ml  nocodazole  is  equivalent  to  33nM)  have  been  shown  to  stabilise 
rather than de-polymerise microtubules, causing spindle checkpoint activation 
by suppression of microtubule dynamic instability (the alternating periods  of 
microtubule  elongation  and  shortening  (Vasquez  et  al.,  1997).  Perhaps  this 
suppression of dynamic instability at low nocodazole doses does not result in 
as  frequent  or  rapid  generation  of unattached  kinetochores  as  the  spindle 
depolymerisation that results from higher nocodazole doses. This could lead to 
fewer cells in the population arresting at the checkpoint, resulting in detection 
of a  lower level  of phosphorylated  securin  in  the  cell  lysates  (e.g.  compare 
lane 4 with lane 5, and lane 22 with lane 23).
Interestingly, this “accumulation” of phosphorylated securin seen in the 
lysates with increasing nocodazole was not detected in U20S cells expressing 
wild-type LT (Figure  5.1, lanes  13-18).  Instead, these cells  show a low level 
of phosphorylated  securin  when  treated with  lOng/ml  nocodazole  (lane  13), 
(comparable with the securin levels seen in the equivalent lanes for the other 
cell lines (lanes 4 and 22)), but the securin levels in the cell population do not 
accumulate further with higher doses of nocodazole (lanes  14-18), remaining 
at the same approximate level as in lane  13,  even with  lOOng/ml nocodazole 
treatment  (lane  18).  It  should  be  noted  that  the  securin  that  is  seen  in 
U20S(wild-type LT) lanes  13-18, although not accumulating with nocodazole, 
is nevertheless phosphorylated,  and is at a higher level than that seen in lane 
12 (cells not treated with nocodazole), indicating that some cells are arrested 
at mitosis, albeit far fewer than seen in the equivalent lanes for the other cell 
lines.  However,  many  U20S(wild-type  LT)  cells  must  be  escaping  spindle 
checkpoint  arrest prematurely,  or  not  arresting  at  all  in  response  to  spindle 
damage,  as  seen  by  lack  of securin  accumulation  in  response  to  increasing 
nocodazole. In contrast, the U20S cells expressing LT with the Bubl  binding 
site  deleted  (dl89-97,  lanes  19-27)  appeared  to  have  a  spindle  checkpoint 
response that was just as robust as that seen in the absence of LT (lanes  1-9),
229demonstrating that interaction of LT with Bubl  is crucial for the ability of LT 
to disrupt spindle checkpoint function.
This  experiment  clearly  demonstrates  that  cells  expressing  wild-type 
LT are not able to effectively arrest at the spindle  checkpoint in response to 
spindle  damage,  and  that  interaction  of  LT  with  Bubl  is  crucial  for  this 
checkpoint inhibition.
5.3.1.2  Inhibition  of  spindle  checkpoint  function  by  LT  is  most  clearly
demonstrated using asynchronous cell cultures
Many  of  the  problems  encountered  in  demonstrating  a  spindle 
checkpoint defect in the U20S cells were thought to be the result of different 
growth  rates  of the  cell  lines,  which  also  made  the  synchronisations  very 
difficult.  The  growth  rates  of the  U20S  lines  were  examined,  as  shown  in 
Figure  5.2.  U20S,  U20S(wild-type  LT)  and  two  independent  clones  of 
U20S(dl89-97 LT) cells (“#2”, and “#4”, the clone used in Figure 5.1  and all 
remaining figures  in this  chapter) were  seeded to  several  10cm plates  at 3  x 
105  cells per plate.  At approximately 24 hour intervals  over the next 4  days, 
two plates for each cell line were independently trypsinised and the cells were 
counted  using  a  haemocytometer.  Counts  from  all  4  comer  squares  of the 
haemocytometer were recorded for each plate, resulting in  8  counts  for each 
cell  line,  at  each time point  (See  Appendix  III  for raw  data  and normalised 
values for these counts).
Figure  5.2  shows  the  relative  growth  rates  of  the  four  cell  lines, 
calculated as normalised (average) cell count values plotted against time (see 
also  Appendix  III).  The  growth  curves  in  this  graph  show  that  U20S  and 
U20S(wild-type  LT)  grow  at very  similar rates,  while  the  two  clonal  U20S 
cell  lines  expressing  dl89-97  LT  both  grow  at  a  noticeably  faster  rate. 
However, several independent clones of each cell line would need to be tested 
to  confirm  with  confidence  that  cells  expressing  this  LT  mutant  always 
proliferate  faster than cells  expressing wild-type  LT or untransfected control 
cells.
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Figure 5.2: Relative growth rates of control U20S cells and U20S cell 
lines expressing wild-type LT or dl89-97 LT.
Untransfected U20S  control  cells, U20S(wild-type  LT),  or U20S(dl89- 
97  LT)  cells  (two  independent  lines  expressing  this  mutant)  were 
seeded, and the number of cells were counted for two plates from each 
line at regular intervals over 4 days. Cell counts were averaged for each 
line and normalised to allow comparison of growth rates over time for 
the lines. These values are plotted against time after plating for each cell 
line.
231An observation made while collecting mitotic shake-off cells from the 
different cell lines  for the experiment shown in Figure  5.1  provided a further 
indication  of the  spindle  checkpoint defect in U20S(wild-type  LT)  cells.  Far 
fewer rounded up  cells  could be collected from the U20S(wild-type LT) line 
than from the U20S or U20S(dl89-97 LT) cell lines. This was seen even when 
the flasks treated with nocodazole for mitotic shake-off had been seeded at the 
same  density,  and  could not be  a  consequence  of the  different growth rates 
shown  in  Figure  5.2  because  the  U20S  and  U20S(wild-type  LT)  cell  lines 
have very similar growth rates. This indicated that fewer U20S(wild-type LT) 
cells  were  arresting  in  response  to nocodazole.  It  also  showed that the  cells 
that  did  arrest  (and  were  re-plated  following  mitotic  shake-off)  still  had the 
potential to override the spindle checkpoint, due to the observation of reduced 
securin  accumulation  in  these  re-plated  U20S(wild-type  LT)  cells  upon 
subsequent nocodazole  treatment (see Figure  5.1  lanes  13-18)  in comparison 
to the other cell lines (Figure 5.1  lanes 4-9 (U20S) and 22-27 (U20S(dl89-97 
LT)).
The  observation  of a  lower  yield  of mitotic  shake-off cells  from  the 
U20S(wild-type  LT)  line  suggested  that perhaps  synchronisation  of the  cell 
lines  would  not  be  necessary  to  demonstrate  a  spindle  checkpoint  defect  in 
response to nocodazole.
U20S,  U20S(wild-type  LT)  and  U20S(dl89-97  LT)  cells  were  seeded 
on several  10cm plates at  1   x  106 cells per plate, and 24 hours later when the 
plates  were  40-60%  confluent,  they  were  treated  with  doses  of nocodazole 
ranging  from  0  to  400ng/ml.  Cells  were  lysed  in  RIPA  buffer  following  15 
hours of nocodazole treatment, protein concentrations were estimated via the 
Bradford Assay, and 10pg samples were run on 12% SDS-PAGE, and western 
blotted for securin,  followed by re-blotting  for Cyclin B,  Mad2,  and actin.  It 
was necessary to load this relatively small quantity of protein (lOpg) for each 
sample to allow a clear comparison of securin levels (See Figure 5.3).
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Figure  5.3:  SV40  large  T  antigen  compromises  spindle  checkpoint 
function via interaction with Bubl.
Asynchronous cultures of U20S (lanes 1-5), U20S(wild-type LT) (lanes 6- 
10) and U20S(dl89-97 LT) (lanes  11-15) cells were lysed following a  15 
hour treatment with doses of nocodazole ranging from  0-400ng/ml.  10/xg 
samples were loaded on  12% SDS-PAGE and western blotted for securin, 
Cyclin  B,  Mad2  and  actin  levels.  Relative  protein  levels  indicated  that 
untransfected  cells  and  cells  expressing  non-Bubl-binding  (dl89-97)  LT 
were arresting at the spindle checkpoint in response to nocodazole, but that 
far  fewer  wild-type  LT-expressing  cells  were  arresting,  resulting  in 
lowered  securin,  cyclin  B  and  Mad2  levels  in  the  lysates  from  this  cell 
line. Therefore interaction of LT with Bubl  is crucial for the ability of LT 
to compromise spindle checkpoint function.
233When treated with 0 or lOng/ml nocodazole for 15 hours, no securin is 
detected in any of the cell lines (see Figure 5.3, securin blot of lanes  1-2, 6-7 
and  11-12).  This  indicates  that  in  the  asynchronous  cultures  lOng/ml 
nocodazole did not cause enough spindle  damage to induce cells to arrest at 
the spindle checkpoint in significant numbers to allow detection of securin, a 
protein whose  expression peaks  at G2/M.  The weak, unphosphorylated form 
of securin observed in Figure 5.1  is not detected in the securin blot of Figure 
5.3, perhaps a further indication of its low abundance. However when treated 
with nocodazole  doses  of 50,  100  and 400ng/ml,  the 28kDa  securin protein 
can be detected in all three cell lines, but at different levels (see lanes 3-5, 8- 
10  and  13-15).  U20S  and  U20S(dl89-97  LT)  cell  lines  both  show 
progressively  more  securin  protein  (presumably  the  phosphorylated  form) 
with increased nocodazole dose, ranging from a relatively weak ~28kDa band 
at 50ng/ml nocodazole treatment (lanes 3 and 13) to a very strong band when 
treated  with  400ng/ml  of the  drug  (lanes  5  and  15).  This  accumulation  of 
securin  with  nocodazole  dose  appears  very  similar  between  these  two  cell 
lines, with the exception that a greater proportion of the cells expressing dl89- 
97  LT  appear to  respond to  lOOng/ml  of nocodazole by arresting  with high 
levels of securin than that seen in the U20S cells (compare lane  14 with lane 
4).  However,  the  cells  expressing the  wild-type  LT  (see  lanes  8-10)  do not 
appear to  respond  to  spindle  damage  induced by  nocodazole  as  well  as  the 
U20S  or  U20S(dl89-97  LT)  cell  lines,  with  only  a  moderate  amount  of the 
28kDa securin protein being detected in the lysates from the U20S(wild-type 
LT)  cells,  even when treated with the highest drug dose, 400ng/ml (compare 
lanes  8-10  (wild-type  LT)  with lanes  3-5  (no  LT)  and  13-15  (dl89-97  LT)). 
Strong, ~50kDa actin bands of approximately equal intensity can be seen in all 
lanes (actin blot, lanes 1-15), demonstrating that all lanes were loaded equally, 
and that the differences seen in securin levels are real.
Cyclin B  levels  show a similar trend to that seen for securin levels  in 
the  nocodazole-treated  U20S  cell  lines  (see  Cyclin  B  blot,  Figure  5.3).  The 
level of ~62kDa Cyclin B1 protein is seen to increase with increased doses of
234nocodazole  in  the  U20S  and  U20S(dl89-97  LT)  cells  (lanes  1-5  and  11-15, 
respectively),  but  not  to  the  same  extent  in  the  U20S(wild-type  LT)  cells, 
staying at a relatively low level at the higher drug doses (lanes 8-10).
Cells expressing SV40 large T antigen have long been known to have 
elevated protein levels and/or associated activities of Cyclin B in comparison 
to untransfected cells (and also Cyclin A, Cdc25C and p34cdc2) (Chang et al, 
1997; Chang and Schlegel,  1996; Kaufmann et al.,  1995). This explains why 
asynchronous U20S(wild-type LT)  (lane  6)  and U20S(dl89-97 LT)  (lane  11) 
cells have a higher level  of Cyclin B than the untransfected U20S cells (lane 
1), and also explains why Cyclin B accumulates to a higher level in response 
to  nocodazole  in  U20S(dl89-97  LT)  cells  in  comparison  to  U20S  cells 
(compare  lanes  11-15  with  lanes  1-5,  respectively).  It  also  emphasises  the 
difference  in  Cyclin  B  accumulation  between  cells  expressing  the  Bubl- 
binding  (wild-type)  and  non-Bubl-binding  (dl89-97)  LT  proteins:  Cyclin  B 
levels are almost identical in the 0-50ng/ml drug treatment lanes for these cell 
lines  (compare  lanes  6-8  with  11-13),  but  at  100  and  400ng/ml  nocodazole 
doses the level of Cyclin B in the U20S(wild-type LT) cells did not increase 
further  (62kDa  bands  in  lanes  8-10  are  approximately  equal  intensity), 
whereas  the  amount  of Cyclin  B  protein  in  the  U20S(dl89-97  LT)  lysates 
increases greatly in the  100 (and 400) ng/ml nocodazole treatments compared 
to  that  seen  at  50ng/ml  (see  lanes  13-15).  A  slower migrating  band  is  also 
observed  in  the  Cyclin  B  blot,  possibly  a  phosphorylated  (or  otherwise 
modified)  form  of this protein.  Interestingly,  this  is  most clearly seen in the 
U20S(wild-type LT) cells treated with 50ng/ml nocodazole (lane 8).
The membranes  were also re-blotted for Mad2.  Mad2  forms a ternary 
complex  with  Cdc20  and  Cdc27,  a  component  of the  anaphase-promoting 
complex/cyclosome (APC/C), to inhibit APC/CC dc20-dependent ubiquitylation 
and degradation, thereby causing a cell cycle arrest in metaphase (Fang et al., 
1998;  Kallio et al.,  1998;  Li  and Benezra,  1996;  Li  et al.,  1997;  Wassmann 
and  Benezra,  1998).  Mad2  is  therefore  an  essential  spindle  checkpoint 
component  because  it  acts  as  a  negative  regulator  of  the  mitotic  APC/C,
235preventing progression to anaphase in the presence of even a single unattached 
kinetochore.
Mad2 levels in the nocodazole-treated U20S cell lines shown in Figure
5.3  are consistent with the securin levels seen in these cell lines (c.f.  securin 
and Mad2 blots, lanes  1-15). In the U20S and U20S(dl89-97 LT) lysates, the 
intensity  of  the  24kDa  Mad2  bands  appear  to  increase  with  dose  of 
nocodazole  (see  lanes  1-5  and  11-15,  respectively).  However  in  the 
U20S(wild-type LT) cells (lanes 6-10), Mad2 levels do not appear to respond 
to nocodazole treatment in the same way, only increasing a moderate amount 
with increased nocodazole.
Although the  budding  yeast Mad2  protein remains  at a constant level 
during the cell cycle (Chen et al.,  1999), a recent study has shown that Mad2 
is  cell  cycle regulated in human  fibroblasts  (IMR90  cells), peaking  at G2/M 
phase (Hernando et al., 2004).  This offers a simple explanation for the Mad2 
protein  levels  observed  in  Figure  5.3:  as  for  securin  and  Cyclin  B,  lack  of 
Mad2  accumulation  with  increased  nocodazole  in  the  U20S(wild-type  LT) 
cells  (lanes  6-10)  indicates  a  spindle  checkpoint  defect  in  these  cells,  with 
cells  failing  to  arrest  in  mitosis  (the  point  at  which  Mad2  levels  peak)  in 
response to spindle damage.
It  has  been  previously  shown  that  some  cancer  cells  displaying 
chromosome instability (CIN) also have reduced steady-state levels of Mad2, 
and an  associated loss  of spindle  checkpoint  control  (Li  and Benezra,  1996; 
Wang et a l, 2002; Wang et al., 2000). However from the Mad2 blot in Figure
5.3 (and subsequent experiments) wild-type LT-expressing cells do not appear 
to have reduced steady-state levels of Mad2  (compare lanes  1,  6 and  11, and 
also see Mad2 blot in Figure 5.6).
50pg of the  same  lysates  shown  in Figure  5.3  were  also run on a 8% 
SDS-PAGE  gel  and  western  blotted  for  other  spindle  checkpoint-related 
proteins, and for LT (see Figure 5.4).
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Figure  5.4:  Relative  expression  levels  of  proteins  involved  in  the 
spindle checkpoint, under conditions of checkpoint activation.
Lysates are the same as shown in Figure 5.3. 50/zg samples were loaded 
on  8%  SDS-PAGE  and  western  blotted  for  Bubl,  LT,  Bub3, 
p55Cdc/hCdc20  and  actin  levels.  Bubl  protein  levels,  observed  as 
multiple  bands,  increase  with  increasing  nocodazole  treatment  in  all 
three cell lines, but to a lesser extent in U20S(wild-type LT) cells. Bub3 
levels  remain  constant,  and  LT  and  p55Cdc  levels  do  not  appear  to 
accumulate with nocodazole treatment in either the U20S(wild-type LT) 
or the U20S(dl89-97 LT) cells. However, p55Cdc does accumulate with 
nocodazole in untransfected U20S cells, as would be predicted by its cell 
cycle-regulated expression.
237Lysates  were blotted  for Bubl  (using NT hBubl  polyclonal  antiserum),  and 
re-blotted  for  LT  (using  anti-LT  monoclonal  PAb423),  Bub3,  p55Cdc  (also 
known  as  hCdc20,  p55Cdc  is  the  human  homolog  of  Cdc20),  and  actin. 
Attempts were also made to blot these lysates for BubRl  and Madl  levels, but 
unfortunately no good antibodies that detected the human homologs of these 
proteins could be obtained during the course of the project.
Expression  of Bubl  is  known  to  be  cell  cycle-regulated,  peaking  at 
G2/M  phase  (Davenport  et  a l,  1999;  Taylor  et  al,  2001),  and  thus  the 
accumulation of Bubl with increasing nocodazole observed for all cell lines in 
Figure 5.4 is as expected. Asynchronous cultures of the U20S cell lines (Bubl 
blot, lanes  1,  6 and  11)  show a faint ~150kDa band, but upon treatment with 
nocodazole,  more  cells  accumulate  in  M  phase,  resulting  in  detection  of 
stronger ~150kDa Bubl  bands (lanes 2-5, 7-10 and 14-15). The Bubl blots in 
Figure  5.4  appear to  show multiple  forms with  slightly different migrations, 
rather than single bands. This is true for all lanes, whether arrested in M phase 
by  nocodazole  or  not,  and  is  probably  due  to  phosphorylation  of the  Bubl 
protein.  However,  some  studies  of  Bubl  phosphorylation  have  stated  that 
Bubl  is not significantly phosphorylated during a normal mitosis, and is only 
hyperphosphorylated  (by  MAP  kinase,  (MAPK))  in  response  to  unattached 
kinetochores  (Chen,  2004;  Taylor  et al,  2001).  This  would  not  explain  the 
apparent Bubl  “doublets” seen with 0 or lOng/ml nocodazole treatment (lanes 
1-2, 6-7 and 11-12), but 2-Dimensional SDS-PAGE would be needed in order 
to determine exactly how many Bubl  bands  are present.  The intensity of the 
Bubl  bands  in  lanes  8-10  (U20S(wild-type  LT))  appears  slightly lower than 
that seen in lanes  3-5  (untransfected U20S),  suggesting as  in Figure  5.3  that 
more  of the  nocodazole-treated  U20S(wild-type  LT)  cells  in  the  population 
have  escaped  spindle  checkpoint  arrest  (and  therefore  have  reduced  Bubl 
expression).  However,  this  spindle  checkpoint  defect  is  much  more  clearly 
demonstrated  by  the  lack  of  accumulation  of  securin  and  Cyclin  B  in 
U20S(wild-type LT) cells in Figure 5.3.
238The LT blot in Figure 5.4 shows that expression of wild-type LT (lanes 
6-10) and dl89-97 LT (lanes  11-15) is not affected by stage of the cell cycle, 
as  seen  by  the  effect  of nocodazole  on  the  cells.  The  level  of dl89-97  LT 
appears to rise slightly with increasing nocodazole, but this is not significant 
due to a slight rise in actin (loading) levels in these lanes (11-15). As observed 
previously, wild-type LT (a very strong ~100kDa band is seen in lanes 6-10) 
appears  to be  expressed  at  a higher level  than  dl89-97  LT  (strong ~100kDa 
band seen in lanes  11-15), and as expected no lOOkDa LT band is observed in 
the untransfected U20S lysates (lanes 1-5).
Bub3  protein  levels  do  not  appear  to  be  affected by  the  presence  of 
either wild-type  or dl89-97  LT,  or by  treatment with nocodazole  (see  Bub3 
blot,  Figure  5.4  lanes  1-15,  a  very  strong  37kDa  Bub3  band  is  observed  in 
each lane).  This  is  in  agreement with previous  findings that Bub3  levels  are 
constant  throughout  the  cell  cycle  in  budding  yeast  (Brady  and  Hardwick, 
2000;  Fraschini  et al.,  2001),  and also  in human  cells  (Martinez-Exposito  et 
al, 1999).
p55Cdc  (the  human  homolog  of  Cdc20  (Weinstein  et  al.,  1994)) 
mediates association of Mad2 to the APC/C and is required for the metaphase- 
anaphase  transition  (Kallio  et  a l,  1998).  The  level  of  p55Cdc  protein 
fluctuates  during  the  cell  cycle.  Synthesis  is  initiated  at  Gl/S,  with  protein 
levels peaking in M phase,  and the protein is abruptly degraded at the M/Gl 
transition (Fraschini et al, 2001; Weinstein,  1997). Degradation of p55Cdc is 
blocked by proteasome  inhibitors,  suggesting that it is targeted by ubiquitin- 
mediated  proteolysis.  As  expected,  in  Figure  5.4  p55Cdc  appears  to 
accumulate  upon  nocodazole  treatment  in  the  untransfected  U20S  cells 
(compare  the  strong  ~55kDa  p55Cdc  bands  in  lanes  3-5  with  the  weaker 
bands in lanes  1-2).  This p55Cdc accumulation with nocodazole treatment is 
clearly observed by comparing the p55Cdc and actin blots in Figure 5.4 lanes 
1-5.  In  agreement  with  previous  observations  for  this  experiment,  when 
comparing  the  p55Cdc  and  the  actin  blots  for  U20S(wild-type  LT)  cells 
(Figure 5.4, lanes 6-10), no p55Cdc accumulation in response to nocodazole is
239observed, with the p55Cdc bands remaining at a relatively weak level that is 
unaffected by increasing the nocodazole dose. This is as would be expected if 
the wild-type  LT-expressing cells  are overriding nocodazole-induced spindle 
checkpoint  arrest.  Interestingly,  the  U20S(dl89-97  LT)  cells  do not show an 
accumulation  of p55Cdc protein upon nocodazole treatement (see Figure 5.4 
lanes  11-15, compare p55Cdc and actin blots), as might be expected from the 
securin and Cyclin B accumulation seen in these lysates in Figure 5.3. Instead, 
strong p55Cdc  bands  are  seen  in  lanes  11-15,  and the protein  levels  do  not 
appear to be affected by the nocodazole treatment.
5.3.1.3  Compartmentalisation of spindle checkpoint proteins is not affected
by LT
The next task was  to  confirm that the  differences  seen in securin  and 
Mad2  levels  between  the  U20S(wild-type  LT)  and  U20S  or  U20S(dl89-97 
LT)  cells  in  response  to  nocodazole  treatment  in  Figure  5.3  were  due  to  a 
spindle  checkpoint  defect  in  the  wild-type  LT-expressing  cells,  rather  than 
being  caused  by  the  method  of detecting  the  protein  levels  present.  It  was 
possible that the lower levels of securin, Mad2 (and perhaps Bubl, see Figure
5.4)  were  due to  a change in  subcellular localisation of these proteins  in the 
U20S(wild-type LT) cells, making them difficult to extract. The lysates shown 
in  Figures  5.3  and  5.4  were  prepared  using  RIPA  buffer,  saving  only  the 
soluble fraction (supernatant) of the lysis. RIPA buffer contains the non-ionic 
detergent Triton X-100, capable of solubilising membrane proteins, as well as 
the ionic detergents  sodium dodecyl  sulphate (SDS) and sodium deoxycholic 
acid (NaDOC).  The RIPA-soluble (supernatant)  fraction of the lysis contains 
predominantly  soluble,  cytosolic  proteins  as  well  as  some  proteins  from 
membranous  organelles  that  are  also  solubilised  by  the  lysis  buffer.  The 
RIPA-insoluble (pellet)  fraction, that was discarded when making the lysates 
in  Figures  5.3  (and  5.4),  would  be  composed  primarily  of  intermediate 
filaments,  remnant  nuclei  and  their  associated  polypeptides,  and  also 
chromatin (Napolitano et al.,  1987).
240U20S,  U20S(wild-type  LT)  and U20S(dl89-97  LT)  cells  were  seeded 
on several  10cm plates at  1.2 x  106 cells per plate, and 24 hours after plating 
were  treated  for  15  hours  with  either  0,  50  or  lOOng/ml  nocodazole.  Cells 
were then lysed with 200pl of RIPA buffer, and both the soluble (supernatant) 
and  insoluble  (pellet,  resuspended  in  lOOpl  2x  Laemmli  Sample  buffer  and 
heated  at  90°C  for  10  minutes)  were  retained.  Protein  concentrations  of the 
soluble  samples  were  estimated  by  the  Bradford  Assay,  and  50pg  soluble 
samples  were  mixed with 2x  Laemmli  sample buffer, heated at 90°C  for  10 
minutes, and loaded on a 5-15% SDS-PAGE gradient gel, and western blotted. 
30pl  of each  insoluble  sample  was  also  loaded  on  the  same  gel  (it  was  not 
possible to estimate protein concentrations for the pellet samples solubilised in 
Laemmli buffer using the Bradford Assay) for comparison.
Figure  5.5  shows  these  samples  western  blotted  for  Bubl,  and  re­
blotted for securin, Mad2, LT and actin. As observed previously in Figures 5.3 
and 5.4,  Bubl  levels  appear to  increase with nocodazole treatment (arrest in 
G2/M)  in  the  soluble  fractions,  but  this  increase  is  less  prominent  in  the 
U20S(wild-type LT)  cells (compare strength of 150kDa Bubl  bands in lanes 
4-6  with  the  lanes  1-3  and  7-9).  Securin  and  Mad2  levels  in  the  soluble 
samples  behave  similarly,  as  previously  described,  with  less  protein 
accumulation  in  the  U20S(wild-type  LT)  cells.  Both  the  unphosphorylated 
securin and the slower migrating phosphorylated form of securin are visible in 
all three cell lines (~28kDa securin bands, Figure 5.5 lanes  1-9), due to better 
resolution of proteins in this gradient gel. As before, LT levels in lanes 4-9 are 
not affected by nocodazole treatment, and actin levels in the soluble fractions 
are very even (lanes 1-9), indicating equal protein loading.
Actin levels  in the  insoluble  fractions  of the  lysates  (Figure  5.5  lanes 
10-18)  appear to increase with nocodazole treatment.  This is unlikely to be a 
consequence of the drug treatment however, because the actin levels in these 
lanes  correlate  with  the  relative  protein  concentrations  of  the  equivalent 
soluble fractions  of the lysates  (as  calculated using the Bradford Assay, data 
not shown).
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Figure 5.5:  Observation of a reduced response to nocodazole in wild- 
type  LT-expressing  cells  is  not  caused  by  difficulties  in  extracting 
total protein from different cell lines.
Comparison of protein levels in the RIPA-soluble (supernatant, lanes 1-9) 
and RIPA-insoluble (pellet,  lanes  10-18)  fractions of RIPA lysates  from 
nocodazole-treated  U20S,  U20S(wild-type  LT)  and  U20S(dl89-97  LT) 
cells.  The  lower Bubl,  securin  and  Mad2  protein  levels  in  nocodazole 
treated  U20S(wild-type  LT)  are  not  due  to  a  change  of  subcellular 
localisation of these proteins in the cells, because the difference cannot be 
accounted for by examining the insoluble fraction as well as the soluble.
242It was not possible to estimate protein concentration from the pellet fractions 
solubilised in Laemmli buffer,  and it was  for this reason that equal volumes 
were  loaded  for  these  samples.  However,  qualitative  interpretation  of  the 
results  is  not  affected  by  the  slightly  uneven  loading.  A  fairly  significant 
proportion  of the  LT  protein  in  both the  U20S(wild-type  LT)  (lanes  13-15) 
and  the  U20S(dl89-97  LT)  cells  (lanes  16-18)  appears  to  be  found  in  the 
insoluble fraction of the lysis, probably bound to the chromatin, although the 
relative proportions present in the soluble versus insoluble fractions does not 
appear to be affected by nocodazole treatment (compare lanes 4-9 with lanes 
13-18; however the relatively low amount of dl89-97 LT in lane  16 may need 
further  investigation).  A  very  small  amount  of the  total  Bubl  in  each  lysis 
appears  to  have  been  localised  in  the  insoluble  fraction  (see  faint  150kDa 
Bubl  bands  in  lanes  11-12,  14-15  and  17-18),  but  the  relative  strengths  of 
these  bands  does  not  give  any  indication  of  a  change  of  subcellular 
localisation  of  the  Bubl  protein  caused  by  expression  of  wild-type  LT, 
because all bands are of similar relative intensities in lanes 10-18 as those seen 
in lanes  1-9.  Finally,  no  securin or Mad2  is  detected in any of the insoluble 
fraction lanes, in any of the cell lines, under any of the conditions tested (see 
lanes  10-18). This indicates that the lower levels of securin observed in lanes 
4-6  compared  to  lanes  1-3  or  7-9  are  due  to  compromise  of  the  spindle 
checkpoint, and not simply an artefact of change of subcellular distribution of 
these  proteins  in  the  wild-type  LT-expressing  cells.  Similarly,  this  also 
confirms that the low  expression  of Mad2  observed in  asynchronous  culture 
(lanes  1, 4 and 7), compared to the higher levels seen in nocodazole-arrested 
cells (lanes 2-3  and 8-9) is due to cell cycle regulated expression of Mad2 in 
these cells, with Mad2 expression peaking at G2/M phase.
Therefore, this experiment further confirms that wild-type LT (but not 
dl89-97,  non-Bubl-binding LT)  is  able  to  compromise the  spindle  assembly 
checkpoint.
2435.3.1.4  The  spindle  checkpoint  itself,  rather than  rate  of adaptation  to  the
checkpoint is affected by LT
The  spindle  checkpoint  is  known  to  have  only  a  limited  capacity  to 
maintain cell cycle arrest in response to spindle damage, resulting in eventual 
“adaptation” and progression to the next phase of the cell cycle in a tetraploid 
state, without correction of errors and satisfaction of the checkpoint (reviewed 
in (Andreassen et al., 2003)). It is possible that the spindle checkpoint defect 
of  the  U20S(wild-type  LT)  cells  could  be  that  they  are  adapting  to  the 
checkpoint at a much faster rate than normal, rather than a failure of the error 
sensing and signal transduction mechanisms of the checkpoint itself.
To test this hypothesis,  asynchronous U20S,  U20S(wild-type LT)  and 
U20S(dl89-97 LT) cells were treated with 0, 50 or 200ng/ml nocodazole for 2, 
4,  6,  8,  10,  12  or  15  hours.  All  samples  were  lysed  with  RIPA buffer,  and 
20pg samples were run on 5-15% SDS-PAGE and western blotted for securin 
and actin. No accumulation of securin in response to nocodazole was observed 
in any of the cell lines until the  15 hour treatment time point, at which point 
results  similar  to  those  seen  in  Figure  5,3  were  observed  (data not  shown). 
This indicated that the U20S(wild-type LT) cells were not simply adapting to 
the spindle checkpoint faster, because if they were, securin bands should have 
been  observed  earlier  than  the  15  hour  time  point  to  indicate  a  transient 
spindle  checkpoint  arrest.  Instead,  it  appears  that  the  U20S(wild-type  LT) 
cells never achieve a spindle checkpoint arrest in response to nocodazole that 
can be detected as an increase in securin protein levels in the cell population.
Longer time  points  of nocodazole  treatment  were  not tested,  because 
prolonged exposures to the drug of 15 hours or more were expected to lead to 
adaptation in all the cell lines (Taylor and McKeon,  1997), and hence would 
not be  informative because  it would not be possible to  differentiate between 
low securin levels induced by override of the spindle checkpoint, or by entry 
into  the  next  cell  cycle  (via  adaptation).  As  will  be  discussed  later,  LT- 
expressing cells are defective for the p53-dependent tetraploidy checkpoint at
244G1  that  would  otherwise  permanently  block  propagation  of tetraploid  cells 
that have adapted to the spindle checkpoint.
5.3.1.5  Preliminary experiments to search for a mechanism by which LT is 
inhibiting  spindle  checkpoint  function:  examination  of  protein 
complexes via co-immunoprecipitation
Having identified conditions under which it could be demonstrated that 
LT was inhibiting spindle checkpoint function, it was then possible to begin to 
examine  the  protein  complexes  present  in  the  U20S  cell  lines  under  these 
conditions.
Asynchronous U20S, U20S(wild-type LT) and U20S(dl89-97 LT) cells 
were  plated  at  a  relatively  low  density  (to  prevent  cell  cycle  arrest  due  to 
contact inhibition), and as before (see Figure  5.3), 24 hours after plating, the 
cells  were  treated  for  15  hours  with  nocodazole  doses  ranging  from  0- 
lOOng/ml.  Cells were then lysed using NP40  lysis buffer, which contains the 
non-ionic detergent Nonidet P40 which is less stringent than the RIPA buffer 
used  in  previous  experiments.  From  previous  experience,  the  LT-Bubl 
interaction  can not be  detected under the stringent conditions  of RIPA  lysis, 
but  can  be  seen  when  cells  are  lysed  with  NP40  lysis  buffer.  Therefore  to 
maintain  intact  LT-Bubl  complexes  (and  any  other complexes)  in  the  cells, 
NP40 lysis buffer was used.
Figure  5.6 panel A shows  50pg of each sample run on a 5-15%  SDS- 
PAGE  (gradient  gel),  and  western  blotted  to  demonstrate  relative  protein 
levels  of  securin,  Mad2,  Bubl,  LT,  Bub3  and  actin  in  these  lysates.  The 
protein  levels  seen  in  Figure  5.6  panel  A  re-iterate  those  seen  for the  same 
treatments of these cell lines previously.  Securin levels accumulate in the cell 
population  with  increased  dose  of  nocodazole  in  the  untransfected  U20S 
(Figure 5.6A, lanes  1-5) and U20S(dl89-97 LT) (lanes  11-15) cells, but not as 
much  in  the  U20S(wild-type  LT)  cells  (lanes  6-10),  again  indicating 
disruption of the spindle checkpoint by LT-Bubl interaction.
245Figure 5.6: Co-immunoprecipitation experiments conducted to begin 
to  dissect  the  mechanism  by  which  LT  is  compromising  spindle 
checkpoint function.
U20S, U20S(wild-type LT) and U20S(dl89-97 LT) cells were treated for 
15 hours with 0-100ng/ml nocodazole, and lysed using NP40 lysis buffer. 
(A): 50pg samples were analysed for securin, Mad2, Bubl, LT, Bub3 and 
actin  levels  via  western  blotting.  (B):  500pg  samples  were
immunoprecipitated using Bubl  antibody,  and western blotted for Bubl 
and LT levels. (C): 500pg samples were immunoprecipitated using Mad2 
antibody,  and western blotted to  look for co-immunoprecipitating Bubl 
and LT proteins.
By looking at protein complexes present in the different cell lines under 
conditions where the checkpoint is functional or abrogated, the aim was 
to gain some insight into the mechanism by which LT might be affecting 
the spindle checkpoint via interaction with Bubl.
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Figure 5.6:  Co-immunoprecipitation  experiments conducted to begin 
to  dissect  the  mechanism  by  which  LT  is  compromising  spindle 
checkpoint function.
247The  securin  doublets  are  seen  in  Figure  5.6  panel  A,  and  as  before  it  is 
presumed  that  the  lower  band  represents  the  unphosphorylated  form  of 
securin,  and the  upper,  stronger band represents the phosphorylated  form of 
securin seen in mitosis. Both bands in the securin doublet seen in U20S(dl89- 
97 LT) cells treated with  lOOng/ml nocodazole (lane  15) appear to be equally 
strong, but the equivalent lane of U20S cells (lane 5) shows the upper securin 
band to be  stronger,  as would be expected in mitosis. This abberantly strong 
lower securin band  in  lane  15  could be  caused by  slight overloading of this 
lane (see actin blot, lane  15), perhaps resulting in saturation in the securin blot 
of this  lane.  The  actin  blot  of Figure  5.6  panel  A  shows  that  the  protein 
loading was  very  even,  but perhaps  with  slight underloading  of lane  11  and 
overloading of lane  15. This allowed direct comparison of the protein levels in 
this  figure,  which  are  consistent  with  previous  experiments  using  RIPA 
lysates.  Mad2  levels  accumulate  with nocodazole  in the  lysates  in  lanes  1-5 
(untransfected)  and  11-15  (dl89-97  LT),  but  do  not  accumulate  to  the  same 
extent in lanes 6-10 (wild-type LT). Bubl  levels accumulate when cells arrest 
in M phase in response to nocodazole-induced spindle damage in all three cell 
lines, but perhaps  slightly less in wild-type LT-expressing cells (lanes  6-10). 
LT expression is not affected by nocodazole in either the U20S(wild-type LT) 
(lanes 6-10) or the U20S(dl89-97 LT) cells (lanes  11-15). Bub3 levels are not 
affected  by  spindle  damage  in  any  of the  cell  lines  (40kDa bands  of equal 
intensity are seen in lanes 1-15).
Figure  5.6  panel  B  shows  Bubl  immunoprecipitations  of the  lysates 
from  panel  A,  western  blotted  for  Bubl  (control)  and  for  LT.  Bubl  was 
immunoprecipitated  using  CT  hBubl  polyclonal  antiserum  and  Protein  A- 
Sepharose  beads.  The  immunoprecipitates  were  loaded  on  a  5-15%  SDS- 
PAGE gradient gel, and western blotted for Bubl  (using NT hBubl polyclonal 
antiserum),  and  LT  (using  anti-LT  monoclonal  PAb423).  As  expected,  an 
accumulation of Bubl  with increased nocodazole is observed in the Bubl blot 
of the Bubl  immunoprecipitations in all three cell lines (Figure 5.6B, lanes  1- 
15).  The  Bubl  bands  seen  in  Figure  5.6  panel  B  are  not  very  clear,  and  in
248particular  look  fainter  than  expected  in  lanes  11-15,  the  U20S(dl89-97  LT) 
cell  line.  The high number of non-specific bands  also recognised by the NT 
hBubl  polyclonal  antiserum  used to  blot  the  immunoprecipitations  was  the 
cause of this problem. Unfortunately at this stage in the project there were no 
other antibodies available that were good for western blotting human Bubl.
The LT blot in Figure  5.6 panel B showed approximately equal levels 
of LT  co-immunoprecipitating  with  Bubl  in  the  U20S(wild-type  LT)  line, 
regardless  of  the  extent  of  spindle  damage  (lOOkDa  LT  bands  are  of 
approximately equal intensity in Figure  5.6B  lanes  6-10).  It is not clear why 
the amount of LT being co-immunoprecipitated with Bubl  does not correlate 
with the levels of Bubl being immunoprecipitated in the cells, but perhaps this 
is an indication that only a small proportion of the LT in the cell interacts with 
Bubl.  Only  very  faint  lOOkDa  LT  bands  are  observed  to  co- 
immunoprecipitate  with  Bubl  in  the  U20S(dl89-97  LT)  lanes  (Figure  5.6B, 
lanes  11-15).  These  co-precipitating  bands  may  be  caused  by  an  indirect 
interaction of this LT mutant with Bubl  via p53 (personal communication, Dr 
Ole  Gjoerup),  rather  than  the  interaction  of LT  residues  89-97  with  Bubl 
observed in lanes 6-10 in the wild-type LT-expressing cell line.
Figure  5.6  panel  C  shows  Mad2  immunoprecipitations  of the  lysates 
from  panel  A,  western  blotted  for  Bubl  and  LT.  The  method  used  for the 
immunoprecipitations was the same as that used for panel B, except that anti- 
Mad2Ll  (an  alternative  name  for  human  Mad2)  monoclonal  antibody  was 
used to immunoprecipitate the Mad2 protein from the lysates, and Protein G- 
rather than Protein A-Sepharose beads were used for the immunoprecipitation 
(because  the  Mad2  antibody  was  IgGl  sub-class,  and  therefore  would  not 
have  high  affinity  for Protein  A,  as  discussed  in  Chapter 4).  As before,  the 
immunoprecipitates  were  run  on  a  5-15%  SDS-PAGE  gradient  gel,  and 
western  blotted  with  antibodies  against  Bubl  (using  NT  hBubl  polyclonal 
antiserum) and LT (using anti-LT monoclonal PAb423).
It has previously been shown that Mad2  does not associate with Bubl 
in  mammalian  cells,  even  in  the  presence  of  nocodazole-induced  spindle
249damage  (Skoufias  et  al.,  2001),  and  so  the  Mad2-Bubl  co- 
immunoprecipitation  results  shown  in  Figure  5.6  panel  C  were  quite 
unexpected  and  novel.  No  co-immunoprecipitation  of Bubl  with  Mad2  is 
observed  in  any  of the  control  (untransfected)  U20S  lysates,  as  would  be 
expected from previous observations by others (Figure 5.6C, lanes  1-5, N.B. a 
non-specific  smear  was  observed  in  the  Bubl  blot  of lane  1,  but  no  clear 
150kDa  Bubl  band  was  seen).  Similarly,  no  Mad2-Bubl  association  is 
suggested  in  the  U20S(wild-type  LT)  lysates  treated  with  0-50ng/ml 
nocodazole (see Figure 5.6C, Bubl blot, lanes 6-9). However, when lOOng/ml 
nocodazole treatment was used,  a very faint  150kDa Bubl  band appeared to 
be co-immunoprecipitating with Mad2, (lane  10, unfortunately it was difficult 
to demonstrate this  clearly in the scan of the  autorad shown in Figure  5.6C). 
The  U20S(dl98-97  LT)  cells  treated  with  lOOng/ml  nocodazole  showed  a 
strong  150kDa  Bubl  band  co-immunoprecipitating  with Mad2  (Figure  5.6C 
lane  15, Bubl  blot), but no Bubl  was found to be associated with Mad2 when 
U20S(dl89-97 LT) cells were treated with lower doses of the drug (lanes  11- 
14).
The Mad2  immunoprecipitations were also blotted for LT, to look for 
association  of  these  proteins  in  the  three  cell  lines  under  conditions  of 
increasing  levels  of spindle  damage  (see  LT  blot,  Figure  5.6  panel  C).  As 
expected,  no  LT  is  detected  in  the  untransfected  U20S  cells  (lanes  1-5,  no 
lOOkDa LT bands are detected). However, when Mad2 is immunoprecipitated 
from the U20S(wild-type LT) lysates, LT appears to co-immunoprecipitate, as 
seen by the strong  lOOkDa LT bands in lanes 6-10. In addition, the amount of 
LT  co-immunoprecipitating  with  Mad2  appears  to  increase  with nocodazole 
dose (see lanes 6-10). Interaction of the spindle checkpoint protein Mad2 with 
SV40  LT  has  not  been  shown  before,  and  was  an  unexpected  and  novel 
finding. The association of these proteins also appears to be greatly enhanced 
by spindle  damage  in the U20S(wild-type  LT)  cells,  because the quantity of 
LT that is co-immunoprecipitated with Mad2 increases with nocodazole dose, 
even though the Mad2  levels remain relatively constant when these cells are
250treated with  nocodazole  (see  Mad2  blot  in  Figure  5.6  panel  A,  lanes  6-10). 
This relatively constant level of Mad2 in the U20S(wild-type LT) cells treated 
with increasing nocodazole doses  should result in immunoprecipitation of an 
equal  quantity of Mad2 protein in each of lanes  6-10  of Figure  5.6 panel  C. 
Therefore,  the  accumulation  of Mad2-associated  wild-type  LT  seen  in  this 
figure seems most likely related to the level of spindle damage in the cells. In 
contrast,  no  such  accumulation  of  Bubl-associated  LT  was  observed  in 
response to spindle damage,  as shown by the  lOOkDa wild-type LT bands of 
equal  intensity  in  lanes  6-10  of Figure  5.6  panel  B.  Mad2  also  appears  to 
associate with dl89-97 LT (see Figure 5.6C, LT blot, lanes  11-15), but only at 
high levels  of spindle  damage,  (see lane  15).  Very faint  lOOkDa dl89-97 LT 
bands  are  seen  to  co-immunoprecipitate  with  Mad2  at  nocodazole 
concentrations from 0-50ng/ml (lanes 11-14), but these bands are much fainter 
than the intense band seen in lane 15.
These  co-immunoprecipitation  experiments  revealed  some  very 
unexpected results,  especially the Mad2 association with Bubl  and LT in the 
U20S(wild-type  LT)  and  U20S(dl89-97  LT)  cells.  Attempts  were  made  to 
verify  that  the  Mad2Ll  antibody  was  specifically  immunoprecipitating  the 
Mad2 protein, but this was very difficult to prove. A Mad2 western blot of the 
Mad2  immunoprecipitations  was  not  informative,  because  the  24kDa  Mad2 
protein migrates at the same molecular weight as the IgG light chain (data not 
shown). The only other antibody available to us that could verify specificity of 
the  Mad2Ll  antibody was  the p55Cdc  antibody used  earlier in this  chapter. 
Mad2  is  known  to  associate  with  Cdc20  (the  human  homolog  of Cdc20  is 
p55Cdc)  (Fang  et a l,  1998;  Sudakin  et al.,  2001;  Wassmann  and  Benezra, 
1998),  and therefore it was thought that detection of co-immunoprecipitation 
of  p55Cdc  with  Mad2  would  provide  further  evidence  in  support  of  the 
efficiency of the Mad2 immunoprecipitations for bringing down the real Mad2 
protein.  However,  western  blotting  of  the  Mad2  immunoprecipitation  for 
p55Cdc  levels  also  failed to  provide  informative  results,  because  the  55kDa 
protein co-migrates with IgG heavy chain and was not easily distinguishable
251on the autorad (data not shown). However, the Mad2Ll  antibody was able to 
detect  the  24kDa  Mad2  protein  clearly  in  a western blot,  demonstrating the 
same relative Mad2 levels in the different cell lines in response to nocodazole 
as  seen  in  Figure  5.3  (data  not  shown),  suggesting  that  the  co- 
immunoprecipitation results seen in Figure 5.6 panel C are real.
Further  investigation  of  the  results  seen  in  Figure  5.6  would  be 
necessary  to  draw  any  firm  conclusions  about  what  is  happening  in  the 
different  cell  lines.  The  co-immunoprecipitation  shown  in lane  15  of Figure
5.6 panel C has been repeated and yielded identical results, but unfortunately 
when more lysate was made for all samples and the experiments in Figure 5.6 
were repeated in full, the interesting results could not be reproduced. However 
the results shown in Figure 5.6 were very convincing, and given more time it 
would be nice to investigate them further to determine for certain if they can 
be reproduced.
If the  results  are  reproducible,  the  experiments  shown  in  Figure  5.6 
reveal three important and novel findings:  Mad2  interaction with Bubl  (only 
in  LT-expressing  cells,  and  only  with  high  spindle  damage),  interaction  of 
Mad2  with  wild-type  LT  (increasing  with  increased  spindle  damage),  and 
interaction  of Mad2  with  dl89-97  LT  (only  in  the  presence  of high  spindle 
damage).
5.3.1.6  Time  lapse  microscopy  of REFs  reveals  that  LT-Bubl  interaction
affects the cellular response to spindle damage
The  importance  of  LT-Bubl  interaction  for  the  spindle  checkpoint 
defect observed in cells expressing wild-type LT was also examined via time 
lapse microscopy, in collaboration with Dr Alan Entwistle (LICR-UCL Light 
Microscopy  Facility).  REF(wild-type  LT)  or  REF(dl89-97  LT)  cells,  as 
described in  Chapter 3, were treated with several  different concentrations of 
nocodazole and their real time response to each concentration was monitored 
overnight  via  time  lapse  microscopy.  At nocodazole  concentrations  greater 
than  15ng/ml no difference was observed between the behaviour of the wild-
252type  and  dl98-97  LT-expressing  cells,  with  both  cell  lines  responding  by 
arresting  in  mitosis,  observed  as  rounded  up  cells.  At  nocodazole 
concentrations  lower  than  15ng/ml,  the  drug  did  not  appear  to  elicit  a 
noticeable  increase  in  numbers  of mitotic,  rounded  cells  (mitotic  index)  in 
either cell line (data not shown).
However,  when  the  cell  lines  were  treated with  15ng/ml  nocodazole, 
differences were observed in the behaviour of the wild-type versus the dl89-97 
(non-Bubl-binding)  LT-expressing  cells.  Nocodazole  was  added  at  a  final 
concentration  of  15ng/ml  to  one  flask  of each  cell  type.  After incubation  at 
37°C  for  30  minutes  they  were  then  placed  on  an  inverted  time  lapse 
microscope,  and  a  phase-contrast  image  of one  field  was  captured  for  each 
flask every two minutes, using a cooled CCD  camera. A total of 450 images 
were  collected  from  each  cell  line.  These  images  have  been  collated  into 
movies,  which  can  be  viewed  from  the  supplemental  CD  attached  to  this 
thesis.  Selected  images  from  the  movies  are  also  displayed  in  Figure  5.7 
(REF(wild-type LT)) and Figure 5.8 (REF(dl89-97 LT)).
Figure 5.7 shows the response of REF(wild-type LT) cells to treatment 
with  15ng/ml nocodazole.  Several of the cells in the field of view have been 
induced to arrest in mitosis, as seen by the bright, rounded up cells that begin 
to accumulate in the population after ~3 hours of nocodazole treatment. Three 
different  cells  that  have  rounded  up  are  indicated  by  arrowheads 
(distinguished  by  different  colours,  blue,  green  and  red),  to  aid  in  the 
observation  of behaviour of the  cells in response to the  drug.  Each indicated 
cell is seen to round up at a slightly different time during the 15 hours shown, 
but  each  is  seen  to  periodically  change  shape  from  a  perfectly  rounded 
structure to  form  elongated,  dumb  bell-like  structures.  The  cell  indicated by 
the blue  arrowhead stretches  into the  dumb bell  shape,  and then following 5 
hours  of  arrest  (a  normal  mitosis  is  completed  in  less  than  an  hour  in 
vertebrate  cells,  (Rieder  et  a l,  1994))  appears  to  adapt  to  the  spindle 
checkpoint  by  re-adhering  to  the  flask  without  going  through  cytokinesis, 
presumably now in a tetraploid state.
253Figure  5.7:  Time  lapse  analysis  of  REF(wild-type  LT)  cells  in
response to 15ng/ml nocodazole.
450 phase-contrast images (one every 2 minutes), a selection of which 
are shown here, were captured to create a time lapse movie of REF(wild- 
type LT) cells treated with 15ng/ml nocodazole (see Supplemental CD). 
Three cells (indicated by arrowheads) demonstrate the general response 
to  the  drug.  Arrested  cells  form  dumb  bell-like  shapes  in  an  apparent 
attempt  to  segregate  their  chromosomes,  even  in  the  presence  of  a 
nocodazole-induced arrest. (Scale bar represents 100pm).
254Figure 5.7: Time lapse analysis of REF(wild-type LT) 
cells in response to 15ng/ml nocodazole.Figure 5.8: Time lapse analysis of REF(dl89-97 LT) cells in response
to 15ng/ml nocodazole.
450 phase-contrast images (one every 2 minutes), a selection of which are 
shown here, were captured to create a time lapse movie of REF(dl89-97 
LT) cells treated with 15ng/ml nocodazole (see Supplemental CD). Three 
cells  (indicated by arrowheads)  demonstrate the general response to the 
drug. Arrested cells remain in a stable, rounded conformation, indicative 
of  a  stable,  nocodazole-induced  spindle  checkpoint  arrest.  (Scale  bar 
represents 100pm)
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Figure 5.8:  Time  lapse  analysis  of REF(dl89-97  LT) 
cells in response to 15ng/ml nocodazole.The other two indicated cells appear to stretch back and forth, but during the 
time of the movie do not adapt to the spindle checkpoint (i.e.  are not seen to 
re-adhere to the  flask).  The overall view of the movie  for the REF(wild-type 
LT)  cells treated with  15ng/ml nocodazole is of cells rounding up,  stretching 
back and forth in an apparent attempt to segregate the chromosomes, but then 
adapting  to  the  spindle  checkpoint,  and  re-adhering  to  the  flask  without 
undergoing cytokinesis.
In contrast,  the  REF(dl89-97  LT) cells in Figure  5.8  appear to behave 
differently in response to the  same dose of nocodazole (15ng/ml).  As  for the 
wild-type  LT-expressing  cells  in  Figure  5.7,  the  rounded-up  dl89-97  LT- 
expressing cells  arrested at the spindle checkpoint begin to accumulate in the 
population  after  ~3  hours  of  nocodazole  treatment.  Three  representative 
rounded-up cells are indicated by different coloured arrowheads (yellow, pink 
and  turquoise).  The  cell  indicated  by  the  yellow  arrowhead  remains  in  a 
perfectly rounded shape for 8 hours, at which point it appears to adapt to the 
spindle  checkpoint,  and  re-adheres  to  the  flask  without  undergoing 
cytokinesis.  The  cell  indicated  by  the  pink  arrowhead  behaves  in  a  similar 
manner.  The  turquoise  arrowhead  points  to  a  cell  that  arrests  much  later 
during  the  time  lapse  analysis  (after ~8  hours  of nocodazole  treatment),  but 
again remains in a very rounded shape, arresting at the spindle checkpoint for 
at  least  7  hours.  In  contrast  to  the  wild-type  LT-expressing  cells  shown  in 
Figure  5.7,  the  dl89-97  LT-expressing  cells  in  Figure  5.8  do  not  appear  to 
attempt  to  segregate  their  DNA  at  all,  remaining  in  a  perfectly  rounded, 
arrested state, and not contorting into dumb bell-like shapes.
These  time  lapse  experiments  suggest  that  cells  expressing  wild-type 
LT make an attempt at segregating their chromosomes even in the presence of 
a nocodazole-induced spindle checkpoint arrest. This observation appeared to 
be dependent on interaction of LT with the checkpoint protein Bubl.
2585.3.2  Karyotype  analysis  of  tumourigenic  and  non-tumourigenic  LT-
expressing cells
A potential end result of a disturbance in spindle checkpoint activation 
caused  by  LT  could  be  chromosomal  instability,  giving  rise  to  aneuploidy. 
One  consequence  of aneuploidy  could be  the  activation  of an  oncogene  by 
amplification,  or loss of a tumour suppressor gene, leading to transformation. 
To examine the possibility that wild-type LT is able to induce aneuploidy to a 
greater extent than non-Bub 1-binding (dl89-97) LT, it was first decided to test 
whether  karyotype  differences  could  be  detected  between  LT-immortalised 
REFs that are tumourigenic, and those that are not when injected into rodents. 
As  shown  in  Chapter  3,  wild-type  LT  is  able  to  both  immortalise  and 
transform rat cells, whereas dl89-97 LT is defective for transformation.  Since 
a  wild-type  LT-immortalised  rat  cell  line  which  is  capable  of  inducing 
tumours  in  irradiated  nude  mice  is  a  very  good  model  for  oncogenic 
transformation,  this  cell  line  (RSV4062),  a  cell  line  derived  from  a tumour 
induced by  RSV4062  (NRSV4062),  and two  wild-type  LT-immortalised rat 
lines not capable of inducing tumours in mice (RSV4068 and RSV40611) (Jat 
and  Sharp,  1986)  were  tested  initially.  The  was  done  to  investigate  the 
likelihood  of  being  able  to  detect  karyotype  differences  between  cells 
expressing  wild-type  LT  (able  to  transform)  and  dl89-97  LT  (not  able  to 
transform) later on.
Metaphase spreads were prepared from each cell line, and stained with 
Propidium  iodide  (PI).  Several  individual  metaphase  spread  images  were 
captured via confocal microscopy to determine the number of chromosomes. 
The  intention  was  that  if a  significant  difference  could be  seen between  the 
tumourigenic  and  non-tumourigenic  lines,  this  would  make  a  large  study  of 
metaphase spreads from wild-type and dl89-97 LT cell lines worthwhile.
Of the images of single cell, metaphase spreads captured, -40 for each 
cell  line  were  chosen  for  chromosome  counting  (images  not  shown).  All 
images chosen had clearly separated chromosomes, but care was taken not to
259choose  spreads  where  the  scatter  of  chromosomes  was  so  great  to  allow 
potential  “loss”  of a  chromosome  to  another  part  of the  slide,  so  that  the 
karyotype  of the  cell  lines  could be investigated with confidence.  Figure  5.9 
shows  histograms  for  the  chromosome  counts  in  each  image,  for  each  cell 
line.  A  diploid rat  cell  has  a chromosomal  count of 42, but none  of the  cell 
lines  shown  in  Figure  5.9  appear to have  a  stable karyotype  of 42,  with the 
histograms  for all  4  cell  lines  showing approximately bell-shaped curves  for 
the  chromosome  counts  from  ~40  metaphase  spreads.  The  chromosome 
counts  for the  RSV4068  metaphase  spreads  appear to be close to the diploid 
number  of  42,  while  the  counts  for  RSV40611  are  centred  at  ~43 
chromosomes. While the overall karyotype of these two cell lines is not stable, 
with  cells  having  different  apparent  degrees  of  aneuploidy,  they  are 
nevertheless very close to diploid. These two cell lines were not able to induce 
tumours  when  injected  into  nude  mice  (Jat  and  Sharp,  1986).  The 
chromosome number of RSV4062 and NRSV4062 cells appears to be centred 
around 45-46 chromosomes per cell, further away from the diploid number of 
42 than that seen for RSV4068 and RSV40611   in Figure 5.9. This could be a 
significant  finding,  because  it  was  the  RSV4062  cell  line  that  was 
tumourigenic  when  injected  into  nude  mice,  and  the  NRSV4062  line  was 
derived from one of the resulting tumours.
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Figure 5.9: Karyotype analysis of REFs immortalised with SV40 large T antigen.
Non-tumourigenic (RSV4068 and RSV40611) and tumourigenic (RSV4062, and NRSV4062, a cell line derived from RSV4062) rat cell 
lines were karyotyped via metaphase spread. Chromosome numbers are plotted against numbers of cells with that chromosome number. 
The diploid number for rat is 42, as indicated on the graphs.5.3.3  Interaction with Bubl does not affect the ability of LT to de-regulate
the p53-dependent Gl/S tetraploidy checkpoint
As  seen in the experiments already detailed in this chapter, when cells 
are  treated  with  microtubule  inhibitors  such  as  nocodazole,  the  spindle 
checkpoint is activated, leading to a mitotic arrest prior to anaphase. However, 
upon prolonged treatment  cells  are  able to  adapt and exit mitosis  aberrantly, 
resulting in the occurrence of tetraploid cells in Gl. These cells are prevented 
from  proliferating  further  by  activation  of  a  postmitotic,  p53-dependent 
checkpoint  in  Gl,  known  as  the  “tetraploidy  checkpoint”  (reviewed  in 
(Andreassen et al.,  2003)).  If a cell proceeds past a tetraploid state,  genomic 
instability is inevitable because tetraploidisation caused by spindle checkpoint 
adaptation results  in  an alteration of centrosome number (Borel et al., 2002). 
An  increased  number  of  centrosomes  will  randomly  alter  the  number  of 
spindle poles in the next mitosis, with more than two spindle poles resulting in 
random chromosome distribution to more than two daughter cells.  Therefore, 
the  tetraploidy  checkpoint  acts  as  a  “fail-safe”  mechanism  that  elicits  a 
durable, cell cycle arrest if the spindle checkpoint has failed to ensure accurate 
chromosome  segregation.  It  has  been  suggested  that  this  p53-dependent 
checkpoint  may  also  be  able  to  impose  Gl  arrest  in  cells  that  become 
aneuploid via mitotic errors (Margolis et al., 2003), although this has yet to be 
proven.
The tetraploid arrest in  Gl  is  dependent  on the presence  of functional 
p53 and p21W A F1  (Andreassen et al, 2001a). It has previously been shown that 
SV40  LT-expressing  cells  are  not  able  to  arrest  at  the  p53-dependent,  Gl 
tetraploidy  checkpoint  in  response  to  cleavage  failure  induced  by  the  drug 
dihydrocytochalasin  B  (DCB).  Instead,  these  cells progress  to higher ploidy, 
presumably  due  to  inhibition  of  p53  by  LT  (Andreassen  et  al.,  2001b). 
Following release  from DCB-induced arrest, LT-expressing cells were shown 
to proceed through the cell cycle and become highly aneuploid.
262Bypass of the spindle checkpoint in the presence of nocodazole should 
be  accompanied  by  endoreduplication  (accumulation  of  cells  with  DNA 
content  greater  than  4N),  indicative  of failure  to  maintain  mitotic  arrest  in 
response to spindle damage, and cell cycle progression (Taylor and McKeon, 
1997). Data have already been published that show that U20S cells expressing 
wild-type LT undergo enhanced endoreduplication in response to nocodazole 
treatment,  whereas  cells  expressing  non-Bubl-binding  (dl89-97)  LT,  or 
untransfected cells, do not (Cotsiki et al., 2004). It was therefore necessary to 
test that the  dl89-97 LT mutant is  still  able to functionally abrogate the p53- 
dependent  tetraploidy  checkpoint  pathway,  otherwise  this  could  provide  an 
alternate explanation for its failure to induce endoreduplication in response to 
nocodazole. To rule out this possibility, untransfected (control) NIH 3T3 cells, 
and NIH 3T3 cells expressing wild-type LT or dl89-97 LT were treated for 24 
hours  with  12pM  of  dihydrocytochalasin  B  (DCB),  an  inhibitor  of  actin 
assembly that is required for cytokinesis (Aubin et al.,  1981; Martineau et al., 
1995),  triggering  exclusively  the  p53-dependent  tetraploidy  checkpoint,  and 
not the spindle checkpoint. Following the 24 hour DCB treatment, cells were 
released from the  drug into  fresh medium.  Samples  from each cell  line were 
collected for PI FACS analysis at the time when the DCB was added (no drug, 
zero  time  control),  following  the  24  hour DCB  treatment,  and  following  24 
hour,  48  hour and  5  day release  from the  drug.  PI  FACS  cell  cycle  analysis 
was then carried out at the FACS laboratory, Cancer Research UK (Lincoln’s 
Inn  Fields,  London),  in  collaboration  with  Dr  Derek  Davies,  as  shown  in 
Figure 5.10.
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Figure 5.10: Deletion of residues 89-97 of LT does not affect its ability 
to de-regulate the Gl/S tetraploidy checkpoint.
Control (untransfected) NIH 3T3 cells, NIH 3T3 cells expressing wild-type 
LT  or dl89-97  (non-Bubl-binding)  LT were treated with the  cytokinesis 
inhibitor  dihydrocytochalasin  B  (DCB)  to  activate  the  p53-dependent, 
Gl/S  tetraploidy checkpoint.  Cells were analysed via PI FACS  for DNA 
content  at  the  time  of drug  addition  (A),  following  24  hours  of DCB 
treatment  (B),  and  following  24  hour  (C),  48  hour  (D),  and  5  day  (E) 
release from the drug. Profiles are gated to show percentage of cells with 
different DNA contents: Ml = 2N (Gl phase) cells, M2 = 2N-4N (S phase) 
cells, M3  = 4N (G2/M phase,  or tetraploid) cells, M4 = >4N (polyploid) 
cells.
Untransfected NIH  3T3  cells respond to DCB by arresting cells with 4N 
DNA content, at the tetraploidy checkpoint, whereas both NIH 3T3(wild- 
type  LT)  and  NIH  3T3(dl89-97  LT)  cells  are  defective  for  the  p53- 
dependent,  tetraploidy  arrest,  with  many  cells  proceeding  to  >4N  DNA 
content  following  DCB  treatment,  and  progression  to  higher  aneuploidy 
following release from the drug.
265Panel  A  of Figure  5.10  shows  that  the  cell  cycle  profiles  (and DNA 
contents) of each cell line were very similar at the time of drug addition, with 
the majority of cells with 2N DNA content (gate Ml), and the remainder with 
between 2N  and 4N content (gates M2  and M3).  It is important to note that 
this suggests that the LT constructs have little or no apparent effect on normal 
cell cycle phase progression in NIH 3T3 cells. Figure 5.10 panel B shows the 
DNA  profiles  following  24  hour  treatment  with  12pM  DCB.  Control 
(untransfected) NIH 3T3 cells responded as expected to the drug, the majority 
of cells  (51.73%)  arresting with tetraploid, 4N DNA content.  However, both 
wild-type  LT  and  dl89-97  LT-expressing  cells  were  unable  to  maintain  a 
stable tetraploidy checkpoint arrest, with a peak of 8N DNA content cells of 
almost  the  same  size  as  the  4N  peak,  indicating  that  many  cells  are 
progressing to the next cell cycle even in the presence of the drug. Following a 
24 hour release from DCB treatment (see Figure 5.10, panel C), the 2N peak 
(Gl  phase cells, Ml  gate) has begun to recover in the untransfected NIH 3T3 
cells,  indicating  that  the  2N  cells  that  were  present  at  the  time  of  drug 
treatment have now come round at least a full cell cycle, and are proliferating 
well.  The  4N  (gate  M3)  peak remains  high  in these untransfected NIH  3T3 
cells following 24 hours (panel C), 48 hours (panel D) and even 5 days (panel 
E)  of release  from DCB,  indicative  of no recovery of the 4N cells that were 
arrested by the tetraploidy checkpoint. These cells remain indefinitely arrested 
due to the tetraploidy checkpoint,  and thus do not contribute to the recovery 
population  (Andreassen  et a l,  2001b).  By  the  5  day  release  (panel  E),  the 
untransfected NIH 3T3 cells have almost recovered to a normal, (as untreated) 
cell  cycle  profile,  apart  form  the  slightly  high  4N  population,  due  to 
representation  of the  permanently  arrested  tetraploid  cells.  In  contrast,  the 
NIH 3T3(wild-type LT) and NIH 3T3(dl89-97 LT) cells appear to never fully 
recover from the DCB treatment, accumulating more and more aneuploidy, as 
can  be  seen  by  the  lack  of clear 2N  and 4N peaks  in panels  C-E  of Figure 
5.10,  and  the  accumulation  of many  cells  with  >4N  content  (gate  M4),  in 
comparison  to  the  proportion  of these  cells  seen  for  the  untransfected NIH
2663T3 line. Also, the profiles of the NIH 3T3(wild-type LT) and NIH 3T3(dl89- 
97  LT)  cells  are  very  similar.  In  an  independent repeat  of this  experiment, 
results identical to those in Figure 5.10 were observed.
This experiment has shown that the ability of dl89-97 LT to  abrogate 
the p53-dependent tetraploidy checkpoint is not diminished in comparison to 
wild-type  LT,  and  thus  the  differences  observed  in  endoreduplication  in 
response to nocodazole between cells expressing the different LT proteins is 
due  to  a  spindle  checkpoint  defect,  and  not  merely  due  to  failure  of the 
tetraploidy  checkpoint  following  spindle  checkpoint  arrest.  This  experiment 
was carried out in parallel by Tom Roberts’  laboratory in U20S cells, giving 
results  that  are  in  agreement  with  the  NIH  3T3  experiment  (personal 
communication).
5.4  SUMMARY & DISCUSSION
An  important  aim  of  the  project  was  to  demonstrate  a  spindle 
checkpoint  defect  in  cells  expressing  wild-type  LT,  and  to  show  that 
interaction  of LT  with  Bubl  is  crucial  for  this  compromise  of checkpoint 
function.  The results  described in this  chapter clearly demonstrate that LT is 
compromising  spindle checkpoint function via its interaction with Bubl, and 
begin to  examine  the  mechanism by which this  spindle  checkpoint defect is 
achieved.
Many attempts were made to demonstrate the spindle checkpoint defect 
caused  by  LT  interaction  with  Bubl  in  NIH  3T3  cells,  using  both  FACS 
analysis and western blotting. Unfortunately no such defect could be detected 
in  this  cell  type  with the methods  used.  Lessons  learnt during the  course  of 
these experiments have suggested that the spindle checkpoint in NIH 3T3 cells 
may  not  be  as  robust  as  the  checkpoint  of U20S  cells,  perhaps  preventing 
detection of a spindle checkpoint defect in the NIH 3T3(wild-type LT) cells. It 
is  possible  that  inability to  detect  a  difference  in  the proportion  of 4N  cells 
between  the  wild-type  LT  versus  dl89-97  LT-expressing  (or  untransfected)
267cells treated with nocodazole via FACS could be due to cytokinesis failure in 
nocodazole treated cells. It has been suggested that a properly formed spindle 
is required for cytokinesis to occur (Maddox and Oegema, 2003).  This could 
suggest  that  the  4N  population  observed  by  FACS  following  nocodazole 
treatment of wild-type LT-expressing cells could contain some tetraploid cells 
which have  escaped a  spindle  checkpoint arrest (and therefore have lowered 
securin levels), but have not segregated their chromosomes into two daughter 
cells.  Using  FACS  analysis,  these cells would not have been distinguishable 
from 4N cells arrested at the spindle checkpoint.
However,  with  adjustment  of  nocodazole  treatment  times  in  U20S 
cells, it was possible to demonstrate a spindle checkpoint defect caused by LT 
interaction  with  Bubl  in  U20S  cells  via  western  blotting,  using  both 
synchronised cells and asynchronous cultures.
Treatment  of asynchronous  U20S  cells  (untransfected,  or  expressing 
either  wild-type  or  dl89-97  LT)  with  0-400ng/ml  nocodazole  for  15  hours 
followed by western blotting of the resulting lysates for securin, Cyclin B (and 
Mad2)  levels  clearly  demonstrated that  LT  compromises  spindle  checkpoint 
function  in  these  cells,  and  that  interaction  with  Bubl  is  required  for  this 
function of LT (see Figure 5.3). These proteins were observed to accumulate 
in  lysates  of U20S  and  U20S(dl89-97  LT)  cells  in  response  to  increasing 
nocodazole  treatment,  indicative  of  spindle  checkpoint  arrest  prior  to 
anaphase,  and  therefore  no  proteolytic  destruction  of securin  and  Cyclin  B. 
Mad2  levels have previously been shown to be cell cycle regulated in human 
cells,  peaking  at  G2/M  (Hernando  et  al.,  2004),  consistent  with  the  Mad2 
levels  seen  in  Figure  5.3.  Lack  of accumulation  of securin,  Cyclin  B  and 
Mad2  in  response  to  increasing nocodazole  in the  U20S(wild-type LT)  cells 
indicates that they are not able to  arrest at the  spindle checkpoint in mitosis, 
with many cells instead progressing further through the cell cycle even in the 
presence  of a  damaged  mitotic  spindle.  Interestingly,  Hernando  et  al.  also 
report  that  when  the  pRB  pathway  is  inactivated,  high  Mad2  levels  are 
observed throughout the  cell  cycle.  However,  contradictory to this,  low (but
268fairly  constant)  levels  of Mad2  were  observed  throughout  the  cell  cycle  in 
U20S(wild-type  LT)  cells in the experiments  described in this  chapter,  even 
though  pRB  is  inactivated  by  wild-type  LT  (Hernando  et  al.,  2004). 
Comparison  of the  securin  and  Mad2  protein  levels  (among  others)  in  the 
soluble  and  insoluble  lysis  fractions  in  Figure  5.5  confirmed  that  the 
checkpoint  defect  observed  in  U20S(wild-type  LT)  cells  when  challenged 
with  nocodazole  was  real,  and  not  an  artefact  of  a  change  in  subcellular 
localisation  of the proteins  in this cell line.  Although the  spindle  checkpoint 
defect induced by LT via its interaction with Bubl has already been published 
(Cotsiki  et al.,  2004),  demonstration of a different response of the U20S cell 
lines  to  increasing  nocodazole via western blotting has  allowed examination 
of levels  of checkpoint  proteins  and  protein  complexes  in  these  cell  lines 
under  the  same  conditions,  to  aid  in  understanding  the  mechanism  of 
checkpoint inhibition by LT.
Western  blotting  of  lysates  from  U20S,  U20S(wild-type  LT)  and 
U20S(dl89-97) following  15 hour treatment with 0-100ng/ml nocodazole was 
used to  investigate  the protein levels  of Bubl,  LT,  Bub3  and Cdc20p55G dc  in 
the different cell lines in response to spindle checkpoint activation (see Figure
5.4).  Other  checkpoint  proteins  were  not  investigated  due  to  lack  of 
availability of suitable antibodies for western blotting.
Bubl  appeared to accumulate with increasing nocodazole concentration 
in all three cell lines, as would be expected due to the cell cycle regulation of 
this protein, peaking at G2/M (Davenport et al.,  1999; Taylor et a l, 2001). In 
accordance  with  the  securin,  Cyclin  B  and  Mad2  levels  in  response  to 
nocodazole  treatment,  Bubl  did  not  accumulate  as  much  in  the  U20S(wild- 
type LT)  cells as in the untransfected U20S cells.  Multiple Bubl  bands were 
present in the western blot at all nocodazole concentrations, possibly the result 
of phosphorylation.  However,  Bubl  is thought to  only be phosphorylated in 
response  to  checkpoint  activation,  and not in  a normal  mitosis  (Chen,  2004; 
Taylor  et  al,  2001),  suggesting  that  multiple  Bubl  bands  should  not  be 
observed in  the untreated lysates.  Further investigation would be required to
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these experiments, although they do not appear to be related to the presence or 
absence  of LT  in the  cells, because they are  observed in all three  cell  lines. 
Therefore,  level  of Bubl  expression  and  Bubl  cell  cycle  regulation  do  not 
appear  to  be  directly  affected  by  LT.  However  it  is  possible  that  LT  is 
affecting the modification of Bubl, perhaps  altering the number of forms  of 
Bubl  present  in  the  cell,  under normal  conditions  or  with  spindle  damage. 
This would not be surprising since members of Tom Roberts’  laboratory have 
established  that  the  auto-kinase  activity  of  Bubl  is  upregulated  by  the 
presence of LT (personal communication).
Levels of expression of wild-type and dl89-97 LT do not appear to be 
cell  cycle  regulated,  staying  at  the  same  level  in  response  to  increasing 
nocodazole  concentration.  An  observation  made  throughout this  project has 
been that wild-type LT is consistently expressed at a higher level than dl89-97 
LT in all cell lines, both in single cell clones and mixed populations of cells. 
Perhaps interaction of LT with Bubl could be important for the stability of the 
LT  protein  in  some  way,  or  alternatively  the  dl89-97  LT  protein  could  be 
lethal to the cells if expressed at a high level.
Bub3 is also not cell cycle regulated in either yeast or mammalian cells 
(Brady and Hardwick, 2000;  Fraschini et al., 2001;  Martinez-Exposito et al., 
1999), and consistent with this, the level of Bub3 expression remains constant 
in  all  three  cell  lines  in  Figure  5.4,  at  all  nocodazole  concentrations.  Bub3 
expression is therefore not affected by the presence of LT.
Cdc20p55C dc  is  known  to  accumulate  in  M  phase  in  normal  cells 
(Fraschini et al., 2001; Weinstein,  1997), and this is also shown to be the case 
in  U20S  cells  treated  with  increasing  doses  of nocodazole  in  Figure  5.4.  In 
agreement  with  the  lack  of accumulation  of securin,  Cyclin  B,  Mad2  and 
Bubl  in  response  to  spindle  damage,  p55Cdc  levels  do  not  accumulate  in 
U20S(wild-type LT) cells, indicative of a spindle checkpoint defect. However, 
it  was  noted  that  p55Cdc  levels  are  high  in  U20S(dl89-97  LT)  cells  at  all 
nocodazole  concentrations,  even  when  no  nocodazole  was  added.  This  is
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differently in the U20S(dl89-97 LT) cell line than in the untransfected U20S 
cells.  Further investigation to confirm this is required, although it is possible 
that  LT  could  modulate  spindle  checkpoint  function  independently  of  its 
interaction with Bubl. However, the non-Bubl-binding (dl89-97) LT has not 
shown  any checkpoint defect to date,  with a spindle  checkpoint as robust as 
that in cells that do not express LT.
An investigation of the protein complexes present under conditions of 
increasing spindle damage was carried out in the U20S, U20S(wild-type LT) 
and U20S(dl89-97 LT)  cells (see Figure 5.6). Bubl  immunoprecipitates from 
the lysates prepared from each cell type with increasing nocodazole treatment 
showed accumulation  of the Bubl  protein with spindle checkpoint activation 
in all three cell lines (Figure 5.6B), as also seen in the straight western blot for 
these  lysates.  However,  when the Bubl  immunoprecipitates were blotted for 
LT,  the  amount  of wild-type  LT  co-immunprecipitating  with  Bubl  did  not 
increase  with  nocodazole  dose  as  might  have  been  expected,  perhaps 
indicating  that  not  all  of the  LT  in  the  cell  is  in  complex  with  Bubl.  This 
would not be surprising considering the very high level of expression of LT in 
the cells. Alternatively, it could equally be the case that not all of the Bubl  in 
the cell is in a conformation that can be recognised and bound by LT, resulting 
in a LT-free pool of Bubl  in the cell.
It has previously been shown that Bubl  does not associate with Mad2 
in normal mammalian cells (Skoufias et a l, 2001). However this did not rule 
out  the  possibility  that  Mad2  and  Bubl  could  be  associating  in  cells  that 
express  LT.  Figure  5.6C  revealed  some  very  interesting  and  novel 
interactions.  The first novel finding was that Bubl  was able to associate with 
Mad2, but surprisingly this interaction was only observed in cells expressing 
non-Bubl  binding LT,  and not in  untransfected U20S  cells,  even though the 
two  cell  lines  express  similar  levels  of  the  two  proteins  in  response  to 
nocodazole treatment,  and arrest in response to nocodazole in a similar way. 
The  observation  that  untransfected  U20S  cells  do  not  show  a  Bubl-Mad2
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agreement  with  previous  studies  in  the  literature.  The  clear  Mad2-Bubl 
interaction  observed  in  U20S(dl89-97  LT)  cells  was  only  seen  when  cells 
were  treated  with  the  relatively  high  nocodazole  dose  of  lOOng/ml,  a 
concentration which results in noticeable securin and Cyclin B accumulation, 
indicative of cell cycle arrest at the spindle checkpoint. Therefore the presence 
of LT in the U20S cell lines, albeit without the ability to interact with Bubl, is 
resulting  in  an  aberrant  spindle  checkpoint  complex,  the presence  of which 
does  not  appear  to  affect  the  ability  of the  cells  to  arrest  at  the  spindle 
checkpoint  in  response  to  spindle  damage.  An  extremely weak Mad2-Bubl 
interaction  may  be  present  in  the  U20S(wild-type  LT)  cells  treated  with 
lOOng/ml nocodazole also, although it is not clear if the reason for the reduced 
levels  of this  complex  observed in  comparison to  in the U20S(dl89-97  LT) 
cells  is  simply  due  to  the  lower  levels  of Mad2  in  this  cell  line  under this 
condition  (see  Figure  5.6A  Mad2  blot).  It  is  therefore possible  that LT  can 
induce the  aberrant  formation of a Mad2-Bubl  complex in U20S  cells upon 
spindle damage, and that this ability is independent of the interaction between 
residues  89-97  of LT  and Bubl.  It remains  a possibility however that Mad2 
interaction with Bubl  in the U20S(dl89-97 LT) cells could be via LT, but via 
a different region of the LT protein,  for example via the p53-binding region, 
which may also be involved in Bubl binding (Personal communication: Dr O. 
Gjoerup,  Dana-Farber Cancer Institute,  Boston,  MA).  However, the aberrant 
Mad2-Bubl  interaction  observed  in  U20S(dl89-97  LT)  cells  treated  with 
nocodazole  cannot  be  explained  by  any  of the  current  models  for  spindle 
checkpoint  activation  because  these  cells  appeared to  have  a robust  spindle
checkpoint function.
Further  novel  findings  were  revealed  when  the  Mad2 
immunoprecipitations in Figure 5.6C were western blotted for LT. First of all, 
this  experiment  demonstrated  a  novel  interaction  between  Mad2  and  LT. 
Mad2  and  wild-type  LT  appeared  to  interact even  in the  absence  of spindle 
damage,  but  the  amount  of  Mad2-LT  complex  present  increased  with
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complex did not increase with increasing spindle damage in Figure 5.6B, the 
amount  of  co-immunoprecipitating  LT  staying  constant  even  when  Bubl 
levels  were  increased  by  increasing  the  nocodazole  dose.  In  addition,  the 
amount  of LT  co-immunoprecipitating  with  Mad2  appears  to  increase  with 
spindle  damage  to  a  much  greater  extent than  could be  expected  if it  were 
simply  due  to  increasing  Mad2,  because  Mad2  hardly  accumulates  with 
nocodazole  at  all  in  the  western  blot  of  this  cell  line  in  Figure  5.6A. 
Interaction of LT with Mad2 could provide a further explanation, in addition 
to  the presence  of the LT-Bubl  interaction, for why wild-type LT  is able to 
compromise  spindle  checkpoint  function.  However,  this  theory  cannot  hold 
because  the  dl89-97  LT,  which does not adversely affect spindle checkpoint 
function  in  U20S  cells,  was  also  able  to  interact  with  the  Mad2  protein, 
although  strong  co-immunoprecipitation  of dl89-97  LT  with  Mad2  is  only 
observed in  cells treated with  lOOng/ml nocodazole, with lower doses of the 
drug  resulting  in  virtually  no  Mad2-dl89-97  LT  complex  formation.  Many 
efforts  have  been  made  to  fit  these  observations  into  a  model  which  might 
explain the spindle checkpoint compromise observed in cells expressing wild- 
type  LT,  but not in cells  expressing non-Bubl  binding (dl89-97 LT), but no 
simple model can be drawn based on the current information. One attempt has 
been  made  to  repeat  these  results  without  success,  although  the  conditions 
were  changed  slightly in  an  attempt to  harvest more lysate  for use in  future 
experiments.  Further  investigations  using  the  original  conditions  would  be 
needed to confirm that the interactions observed are real. If the results can be 
repeated then they are very important and novel, and it could be the case that 
LT  induces  spindle  checkpoint proteins  to  complex in  an  aberrant way,  and 
this ability is not limited to the wild-type, Bubl-binding LT. However, the full 
concert of proteins and protein complexes (including other spindle checkpoint 
components  such  as  Madl  and  BubRl)  present  under  the  different  spindle 
damage conditions in the presence of wild-type and dl89-97 LT needs further 
investigation  to  dissect  the  mechanism  by  which  LT  exerts  its  spindle
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Mad2  in  the  cell,  as  the  amount  of LT  interacting  with  Mad2  appeared  to 
increase  with  nocodazole  concentration,  i.e.  under  conditions  of increasing 
spindle damage. Perhaps LT compromises the spindle checkpoint by reducing 
levels of functional Mad2, and thus preventing formation of active MCC. This 
compromise may not be fully dependent on Bubl  interaction with LT, which 
may  instead  act  to  bring  LT  into  proximity  with  Mad2.  These  possibilities 
could  be  addressed  in  the  future  by  co-immunoprecipitation  and 
immunofluorescence  studies  of  the  checkpoint  components  and  LT  under 
conditions of spindle damage. It would be important to determine if formation 
of  Mad2-containing  protein  complexes  such  as  the  MCC  is  altered  either 
temporally or spatially under these conditions in cells which express LT (wild- 
type  and  dl89-97  LT).  The  relevance  of the  Bubl-LT  interaction  for  the 
checkpoint compromise and the Mad2-LT interaction could be investigated by 
conducting  similar  experiments  in  cells  where  Bubl  levels  have  been 
significantly reduced via RNAi.
Time  lapse  movies  of REF(wild-type LT)  and REF(dl89-97 LT) cells 
treated with  15ng/ml nocodazole also revealed a different response to spindle 
checkpoint activation by the two cell lines (See Figures  5.7 and 5.8, and the 
supplemental  CD  that  accompanies  this  thesis).  REF(wild-type  LT)  cells 
formed dumb bell-like shapes (perhaps indicating an attempt at chromosome 
segregation), whereas REF(dl89-97 LT) cells remained in a perfectly rounded, 
arrested  conformation,  prior to  adaptation  to  the  spindle  checkpoint.  It  has 
been shown that when administered at micromolar concentrations, nocodazole 
rapidly  depolymerises  microtubules,  causing  cells  to  arrest  in  mitosis  (De 
Brabander  et  a l,  1976).  lpM  nocodazole  (FW  =  301.3)  is  equivalent  to 
~300ng/ml,  the  approximate amount of nocodazole treatment that resulted in 
observation  of  significant  differences  in  the  amount  of securin  in  the  cell 
population  (and  hence  spindle  checkpoint  arrest)  between  wild-type  LT  and 
dl89-97  LT-expressing  cells  (see  Figure  5.3).  However,  when treated with 
nanomolar  concentrations  of  nocodazole,  as  in  the  time  lapse  experiment
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arrested in mitosis by the drug, but without significant changes in microtubule 
polymer level  (Jordan et a l,  1992). A study of mitotic checkpoint control in 
HeLa  cells  has been published in which the  authors used  50nM nocodazole 
(equivalent  to  15ng/ml)  to  clearly  arrest  cells  at  the  spindle  checkpoint, 
suggesting  that  this  nocodazole  concentration  should  also  be  sufficient  to 
activate the spindle checkpoint in REFs (Wang et al., 2002). Low (nanomolar) 
concentrations of nocodazole have been shown to result in an overall decrease 
in  microtubule  turnover in  the  cells,  and it has  been  suggested that the  cell 
cycle  block  observed  is  due  to  microtubule  stabilisation  (Vasquez  et  al.,
1997).  Therefore,  it  seems  likely  that  the  formation  of dumb  bells  in  the 
REF(wild-type LT) cells treated with 15ng/ml nocodazole could be indicative 
of an attempt to override the spindle checkpoint arrest induced by the drug in 
these cells. The time lapse experiment was repeated twice with similar results, 
but  although  dumb-bells were  seen in the REF(wild-type LT)  cells, no  cells 
succeeded in completing cytokinesis in the presence of the drug.  It has been 
proposed  that  cytokinesis  requires  overlapping  microtubules  from  the  two 
spindle  poles  for  recruitment  of the  component(s)  necessary  for  cleavage, 
(Maddox and Oegema, 2003), suggesting that the REFs treated with  15ng/ml 
nocodazole failed to undergo cytokinesis due to absence of a properly formed 
anaphase  spindle,  even  when  the  spindle  checkpoint  is  compromised  (for 
example,  by  SV40  LT).  In  contrast, the  REF(dl89-97  LT)  cells  treated with 
15ng/ml nocodazole appeared to stably arrest at the spindle checkpoint, with 
no formation of dumb bells indicating that the cells make no obvious attempt 
to segregate their chromosomes. This might suggest that cells expressing non- 
Bubl-binding  (dl89-97)  LT  are  able  to  maintain  a  “more  stable”  arrest  in 
response  to  low  doses  of nocodazole,  in  accordance  with  their  seemingly 
uncompromised spindle checkpoint in response to high nocodazole doses (see 
Figure  5.3).  Importantly,  the  observation  that  the  REF(wild-type  LT)  cells 
attempt  chromosome  segregation  even  in  the  absence  of a properly  formed 
spindle  (due  to  nocodazole)  suggests  that  in  a  normal  mitosis  (without
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formed  a  bipolar  attachment  may  occur  in  these  cells,  and  be  followed by 
cytokinesis, resulting in aneuploidy. It would have been interesting to examine 
the  response  of  REFs  to  15ng/ml  nocodazole  in  the  absence  of  LT,  but 
unfortunately REFs senesce in the absence of an immortalising gene such as 
LT,  and  the  use  of  spontaneous  immortal  rat  cell  lines  would  have  the 
disadvantage of not knowing the identity of the immortalising agent. However 
it might be possible to examine the response of early passage primary REFs to 
nocodazole treatment via time lapse microscopy to determine if they have the 
same  response  to  nocodazole  as  the  REF(dl89-97  LT)  cells.  In  addition  it 
would be informative to repeat the time lapse analysis further and attempt to 
quantify  the  observed  behaviour  of  the  different  cell  lines  to  nocodazole 
treatment over time.
The chromosome count study of tumourigenic versus non-tumourigenic 
rat  cell  lines  indicated  that  while  the  non-tumourigenic  lines  were  near 
diploid,  the  counts  from  the  tumourigenic  cell  lines  were  slightly  further 
removed from a diploid phenotype (See Figure 5.9).  This might suggest that 
wild-type  LT  could  produce  “more  aneuploidy”  in  cells  than  the 
transformation-defective, dl89-97 LT mutant. However, all cell lines tested in 
Figure 5.9 showed some variability of karyotype. Human mammary epithelial 
cells  immortalised  in  the  laboratory  with  a  combination  of  hTERT  (the 
catalytic  sub-unit  of  telomerase)  and  either  Bubl-binding  or  non-Bubl- 
binding  (dl89-97)  LT  have  recently  been  karyotyped,  to  determine  if 
interaction  of LT  with Bubl  results in aneuploidy in the immortalised cells. 
As predicted, the cells immortalised with dl89-97 LT (and hTERT) were near­
diploid,  whereas  the cells immortalised with Bubl-binding LT (and hTERT) 
were noticeably aneuploid (Prof. P.S. Jat, personal communication). The same 
results  were  also  obtained  using  human  mammary  fibroblasts.  This  finding 
demonstrates  that  the  interaction  of  LT  with  Bubl  not  only  results  in  a 
compromise  of  spindle  checkpoint  function,  causing  a  failure  to  arrest  in
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aneuploidy, as expected.
Following prolonged treatment with nocodazole cells eventually adapt 
to  the  spindle  checkpoint  arrest,  exiting  mitosis  aberrantly  without  sister 
chromatid  segregation  and  cytokinesis,  resulting  in  a  tetraploid,  4N  DNA 
content.  The lack of securin and Cyclin B accumulation in wild-type LT but 
not  in  dl89-97  LT-expressing  or  untransfected  cells  following  15  hours  of 
nocodazole treatment (see Figure 5.3), taken to indicate a spindle checkpoint 
defect in the wild-type LT-expressing cells, was tested to confirm that it was 
not  simply  the  result  of a  difference  in  the  rate  of adaptation  of the  cells. 
However, at no time point leading up to 15 hours of nocodazole treatment was 
a high level of securin or Cyclin B accumulation observed in the wild-type LT 
cells,  suggesting  that  they  were  bypassing  the  spindle  checkpoint  and  not 
simply adapting to the nocodazole arrest faster than the untransfected or dl89- 
97 LT-expressing cells.
In normal  cells,  following  spindle checkpoint adaptation the resulting 
tetraploid  cells  are  prevented  from  proliferating  by  induction  of  the  p53- 
dependent tetraploidy checkpoint in  Gl,  a more permanent cell  cycle  arrest. 
SV40  large  T  antigen  inhibits  p53,  thus  disrupting  the  Gl  tetraploidy 
checkpoint  arrest,  leading  to  endoreduplication  and  genomic  instability.  (A 
very  recent  study  has  argued  that  mammalian  cells  do  not  possess  a 
‘Tetraploidy  checkpoint” because when low doses  of DCB  are used to block 
cleavage, binucleate cells are able to undergo DNA synthesis and proceed to 
mitosis (Uetake and Sluder, 2004). However it was confirmed that high doses 
of DCB  (similar to those used here) do cause binucleate cells to arrest in Gl, 
although  no  mechanism  was  proposed  for  why  this  occurs).  It  had  already 
been  shown that cells  expressing wild-type LT undergo endoreduplication in 
the  presence  of nocodazole,  indicative  of bypass  of the  spindle  checkpoint, 
whereas  cells  expressing  dl89-97  LT  did not  endoreduplicate  in response to 
nocodazole  (Cotsiki et al., 2004).  Therefore it was necessary to confirm that 
the  failure  of the  dl89-97  LT-expressing  cells to endoreduplicate was purely
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inability of dl89-97 LT to abrogate the Gl tetraploidy checkpoint. To test this 
hypothesis, untransfected NIH 3T3 cells, and NIH 3T3 cells expressing wild- 
type or dl89-97 LT were treated with the drug dihydrocytochalasin B (DCB) 
to  specifically  activate  the Gl  tetraploidy checkpoint.  As  expected,  dl89-97 
LT was just as defective for the p53-dependent Gl  tetraploidy checkpoint as 
wild-type  LT,  with  DCB  treatment  resulting  in  accumulation  of polyploid 
cells  (See  Figure  5.10).  This not only shows that the  89-97  region  of LT is 
crucial  for  the  spindle  checkpoint  defect  of cells  expressing  LT,  but  also 
shows  that  the  dl89-97  LT  mutant  is  still  capable  of  abrogating  p53 
checkpoint function.
2786. Summary and Final Discussion
Accurate transmission of genetic information is  absolutely critical  for 
both  cell  and organism survival.  This is regulated by intrinsic properties of 
the  cell  cycle, which ensure that appropriate events occur at the correct time 
and in the correct order.  A further level of control is provided by checkpoints 
that  prevent  cell  cycle  progression  in  the  presence  of any  errors  that  may 
threaten  the  fidelity  of cell  division.  Mitosis  is  considered  to  be  the  most 
dramatic  and  potentially  dangerous  event  in  the  cell  cycle  because  sister 
chromatids  are  irreversibly  segregated  to  daughter  cells.  Correct  assembly 
and  positioning  of the  mitotic  spindle  are  critical  for  accurate  chromosome 
segregation.  The  checkpoint  that  monitors  this  process  is  the  spindle 
checkpoint.  It  ensures  that  one  chromosome  of each pair  of chromatids  is 
segregated to each daughter cell, and is able to detect even a single unattached 
chromosome  and in response generate a "wait signal” until  all chromosomes 
are attached and aligned correctly.  Defects in the spindle checkpoint can lead 
to chromosomal instability (CIN) and cancer.
SV40  large  T  antigen  (LT)  is  a  viral  oncoprotein  known  to  induce 
chromosome  aberrations  leading  to  aneuploidy  in  its  cellular  host.  An 
interaction  between  LT  and  the  spindle  checkpoint  protein  Bubl  was 
identified  in  the  Jat  laboratory.  It  was  proposed  that  LT  might  be 
compromising the spindle checkpoint function of Bubl  via this interaction. If 
this  were  the  case,  it  seemed  reasonable  to  suggest  that  LT  overrides  the 
spindle  checkpoint  to  allow  accumulation  of mitotic  errors  in  its  host  cells, 
potentially leading to aneuploidy and a transformed phenotype. The aim of the 
research described in this thesis has been to attempt to answer these questions. 
Progress  has  been  made  in  elucidating  the  function  of LT-Bubl  interaction 
and some of the data presented in this thesis is now published (Cotsiki et a l, 
2004).
2796.1 SUMMARY OF RESULTS
The interaction site of Bubl on LT was initially mapped to residues 89- 
97  of  LT  using  co-immunoprecipitation  experiments  in  lysates  from  cells 
expressing different LT mutants. The site was then finer mapped using single 
amino  acid mutations to alanine.  The results  suggested that three tryptophan 
residues in the 89-97 region that are conserved between large T antigens from 
several  different  viruses  were  the  most  critical  for  Bubl  interaction.  The 
importance  of Bubl  interaction  for  the  immortalisation  and  transformation 
functions  of  LT  were  next  examined.  While  LT  was  able  to  efficiently 
immortalise  primary rat  cells  in the  absence  of Bubl  interaction,  the  Bubl- 
binding  residues  of  LT  were  shown  to  be  critical  for  the  transformation 
activities of the viral protein.
To  aid  subsequent  experiments,  three  highly  specific  monoclonal 
antibodies  were  generated  against the  mouse  Bubl  protein.  While  verifying 
the  specificity  of the  new  antibodies  to  the  Bubl  protein,  the  migration  of 
Bubl  on  SDS-PAGE  was  confirmed  to  be  at  ~150kDa,  higher  that  the 
predicted  molecular  weight  for  the  protein  of  ~120kDa.  The  mBubl 
monoclonal  antibodies  were  used  for immunofluorescence  studies  of mouse 
cells expressing wild-type LT. Bubl  localisation in these cells did not appear 
to  differ from that previously reported in normal mammalian cells under the 
conditions tested.
It  was  clearly  demonstrated  that  LT  compromises  the  ability  of the 
spindle  checkpoint to  arrest  cells  in response to  nocodazole-induced spindle 
damage. Wild-type LT prevented cell cycle arrest in nocodazole treated cells, 
as  observed  by  inappropriate  destruction  of  securin  in  the  absence  of  a 
properly  formed  spindle.  Time  lapse  experiments  also  suggested  that  wild- 
type  LT-expressing  cells  attempt  to  segregate  their  chromosomes 
inappropriately  even  in  the  presence  of  nocodazole.  This  checkpoint 
abrogation  by  LT  was  dependent  on  LT-Bubl  interaction,  as  shown  by 
evidence of robust spindle checkpoint function in dl89-97 LT-expressing cells.
280Initial  attempts  to  examine  the  mechanism  by  which  LT  is  affecting  the 
spindle checkpoint provided a hint that the Mad2 checkpoint protein may also 
be involved.
Tumourigenic and non-tumourigenic rat cells were karyotyped to help 
determine  if  the  transformation  (and  therefore  perhaps  the  Bubl-binding) 
functions  of LT  could  be  related  to  chromosomal  instability.  Initial  results 
suggested  that  this  might  be  the  case.  In  addition,  karyotyping  of primary 
human cells immortalised with hTERT and either wild-type or dl89-97 LT has 
also linked the LT-Bubl  interaction to aneuploidy. Furthermore, experimental 
evidence  suggests that LT may be inhibiting spindle checkpoint function via 
Bubl  to  produce  chromosome  aberrations  which  can  then  go  undetected  at 
later checkpoints that are independently abrogated by LT. In agreement with 
this, FACS analysis of cells treated with dihydrocytochalasin B (DCB) (a drug 
that  specifically  activates  the  tetraploidy  checkpoint)  showed  that  in  cells 
expressing  dl89-97  LT  the  p53-dependent  tetraploidy  checkpoint  is  de­
regulated to the same extent as in cells expressing wild-type LT.
6.2  FUTURE DIRECTIONS
It would be interesting to further investigate the nature of the LT-Bubl 
interaction.  The  importance  of  residues  89-97  of  LT  (and  especially  the 
conserved tryptophan residues in this region) has already been highlighted, but 
this  does  not rule  out the possibility that the interaction site  of Bubl  on LT 
may extend further. It has been suggested by Dr Ole Gjoerup that residues 98- 
102  of LT may also play a role in Bubl  binding  (personal  communication). 
These  residues  were  recently  implicated  in  binding  of  LT  with  Cul7,  a 
member of the cullin family involved in forming the scaffold for multi-subunit 
complexes  that  target proteins  for ubiquitination  (Ali  et al.,  2004).  Like  the 
Bubl-binding  region  of  LT,  the  Cul7-binding  region  was  shown  to  be 
important  for  the  transformation  functions  of  LT,  but  not  for  the 
immortalisation  activities.  However, while the Bubl  interaction site of LT is
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function  of LT.  Therefore  it  would be  important to  determine  if the  89-97 
region of LT is involved in both Cul7 and Bubl  binding. This would help to 
determine if dissociation of immortalisation and transformation activities seen 
in the  dl89-97  LT mutant involves  simply Bubl, or if it involves both Bubl 
and  Cul7  proteins.  The possibility also remains that LT-Bubl  interaction  is 
not direct, and could in fact involve the Cul7 protein. Bub3 could also act as a 
bridging  protein  for  the  LT-Bubl  interaction,  as  it  was  found  in  the  same 
complex (Cotsiki et al., 2004). However, it has been reported that a GLEBS- 
like  (GLE2p-Binding  Sequence) motif located at residues 249-264  of hBubl 
is  sufficient  for  Bub3  binding  (Wang et al.,  2001b).  It therefore  seems  less 
likely (although not impossible) that endogenous yeast Bub3 could have been 
acting as  a bridging protein for LT-Bubl  interaction, since only amino acids 
600-1085  of hBubl  were  encoded by  the  cDNA  that  was  identified  in  the 
original  yeast  two-hybrid  screen.  In  vitro  binding  assays  could  be  used  to 
confirm whether or not the LT-Bubl interaction is direct.
Closer mapping of the LT interaction site within residues 600-1085 of 
Bubl would also be useful. This information could provide clues to how LT is 
compromising  Bubl  functions.  It  is  known  that  Bubl  kinase  activity  is 
modulated by LT (personal communication, Dr Ole Gjoerup), and it would be 
interesting  to  find  out  if LT  directly  binds  to  the  Bubl  carboxy-terminal 
kinase  domain.  A  Bubl  mutant  defective  for  LT  interaction  could  be 
ectopically expressed  in  cells  in which levels  of the  endogenous  Bubl  have 
been  significantly reduced via immunodepletion or RNAi.  This would allow 
examination  of the  activities  of a non-LT-binding  Bubl  in both  the  spindle 
checkpoint  and  chromosome  segregation.  The  Bubl  kinase  activity  and 
downstream targets of the Bubl  kinase in cells expressing wild-type or dl89- 
97  LT  could  also  be  further  examined,  both  with  and  without  nocodazole 
treatment. It has recently been demonstrated that Bubl directly phosphorylates 
Cdc20  and  inhibits  APC/CC dc20  activity  in  a  catalytic  manner  (Tang  et  a l, 
2004).  Bubl-mediated  phosphorylation  of Cdc20  was  necessary  for proper
282checkpoint signalling, further highlighting the importance of investigating the 
kinase activity of Bubl in the presence of LT.
The mBubl  monoclonal  antibodies generated could be used for more 
in-depth immunofluorescence studies in cells expressing wild-type or dl89-97 
LT,  as well  as  in untransfected cells.  Co-localisation  of checkpoint proteins 
with the kinetochore  (and with  LT)  could be  compared  in both  cycling  and 
nocodazole-arrested cells. FRAP (fluorescence recovery after photobleaching) 
experiments  would  also  allow  analysis  of  the  dynamics  of  the  spindle 
checkpoint  proteins  at  kinetochores  in  these  cells.  hBubl  monoclonal 
antibodies  are  now  being  generated  in  the  laboratory,  and  may  provide  a 
further useful tool for these studies.
As a direct continuation of the work begun in this thesis, an important 
next  step  would  be  to  follow  up  investigation  of  checkpoint  proteins  and 
complexes  present  in  cells  expressing  wild-type  or  dl89-97  LT  under 
conditions of spindle damage. Co-immunoprecipitation experiments similar to 
those reported here would be used. This could later be followed by proteomic 
approaches  such  as  2-Dimensional  SDS-PAGE  and  mass  spectrometry  to 
positively identify proteins that are complexed or modified differently in the 
presence of wild-type versus dl89-97 LT.
A separation-of-function allele of Bubl  has recently been identified in 
fission  yeast,  demonstrating  that  the  spindle  checkpoint  role  of  Bubl  is 
separate from the chromosome segregation role of the protein (Vanoosthuyse 
et  a l,  2004).  An  amino-terminal  domain  of Bubl,  required  for targeting  of 
Bubl, Bub3  and Mad3  to kinetochores and spindle checkpoint function, was 
not  required  for  the  role  of Bubl  in  chromosome  congression,  which  was 
dependent  on  the  carboxy-terminal  region  of Bubl  that  includes  the  kinase 
domain.  LT  compromises  the  spindle  checkpoint  function  of  Bubl,  but 
observations  of lagging chromosomes  and other segregation defects  in wild- 
type  LT  (unpublished  observations:  Dr Ole  Gjoerup)  might  suggest that the 
other  functions  of Bubl  may  also  be  perturbed by  LT  interaction  with  the 
carboxy-terminal  region  of  the  protein.  Therefore  if  Bubl  kinetochore
283localisation  functions  remain  intact  in  LT-expressing  cells,  it  would  be 
interesting to determine how LT is achieving the observed spindle checkpoint 
perturbation.
One possible reason for why wild-type but not dl89-97 LT can induce 
cell transformation might be that LT induces genetic instability via interaction 
with  Bubl.  This  would  then  increase  the  likelihood  of acquiring  a  second 
event that can give rise to cell transformation. There is some evidence in the 
literature to link Bubl  inhibition to aneuploidy in cancer cells  (Cahill et al.,
1998), but it is still not clear if this is a causal relationship because others have 
reported  different  observations.  A  robust  spindle  checkpoint  has  been 
observed  in  aneuploid  cells  (Tighe  et  al.,  2001),  and  two  colorectal  cancer 
lines  with  mutations  in  Bubl  were  shown  to  be  tetraploid,  a  less  severe 
karyotype  defect  than  that normally  observed  with  chromosomal  instability 
(Grigorova  et  al.,  2004).  However,  preliminary  studies  have  shown  that 
primary human  cells  immortalised  with  hTERT  and  wild-type  LT  have  an 
aneuploid karyotype, whereas the karyotype of cell lines generated using non- 
Bubl-binding dl89-97 LT is near diploid.  These studies need to be extended 
to  give  statistically  meaningful  data.  It  would  then  be  important to  analyse 
these cell lines for both focus formation and anchorage-independent growth in 
soft  agar,  to  determine  if  genetic  instability  in  any  way  correlates  with 
transformation  phenotype.  The  robustness  of the  spindle  checkpoint  could 
then be  compared in transformed versus  non-transformed  cultures  generated 
from these assays.
It has been suggested that interaction of LT with Ran (a small GTPase 
that is involved in mitotic spindle organisation among other functions) could 
be one mechanism by which LT  causes  genomic instability (De  Luca et al, 
2003). Modulation of levels of Ran’s exchange factor, RCC1, have also been 
shown to abrogate the spindle checkpoint (Amaoutov and Dasso, 2003). This 
suggests  that the  spindle  checkpoint  is  directly responsive  to  levels  of Ran- 
GTP  in  the  cell,  and  could  therefore  lead  to  the  possibility  that  SV40  LT 
interaction  with  Ran  might  affect  the  spindle  checkpoint  directly.  It  is  not
284known which residues of LT are involved in binding to Ran, but this would be 
interesting  to  investigate  as  it  would  provide  further  insight  into  the 
mechanisms  by  which  LT  is  inducing  genomic  instability  and  perturbing 
spindle checkpoint function.
6.3  FINAL REMARKS
In  conclusion,  the  results  presented  in  this  thesis  have  suggested  a 
possible mechanism by which LT can transform cells to tumourigenicity.  By 
understanding how this viral oncoprotein carries out its transforming functions 
it may be possible to gain greater insight into the cellular processes that lead 
to  cancer.  Examination  of the mechanism by which LT perturbs  the  spindle 
checkpoint  function  of Bubl  may  serve  as  a  new  direction  from  which  to 
approach  analysis  of  the  spindle  checkpoint  pathway  in  normal  cells.  In 
addition, use of the dl89-97 LT mutant for generation of cell lines to study the 
basis  of  human  diseases  will  provide  a  very  useful  tool  if  it  eliminates 
problems  associated with induction of aneuploidy during  immortalisation by 
LT.
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319Appendix I
pcDNA3.1 Vectors
The figure below summarizes the features of the pcDNA3.1(+) and pcDNA3.1(-) vectors. 
The complete sequences for pcDNA3.1(+) and pcDNA3.1(-) are available for down­
loading from our World Wide Web site (www.invitrogen.com) or from Technical 
Service (see page 13). Details of the multiple cloning sites are shown on page 3 for 
pcDNA3.1(+) and page 4 for pcDNA3.l(-).
(+)
Comments for pcDNA3.1  (+)
5428 nucleotides
CMV promoter: bases 232-819 
T7 promoter/priming site: bases 863-882 
Multiple cloning site: bases 895-1010 
pcDNA3.1/BGH reverse priming site: bases 1022-1039 
BGH polyadenylation sequence: bases 1028-1252 
f1  origin: bases 1298-1726 
SV40 early promoter and origin: bases 1731-2074 
Neomycin resistance gene (ORF): bases 2136-2930 
SV40 early polyadenylation signal: bases 3104-3234 
pUC origin: bases 3617-4287 (complementary strand)
Ampicillin resistance gene (bla): bases 4432-5428 (complementary strand) 
ORF:  bases 4432-5292 (complementary strand)
Ribosome binding site: bases 5300-5304 (complementary strand) 
bla promoter (P3): bases 5327-5333 (complementary strand)
(reproduced from website: www.invitrogen.com)
* »
— CO  — —  >
©  g =
O f   c   Q. 5  .
pcDNA3.1 (+/-)
5428/5427 bp
Map of
pcDNA3.1(+) and 
pcDNA3.1(-)
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pSUPERretro vector map (RNAi system from OligoEngine):
— Hindlll 
— 6 g  III 
— BstAPI
”  tsiS l
-   -S fo l 
“ Obel 
"''"B isH II
pSUPEDietio
pr^nnro'
(reproduced from website: www.oligoengine.com)
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U20S growth rate data:
Table 1: raw data and normalised average values 
(used to plot graph in Figure 5.2):
U20S
Hours after plating @ 3x10A5/plate: 20 41 66 90
Cell counts(platel) (104) 37 41 94 215
27 59 117 205
29 45 89 175
28 58 73 180
Cell counts(plate2) (104) 24 35 79 199
36 52 68 188
25 57 76 172
24 37 63 159
Average Plate 1  count 30.25 50.75 93.25 193.75
Average Plate 2 count 27.25 45.25 71.5 179.5
Overall Average 28.75 48 82.375 186.625
Average Value,  Normalised 1.000 1.670 2.865 6.491
U20S(wild-type LT)
Hours after plating @  3x10A  5/plate: 20 41 66 90
Cell counts(platel) (104) 42 61 91 338
37 74 118 288
33 69 109 297
43 45 124 286
Cell  counts(plate2) (104) 56 67 148 313
56 50 156 297
52 51 147 242
40 102 183 242
Average Plate  1  count 38.75 62.25 110.5 302.25
Average Plate 2 count 51 67.5 158.5 273.5
Overall Average 44.875 64.875 134.5 287.875
Average  Value,  Normalised 1.000 1.446 2.997 6.415
U20S(dl89-97 LT) clone #2
Hours after plating @ 3x10A5/plate: 20 41 66 90
Cell counts(platel) (104) 44 73 176 357
47 67 172 452
44 79 160 352
40 86 140 352
Cell counts(plate2) (104) 45 91 150 405
49 70 172 392
37 94 162 333
35 69 154 358
Average Plate 1  count 43.75 76.25 162 378.25
Average Plate 2 count 41.5 81 159.5 372
Overall Average 42.625 78.625 160.75 375.125
Average  Value,  Normalised 1.000 1.845 3.771 8.801
U20S(dl89-97 LT) clone #4
Hours after plating @ 3x10A5/plate: 20 41 66 90
Cell counts(platel) (104) 37 52 134 285
35 54 141 288
42 49 132 299
28 47 131 276
Cell counts(plate2) (104) 21 59 139 287
31 62 132 247
40 65 130 265
37 54 127 258
Average Plate 1  count 35.5 50.5 134.5 287
Average Plate 2 count 32.25 60 132 264.25
Overall Average 33.875 55.25 133.25 275.625
Average Value,  Normalised 1.000 1.631 3.934 8.137
Average Value, Normalised
= Overall Average/(Overall Average at 20 hours)
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U20S growth rate data, normalised,
showing 95% confidence interval calculations (see Figure 5.2):
Table 2: normalised data and 95% confidence intervals:
U20S
Hours after plating @ 3x10A5/plate: 20 41 66 90
Normalised counts (plate 1) 1.287 1.426 3.270 7.478
0.939 2.052 4.070 7.130
1.009 1.565 3.096 6.087
0.974 2.017 2.539 6.261
Normalised counts (plate2) 0.835 1.217 2.748 6.922
1.252 1.809 2.365 6.539
0.870 1.983 2.643 5.983
0.835 1.287 2.191 5.530
Average Value,  Normalised 1.000 1.670 2.865 6.491
Standard Deviation (S.D),  Normalised 0.178 0.339 0.602 0.651
1.96 x S.D.  (95% confidence interval) = +/- 0.349 0.665 1.181 1.276
U20S(wild-type LT)
Hours after plating @ 3x10A5/plate: 20 41 66 90
Normalised counts (platel) 0.936 1.359 2.028 7.532
0.825 1.649 2.630 6.418
0.735 1.538 2.429 6.618
0.958 1.003 2.763 6.373
Normalised counts (plate2) 1.248 1.493 3.298 6.975
1.248 1.114 3.476 6.618
1.159 1.136 3.276 5.393
0.891 2.273 4.078 5.393
Average Value, Normalised 1.000 1.446 2.997 6.416
Standard Deviation (S.D.),  Normalised 0.195 0.405 0.657 0.731
1.96 x S.D.  (95% confidence interval) = +/- 0.383 0.793 1.287 1.432
U20S(dl89-97 LT) clone #2
Hours after plating @ 3x10A5/plate: 20 41 66 90
Normalised counts (platel) 1.032 1.713 4.129 8.375
1.103 1.572 4.035 10.604
1.032 1.853 3.754 8.258
0.938 2.018 3.284 8.258
Normalised counts (plate2) 1.056 2.135 3.519 9.501
1.150 1.642 4.035 9.196
0.868 2.205 3.801 7.812
0.821 1.619 3.613 8.399
Average Value, Normalised 1.000 1.845 3.771 8.801
Standard Deviation (S.D.),  Normalised 0.114 0.247 0.291 0.911
1.96 x S.D.  (95% confidence interval) = +/- 0.224 0.485 0.5/1 1.785
U20S(dl89-97 LT) clone #4
Hours after plating @  3x10A5/plate: 20 41 r   66 90
Normalised counts (platel) 1.092 1.535 3.956 8.413
1.033 1.594 4.162 8.502
1.240 1.446 3.897 8.827
0.827 1.387 3.867 8.148
Normalised counts (plate2) 0.620 1.742 4.103 8.472
0.915 1.830 3.897 7.292
1.181 1.919 3.838 7.823
1.092 1.594 3.749 7.616
Average Value,  Normalised 1.000 1.631 3.934 8.137
Standard Deviation (S.D.),  Normalised 0.204 0.185 0 137 0.519
1.96 x S.D.  (95% confidence interval) =  +/- 0.399 0.363 0.269 1.016
All  counts  in  Table  1  (Appendix  III)  were  normalised,  to  allow  calculation  of the 
standard deviation (S.D.), using Microsoft Excel.
Normalised count = count/(overall average at 20 hours)
N.B. the "Average Value, Normalised" for each cell line, at each time point shown in 
this table is the same as that calculated using the raw data, shown in Table 1.
95% confidence interval = +/- (1.96 x S.D.)
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